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''I have serious reason to believe that the planet from which the little prince came is the 
asteroid known as B-612. This asteroid has only once been seen through the telescope. That 
was by a Turkish astronomer, in 1909. On making his discovery, the astronomer had 
presented it to the International Astronomical Congress, in a great demonstration. But he was 
in Turkish costume, and so nobody would believe what he said.  
 
Grown-ups are like that... 
 
 
Fortunately, however, for the reputation of Asteroid B-612, a Turkish dictator made a law that 
his subjects, under pain of death, should change to European costume. So in 1920 the 
astronomer gave his demonstration all over again, dressed with impressive style and elegance. 
And this time everybody accepted his report.  
If I have told you these details about the asteroid, and made a note of its number for you, it is 
on account of the grown-ups and their ways. '' 
 
The Little Prince 
Antoine de Saint-Exupéry 
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Abstract 
 
The present work aimed to study the transition-metal-catalyzed direct C-H arylation of 
various nitro-substituted heteroarenes, including 4-nitroimidazole derivatives, 4-nitropyrazole 
derivatives, fused 3-nitropyridines, nitro-substituted pyrrole and thiophene. Under optimized 
reaction conditions a wide range of coupling partners were perfectly tolerated. Additional 
empirical studies indicated that the nitro group has influence on the regioselectivity of the 
reactions. In addition, the multipurpose nature of nitro group as a versatile directing group 
was explored. Particularly, the nitro group can be easily transferred to amino, N,N-
dimethylamino groups etc via reduction; on the other hand, the nitro group was transferred to 
bromo substituent in one step which makes the substrates readily available for further C-C 
bond forming cross-coupling reactions.  
 
 
 
Kurzbeschreibung 
 
Die vorliegende Arbeit beschäftigt sich mit Studien von Übergangsmetall-katalysierten, 
direkten C-H-Arylierungsreaktionen (Arylierungen unter direkter C-H-Bindungsaktivierung) 
von verschiedenen Nitro-substituierten Heteroarenen einschließlich von Derivaten des 4-
Nitroimidazols, des 4-Nitropyrazols, kondensierter 3-Nitropyridine sowie Nitro-substituierter 
Pyrrole und Thiophene. Unter optimierten Reaktionsbedingungen konnte eine breite Palette 
an Kupplungspartnern erfolgreich eingesetzt werden. Weitere empirische Studien ergaben, 
dass die Nitrogruppe auch Einfluss auf die Regioselektivität bei derartigen 
Kupplungsreaktionen haben kann. Ferner wurden Umwandlungen sowie die vielseitigen 
dirigierenden Eigenschaften der Nitrogruppe im Detail untersucht. Speziell die 
Umwandlungen in Amino-, N,N-Dimethylamino- und andere Gruppen durch Reduktion aber 
auch die in einem Schritt durchführbare Substitution durch einen Brom-Substituenten, die das 
Substrat für weitere C-C-Knüpfungsreaktionen zugänglich macht, konnten durchgeführt 
werden.  
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1. Introduction: Biaryls in Industry, Medicine and Life Sciences 
 
The Ar-Ar C-C bond forming reactions are not only of academic interest, but also play an 
increasingly important role in a number of industrial processes, life sciences, synthesis of 
natural products, chemistry of chiral catalysts, chiral stationary phase chemistry, production 
of electronic devices etc.1  
In particular, several approaches have been employed to identify privileged substructures 
from the database of known drugs using pharmacophore modeling techniques and a variety of 
fragmentation algorithms. Interestingly, Bemis and coworkers identified a set of 32 molecular 
substructures which described almost 50% of all known drugs.2 Among others the biaryl 
framework was found in more than 5% of all known drugs, indicating that the biaryl 
substructure is without doubt a privileged substructure.3 The Comprehensive Medicinal 
Chemistry Database indicates the following distinct therapeutic classes for known drugs 
which contain biaryl framework: antiamebic, antifungal, antiinfective, 
antihypercholesterolemic, antihyperlipoproteinemic, fasciolicide, antirheumatic, analgesic, 
antiinflammatory, antithrombotic, uricosuric, and antiarrhythmic.2,3 Biaryls are also known to 
possess an antitumor,4 antihypertensive,5 and antiatherosclerotic6 activity.  
 
 
Figure 1.1. Some biaryl based pharmaceuticals. 
 
Noteworthy, along with hydrophobic interactions with appropriate targets (receptors) 
aromatics have also been shown to form favorable interactions with polar substituents and 
even charged groups.7 With this degree of versatility in binding interactions, it is not 
surprising that the biaryl framework is so common in pharmaceuticals. Some representatives 
of widely used drugs containing the biaryl fragment are presented in the Figure 1.1. The list 
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includes Amrinone 1.1a - a vasodilator agent,8a Flavoxate 1.1b - an anticholinergic agent,8b 
Apomorphine 1.1c - a non-selective dopamine agonist,8c Celecoxib 1.1d - a nonsteroidal anti-
inflammatory drug,8d Diflunisal 1.1e - an analgesic and anti-inflammatory drug,8e Viagra 
(Sildenafil citrate) 1.1f - a drug used to treat erectile dysfunction,8f Lamotrigine (Lamictal) 
1.1g - an anticonvulsant drug8g etc (Figure 1.1). Many others can be found in classical 
textbooks on pharmacology.8h  
Furthermore, biaryl based structures are widespread in many of naturally occurring products 
including alkaloids, lignans, terpenes, flavonoids, tannins, as well as polyketides, coumarins, 
peptides, glycopeptides etc (Figure 1.2). For instance, Vancomycin 1.2a is a basic structure of 
several related glycopeptide antibiotics,9a the Dragmacidin D 1.2b represents an emerging 
class of bioactive marine natural produc,9b Lamellarin D 1.2c is a potent cytotoxic agent 
isolated from the marine prosobranch mollusc Lamellaria,9c Dictyodendrin A and B 1.2d,e 
(isolated from the marine sponge Dictyodendrilla verongiformis) possess strong inhibitory 
activity against telomerase.9d Besides, a lot of natural pigments are based on biaryl 
framework; e.g. Gossypol 1.2f, which is the major constituent of cottonseed pigment, 
possessing a male antifertility action.9e Among lignans, an illustrative example is Steganacin 
1.2g (a constituent of Steganotaenia araliacea), an important synthetic target of many 
scientific papers which possesses a significant antileukemic activity (Figure 1.2).9f,g Many 
others can be found in classical textbooks on biochemistry and phytochemistry.  
 
 
Figure 1.2. Some biaryl based naturally occurring products. 
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The biaryl structures are the basis of numerous chiral separations by crown ethers, inclusion 
complexes or preparative chromatography on the chiral stationary phases.10 Biaryls play an 
increasingly important role in molecular recognition and development of artificial fluorescent 
chemosensors.11 Chiral biaryls, binaphthols and related chiral auxiliaries are widely employed 
chemicals in some impressive industrial processes.12 The simplest and historically the most 
important chiral biaryl molecule is 1,1'-bi-2-naphthol (BINOL) 1.3a which is used as a chiral 
ligand or starting material in the production of several valuable catalysts for certain 
stereoselective reactions (Figure 1.3).13  
 
 
Figure 1.3. Selected examples of biaryl based substances used in industrial processes. 
 
BINOL itself, however, does not always give satisfactory results in asymmetric catalysis, thus 
there is an ongoing interest in modified BINOL ligands.13b,14 For this purpose a number of 
heterobidentate binaphthyls were prepared and successfully applied in asymmetric catalysis. 
The most frequently used binaphthyls are BINAP 1.3b,15a BINEPINES 1.3c,15b BINAM 
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1.3d,14 MOP 1.3e,14 NOBIN 1.3f,14 and their substituted analogues.15c-l Besides, the rapid 
development of homogeneous catalysis, especially during the last decade, is largely driven by 
the implementation of new classes of ligands based on biaryl framework. The biaryl based 
phosphine ligands have proven to provide especially active catalysts in this context; 
representative examples are DavePhos 1.3g, MePhos 1.3h, SPhos 1.3i and XPhos 1.3j (Figure 
1.3).16 In addition, several heterobiaryls are among the important ligands in the coordination 
chemistry and in certain important catalysts. For instance, 2,2'-bipyridine 1.3k,17a,b its 
derivatives and other heterobiaryls 1.3l,m along with cyclometalated ligands 1.3n17c are 
widely employed in homogeneous catalysis. Another example is terpyridine 1.3o and its 
heteroanalogues 1.3p,q which have been utilized as ligands in asymmetric catalysis; however, 
nowadays they have found another interesting application: namely they are able to form 
''mixed complexes'' with transition metal ion forming novel supramolecular architectures 1.3r 
(Figure 1.3).18 That is to say, the current state of homogeneous and/or asymmetric catalysis 
would not have been possible without these valuable classes of ligands based on biaryls.  
Moreover, many commercial dyes and fluorescent probes contain several aromatic rings 
bound together via Ar-Ar C-C bond.19 Last but not least, π-conjugated systems of oligomers 
and/or polymers based on the Ar-Ar fragments are of considerable interest as futuristic 
materials for the development and production of the next generation of electronics.20 Selected 
representatives of organic semiconductors 1.3s-v are presented in Figure 1.3.  
Owing this the synthesis of biaryls via Ar-Ar C-C bond construction was and remains an 
actual task.  
 
2. Methods of Ar-Ar C-C Bond Construction: Past, Present and the Future 
 
The construction of an Ar-Ar C-C bond remains one of the most important goals in the field 
of organic chemistry. The development of highly efficient methodologies for the synthesis of 
biaryls has been under considerable attention for over a century. Since Ullmann's initial 
reports more than a century ago, about the coupling reactions of aryl halides to biaryls 
initiated by copper bronze,21 a number of highly efficient reactions and methods have been 
disclosed.1  
Currently, the synthesis of biaryls continues to be the theme of numerous papers. This clearly 
shows the results of SciFinder search on keyword ''arylation'' (Figure 2.1). On the chart one 
can see that this field of research has been growing enormously especially during the last 
decade.  
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Figure 2.1. The number of publications in the period 1970-2013 on the topic of arylation. The 
data for the bar chart was obtained by a SciFinder search in November 2014 using keyword 
''arylation''. 
 
Apart from the several recent successful developments in the field of synthesis of biaryls, a 
number of basic problems are still waiting for efficient solutions. Most of the current methods 
for the construction of biaryls require prefunctionalization of substrates in order to activate the 
site of interest of the molecule that allows the construction of desired Ar-Ar bond with proper 
chemo- and regioselectivity. Alternatively, much more straightforward would be the direct 
and selective coupling of two unfunctionalized starting arenes to appropriate biaryls. A 
number of innovative methods of this type are emerging (see below), nevertheless they are 
still far from being applicable to a broad range of target complex natural product structures. In 
order to solve this problem once and for all, one should learn from the nature. In most of the 
cases the unifying principle for the construction of biaryls in natural product biosynthesis is 
based on oxidative couplings of phenols or aromatic amines (Scheme 2.1).22 This oxidative 
process is commonly considered to involve an oxidative enzyme, such as a laccase, a 
peroxidase or a cytochrome P450 enzyme. In particular, the oxidative enzyme generates a 
radical at the phenol derivative 2.1a either by deprotonation and single-electron transfer or by 
abstraction of a hydrogen atom from the phenol; accordingly creating the intermediate 2.1b 
(similar considerations are equally actual for appropriate aromatic amines). Since the 
generated radical is delocalized in the phenol/aniline ring, the latter could either react with a 
second radical substrate generated by the enzyme or with another aromatic system via single-
radical coupling with a subsequent abstraction of an atom of hydrogen (free-radical 
substitution at the aromatic ring) generating one of possible isomer products. That is to say, 
the both reaction pathways ultimately lead to the overall abstraction of two protons and two 
electrons (two hydrogen atoms) giving rise to corresponding biaryls 2.1d-f or biaryl 
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ethers/arylamines 2.1c (Scheme 2.1). This general process results in a large set of possible 
regiodivergent products with C-O-C (C-N-C in case of aromatic amines) or C-C linkages.22  
 
 
Scheme 2.1. Enzymatic Ar-Ar C-C bond construction in the nature. 
 
In the present chapter an attempt will be made to present both older methods, which are still 
competitively efficient, and more recent concepts in the field of Ar-Ar C-C bond construction. 
The evolution of this field is also a good illustration of the development of modern organic 
synthesis; particularly, the increasingly important role of transition-metal-catalysis (TM-
catalysis) in the chemistry. Every effort has been made to comprehensively review the 
literature within the framework outlined above, however due to the sheer size and scope of 
this work it is impractical to cover every detail. However, the vast amount of references 
provided in the work should fulfill the gap.  
 
2.1. Classical Methods for Synthesis of Biaryls 
 
The Motherwell biaryl synthesis. Motherwell and coworkers developed an original 
approach for the synthesis of biaryls based on the intramolecular free-radical ipso-substitution 
reaction in respective sulfonates and sulfonamides 2.1.1a (Scheme 2.1.1).23 The method offers 
a useful strategy for the construction of biaryls and heterobiaryls. The reaction initiates the tri-
n-butyltin hydride/azobisisobutyronitrile (AlBN) system (a typical radical initiator) in 
refluxing liquid arene producing spirocyclic intermediate 2.1.1b, which, upon extrusion of 
sulfur dioxide, affords the substituted biphenyls 2.1.1c from moderate to good yields.  
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Scheme 2.1.1. The Motherwell biaryl synthesis. 
 
Intermolecular free-radical arylation of arenes. This includes the application of several 
typically substituted arenes which under some special circumstances are prone to generate 
corresponding aryl radicals. In particular Demir and coworkers showed that Mn(OAc)3 can 
act as a selective oxidant for the generation of aryl radicals from arylhydrazines 2.1.2a24a,b and 
arylboronic acids 2.1.2b.24c When the oxidation is conducted in liquid arene (solvent), the 
free-radical arylation takes place to give corresponding biaryls 2.1.2c in moderate yields 
(Scheme 2.1.2). Similarly, arylcadmium reagents in the presence of oxygen are prone to 
generate appropriate aryl radicals; in particular, diphenylcadmium 2.1.2d in benzene in the 
presence of oxygen produces appropriate biphenyl 2.1.2c along with some amounts of phenol 
(Scheme 2.1.2).24d Another typical example includes diaroyl peroxides 2.1.2e which at 
elevated temperatures are prone to dissociate by homolytic pathway generating the 
arylcarboxy-radicals, ArCO2˙, which readily undergo a rapid decarboxylation forming the aryl 
radicals. The latter can react with the arene used as solvent, by the free-radical arylation 
mechanism.24e-i The main disadvantage of these methods is the formation of disastrous 
mixture of isomer biaryls (ortho, meta, para) in case of substituted starting arenes.  
 
 
Scheme 2.1.2. Intermolecular free-radical arylation of arenes. 
 
The Gomberg-Bachmann-Hey arylation and related reactions. The arylation of aromatic 
compounds with aryldiazonium salts initiated by a base is known as Gomberg-Bachmann-Hey 
reaction (for simplicity GBH reaction).25 In this case the base reacts with the aryldiazonium 
salt 2.1.3b producing the covalent dimer 2.1.3c which is prone to undergo a homolytic 
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decomposition accompanied with generation of suitable aryl radical.26 The latter can react 
with the arene used as solvent, to give corresponding biaryl 2.1.3d in moderate yields 
(Scheme 2.1.3). Similar to the previous case here as well substituted starting arenes form a 
mixture of isomer biaryls. Additionally, there are some other common side processes, 
including the formation of polyaryls, parent arene, and arylazo compounds. However, the 
major limitation of the GBH reaction is that the parent arene has to be used as solvent; that is, 
it should be liquid and/or fusible. Since the original GBH reaction rarely gives satisfying 
results, further improvements have been introduced.27 The more recent alterations of the GBH 
reaction are based on the thermal decomposition of appropriate aryltriazenes 2.1.3e which 
generates corresponding aryl radicals (Scheme 2.1.3).28  
 
 
Scheme 2.1.3. The Gomberg-Bachmann-Hey arylation and related reactions. 
 
The Meyers synthesis of biaryls and related reactions. A number of good leaving groups 
for aromatic nucleophilic substitution can be effectively substituted by aryllithiums or aryl 
Grignard reagents 2.1.4b giving rise to certain biaryls 2.1.4d (Scheme 2.1.4). In this context, 
the substitution of methoxy group is well-known as Meyers synthesis of biaryls.29  
 
 
Scheme 2.1.4. The Meyers synthesis of biaryls and related reactions. 
 
On the basis of the Meyers approach, others have introduced several related procedures based 
on arenes bearing various electron-withdrawing substituents which activate the leaving group 
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towards nucleophilic substitution.30 On the other hand, electron deficient arenes, such as 
pyridines, pyrimidines 2.1.4c etc, do not require electron-withdrawing substituents and are 
active enough to undergo an efficient nucleophilic substitution. Moreover, in these systems 
even hydrogen can serve as a good leaving group (Scheme 2.1.4).31  
Alternatively, another interesting reaction was discovered by Wittig and Franzen. Thus, they 
have shown that triarylsulfonium salts 2.1.4e are prone to react with phenyllithium 2.1.4b 
giving rise to corresponding sulfide and biaryl (Scheme 2.1.4).32  
Synthesis of biaryls from arynes. The arynes, generated in situ,33 are prone to react with a 
number of aryl organometallics, including themselves, producing corresponding biaryls 
2.1.5e,f in various yields.34 In this respect, as aryne 2.1.5d precursors were applied 
benzenediazonium carboxylate 2.1.5a, 1-aminobenzotriazole 2.1.5b, 2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate 2.1.5c etc (Scheme 2.1.5).33  
 
 
Scheme 2.1.5. Synthesis of biaryls from arynes. 
 
Synthesis of biaryls via benzidine rearrangement. Another interesting approach to biaryls 
represents the acid-catalyzed rearrangement of N,N'-diarylhydrazines 2.1.6a to para, para-
diaminobiaryls 2.1.6b (Scheme 2.1.6).35 The benzidine rearrangement is an efficient approach 
for the synthesis of unsymmetrical biaryls and heterobiaryls, using suitable unsymmetrically 
substituted N,N'-diarylhydrazines.35f,h,i The main disadvantage of the reaction is that besides 
para, para-product, the rearrangement always produce some amounts of ortho, para-product 
2.1.6c.35o  
 
 
Scheme 2.1.6. Synthesis of biaryls via benzidine rearrangement. 
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Photochemical synthesis of biaryls. The Ar-Ar C-C bond construction can be realized by 
photochemical irradiation of suitable aryl iodides or bromides, which upon 
photodehydrohalogenation form corresponding biaryls (Scheme 2.1.7).36 This process has a 
free-radical nature. The photochemical syntheses of biaryls 2.1.7b can be performed either 
intra- 2.1.7a or intermolecularly 2.1.7c.  
 
 
Scheme 2.1.7. Photochemical synthesis of biaryls. 
 
Electrochemical synthesis of biaryls. During the electrolysis corresponding substrate is 
subjected to the removal (anodic oxidation) or addition (cathodic reduction) of electrons. 
Particularly, at the anode, electron-rich arenes 2.1.8a, anilines and phenols dimerize or react 
with appropriate arenes generating corresponding biaryls 2.1.8c-e via intermediate radical 
cations 2.1.8b (Scheme 2.1.8).37 The basis of this process is the anodic transformation of the 
substrate to radical cation by removal of an electron.  
This process is very much similar to the enzymatic Ar-Ar C-C bond construction in the nature 
(Scheme 2.1); however, usually the process is not selective, hence the formation of isomer 
products 2.1.8c-e is commonly observed.  
 
 
Scheme 2.1.8. Electrochemical synthesis of biaryls. 
 
Synthesis of biaryls from hypervalent iodine compounds. Aryliodonium salts 2.1.9a and 
some other hypervalent aryliodonium compounds38 in the presence of Pd-catalysts smoothly 
react with arylboronic acids, diaryltellurium dichlorides and other organometallics 2.1.9b 
forming certain biaryls 2.1.9c in good yields (Scheme 2.1.9).39 Empirical studies indicated 
that in unsymmetrical diaryliodonium salts, only the electron-rich aryl group participates in 
the formation of appropriate biaryl. Besides, triaryliodane and related compounds 2.1.9d, 
being rather unstable, are prone to decompose to corresponding iodoarene and biaryl.38b,39a  
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Scheme 2.1.9. Synthesis of biaryls from hypervalent iodine compounds. 
 
Synthesis of biaryls via aryllead(IV), arylbismuth and arylantimony reagents. The 
aryllead(IV) tricarboxylates 2.1.10a are prone to arylate the electron-rich arenes 2.1.10b 
under mild conditions within a few hours, generating appropriate biaryls 2.1.10d in moderate 
yields (Scheme 2.1.10).40  
 
 
Scheme 2.1.10. Synthesis of biaryls via aryllead(IV), arylbismuth and arylantimony reagents. 
 
In this case the aryllead(IV) tricarboxylates supposedly act as an aryl-cation donors, hence the 
transformation represents a kind of electrophilic aromatic substitution reaction. Expectedly, in 
case of monosubstituted arenes, all three isomeric biaryls were obtained. The main side 
process of the reaction is acid initiated protodeplumbylation of aryllead(IV) tricarboxylates 
which produces the parent arene. Related useful classes of organometallics for the synthesis 
of biaryls represents arylbismuth and arylantimony reagents.41 Whereas the arylbismuth(III) 
2.1.10f and triarylantimony(III) 2.1.10e reagents are convenient precursors for the Pd-
catalyzed synthesis of symmetrical biaryls,41c,d the triarylbismuth(V) reagents 2.1.10c are tend 
to act as aryllead(IV) tricarboxylates, thus, the direct arylation reaction of electron-rich arenes 
proceeds via electrophilic aromatic substitution generating biaryls in moderate yields.41b  
Pschorr arylation and related reactions. The intramolecular coupling reaction of 
aryldiazonium salts 2.1.11a with the arene subunit initiated by copper or an acid, is known as 
the Pschorr cyclization reaction (Scheme 2.1.11).42a The Cu-induced decomposition of 
aryldiazonium salts is a well-known process which is assumed to proceed through one 
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electron reduction with generation of an aryl radical, obviously not free, but held on the Cu 
surface.42,43 The latter is prone to undergo further intramolecular arylation, a process which is 
somewhat similar to the Gomberg-Bachman-Hey reaction (Scheme 2.1.3). In spite of 
numerous attempts to increase the yields and versatility of the reaction, the Pschorr 
cyclization still remains an inconvenient and low yielding process. A closely related reaction 
to Pschorr arylation is the Gatterman synthesis of biaryls which includes the coupling reaction 
of two aryldiazonium salts 2.1.11c initiated by metallic Cu or Cu(I) salts (Scheme 2.1.11).44  
 
 
Scheme 2.1.11. Pschorr arylation and related reactions. 
 
Ullmann arylation and related reactions. The synthesis of biaryls 2.1.12c by the coupling 
of two molecules of an aryl halide 2.1.12a in the presence of copper is one of the oldest 
methods in the field which is well-known as Ullmann arylation (Scheme 2.1.12).21,45 Due to 
its simplicity, the Ullmann arylation was widely applied in the synthesis of numerous 
symmetrical and some classes of unsymmetrical biaryls.45,46  
Usually the reaction requires from three to tenfold excess of Cu which limits the scalability of 
the reaction. In general, the order of reactivity of aryl halides is I > Br >> Cl; in the reaction 
fluorine usually remains intact.45 Additionally, electronegative substituents exhibit an 
activating effect on the aryl halide. However, OH, NHR and free-carboxylic acid substituents 
as a rule prevent the formation of target biaryls due to some additional competing reaction 
pathways.47  
The efficiency of Ullmann arylation towards unsymmetrical biaryls can be enhanced via using 
aryl halides with different reactivity; otherwise the result may be a complex mixture of 
products.45 In this case another side reaction may arise, which is the halogen-exchange 
reaction induced by Cu.48 Another modification of the Ullmann arylation is based on 
copper(II)-induced intra- and intermolecular homo-couplings of various arylmetallic reagents 
2.1.12b generated in situ from suitable aryl halides (Scheme 2.1.12). In this case the 
arylmetallic reagent undergoes transmetallation with the Cu(II) salt forming suitable 
diarylcopper(II) intermediate which is prone to undergo a rapid reductive elimination to form 
corresponding biaryl 2.1.12c.49  
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Scheme 2.1.12. Ullmann arylation and related reactions. 
 
Transition-metal-induced coupling reactions of aryl halides and sulfonates. Due to the 
numerous disadvantages and complications connected with classical Ullmann arylation and 
other methods described above, a number of attempts have been made to describe some more 
efficient alternatives for Ar-Ar C-C bond construction.50 As a result, it was found that aryl 
halides and sulfonates 2.1.13a,c,d can be coupled to biaryls 2.1.13b using various salts and 
complexes of transition metals (Scheme 2.1.13). In the early phases, the transition metals 
were used as stoichiometric reagents.50 In contrast, recent methods require only a catalytic 
amount of suitable transition metal complex in the presence of an inexpensive ultimate 
reductant. Among others, the Ni(0)51 and Pd(0) complexes,52 as well as Cu(I) salts in 
stoichiometric amounts,53 proved to be the most promising initiators for coupling of aryl 
halides and sulfonates to corresponding symmetrical and unsymmetrical biaryls. In this 
regard, the most important methods for coupling of aryl halides to biaryls are based on the 
usage of catalytic amounts of Pd(0)-based catalysts. The basic principle of catalytic method is 
that the Pd(II) complex, formed during Pd(0)-catalyzed biaryl synthesis, is in situ reduced 
back to active Pd(0) catalyst with an ultimate reductant (the same refers to the Ni).51,52  
 
 
Scheme 2.1.13. Transition-metal-induced coupling reactions of aryl halides and sulfonates. 
 
In addition to the coupling reactions catalyzed by Ni(0) and Pd(0) complexes, the active forms 
of metallic Ni,54a-c Co,54c and even In54d proved to be highly effective alternatives for the 
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homo-coupling of aryl halides. The efficient synthesis of unsymmetrical biaryls via Ni- or Pd-
catalyzed coupling reactions of aryl halides still can be achieved under special 
circumstances;55 although, the selectivity of the process is not that high. Accordingly, the 
most efficient approach to unsymmetrical biaryls is based on the use of an aryl halide with 
increased reactivity together with relatively inactive one (Scheme 2.1.13). Usually this 
approach causes preferential formation of the unsymmetrical cross-coupling product.55  
Homo-coupling reactions of arylmetallic reagents to biaryls. A number of arylmetallic 
reagents as formal aryl-carbanion donors are prone to be oxidatively coupled to symmetrical 
biaryls.56 A representative example is the modified Ullmann arylation based on the 
homocoupling of aryllithiums induced by Cu(II) salts (Scheme 2.1.12, see also Scheme 
2.1.10).49 That is to say, transition metals which can be considered as one- or two-electron 
oxidants, as well as transition metals which tend to form suitable thermally unstable 
biarylmetals, can affect the homo-coupling reaction of appropriate organometallics 2.1.14a 
(Scheme 2.1.14). For instance, aryllithiums, apart from the modified Ullmann arylation, have 
been coupled by Fe(acac)3 which is an efficient one-electron oxidant.
57 Similarly, the aryl 
Grignard reagents,58 arylzincs,59 arylzirconiums,60 arylboronic acids and tetraarylborates,61 
Stille reagents (aryltrimethyl- or tri-n-butylstannanes),62 arylsilicon reagents,63 arylmercuric 
halides64 as well as diaryltellurium dichlorides65 can be converted to symmetrical biaryls 
2.1.14b using different well established oxidant or TM-based coupling procedures.  
 
 
Scheme 2.1.14. Homo-coupling reactions of arylmetallic reagents to biaryls. 
 
Synthesis of biaryls by oxidative couplings of arenes. The direct construction of Ar-Ar C-C 
bond between two aromatic rings without pre-functionalization can be accomplished using 
various oxidative couplings (Scheme 2.1.15).66 The methodology is especially suitable for 
electron-rich arenes such as thiophenes, pyrroles, phenols, anilines etc. However, benzene and 
electron-poor aromatics also can be subjected to the oxidative coupling reactions to form 
corresponding biaryls under certain circumstances.66 The reaction supposedly proceeds 
through an aryl radical-cation 2.1.15b which reacts with the second molecule of arene 2.1.15c 
to give a bicyclohexadiene radical-cation 2.1.15d which tends to lose two protons and an 
electron, initiated by an oxidant, providing corresponding biaryls 2.1.15e (Scheme 2.1.15). In 
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this respect a number of reagents are able to produce an aryl radical-cation from parent 
arenes. The representative classes of reagents include: Bronsted acids, e.g. H2SO4 etc; Lewis 
acids, e.g. AlCl3, SnX4 etc; some salts of transition metals, e.g. salts of Ag(II), Cu(II), Co(III), 
Ce(IV), Mo(V), V(IV) etc; halogens and many others.66 Interestingly, some reagents can 
serve both as Lewis acid and oxidant, offering a highly efficient means for overall 
transformation. Thus, the oxidative coupling of simple arenes to biaryls have been performed 
using stoichiometric amounts of Tl(III) salts,67 salts of Cr,68 salts of Mn,69 activated PbO2,
70 V 
oxides,71 salts of Ti,72 salts of Mo,73 salts of Ce,74 salts of Pb,75 salts of Ag,76 salts of Cu,77 
salts of Pd,78 salts of Fe,79 salts of Ru,80 salts of Co,81 hypervalent iodine compounds,82 and 
other reagents.83 These processes are similar to the enzymatic Ar-Ar C-C bond construction 
(Scheme 2.1); nevertheless, the amount and toxicity of used oxidants together with reduced 
selectivity of the reaction dramatically limits the overall applicability of the process.  
 
 
Scheme 2.1.15. Synthesis of biaryls by oxidative couplings of arenes. 
 
Cross-coupling reactions of arylmetallic reagents with aryl halides and related reagents. 
In general, in the presence of TM-based catalysts arylmetallic reagents 2.1.16b smoothly react 
with aryl halides, triflates and other related reagents 2.1.16a, producing certain biaryls 2.1.16c 
(Scheme 2.1.16).84 In TM-catalyzed cross-coupling reactions, the organometallics of both 
electronegative (Sn, Hg etc) and electropositive (Li, Mg etc) metals as well as corresponding 
metalloids (B, Si etc) act as formal carbanion-donors, whereas the aryl halides, triflates and 
related reagents are formal carbocation-donors. Historically, the initial cross-coupling 
reactions of aryl halides were performed using Grignard and organolithium reagents. 
However, since these organometallics do not tolerate a number of common functional groups, 
accordingly, some less reactive organometallics were introduced. The reactivity of aryl 
halides in cross-coupling reactions follows the general order: I > Br >> Cl. Additionally, a 
number of other functionalized arenes such as diazonium salts, carboxylates, sulfonates, 
nitriles and even thioethers can be employed as alternative coupling partners (Scheme 
2.1.16).85 However, some of these functionalized arenes are less reactive than appropriate aryl 
halides; nevertheless, application of more active catalysts makes this approach to biaryls 
widely applicable.85 The cross-coupling reactions can involve arylmetallic reagents of Zn, Sn, 
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B, Si, Hg, Cu, Mg as well as the slightly less studied Ti, In and Ge reagents and some others 
(Scheme 2.1.16).86,56 Most of the cross-coupling reactions are well-known name reactions. 
For instance, the coupling of Grignard reagents with aryl halides is known as the Kharasch 
reaction, the arylzinc based analogue is called the Negishi reaction, the organostannanes are 
used in the Stille reaction, while the most important reaction in the field is based on 
organoboron reagents and is well-known as the Suzuki-Miyaura reaction. Noteworthy, these 
reactions can be widely used in the sp2-sp3, sp2-sp, sp2-sp2, sp-sp, sp3-sp, as well as sp3-sp3 C-
C bond forming processes.84,87 This chemistry was awarded by the Nobel prize in 2010, which 
indicates on the great importance of these transformations.88  
 
 
Scheme 2.1.16. Cross-couplings of arylmetallics with aryl halides and related reagents. 
 
The Kharasch reaction. As it was mentioned above, aryllithium and Grignard reagents, 
derived from simple arenes, smoothly react with aryl halides and other related reagents, in the 
presence of various Ni- or Pd-based catalysts, giving rise to unsymmetrical biaryls in 
moderate yields (Scheme 2.1.16, M = Li, MgHal).89-91 Since the aryllithiums and Grignard 
reagents are very strong bases and nucleophiles, several functional groups such as aldehydes, 
esters, amides etc, should be protected before the reaction. In this respect, the aryllithiums are 
more commonly subjected to transmetallation with MgBr2, ZnCl2, ClSnR3, B(OR)3 etc, to 
form corresponding ArMgBr, ArZnCl, ArSnR3 and ArB(OR)2 reagents which are far more 
convenient precursors for cross-coupling reactions.92 In this regard, the Grignard reagents are 
relatively more convenient coupling partners for the Ni- and Pd-catalyzed89 Kharasch cross-
coupling reaction with aryl halides and other related reagents,90 producing a wide variety of 
substituted biaryls in moderate yields.91  
The Negishi reaction. Arylzinc reagents, being significantly less reactive organometallics 
than aryllithium and Grignard reagents, have become an extremely convenient class of 
compounds for TM-catalyzed cross-coupling reactions with aryl halides and other related 
reagents,93 providing the formation of various valuable unsymmetrical biaryls in good yields 
(Scheme 2.1.16, M = ZnHal). In general, the Negishi reaction can be effectively catalyzed by 
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different combinations of salts of Ni and Pd with various ligands.93,94 Thus, the Negishi cross-
coupling reaction has been successfully employed by different groups in the synthesis of 
different types of unsymmetrical biaryls.93-95  
The Stille reaction. Arylstannanes of general structure ArSnAlk3, in the presence of various 
Pd(0)-catalysts, are prone to react with aryl halides and other related reagents96 giving rise to 
the formation of suitable unsymmetrical biaryls in good yields (Scheme 2.1.16, M = SnR3). 
The methodology represents another powerful tool for the construction of certain Ar-Ar C-C 
bond of interest. The most efficient catalysts for the Stille reaction appeared to be various 
salts of Pd combined with different ligands.96 Besides, it was found that Cu(I) salts in 
stoichiometric quantities can dramatically accelerate the reaction.97a In addition, it has been 
shown that the salts of Cu(I) and Mn(II) can initiate the reaction in the absence of Pd-based 
catalysts.97b,c In general, the Stille cross-coupling reaction have been extensively used for the 
synthesis of numerous unsymmetrical biaryls.96-98 However, the toxicity of arylstannanes 
dramatically limits the applicability of the reaction.  
The Hiyama reaction. In the presence of Pd-based catalysts arylsilane reagents of general 
structure ArSi(OR)3 (R = Alk, H), along with polysiloxanes bearing aryl groups, 
(Si(Ar)(Me)O)n, are prone to react with different aryl halides generating appropriate biaryls in 
good yields (Scheme 2.1.16, M = SiR3).
99 The most efficient catalysts of the reaction are 
based on various combinations of Pd-salts and ligands; additionally, sometimes some 
cocatalysts like TBAF, KF, Ag2O etc may be required.
99 The synthesis of unsymmetrical 
biaryls on the basis of arylsilanes being more environmental friendly approach than other 
cross-coupling reactions currently is under the focus of extensive research.  
The Suzuki-Miyaura reaction. The TM-catalyzed cross-coupling reactions of various 
organoboron compounds (boronic acids, esters etc) with aryl halides and other related 
reagents to produce unsymmetrical biaryls are well-known as Suzuki-Miyaura reaction 
(Scheme 2.1.16, M = B(OR)2).
86-88,100 Noteworthy, the arylboronic acids and esters mostly are 
thermally stable and inert to water and oxygen; however, under special circumstances the 
organoboron compounds are prone to act as carbanion-donors similar to other arylmetallic 
reagents. The enhanced stability of organoboron compounds allows to perform the Suzuki-
Miyaura reaction applying a wide range of reaction conditions (even in the water) using 
arenes bearing a wide variety of reactive functionalities, which is a difficult task for the most 
of arylmetallic reagents.101 In most of the cases the Suzuki-Miyaura reaction was performed 
by using various Pd-based catalysts;102 nevertheless, the reaction can be performed using Ni-
based catalytic systems,103 which are cheaper than Pd-based catalysts. Additionally, the Ni-
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based catalysts usually are more reactive than Pd-based complexes; thereby they can be 
applied with less reactive substrates such as aryl chlorides, sulfonates etc.103 Accordingly, the 
Suzuki-Miyaura reaction was widely applied in the synthesis of variously substituted 
biphenyls,104 heterobiaryls105 and some other classes of biaryls.106 In case of arenes bearing 
several halogens or related substituents the cross-coupling reactions can be performed chemo- 
and/or regioselectively.107 In this context the group of Langer has significantly contributed in 
the field.108  
Cross-coupling reactions of miscellaneous arylmetallic reagents. Beletskaya and 
coworkers found that diarylmercurials of general structure Ar2Hg, are prone to undergo the 
Pd-catalyzed cross-coupling with various aryl halides producing corresponding 
unsymmetrical biaryls in good yields (Scheme 2.1.16, M = HgAr).109 Noteworthy, the both 
aryl groups can be effectively incorporated into the product; hence, the diarylmercurials can 
be used only in a half equivalent of aryl halide. It should be noted that despite the ecological 
problems connected with the use of diarylmercurials, the latter shows enhanced stability 
towards water, air and numerous functional groups.  
Nilsson and coworkers found that in the presence of Pd-catalysts arylcopper(I) reagents of 
general structure ArCu readily react with aryl halides, producing suitable unsymmetrical 
biaryls in moderate yields (Scheme 2.1.16, M = Cu).109a,110 Although, the reaction itself 
represents rather perspective approach to biaryls; the further developments are rare.  
Another example includes the arylmanganese reagents of general structure ArMnX, which 
exhibit slightly less reactivity compared to corresponding arylzinc reagents (the Negishi 
reaction); hence, they are prone to react with suitable aryl halides selectively, tolerating a 
number of functionalities, giving rise to unsymmetrical biaryls in good yields (Scheme 2.1.16, 
M = MnHal).111  
In addition, the aryltrialkoxytitanium (ArTi(OR)3), diaryldialkoxytitanium reagents 
(Ar2Ti(OR)2),
112 as well as triarylindium reagents (Ar3ln)
113 have been successfully applied 
for the Ar-Ar C-C bond construction in Pd-catalyzed cross-coupling reactions with aryl 
halides (Scheme 2.1.16, M = TiR3, InR2). Similar to the diarylmercurials the 
diaryldialkoxytitanium reagents act as two Ar-group donors. In this respect, the triarylindium 
reagents act as extremely efficient organometallics which are able to transfer all three aryl 
groups. Interestingly, except triarylindium reagents, diarylindium halides (Ar2InHal) and even 
arylindium dihalides (ArInHal2), which tolerates water and numerous functional groups, are 
prone to react with aryl halides, under the standard Pd-catalyzed procedure, producing the 
biaryls in good yields.113 Last but not least, corresponding arylgermanes reagents represent 
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another interesting class of organometallics capable for Pd-catalyzed cross-coupling reactions 
with appropriate aryl halides to produce various biaryls (Scheme 2.1.16, M = GeR3).
114 
Generally, the synthesis of biaryls using the organometallics listed here is under extensive 
investigations which would undoubtedly result in significant developments in the field.  
Summarizing the chapter one should admit that the cross-coupling reactions are one of the 
most important methodologies for the selective synthesis of unsymmetrical biaryls of interest; 
however, several serious disadvantages dramatically limits the applicability of these methods. 
Among others, the most important drawback of the method represents the need for pre-
functionalized starting materials. In particular, common methods to organometallics require 
the use of highly corrosive and unstable reagents (nBuLi etc); on the other hand, most of the 
starting materials themselves are not stable. Additionally, some of them are extremely toxic 
and far from being environmentally friendly. Besides, several side reactions are common for 
all cross-coupling reactions; the most important one is the homocoupling reaction of aryl 
organometallics to symmetrical biaryls. In other words, the diversity of the synthetic methods 
for synthesis of biaryls described in this chapter indicates that none of them is self-sufficient 
for practical organic synthesis.  
 
2.2. The Present State of the Field: Direct C-H Arylation 
 
The construction of new Ar-Ar C-C bond remains one of the most actual tasks of organic 
chemistry for the highly efficient synthesis of new target compounds and structures. In this 
context, as was demonstrated in the previous chapter, the cross-coupling reactions were the 
most useful tool to solve this problem over the past century (Scheme 2.1.16).  
 
 
Scheme 2.2.1. Cross-coupling reactions and direct C-H arylation. 
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However, as it was described, in cross-coupling reactions the starting coupling partners 
should bear either a metal-containing functionality 2.2.1b (nucleophilic component) or a 
halogen atom and related groups 2.2.1a (electrophilic component) (Scheme 2.2.1). In this case 
in fact the preliminary preparation of two independent, expensive, starting materials is 
required. This process, except a number of disadvantages (generating stoichiometric amounts 
of waste materials, the use of unstable and corrosive chemicals etc), is time consuming. On 
the other hand, several alternative approaches to biaryls were well-established (Chapter 2.1); 
however, most of them have limited substrate scope and often are not selective. Alternatively, 
direct arylation of arenes 2.2.1d via "C-H activation" constitutes a much more attractive 
approach, since in this case the preparation of aryl organometallics 2.2.1b can be skipped 
(Scheme 2.2.1).  
C-H bonds are ubiquitous in arenes, although most of them usually are inert and do not 
participate in the chemical reactions. Nevertheless, under special circumstances via "C-H 
activation" it is possible to overcome the inert nature for most of the C-H bonds, thus making 
them readily available for chemical transformations. The term "C-H activation" means 
treating a C-H bond in some way that would allow a reagent to smoothly react with the carbon 
atom of C-H bond.115 Particularly, this process can be accomplished by using various 
complexes of transition metals.  
 
 
Figure 2.2.1. The number of publications on the topic "C-H activation". The data for the bar 
chart was obtained by a SciFinder search in January 2015 using keyword "C-H activation". 
 
The recent unstoppable rush in TM-catalyzed direct C-H functionalizations, in particular C-H 
arylations, undoubtedly will have a significant impact on the further developments of 
synthetic organic chemistry (Figure 2.2.1).116 Furthermore, these reactions certainly will 
revolutionize the chemical industry in the nearest future, since C-H activation allows 
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corresponding functional groups of interest be placed directly in the molecule preventing the 
preliminary functionalizations, a process that previously was not possible in a single step.117 
Besides, the C-H activation is of special value in shortening of multi-step synthesis which is 
commonly used in drug discovery and total synthesis of natural products.117  
Noteworthy, the TM-catalyzed C-H activation is not that easy to attain as it might seem: first 
of all, the "activation" of single C-H bonds in the arene, so that they become active enough for 
chemical attack, is not always achievable. However, if, the "activation" of single C-H bonds 
in the arene is possible, another problem may arise; in particular, usually the distinction 
between reactivity of various C-H bonds in arene is negligible, hence targeting a specific C-H 
bond may be problematic. In this context, currently there are some approaches to overcome 
these problems, which will be discussed in detail.  
Accordingly, various salts and complexes of Au,118 Cu,119 Fe,120 Ni,121 Os,122 Rh,123 Ru,124 
Pd,125 Re,126 rare earth metals127 and others128 proved to be capable to ''activate'' and ''cleave'' 
the C-H bond of interest by different mechanisms; thus, making them readily available for 
further transformations (Scheme 2.2.2). In particular, for TM-induced C-H activation of 
various aromatic substrates five distinct mechanisms were proposed: C-H activation via 
oxidative addition (A), σ-bond metathesis (B), Heck-type addition (C), metalloradicals (D), 
and electrophilic substitution (E).129,118-128  
 
 
Scheme 2.2.2. Possible mechanisms of C-H activation. 
 
The oxidative addition to the C-H bond is typical for electron-rich, low valent ''late'' transition 
metal complexes (Re, Fe, Ru, Os, Rh, Ir, and Pt). In contrast to this, the C-H activation via σ-
bond metathesis is typical for alkyl or hydride complexes of ''early'' transition metals, such as 
transition metals of groups 3-5. The pathway of Heck-type addition was proposed for C-H 
activation of electron rich heterocycles with low valent ''late'' transition metal catalysts. The 
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C-H activation via metalloradicals is common for some porphyrin complexes of ''late'' 
transition metals. Eventually, the C-H activation via electrophilic substitution is typical for 
late- or post-transition metals in high oxidation states, such as Pd(II) and/or Pd(IV), Pt(II) 
and/or Pt(IV), Hg(II), Tl(III) etc. Noteworthy, this mechanism is the most probable 
mechanism for Pd-catalyzed C-H arylation of arenes.130  
A more difficult task remains the chemo- and regioselectivity of C-H activation. This can 
become a real problem if several C-H bonds are capable to activation at the same time, 
resulting in the formation of various mixtures of isomers, or in some cases multi-
functionalized final products. In this respect, there are two different strategies to solve the task 
of selectivity (Scheme 2.2.3).  
 
 
Scheme 2.2.3. TM-catalyzed ''innate'' and ''guided'' C-H activation. 
 
In most of the cases, there is, in principle, a natural distinction in reactivity between C-H 
bonds based on steric or electronic effects of corresponding arene, which in some cases may 
direct the C-H functionalization to specific positions without guidance. The TM-catalyzed 
direct and selective C-H functionalization of arenes, where the selectivity is caused by the 
different distribution of the electron density, is well-known as ''innate'' C-H activation 
(Scheme 2.2.3, A). In this context, Gorelsky131 and others132 have conducted several 
impressive mechanistic studies on the Pd-catalyzed direct arylation and related C-H activation 
reactions of various substrates including substituted benzenes,133 tethered arenes,134 
heteroarenes like pyridine,135 pyridine N-oxide136 etc. Using density functional theory (DFT) 
calculations, activation barriers for Pd-catalyzed cleavage of various aromatic C-H bonds 
were assessed; the representative examples are presented in the Scheme 2.2.4.131 Furthermore, 
the calculated barriers are in good correspondence with the experimental regioselectivity and 
relative reactivities of various arenes in the Pd-catalyzed direct C-H functionalizations; 
including, substituted benzenes,137 benzene fused with heterocycles,138 fused pyridines,139 
oxazoles,140 thiazoles,141 imidazoles,142 triazoles and related heterocycles,143 pyrazoles,144 
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pyrroles and related heterocycles,145 pyridines,146,135 pyridine N-oxides and related 
heterocycles147 and many others.148  
 
 
Scheme 2.2.4. Gibbs free energies of Pd-catalyzed C-H activation (∆G‡298 K, kcal mol-1). 
 
In contrast to ''innate'' C-H activation, it seems clear that TM-catalyzed C-H functionalization 
of the other positions of the same molecules have to be ''guided'' in order to get at least 
moderate levels of selectivity, because usually these positions are not accessible due to 
electronic and/or steric factors (Scheme 2.2.3, B). The ''guided'' C-H functionalization 
together with the ''innate'' C-H activation represents a straightforward approach for selective 
C-H activation of all targeted positions of a given substrate.  
The most extended strategy to achieve a ''guided'' C-H functionalization lies on the use of 
functional groups bearing atoms with free lone pairs of electrons, such as N, O, P, S, or 
others; that is, atoms capable for the coordination, even weakly, to the catalyst (Scheme 
2.2.5). As a result, the substrate 2.2.5a, being a special type of ligand, forms an intermediate 
complex with the catalyst. In this way, once the catalyst is linked by the directing group, only 
certain C-H bonds fall in the vicinity of the catalyst; hence, only selected positions can be 
functionalized 2.2.5b,c.149 In principle, the number of directing groups suitable for the 
coordination of the catalyst to the position of interest is almost unlimited, since the only 
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requirement is to contain a heteroatom with free lone pairs of electrons capable for 
coordination. Accordingly, various functional groups such as pyridine,150 pyrimidine151 and 
related groups,152 pyrazole,153 oxazoline154 and related groups,155 imines,156 amides,157 
anilides158 and related groups,159 carbonyl,160 carboxyl,161 ester162 and related groups,163 
amines,164 alcohols165 and many others166 are well-known to direct the C-H activation.  
Traditional directing groups which usually contain heteroatoms like N, S or P, being a strong 
σ-donors and/or π-acceptors strongly chelate the catalyst, forming thermodynamically stable 
five- or six-membered metallacycles 2.2.5b.149 Accordingly, most of the known directed C-H 
activations fall into this category. The major disadvantage of this approach is that most of the 
directing groups mentioned above are synthetically restrictive, either because they are not the 
permanent part of the target molecule or because of inert nature they cannot be transformed to 
the other useful functional groups.  
 
 
Scheme 2.2.5. Common directing groups (DG) in TM-catalyzed C-H activation. 
 
Another problem is that strongly chelating directing groups commonly form 
thermodynamically stable cyclometalated intermediates 2.2.5b which may be less reactive in 
the subsequent functionalization step. In some special circumstances the cyclometalated 
intermediates 2.2.5b are stable enough to be used as catalyst for some typical cross-coupling 
reactions etc.167 Furthermore, in some special cases the cyclometalated intermediates can be 
subjected to chemical transformations at aromatic ring without destruction.168 This 
phenomenon may dramatically limit the range of useful nucleophiles and electrophiles for 
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directed C-H functionalizations. On the other hand, the C-H activation using weakly 
coordinating directing groups, such as nitro, carbonyl, carboxyl etc, have been far less 
actively studied; nevertheless, with weakly coordinating directing groups, the resulting 
metallacycles being thermodynamically less stable, and not necessarily isolable, may be 
coupled with a wide variety of coupling partners.169  
The transition metals can catalyze a number of C-H functionalizations at aromatic ring 
including C-H alkylation,170 alkynation,171 olefination,172 amination,173 hydroxylation and 
related reactions,174 halogenation175 and fluorination,176 carbonylation177 and carboxylation,178 
borylation179 etc.180 Nevertheless, perhaps the most developed area in the field remains the 
Ar-Ar C-C bond formation via TM-catalyzed direct C-H arylation.181 This involves the use of 
a preactivated aryl substrate as one coupling partner (in most of the cases as electrophilic 
component) and a simple unactivated aryl substrate as the other (nucleophilic component) 
(Scheme 2.2.6, see also Scheme 2.2.1). In this context, the extensive studies in the field 
showed that as coupling partners for direct arylation of aromatic C-H bonds can be used aryl 
halides (including fluoroarenes) (A),181,182 phenols and their derivatives (B),183 
diaryliodonium salts (C),184 organoboron compounds (D),185 aryl carboxylic acids and their 
derivatives (E),186 derivatives of aryl sulfonic acid (F),187 7-oxabenzonorbornadienes (G),188 
diazonium salts (H),189 arylhydrazines,190 Grignard reagents,191 organozinc reagents,192 aryl 
silanes193 and arylstannanes (I)194 (Scheme 2.2.6).  
 
 
Scheme 2.2.6. TM-catalyzed direct C-H arylation. 
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Regarding the reaction conditions of direct C-H arylation, the majority of transition metals of 
groups 8-11 can effectively catalyze the Ar-Ar C-C bond formation via C-H activation;118-
125,181 however, the second-row transition metals in low oxidation states (especially Ru, Rh 
and Pd) have proved to be the best catalysts for this transformation. Generally, depending on 
the nature of coupling partner, Ar-X, may arise a need for using a ligand (Scheme 2.2.6); for 
instance, in case of less reactive aryl chlorides and sulfonates bulky ligands or bidentate 
ligands with big bite angles are used in order to generate more active forms of the catalyst.195 
Although, sometimes the effect of the ligand on the catalyst may be rather complicated.196 
The direct arylation reactions usually require the use of base; in this respect, inorganic bases 
such as K2CO3, Cs2CO3, KOAc, KOPiv, and CsOPiv are frequently used. These carboxylates 
are prone to induce the C-H activation via a concerted base-assisted deprotonation of the 
arene.197,130 Subsequently, for efficient decarboxylation of aryl carboxylic acid coupling 
partners, as base were applied appropriate salts of Ag and Cu (Scheme 2.2.6, E).186 The TM-
catalyzed C-H arylation was successfully performed using polar aprotic solvents such as 
MeCN, DMF, DMA, NMP, DMSO etc; though, nonpolar solvents like toluene, xylene etc 
also were effective. Furthermore, in some cases the C-H arylation can be effectively 
performed in the water.198 Once the coupling partners are aryl organometallics, typically the 
use of oxidants is required in order to perform the reaction applying catalytic amounts of 
corresponding transition metal (Scheme 2.2.6, D, I).185,191-194 In addition, usually the reactions 
require temperatures higher than 100oC; besides, heating from several hours to days may be 
required.  
 
2.3. The Future Perspectives of Direct C-H Arylation 
 
The TM-catalyzed C-H arylation has played a crucial role in development of organic 
synthesis over the past decade (Figure 2.2.1). The results are spectacular, yet the needs of 
''green chemistry'' continually move chemists forward to substitute well established C-H 
arylation methods with more ''greener'' protocols, which may further improve already 
traditional TM-catalyzed C-H activation methodologies. In this context, as an illustrative 
example, one should notice the possibility to perform the C-H arylation in water, which was 
described above.198 Nevertheless, the substrate scope for these reactions is rather limited; 
hence, further improvements are needed.  
On the other hand, in theory, the most direct approach to suitable biaryls is based on oxidative 
construction of the Ar-Ar C-C bond from two C-H bonds with a net loss of two protons. The 
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synthesis of biaryls in the nature is based on this principle (Scheme 2.1). Besides, an attempt 
to prepare symmetrical biaryls by oxidative coupling of electron rich arenes was made 
previously (Scheme 2.1.15); however, the limited substrate scope, reduced selectivity and the 
need for using hazardous oxidants in stoichiometric amounts dramatically limits the 
applicability of the reaction. Nevertheless, compared to traditional methods for the synthesis 
of biaryls, the selective oxidative cross-coupling of two different unfunctionalized arenes may 
dramatically increase the synthetic efficiency of the process, since additional steps for pre-
activation of starting arenes are not required. This approach has been feeding the minds of 
chemists for decades with the aim to develop modern, highly efficient synthetic protocols to 
biaryls. The huge catalytic potential of transition metals makes these approaches more real. 
Compared to classical oxidative coupling of electron rich arenes (Scheme 2.1.15) the TM-
catalyzed dehydrogenative cross-coupling of unfunctionalized arenes can overcome the 
problems of selectivity and reduced substrate scope. Besides, this approach allows the 
synthesis of biaryls using mild and far less toxic oxidants.  
 
 
Scheme 2.3.1. Catalytic dehydrogenative cross-couplings of unfunctionalized arenes. 
 
Historically, the first TM-catalyzed dehydrogenative cross-couplings of unfunctionalized 
arenes were intramolecular processes (Scheme 2.3.1, A).199 In order to switch on the selective 
intermolecular cross-couplings, either the ''innate'' reactivity of arenes200 or proper directing 
groups201 must be used (B). Otherwise, one may face a problem connected with undesired 
homocoupling pathways of the reaction (C).202 The last issue may become a serious problem 
forming disastrous mixtures of homocoupled and heterocoupled products; thereby, 
dramatically decreasing the applicability of the reaction. Even though the examples of 
  
28 
selective intermolecular TM-catalyzed dehydrogenative cross-couplings of unfunctionalized 
arenes are rare, however, the process being environmentally friendly and less time consuming 
undoubtedly will only continue to evolve.  
Another important direction for development of the field may become the design of new 
multipurpose directing groups. As it was mentioned above, in spite of a wide variety of 
directing groups suitable for TM-catalyzed C-H activation, most of them are not a permanent 
part of target molecules and/or are not prone to undergo some further transformations. A 
typical example is the pyridine, the most widely used directing group in the field, which is 
usually no longer needed after the direct C-H activation step. However, the pyridine, being 
rather inert towards chemical transformations, dramatically limits its practical application as 
directing group. Moreover, the needs of ''green chemistry'', which require high levels of atom 
economy and minimum wastes and subproducts, does not tolerate the presence of non-
convertible functional groups. Accordingly, the development of multifunctional directing 
groups is of considerable practical interest.203 A clear example of recent developments in the 
field is the use of oxidizing directing groups (Scheme 2.3.2).203c In this case, the directing 
group along with directing effect is responsible for oxidation of the catalyst; thus, avoiding 
the need for using external hazardous oxidants in stoichiometric amounts, which generate big 
quantities of waste.  
 
 
Scheme 2.3.2. Directing groups with internal oxidant. 
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Accordingly, the recent examples include the use of benzoyl hydroxamate derivatives for the 
synthesis of alkenylated arenes, isoquinolones and related systems (A);204 ketoximes for the 
synthesis of isoquinolines and pyridine derivatives (B);205 oxime esters (C)206 and N-
nitrosoanilines (D)207 for the synthesis of indoles; hydrazones for the synthesis of 
isoquinolines (E);208 quinoline-N-oxides for the synthesis of 2-alkenylated quinolines (F);209 
N-oxides for the synthesis of alkenylated tertiary anilines (G)210 and N-
phenylbenzhydroxamic acid derivatives for the synthesis of alkylated anilides (H).211 
Noteworthy, the oxidizing directing groups were not used in the TM-catalyzed 
dehydrogenative cross-couplings of unfunctionalized arenes (Scheme 2.3.1), however, this is 
only a matter of time.  
Another way to plan an efficient multi-step synthesis includes the use of multifunctional or 
removable directing groups (Scheme 2.3.3).203a,b In this case the basic idea of using 
multifunctional or removable directing groups is that after proper orientation of the reaction, 
the directing group (or part of it) can be easily transformed to another group of interest or 
removed during further steps of the synthesis.  
 
 
Scheme 2.3.3. Multifunctional and removable directing groups. 
 
In this respect, recently several directing groups, such as 2-pyridyl sulfoxide (A),212 2-pyridyl 
ether (B),213 thioether (C),214 pyridyldiisopropylsilyl (D),215 nitrile (E),216 triazene (F),217 
silanol (G),218 carboxylates (H)219 and some other groups203a,b have been developed and 
successfully applied in various TM-catalyzed C-H functionalizations (Scheme 2.3.3).  
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All these transformations can be considered as two-step processes. In the first step 
corresponding directing group orients the proper C-H bond activation. Further, the directing 
group is removed or transformed to another useful functional group via some additional 
operations. In fact, sometimes these two operations can be conducted in one-pot, otherwise, it 
is still possible to perform these transformations using semi-one-pot procedures. The 
development of new, highly efficient, multifunctional directing groups for TM-catalyzed 
direct C-H functionalizations undoubtedly will become one of the important topics of research 
over the next few decades.  
 
3. Why Nitro Group, and Why Nitroarenes? Our Strategy 
 
Basing on the general movements in the field, one can state, that the nitro group due to its 
huge potential as multipurpose directing group may become an interesting alteration to 
classical directing groups for direct C-H arylation. It can behave as a classical directing 
group,220 selecting the position where the metal has to be incorporated and, in addition, the 
tremendous chemical potential of nitro group makes it readily available for further 
functionalizations for the synthesis of multi-functionalized target products.  
Particularly, Ozerov and coworkers during the course of investigations, regarding the 
oxidative addition of some aryl halides containing a para-NO2 group 3.1b to four-coordinate 
pincer complexes of Rh ((PNP)Rh(L)) 3.1a, observed an interesting product of C-H activation 
directed by nitro group 3.1c (Scheme 3.1).220b Analogous C-H activation product 3.1f was 
observed for nitrobenzene 3.1e as well. However, the C-H activation products 3.1c were 
thermodynamically unstable with respect to the isomeric oxidative addition products of aryl 
halide 3.1d, to which they convert upon thermolysis (Scheme 3.1). In this regard, earlier, 
Goldman and coworkers reported the C-H activation of nitrobenzene 3.1e by closely related 
pincer complexes of Ir ((PCP)Ir) 3.1g with apparently quantitative selectivity for the position 
ortho to the nitro group (Scheme 3.1).220a The product of cyclometalation 3.1h was 
characterized by 1H and 31P NMR and X-ray analysis. These findings clearly demonstrate that 
the nitro group can effectively direct the TM-catalyzed C-H activation, in particular C-H 
arylation.  
Nevertheless, the practical use of the nitro group as a regiodirecting substituent in C-H 
activations has scarcely been reported to date.221 Accordingly, in 2008 Fagnou and coworkers 
showed that nitro-substituted benzenes 3.2a exhibit useful reactivity in Pd-catalyzed direct 
arylation which allows to use them in the synthesis of a variety of functionalized biaryls 3.2c 
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(Scheme 3.2).221a  
 
 
Scheme 3.1. Nitro group directed cyclometalation of nitrobenzenes. 
 
Noteworthy, in the study the authors used nitrobenzenes in large excess (as cosolvent). In 
most of the cases the conversion of aryl halides 3.2b was complete leading to the ortho-
arylation products in good yields and regioselectivity (Scheme 3.2). Besides, very recently, 
Sames and coworkers reported a new Pd-catalyzed protocol for selective C-H arylation of 
positions 4 and 5 of pyridines containing common and synthetically versatile electron 
withdrawing substituents such as nitro group, nitrile and halogens.221b  
 
 
Scheme 3.2. C-H arylation of nitrobenzenes. 
 
In spite of this, the authors did not demonstrate the huge chemical potential of nitro group for 
the synthesis of functionalized biaryls (Scheme 3.3). This two-step approach undoubtedly has 
an enormous synthetic capacity.222 For instance, the nitro group can be easily replaced by aryl, 
alkyl, hydroxy, amino, thio groups etc, via aromatic nucleophilic substitution of nitro group 
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(A).223 On the other hand, in similar reaction conditions nucleophilic aromatic substitution of 
hydrogen of nitroarenes may lead to the formation of various valuable polyfunctionalized 
biaryls (B).224,31 Nevertheless, the main chemical transformation of nitro compounds is the 
reduction, enabling the synthesis of various nitrogen compounds, such as amines, imines, 
oximes etc (C, D).225 Besides, it is known that some heteroarenes are prone to undergo a 
Diels-Alder reaction despite their aromaticity. In this context, the strong electron withdrawing 
nitro group dramatically increase the dienophilicity of heteroarenes, thus, making them 
readily available for cycloaddition reactions (E).226 Moreover, transformation of nitro group 
to diazonium salts, using a semi-one-pot procedure, makes them readily available for well-
defined cross-coupling reactions (F),85c,k azo-coupling (J)227 etc (G-I).228  
 
 
Scheme 3.3. The chemical potential of nitro group. 
 
In the current work an attempt was made to investigate the directing ability of nitro group 
within the range of nitro-substituted heteroarenes for the synthesis of functionalized biaryls 
via C-H arylation. The list of heteroarenes, used in the work, is presented on the Scheme 3.4. 
Noteworthy, most of the heteroarenes presented here are of considerable interest, since their 
analogues possess numerous valuable properties which make them important targets for 
synthetic organic chemists. Accordingly, imidazole derivatives 3.4d,e are versatile precursors 
for N-heterocyclic carbenes which represent one of the biggest classes of ligands used in 
homogeneous catalysis;229 besides, they are widely applied in organocatalysis.230 Moreover, 
imidazolium salts can be used as environmentally friendly ionic solvents231 etc.232 Pyrazole 
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derivatives 3.4f are widespread in commercial drugs; in addition, a lot of ligands, used in 
homogeneous catalysis, are based on pyrazole framework.233 Fused pyridines 3.4h-t are an 
important class of purine-like compounds which are of great importance over the last six 
decades as anticancer agents etc (Scheme 3.4).234  
 
 
Scheme 3.4. The scope of the work. 
 
Following the general movements in the field, in order to achieve the desired arylation, a 
number of crucial challenges had to be overcome: 1) first, the reaction conditions should be 
optimized, so that only stoichiometric amounts of coupling partners could be used; 2) next, 
the regioselectivity of the reaction should be thoroughly investigated, since in most of the 
cases we have several directing groups and potentially activatable C-H bonds; 3) in this 
regard interrelation between ''guided'' and ''innate'' C-H arylation reactions should be 
investigated. Subsequently, the following criteria for an ideal directing group for C-H 
arylation should be fulfilled: 1) the group should be capable for directing the catalyst to 
corresponding C-H bonds; 2) the directing group should be sufficiently stable under typical 
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reaction conditions for TM-catalyzed C-H arylation; 3) and finally, it is extremely important 
to demonstrate the utility of nitro group in follow-up chemistry within the range of chosen 
heteroarenes.  
 
4. Direct C-H Arylation of Nitroimidazoles 
 
4.1. Preparation of Starting Nitroimidazoles 
 
Inspired by the tremendous chemical potential of nitro group222-228 in conjunction with the 
ability of nitro group to direct the C-H activation220 and based on recent successful results on 
C-H arylation of different heteroarenes performed in our group,235 we started the present 
study on C-H arylation of nitroimidazoles.236  
In order to prevent the TM-catalyzed arylation of unprotected 1H-imidazoles,237 it was 
decided to alkylate the starting nitroimidazoles by various alkyl groups. Accordingly, the 
starting N-substituted 4-nitroimidazoles 4.1.3a-h were prepared applying simple alkylation of 
commercially available 4(5)-nitroimidazoles 4.1.1a,b with suitable alkyl bromides 4.1.2 as 
illustrated in Table 4.1.1.238  
 
 
4.1.3 R1 R2 Yield (%) 
a Me Ethyl 82 
b Me n-Butyl 88 
c Me (CH2)2Ph 93 
d H (CH2)2Ph 80 
e Me (CH2)3Ph 78 
f Me (CH2)2OPh 89 
g Me CH2-4-Tol 83 
h Me CH2-C6H4-2-Br 83 
Table 4.1.1. Synthesis of starting N-substituted 4-nitroimidazoles. 
 
The alkylation reaction was performed under inert atmosphere in DMF at 90oC using K2CO3 
as base. Noteworthy, the starting nitroimidazoles constitute a mixture of two tautomeric 
structures; however, upon alkylation only 1-alkyl-4-nitroimidazoles 4.1.3 were observed as a 
sole isomer. This observation may be the result of steric and/or electronic effects of nitro 
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group. Applying the simple general procedure, eight distinct examples of N-substituted 4-
nitroimidazoles 4.1.3 were prepared from good to excellent yields (Table 4.1.1). The reaction 
was well reproducible; all products were purified by simple recrystallization.  
Additionally, we were interested in comparison of traditional cross-coupling reactions with 
TM-catalyzed direct C-H arylation of nitroimidazoles. To this end the bromination of 
commercially available nitroimidazole 4.1.1a was performed utilizing a previously developed 
procedure (Scheme 4.1.1).239 The bromination was accomplished in DMF with molecular 
bromine, using NaHCO3 as base. After a standard work-up (dilution with solution of NH4OH, 
filtration) desired 4(5)-bromo-5(4)-nitro-1H-imidazole 4.1.5 was isolated in 83% yield 
(Scheme 4.1.1).  
 
 
Scheme 4.1.1. The synthesis of 5(4)-bromo-4(5)-nitro-1H-imidazole. 
 
Further the 4(5)-bromo-5(4)-nitro-1H-imidazole 4.1.5 was alkylated in order to prepare 
desired starting N-substituted imidazoles. It should be mentioned that unlike alkylation of 
simple 4-nitroimidazoles (Table 4.1.1), the alkylation reaction of 4(5)-bromo-5(4)-nitro-1H-
imidazole 4.1.5 afforded to a mixture of 5-bromo-4-nitroimidazole 4.1.6 and 4-bromo-5-
nitroimidazole 4.1.7, approximately in 2:1 ratio. This phenomenon can be explained by two 
distinct tautomeric forms of starting imidazole. As a result, applying the general procedure for 
alkylation, three pairs of N-substituted nitroimidazoles were prepared in moderate yields (31-
58%) (Table 4.1.2).  
 
 
4.1.6, 4.1.7 R2 Yield of 4.1.6 (%) Yield of 4.1.7 (%) 
a (CH2)2Ph 57 31 
b (CH2)2OPh 58 38 
c (CH2)3Ph 55 40 
Table 4.1.2. Synthesis of N-substituted 5(4)-bromo-4(5)-nitroimidazoles. 
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4.2. C-H Arylation of Nitroimidazoles: Scope and Limitations 
 
With the set of N-substituted 4-nitroimidazoles 4.1.3a-h in hand, on the next stage of the 
work the optimization of reaction conditions for direct C-H arylation of nitroimidazoles was 
explored. For this purpose, in order to avoid further complications, regarding regioselectivity 
of the reaction etc, it was decided to use as a model compound 4-nitroimidazole 4.1.3e. 
Basing on the previous results of our colleagues235 and others,240 the Pd-based catalysts with 
CuI as additive were considered to be the starting point in this study.  
Gratifyingly, pilot experiments have indicated that indeed Pd/CuI catalytic system is rather 
efficient in order to activate C(5)-H bond of 4-nitroimidazole 4.1.3e (Table 4.2.1, entry 1-5), 
in particular the best catalyst for the model compound 4.1.3e turned up PdCl2(PPh3)2, the 
desired product 4.2.1a was isolated in 96% yield (entry 4).  
 
 
Entry Catalyst Ligand Additive 1 Additive 2 Base Solvent oC %a 
1 Pd(OAc)2 Cy3PxHBF4 CuI PivOH K2CO3 DMA 130 78 
2 Pd(OAc)2 - CuI PivOH K2CO3 DMA 130 76 
3 - - CuI PivOH K2CO3 DMA 130 - 
4 PdCl2(PPh3)2 - CuI PivOH K2CO3 DMA 130 96 
5 PdCl2(PPh3)2 - - PivOH K2CO3 DMA 130 71 
6 PdCl2(PPh3)2 - CuCl PivOH K2CO3 DMA 130 83 
7 PdCl2(PPh3)2 - Ag2CO3 PivOH K2CO3 DMA 130 63 
8 PdCl2(PPh3)2 - CuI - K2CO3 DMA 130 25 
9 PdCl2(PPh3)2 - CuI Ph3CCO2H K2CO3 DMA 130 22 
10 PdCl2(PPh3)2 - CuI PivOH K3PO4 DMA 130 46 
11 PdCl2(PPh3)2 - CuI - KOAc DMA 130 80 
12 PdCl2(PPh3)2 - CuI PivOH K2CO3 DMF 130 94 
13 PdCl2(PPh3)2 - CuI PivOH K2CO3 NMP 130 90 
14 PdCl2(PPh3)2 - CuI PivOH K2CO3 dioxane 100 - 
15 PdCl2(PPh3)2 - CuI PivOH K2CO3 toluene 100 15 
16 NiCl2(PPh3)2 - CuI PivOH K2CO3 DMA 130 64 
Table 4.2.1. Optimization of reaction conditions; a isolated yields. 
 
It was found that addition of phosphine ligands, such as Cy3P, Ph3P, as well as bidentate 
ligands like 1,10-phenanthroline, has no real impact on overall yields of the reaction (entry 1, 
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2, 4). Notably the use of copper(I) salt, such as CuI in stoichiometric amount provided desired 
arylation product in almost quantitative yield (entry 4). Though, absence or substoichiometric 
amounts of CuI did not prevent the C-H arylation, namely the desired product 4.2.1a was 
isolated with reduced yield (entry 5).  
Noteworthy, the use of Lewis acids like CuCl or Ag2CO3 still provided the desired C-H 
arylation product, however, with reduced yields (entry 6, 7). This may be the result of low 
solubility and/or side reactions. The best base for the reaction was found to be K2CO3/PivOH 
system; the replacement of pivalic acid (PivOH) by triphenylacetic acid as well as potassium 
carbonate by other salts of potassium decreased the yields of the reaction (entry 8-11). 
Additionally, employment of different solvents and temperatures has shown that the reaction 
runs effectively in DMF, DMA and NMP at 130oC without any notable differences in yields 
(entry 4, 12-15). The rebuff of the reaction in 1,4-dioxane and toluene may be the result of 
reduced solubility of reaction components, solvation effects etc (entry 14, 15). Finally, the 
screening of other transition metal based catalysts experienced a failure. However, perhaps, 
unsurprisingly the reaction catalyzed by NiCl2(PPh3)2 occurred uneventfully leading to the 
formation of desired C-H arylation product; although, the conversion of reactants was not that 
high (Table 4.2.1, entry 16).  
Having the optimized reaction conditions in hand, next, the generality of this protocol towards 
coupling partners was examined (Scheme 4.2.1). Gratifyingly, it was found that direct C-H 
arylation of imidazoles works well for both electron-rich and electron-deficient arenes. 
Notably, a broad number of functionalities, such as F (4.2.1p), Cl (4.2.1h), CF3 
(4.2.1a,e,h,m), OMe (4.2.1d,i,o,r,t), and variety of other functional groups, like acyl (4.2.1s), 
NO2 (4.2.1b), and even aldehyde (4.2.1c,d,g,i,j,l,t) as well as heterocycles (4.2.1f,n,q) were 
perfectly tolerated under the optimal reaction conditions, providing target arylated 
nitroimidazoles from good to quantitative yields.  
The broad functional group tolerance is significant, since most of these functionalities are 
unstable and/or reactive in the presence of TM-catalysts. For instance, fluorine can be 
replaced by other groups via nucleophilic substitution241 or so called ''C-F activation'';242,182 
aryl chlorides can act as coupling partners for C-H arylation;181 the TM-catalyzed 
functionalization of CF3 group is an area of current interest, since the C-F bond represents one 
of the most inert functionalities in organic chemistry;243 the methoxy and acyl groups can be 
arylated via so called TM-catalyzed ''sp3 C-H activation'';244 the nitro group can be easily 
reduced to amino group in the presence of transition metals and a reductant;225 similarly, the 
aldehyde can be oxidized in the presence of transition metal and an oxidant245 etc.  
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Scheme 4.2.1. Scope of the reaction with respect to aryl halides and N-substituted 4-
nitroimidazoles. 
 
Expectedly, the functional group tolerance was equally actual for a wide range of N-
substituted 4-nitroimidazoles with no changes in the reaction conditions. Besides, the usage of 
aryl iodides (4.2.1a,b,e,o) resulted in formation of a great amount of corresponding 
symmetrical biaryls due to the homocoupling of aryl iodides induced by CuI:53 this demanded 
the large excess of the aryl iodides, and the overall yields were visibly lower than with aryl 
bromides. Similarly, in case of reactive aryl bromides (electron-deficient aryl bromides) some 
amount of corresponding symmetrical biaryls was observed (see also Scheme 2.1.13).50-53 
Due to this side process, two equivalents of corresponding aryl bromides were required; 
otherwise, the overall yields of final C-H arylation products were reduced. Together with this, 
aryl chlorides, in general, were not active enough under optimized reaction conditions 
(4.2.1h). Subsequently, the scope and generality of the Ni-catalyzed C-H arylation reaction of 
appropriate 4-nitroimidazoles was examined. It was found that the reaction has general 
character and high functional group tolerance; thus, providing an efficient method for 
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introduction of an aryl group into the imidazole ring in moderate yields (Scheme 4.2.1, 
4.2.1a,b,e,f,g,k,m,n,r).  
Surprisingly, during the course of optimization of the reaction conditions another interesting 
process was discovered. Namely, when CuI was replaced by Ag2CO3 along with C-H 
arylation by aryl bromide (Table 4.2.1, entry 7, 63%), a Pd-catalyzed intramolecular 
dehydrogenative cross-coupling occurred leading to the formation of an interesting fused 
system 4.2.2a in 8% yield (Scheme 4.2.2).66d,171b,199,246 Initially were observed traces of 
cyclisation product 4.2.2a (8%) together with direct C-H arylation product 4.2.1a (63%); 
nevertheless, further examinations have shown that reduction of the amount of aryl bromide 
dramatically increases the yield of intramolecular dehydrogenative cross-coupling reaction. In 
this context, it was shown that in the absence of aryl halide coupling partner presence of an 
oxidant (in this case Ag2CO3) can initiate an intramolecular dehydrogenative cross-coupling 
of 4-nitroimidazoles, leading to different fused systems 4.2.2a-c from good to excellent yields 
(Scheme 4.2.2). These findings will be the basis for further investigations towards direct C-H 
arylation of nitroimidazoles via TM-catalyzed intermolecular dehydrogenative cross-coupling 
reaction.  
 
 
Scheme 4.2.2. Synthesis of fused systems 4.2.2a-c. 
 
Naturally, after the development of an efficient Pd- and Ni-catalyzed method for arylation of 
5-unsubstituted 4-nitroimidazoles, next we were interested in exploration of this procedure 
towards regioselective C-H arylation of 2,5-unsubstituted 4-nitroimidazole 4.1.3d. Analysis of 
the literature shows that the regioselectivity of Pd-catalyzed C-H activation of simple 
imidazole depends on the used catalytic system.142,240a,d,e Accordingly, empirical studies 
indicate that in the presence of Pd-based catalyst, weak base and phosphine ligand the C-5 
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position of imidazole exhibits higher reactivity towards direct C-H arylation, than that at the 
C-2 position. The C-4 position remains relatively less reactive in this respect. Together with 
this, Miura and coworkers demonstrated that the addition of Cu(I) salts alters the bias toward 
the C-2 position.142,240a This reactivity pattern was consistent also with theoretically calculated 
CMD (concerted metalation-deprotonation) barriers for N-methylimidazole.247 However, in 
case of current object of exploration the situation is different due to the nitro group that can 
direct the C-H arylation. Thus, when in the standard reaction conditions the Pd-catalyzed C-H 
arylation of 4-nitroimidazole 4.1.3d was performed using 2.5 equivalents of aryl bromide, 
corresponding 2,5-diarylated imidazoles 4.2.3a-c were observed in good yields (Scheme 
4.2.3). Nevertheless, when the amount of aryl bromide was decreased to 1.1 equivalents, 
remarkably C-5 arylated 4-nitroimidazoles 4.2.4a-c were the only observed regioisomer 
(Scheme 4.2.3). The changes of quantities of aryl bromide affected adversely on the outcome 
of the reaction; namely, in case of increased quantities of aryl bromide a mixture of products 
was observed, otherwise the yield of final product decreased significantly. Additionally, when 
the reaction was performed in the absence of CuI, the yield of the product decreased without 
any changes in regioselectivity (see also Table 4.2.1, entry 4, 5).  
 
 
Scheme 4.2.3. Regioselective C-H arylation of 4-nitroimidazole 4.1.3d; i: PdCl2(PPh3)2 (5 
mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), K2CO3 (2.3 equiv.), DMA, under argon, 130
oC, 
14h; ii: PdCl2(PPh3)2 (5 mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), K2CO3 (1.3 equiv.), 
DMA, under argon, 130oC, 14h. 
  
41 
These observations indicates the ''guiding'' effect of nitro group on C-H arylation of 4-
nitroimidazole 4.1.3d, which dramatically changes the regioselectivity of the reaction, even 
though in the reaction medium stoichiometric amount of CuI was presented. After these 
astonishing findings, further a stepwise synthesis of 2,5-diaryl-4-nitroimidazole with two 
different aryl groups was performed. Thus, starting from compound 4.2.4c under standard 
reaction conditions corresponding 2,5-diarylated imidazole 4.2.5a was successfully prepared 
in 78% yield (Scheme 4.2.3).  
Inspired by the successful results on regioselective C-H arylation of positions 2 and 5 of 4-
nitroimidazoles, next it was proposed that TM-catalyzed C(4)-H arylation of commercially 
available 5-nitroimidazole 4.1.3i can be an excellent extension of scope of the work (Scheme 
4.2.4). For this purpose, a number of conditions were designed and tested; nevertheless, the 
reaction failed. For all cases, in spite of partial conversion of starting 5-nitroimidazole, only 
an inseparable mixture of products was observed. At this point the problem was solved 
applying another suitable procedure towards 4-arylaed 5-nitroimidazoles.  
 
 
Scheme 4.2.4. Unsuccessful trials on C(4)-H arylation of 5-nitroimidazole 4.1.3i. 
 
4.3. Arylation of Nitroimidazoles via Suzuki-Miyaura Cross-Coupling Reaction 
 
Since it was not possible to get any positive result from TM-catalyzed C-H arylation reaction 
of commercially available 5-nitroimidazole 4.1.3i, further it was decided to overcome this 
problem applying well-defined TM-catalyzed cross-coupling reactions. For this purpose the 
Suzuki-Miyaura cross-coupling reaction of 5(4)-bromo-4(5)-nitroimidazoles 4.1.6, 4.1.7 was 
studied. In order to identify a practical and versatile catalytic procedure for efficient arylation 
of nitroimidazoles, numerous reaction parameters were designed and thoroughly examined, 
including transition metal catalyst; base; loading of reactants; solvent and temperature; the 
selected results are listed in Table 4.3.1. According to the new pathway for the test reaction, 
the imidazole 4.1.6a and 2-formylphenylboronic acid were used as model coupling partners 
(Table 4.3.1). As a catalyst for this transformation Pd(PPh3)4 was chosen, since analysis of the 
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literature indicates that the latter is the most successful Pd source for Suzuki-Miyaura cross-
coupling reaction.86-88,102 During the course of optimization of the reaction conditions initially 
the influence of solvent on the outcome of the reaction was examined. Thus, a number of 
solvents were tested such as dioxane, toluene etc. Unfortunately, all primary attempts to 
perform the desired coupling appeared unsuccessful, most probably due to the reduced 
solubility of the reaction components, solvation effects etc (Table 4.3.1, entry 1, 2). Hence, at 
this stage different combinations of solvents were used. Gratifyingly, it was found that when 
the reaction was performed in standard solvents mentioned above, using a drop of water, the 
desired arylation of nitroimidazole occurs in 20% and 27% yields in dioxane/H2O and 
toluene/H2O systems respectively (entry 3, 4).  
 
 
Entry Catalyst ArB(OH)2 Base Solvent %a 
1 Pd(PPh3)4 10 mol% 1.3 equiv. K2CO3 (2 equiv.) dioxane - 
2 Pd(PPh3)4 10 mol% 1.3 equiv. K2CO3 (2 equiv.) toluene - 
3 Pd(PPh3)4 10 mol% 1.3 equiv. K2CO3 (2 equiv.) dioxane/H2O (4:1) 20 
4 Pd(PPh3)4 10 mol% 1.3 equiv. K2CO3 (2 equiv.) toluene/H2O (4:1) 27 
5 Pd(PPh3)4 10 mol% 1.3 equiv. K3PO4 (2 equiv.) toluene/H2O (4:1) 15 
6 Pd(PPh3)4 10 mol% 1.3 equiv. K2CO3 (2 equiv.) toluene/MeOH (5:1) 36 
7 Pd(PPh3)4 10 mol% 1.3 equiv. 2M aq. K2CO3 (1 mL)b toluene/MeOH (5:1) 62 
8 Pd(PPh3)4 10 mol% 1.0 equiv. 2M aq. K2CO3 (1 mL)b toluene/MeOH (5:1) 50 
9 Pd(PPh3)4 10 mol% 2.0 equiv. 2M aq. K2CO3 (1 mL)b toluene/MeOH (5:1) 61 
10 Pd(PPh3)4 5 mol% 1.3 equiv. 2M aq. K2CO3 (1 mL)b toluene/MeOH (5:1) 56 
Table 4.3.1. Optimization of reaction conditions for the synthesis of compound 4.3.1a; a 
isolated yields; b for 1 mmol of starting imidazole. 
 
Meanwhile, the replacement of K2CO3 by K3PO4 decreased the yield of product (Table 4.3.1, 
entry 5), therefore, during further test reactions only K2CO3 was used as a base. In addition, 
once distilled technical MeOH was used instead of water, curiously the yield of the reaction 
increased up to 36% (Table 4.3.1, entry 6). Moreover, via using an aqueous solution of K2CO3 
as a base, the yield of desired arylation product was increased up to 62% (Table 4.3.1, entry 
7). During the next steps of optimization, attempts were made to increase the yields by 
changing the loading of 2-formylphenylboronic acid. Nevertheless, the results were quite 
unsuccessful, 1.3 equivalent of 2-formylphenylboronic acid showed the best efficiency (Table 
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4.3.1, entry 7-9). Similar observations were obtained on loading of catalyst (Table 4.3.1, entry 
10). Finally, it should be mentioned that performing the reaction at slightly high temperatures 
(under reflux) in inert atmosphere was essential in order to get good yields of arylated 
nitroimidazole. Naturally, after development of an efficient Pd-catalyzed Suzuki-Miyaura 
cross-coupling reaction of 5-bromo-4-nitroimidazoles 4.1.6, on the next stage of the work 
under the newly developed conditions an attempt was made to prepare similar arylated 
nitroimidazoles to those that were prepared by TM-catalyzed direct C-H arylation of 
nitroimidazoles (Scheme 4.3.1).  
 
 
Scheme 4.3.1. Scope of the Suzuki-Miyaura reaction; * in the brackets on red are mentioned 
the yields of C-H arylation (see also Scheme 4.2.1). 
 
The comparison of these two procedures as well as replacement of traditional cross-coupling 
reactions by corresponding direct C-H transformations remains an actual task, since cross-
coupling reactions require more synthetic effort and expensive starting materials (Scheme 
2.2.1). In this context, the exploration of substrate scope of the reaction showed that the yields 
of Suzuki-Miyaura cross-coupling reaction of 5-bromo-4-nitroimidazoles 4.1.6 are slightly 
lower in comparison to the yields obtained for similar compounds in direct C-H arylation of 
4-nitroimidazoles. Altogether, using this procedure six examples of arylated nitroimidazoles 
4.3.1a-f were prepared from moderate to good yields (Scheme 4.3.1). The reduced yields may 
be the result of steric factors and/or poor solubility of the reaction components. On the other 
hand, while in TM-catalyzed couplings the comparative reactivity of aryl halides increases 
together with electron-withdrawing ability of substituents on aromatic ring the reactivity of 
aryl boronic acids is contrary to this rule (aryl halides with electron-withdrawing groups are 
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more reactive than aryl halides with electron-donating groups while aryl boronic acids with 
electron-withdrawing groups are less reactive than aryl boronic acids with electron-donating 
groups).86-88 This may be another reason for relatively poor yields.  
Although the C(4)-H bond of 5-nitroimidazoles exhibits very low reactivity in the Pd- and Ni-
catalyzed C-H arylation (Scheme 4.2.4), precluding direct arylation of this position, 
nevertheless, it was possible to overcome this problem applying the Pd-catalyzed Suzuki-
Miyaura cross-coupling reaction of 4-bromo-5-nitroimidazoles 4.1.7. Accordingly, using the 
procedure developed for 5-bromo-4-nitroimidazoles, a number of 4-arylated-5-
nitroimidazoles 4.3.2a-e were prepared with good yields (73-80%) (Scheme 4.3.2).  
 
 
Scheme 4.3.2. Synthesis of 4-arylaed 5-nitroimidazoles via Suzuki-Miyaura reaction. 
 
4.4. Exploration of Further Transformations of Nitro Group 
 
In this part of the work in order to fully demonstrate the synthetic potential of this 
methodology, it was decided to briefly explore the chemical versatility of directing group. For 
this purpose the simple reduction of nitro group was tested first (Scheme 4.4.1). However, at 
this stage of the work an inseparable mixture of products was observed along with an 
intensive polymerization, because of instability of formed 4(5)-aminoimidazoles 4.4.1. 
Noteworthy, 4(5)-aminoimidazoles are rather unstable compounds, although they can be 
prepared in situ for subsequent transformations.448 Unfortunately, the reduction of arylated 
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nitroimidazoles in the presence of an excess of formalin also experienced a failure; in 
particular, instead of N,N-dimethylamines 4.4.2 an inseparable mixture of products was 
obtained. In this regard, the overall instability of 4(5)-aminoimidazoles significantly 
diminished the efficiency of further transformations of directing group. Fortunately, in the 
course of further examinations it was found that the reduction of arylated 4(5)-
nitroimidazoles, which contain an ortho carbonyl group 4.2.1t 4.3.1a,b 4.3.2a,e, leads to the 
formation of imidazo[4,5-c]isoquinoline system as a single product in good yields. In this case 
probably in situ generated reduction product amine undergoes a subsequent intramolecular 
cyclocondensation with carbonyl group which leads to the formation of aromatic isoquinoline 
system. The reaction has general character for arylated nitroimidazoles which contain an 
ortho carbonyl group. Namely, the Pd-catalyzed reduction of suitable nitroimidazoles in 
MeOH under hydrogen atmosphere at ambient temperature leads to the formation of 
corresponding products 4.4.3a-e in 62-74% yields (Scheme 4.4.1).  
 
 
Scheme 4.4.1. Reduction of nitro group; i: MeOH, H2 balloon, Pd/C (10 mol%), 20°C, 5h; ii: 
MeOH, H2 balloon, Pd/C (10 mol%), CH2O in H2O (37%, 6 equiv.), 20°C, 5h. 
 
4.5. Possible Mechanisms of Transformations and Further Experiments 
 
The regioselectivity of direct C-H arylation of 4-nitroimidazoles might be explained by an 
assumption that the catalyst (Pd or Ni) coordinated by the nitro group initiates the C(5)-H 
arylation via concerted metalation-deprotonation (CMD) as illustrated in Scheme 4.5.1 (B). 
This hypothesis is strongly supported by numerous theoretical calculations and practical 
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observations.130,131,133-136,197 In this context, it should be mentioned that the salt of copper via 
double chelation by nitro group and nitrogen of imidazole ring can immobilize the nitro group 
in the plane of imidazole, thus supporting the C-H bond cleavage by Pd or Ni (Scheme 4.5.1, 
A, B). This assumption supports the recent work of Huang and coworkers in which they found 
that the lone pair on the nitrogen atom in benzothiazole, 1-methylbenzimidazole and related 
systems can bind to the copper center thereby initiating Pd-catalyzed C-H bond cleavage.249  
 
 
Scheme 4.5.1. Proposed mechanistic explanation of the regioselectivity. 
 
Based on these considerations we assume that the catalytic cycle starts with oxidative addition 
of aryl bromide to the catalyst Pd(0) delivering Ar-Pd(II)-Br complex (Scheme 4.5.2, A, 
similar considerations are equally true for Ni). Noteworthy, the oxidative addition of aryl 
halide to the catalyst represents the rate determining step for many coupling reactions. In the 
next step the product of oxidative addition undergoes a ligand exchange reaction with 
potassium pivalate (B). It should be noted that the real base of the reaction is KOPiv which is 
formed by the reaction of K2CO3 and PivOH and is far more soluble in DMA (DMF, NMP).  
Subsequently, the Ar-Pd(II)-OPiv species first coordinates to the nitro group of imidazole 
which is followed by a carboxylate-assisted C-H bond cleavage via concerted metalation-
deprotonation (C, D). This process is accompanied by regeneration of PivOH; therefore, the 
PivOH can be used in catalytic amounts (E, F). In the final step of the process the reductive 
elimination of catalyst Pd(0) leads to the formation of desired Ar-Ar C-C bond and 
regeneration of components of catalytic cycle (Scheme 4.5.2, G).  
Accordingly, for Pd-catalyzed C(2)-H arylation of imidazoles we assume that a cooperative 
action of Pd and Cu, chelated by a bidentate ligand (solvent, carboxylate), may enable the 
direct C-H activation (Scheme 4.5.1, C).250 Concerning the low reactivity of C(4)-H bond of 
imidazoles towards Pd-catalyzed C-H activation, several authors described this phenomenon 
by the electronic repulsion between the electron lone pair on the N-(3) of imidazole and the 
C-Pd bond (Scheme 4.5.1, D).251 Eventually, we do not exclude the possibility of formation of 
appropriate cuprates of imidazole200q,202f,252 which can be followed by transmetallation to Pd 
or Ni (Scheme 4.5.1, E, F). In this respect, recently DFT calculations made by Fu and 
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coworkers indicate that the C-H activity of different Ar-H species and both the dissociation of 
the Ar-H bond and the formation of the Ar-Cu bond make important contributions to the 
concerted C-H activation.252g  
 
 
Scheme 4.5.2. Possible mechanism of Pd-catalyzed C(5)-H arylation of 4-nitroimidazoles. 
 
In order to obtain more insights into the reaction mechanism and the directing ability of nitro 
group, the imidazole 4.1.3j was synthesized applying the procedure described in Table 4.1.1. 
Afterwards, the latter was subjected to our standard Pd-catalyzed reaction conditions (Scheme 
4.5.3). Nevertheless, all attempts to perform the C-H arylation in standard conditions, 
developed for 4-nitroimidazoles were unsuccessful; an inseparable mixture of products was 
formed along with some quantities of starting imidazole 4.1.3j. These findings clearly show 
the crucial effect of nitro group on the outcome of the reaction.  
Subsequently, to gain more insight into the reaction pattern, a competitive experiment was 
conducted between imidazole 4.1.3c and two electronically different aryl bromides, namely 
with 1-bromo-3-methoxybenzene and 1-bromo-3-nitrobenzene (Scheme 4.5.4).  
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Scheme 4.5.3. Exploration of directing ability of nitro group. 
 
The aim of the study was the identification of comparable reactivities of electronically 
different aryl bromides in Pd-catalyzed direct C-H arylation of 4-nitroimidazoles. The results 
revealed that under applied conditions the reaction is favoured by electron-deficient aryl 
bromides. In particular, performing the competitive arylation with two different aryl bromides 
(Scheme 4.5.4, A), it was possible to isolate only one product 4.2.1u corresponding to C-H 
arylation by 1-bromo-3-nitrobenzene in 82% yield. This experiment clearly shows that aryl 
bromides with electron-withdrawing groups are much more reactive in Pd-catalyzed C-H 
arylation reactions than the respective aryl bromides with electron-donating groups.  
 
 
Scheme 4.5.4. The competitive experiments between imidazoles and aryl bromides. 
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On the next stage of the study the reaction between various imidazoles (4.1.3c and 4.1.3g) and 
electron-deficient 1-bromo-3-nitrobenzene was explored (Scheme 4.5.4, B). In this case the 
aim of the study was the identification of comparable reactivities of two different N-
substituted imidazoles. Understanding of the impact of steric influence of substituents in the 
position 1 of imidazole ring represents another actual task. Interestingly, during the course of 
the study it was found that there is almost no distinction between two imidazoles; in 
particular, a mixture of both arylated imidazoles with almost similar quantities was observed 
(Scheme 4.5.4, B).  
The possible mechanism of Pd-catalyzed Suzuki-Miyaura cross-coupling reaction of 5-
bromo-4-nitroimidazoles is depicted on the Scheme 4.5.5. The Pd-catalyzed cross-coupling 
reaction of arylboronic acids with aryl halides starts with oxidative addition of aryl halide to 
the catalytically active Pd(0) complex affording Ar-Pd(II)-Br intermediate (Scheme 4.5.5, A). 
In the next step the product of oxidative addition undergoes a ligand exchange reaction with 
potassium carbonate (B). Noteworthy, these two steps are very much similar to the initial 
steps of Pd-catalyzed C-H arylation (Scheme 4.5.2).  
 
 
Scheme 4.5.5. Possible mechanism of Pd-catalyzed Suzuki-Miyaura cross-coupling reaction. 
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The next step of the process represents transmetallation of the Ar-group from the parent 
arylboronic acid to the Ar-Pd(II)-CO3K species giving rise to the Ar2Pd(II) complex (D). As it 
was mentioned in the Chapter 2.1, the C-B bond possesses a strong covalent character; 
however, under special circumstances the arylboronic acids can act as aryl carbanion-donors 
similar to other typical aryl organometallics.  
In particular, the coordination of potassium carbonate to the boron atom is an efficient method 
for increasing the carbanionic nature of aryl group which further can be readily transferred 
from boron to the electrophilic Pd(II) (C, D). The final step of catalytic cycle constitutes the 
reductive elimination of arylated nitroimidazole with regeneration of catalytically active Pd(0) 
complex (E) which is closely related to the final step of Pd-catalyzed C-H arylation of 
nitroimidazoles (Scheme 4.5.2).  
 
4.6. Structure Identification 
 
The structures of synthesized compounds were mainly established by NMR, IR spectroscopy 
and mass spectrometry. Noteworthy, in all arylated nitroimidazoles the aryl groups do not 
possess bulky functional groups near imidazole ring which indicates on free rotation around 
newly formed Ar-Ar C-C bond and absence of atropisomers (at room temperature).1e,f,253  
 
 
Figure 4.6.1. Observations from NMR experiments. 
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In the 1H NMR spectra of starting imidazoles 4.1.3 the singlets of CH bonds of imidazole ring 
appears at 7.17-7.81 ppm (CDCl3) (Figure 4.6.1). In the products of C-H arylation 4.2.1-4.2.4 
the singlet disappears; instead of this the number of aromatic signals increases (Figure 4.6.2). 
The singlet of Me group of imidazole ring appears at 2.08-2.48 ppm (CDCl3) and 2.06-2.45 
ppm (DMSO-d6). Additionally, the typical signals of CH2 groups of N-alkyl substituents 
appear at range 1.7-4.9 ppm. In particular, the triplets of CH2 groups of phenethyl 
functionality were detected at 2.7-2.8 ppm (CH2Ph) and 3.8-4.1 ppm (NCH2) (CDCl3) with a 
coupling constant 3J = 6.4-7.1 Hz (Figure 4.6.1, 4.2.1e-g). The multiplets of CH2 groups of 
phenyl propyl functionality appears at 1.7-1.8 ppm (CH2CH2CH2Ph), 2.4-2.7 ppm 
(CH2CH2CH2Ph) and 3.7-4.0 ppm (CH2CH2CH2Ph) (DMSO-d6) (Figure 4.6.1, 4.2.1a-d). The 
multiplets of phenoxyethyl CH2 groups were seen at 3.9-4.2 ppm (DMSO-d6) (Figure 4.6.1, 
4.2.1h-j). The singlet of Me group of p-methylbenzyl functionality along with the signal of 
benzyl CH2 group appears at 2.2-2.4 ppm and 4.6-5.1 ppm respectively (DMSO-d6) (Figure 
4.6.1, 4.2.1k-s). Finally, the triplets of CH2 groups of phenethyl functionality of C-H arylation 
products 4.2.4 and 4.2.3 were detected at 2.9-3.0 ppm (CH2Ph), 4.0-4.2 ppm (NCH2) and 2.4-
2.5 ppm (CH2Ph), 4.1-4.2 ppm (NCH2) respectively with a coupling constant 
3J = 6.6-6.8 Hz 
(CDCl3) (Figure 4.6.1).  
 
 
Figure 4.6.2. Comparison of 1H NMR spectra of starting imidazole 4.1.3c and corresponding 
C-H arylation product 4.2.1e. 
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Compound Crystal structure Structure 
4.1.3g 
 
 
4.1.6a 
 
 
4.2.1d 
 
 
4.2.1t 
  
4.2.2b 
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Compound Crystal structure Structure 
4.2.4a 
  
4.2.4c 
 
 
4.3.1a 
(4.2.1g) 
  
Table 4.6.1. Crystal structures of compounds 4.1.3g, 4.1.6a, 4.2.1d,t, 4.2.2b, 4.2.4a,c, 4.3.1a. 
 
The singlet of C(5)-H bond of pyridine ring in reduction product imidazo[4,5-c]isoquinolines 
4.4.3 was detected at 8.5-8.9 ppm (CDCl3). Besides, in the 
13C NMR spectra of synthesized 
compounds the Me and CH2 groups as well as typical quartets of CF3 group (
1J = 270-274 Hz, 
DMSO-d6) were observed. In the 
19F NMR spectra the CF3 group appears from -61.0 to -62.9 
ppm (DMSO-d6). Furthermore, in the IR spectra of nitroimidazoles the N-O stretching 
vibrations of NO2 group (medium intensity) were observed at 1506-1574 cm
-1 (asymmetrical) 
and 1328-1358 cm-1 (symmetrical).  
The structures of compounds 4.1.3g, 4.1.6a, 4.2.1d,t, 4.2.2b, 4.2.4a,c and 4.3.1a (4.2.1g) 
were confirmed by X-ray single crystal analyses (Table 4.6.1). Thus, the regioselectivity of 
alkylation of unprotected nitroimidazoles as well as TM-catalyzed direct C-H arylation was 
independently proved by X-ray analysis.  
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5. Direct C-H Arylation of 4-Nitropyrazoles 
 
5.1. Preparation of Starting 4-Nitropyrazoles 
 
Inspired by successful results on TM-catalyzed direct C-H arylation of 4-nitroimidazoles 
(Chapter 4)236 we started the current study on C-H arylation of 4-nitropyrazoles.254 In this case 
as well in order to prevent the TM-catalyzed arylation of unprotected 1H-pyrazoles237 it was 
decided to alkylate the starting commercially available 4-nitro-1H-pyrazole 5.1.1 beforehand 
(Table 5.1.1). Accordingly, the N-substituted 4-nitropyrazoles 5.1.3a-e were prepared 
utilizing the alkylation procedure which was applied for alkylation of nitroimidazoles (Table 
4.1.1, 4.1.2).238 In particular, the alkylation of commercially available 4-nitro-1H-pyrazole 
5.1.1 with suitable alkyl bromides 5.1.2 was performed in DMF using K2CO3 as base; thus, 
five distinct examples of 4-nitropyrazoles were prepared from good to excellent yields.  
 
 
5.1.3 R Yield (%) 
a n-Butyl 84 
b (CH2)2Ph 89 
c (CH2)3Ph 87 
d (CH2)2OPh 93 
e CH2-4-Tol 83 
Table 5.1.1. Synthesis of starting N-substituted 4-nitropyrazoles via alkylation. 
 
 
5.1.3 R Yield (%) 
f Me 81 
g 4-Tol 87 
Table 5.1.2. Synthesis of starting N-substituted 4-nitropyrazoles via cyclocondensation. 
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Alternatively, the target N-substituted 4-nitropyrazoles 5.1.3f,g were synthesized utilizing the 
cyclocondensation reaction of corresponding hydrazines 5.1.5 and enolate of 
nitromalonaldehyde 5.1.4 (Table 5.1.2).255 The reaction was conducted in a pressure tube 
using TMSCl as a water scavenger.256 Thus, two examples of 4-nitropyrazole were prepared 
in good yields (81-87%).  
 
5.2. C-H Arylation of 4-Nitropyrazoles: Scope and Limitations 
 
With the desired starting N-substituted 4-nitropyrazoles 5.1.3a-g in hand, the optimization of 
reaction conditions for direct C-H arylation of 4-nitropyrazoles was studied. To this end, as a 
starting point the reaction of model compound 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g and 4-
bromotoluene was explored. The 4-nitropyrazole 5.1.3g is an interesting substrate, since it has 
several directing groups and potentially activatable C-H bonds. During the optimization of 
reaction conditions a number of parameters were thoroughly examined. Some of 
representative trials are presented in Table 5.2.1.  
Basing on previous results on Ni- and Pd-catalyzed direct C-H arylation of nitroimidazoles236 
and other systems,235 the Pd/Cu catalytic system was considered to be the starting point in this 
study. Accordingly, a number of parameters were changed to optimize the Pd/Cu system 
catalyzed C-H arylation (Table 5.2.1, entries 2-10). Gratifyingly, it was found that the C(5)-H 
arylation product 5.2.1a of model 4-nitropyrazole 5.1.3g represents the only regioisomer 
which forms in the presence of Pd/Cu catalytic system. The best yield of C(5)-H arylation 
product 5.2.1a (83%) was obtained in the presence of 4 equivalents of 4-bromotoluene using 
PdCl2(PPh3)2 (5 mol%) as catalyst with stoichiometric amounts of CuI (1.2 equivalents) 
(Table 5.2.1, entry 5).  
Exploration of other parameters showed that the reaction runs effectively in the presence of 
K2CO3/PivOH system using DMF as solvent at 120
oC (Table 5.2.1, entry 5). The change of 
base (K2CO3) and/or replacement of PivOH by other carboxylic acids decreased the yields of 
C-H arylation. On the other hand, it was found that the reaction can be effectively performed 
in DMA (entry 9, 81%); however, the use of other solvents, such as toluene and dioxane, 
turned to be ineffective (entries 7, 8). In addition, the use of various ligands had no effect on 
overall outcome of the reaction. Perhaps unsurprisingly, these findings are quite similar to the 
observations on 4-nitroimidazoles (Chapter 4.2, Table 4.2.1).  
Noteworthy, the use of salts of copper(I) or silver(I) in stoichiometric amounts was crucial. In 
these cases only one regioisomer was observed, namely the C(5)-H arylation product, 
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otherwise the conversion of pyrazole was reduced together with formation of some undesired 
side products. In particular, in the absence of CuI a product of C-H arylation at both pyrazole 
and phenyl rings 5.2.1' (12%) was observed. Besides, it was possible to isolate another 
unusual product corresponding to the structure 5.2.1'' (30%), as a result of sequential C(5)-H 
arylation of the pyrazole and subsequent cleavage of the N-N bond (Table 5.2.1, entry 1). It is 
worth mentioning that this type of TM-induced N-N bond cleavage was previously observed 
by other authors on related systems.257 This observation will be explored in our ongoing 
research program.  
 
 
Entry Catalyst Ligand Additive 1 Additive 2 Base Solvent oC % of 5.2.1aa 
1 Pd(OAc)2 Cy3PxHBF3 - PivOH K2CO3 DMF 120 mixture 
2 Pd(OAc)2 - Ag2CO3 PivOH K2CO3 DMF 120 30 
3 Pd(OAc)2 - CuI PivOH K2CO3 DMF 120 63 
4 Pd(OAc)2 - CuI PivOH Cs2CO3 DMF 120 60 
5 PdCl2(PPh3)2 - CuI PivOH K2CO3 DMF 120 83 
6 PdCl2(PPh3)2 - CuI Ph3CCO2H K2CO3 DMF 120 66 
7 PdCl2(PPh3)2 - CuI PivOH K2CO3 toluene 100 - 
8 PdCl2(PPh3)2 - CuI PivOH K2CO3 dioxane 90 - 
9 PdCl2(PPh3)2 - CuI PivOH K2CO3 DMA 120 81 
10 PdCl2(PPh3)2 - CuI - K2CO3 DMF 120 5 
11 NiCl2[dppe] - CuI PivOH K2CO3 DMF  120 30 
12 NiCl2[dppp] - CuI PivOH K2CO3 DMF 120 34 
13 NiCl2(PPh3)2 - CuI PivOH K2CO3 DMF 120 45 
14 [Ru(p-cymene)Cl2]2 - CuI PivOH K2CO3 DMF 120 - 
15 [Rh(cod)Cl]2 - CuI PivOH K2CO3 DMF 120 - 
Table 5.2.1. Optimization of reaction conditions; a isolated yields. 
 
Next, the Ni/Cu system catalyzed C-H arylation of 4-nitropyrazole 5.1.3g was explored 
(entries 11-13). In this regard numerous Ni-based catalysts, including Ni with different 
bidentate ligands, were thoroughly examined. Gratifyingly, the reaction catalyzed by 
NiCl2(PPh3)2 (5 mol%) under otherwise identical conditions, provided the desired C(5)-H 
arylation product of 4-nitropyrazole 5.2.1a in 45% yield (Table 5.2.1, entry 13). The other Ni-
based catalysts were less effective; besides, the Ni-based catalysts proved to be inefficient in 
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the absence of CuI and, in general, were less effective than the Pd/Cu catalytic system (entry 
5, 13). In this respect, a number of other transition metal based catalysts, including salts of 
Rh, Ru, Ir, Co, and Fe were studied; however, the results were quite unsatisfactory (entry 14, 
15).  
 
 
Scheme 5.2.1. Scope of C-H arylation of 4-nitropyrazoles. 
 
With the optimal reaction conditions in hand, next, the scope and limitations of the 
methodology towards N-substituted 4-nitropyrazoles and aryl halide coupling partners were 
explored (Scheme 5.2.1). Gratifyingly, in this case as well it was possible to demonstrate that 
the TM-catalyzed direct C(5)-H arylation of various 4-nitropyrazoles works well for a broad 
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range of aryl bromides. Namely, the reaction of pyrazoles 5.1.3a-g with diverse aryl bromides 
afforded corresponding arylated 4-nitropyrazoles 5.2.1a-ä in good yields and excellent 
regioselectivity (Scheme 5.2.1). It is worth mentioning that under optimized conditions any 
other regioisomer and/or TM-induced N-N bond cleavage was not observed.  
Notably, in this case as well a broad number of functional groups, such as F (5.2.1g), CF3 
(5.2.1d,w), CN (5.2.1c), OMe (5.2.1b,e,l,m,t), acyl (5.2.1n), NO2 (5.2.1k,r,x) and aldehyde 
(5.2.1e,q,s,t,ä) as well as various heteroarenes (5.2.1h,i,j,o,u,v,y,z) were perfectly tolerated 
under the optimal reaction conditions. Expectedly, under optimized conditions the functional 
group tolerance turned out to be equally actual for a wide range of N-substituted 4-
nitropyrazoles (Scheme 5.2.1).  
In general, under the applied reaction conditions aryl bromides proved to be the most 
successful coupling partners, while corresponding aryl chlorides were unreactive. In the case 
of aryl iodide coupling partners, an extensive formation of symmetrical biaryls was observed 
via homocoupling of aryl iodides induced by CuI:53 this demanded the large excess of the aryl 
iodides, and the overall yields were visibly lower than with aryl bromides. Similarly, for 
electron-deficient aryl bromides as well, some amount of corresponding symmetrical biaryls 
was observed (see also Chapter 2.1, Scheme 2.1.13).50-53  
Due to this side process, in order to get good yields of target arylated pyrazoles and full 
conversion of the reactant, 4 equivalents of corresponding aryl bromides were required. These 
observations were similar to those observed on nitroimidazoles (Chapter 4.2). In addition, it is 
worth to note that the Pd-catalyzed C-H arylation of 4-nitropyrazoles can be performed on a 
gram scale; for instance, compound 5.2.1n was successfully prepared in 10 gram scale with 
78% yield. It should be noted that unlike N-substituted nitroimidazoles for corresponding 4-
nitropyrazoles the oxidant (Ag2CO3) induced intramolecular dehydrogenative cross-coupling 
reaction did not work (Chapter 4.2, Scheme 4.2.2), even though the reaction was performed in 
the absence of aryl halide coupling partner. In this respect 4-nitropyrazoles appeared to be less 
reactive than corresponding nitroimidazoles.  
Subsequently, the scope and limitations of the Ni-catalyzed C-H arylation reaction of N-
substituted 4-nitropyrazoles was explored. Gratifyingly, for 4-nitropyrazoles as well it was 
found that the reaction has general character and high functional group tolerance, allowing an 
efficient introduction of an aryl group into the pyrazole ring in moderate yields (Scheme 
5.2.1, 5.2.1a,b,c,d,f,g,i,m,z).  
Inspired by the successful results on regioselective C(5)-H arylation of 4-nitropyrazoles, next 
the TM-catalyzed C(3)-H arylation of C(5)-H arylation product 4-nitropyrazoles 5.2.1 was 
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considered as an excellent extension of scope of the work (Scheme 5.2.2). For this purpose a 
number of reaction conditions were designed and thoroughly examined.  
 
 
Scheme 5.2.2. TM-catalyzed direct C(3)-H arylation of 5-aryl-4-nitropyrazoles. 
 
In particular, besides Ni- and Pd-based catalysts a number of other TM-based catalysts were 
examined, including salts of Ag, Fe, Ru, Rh, Ir, Co, and Pt. In addition, an attempt was made 
to switch the regioselectivity by variation of ligands. To this end, the influence of different 
phosphine-based ligands on TM-catalyzed C(3)-H arylation of 4-nitropyrazoles was 
examined. Trials included monodentate phosphine ligands like SPhos, XPhos, PCy3, P(tBu)3, 
(2-biphenyl)di-1-adamantylphosphine, rac-2-(di-tert-butylphosphino)-1,1′-binaphthyl, 
(C6H5O)3P, tris(diethylamino)phosphine, (C6F5)3P, (C6F5)2PhP; as well as bidentate ligands 
including dppm, dppe, dppp, dppf, BINAP, DIOP, XantPhos, DPEPhos, 1,2-
bis(diphenylphosphino)benzene and 1,2-bis(dicyclohexylphosphino)ethane. Nevertheless, for 
all cases in spite of partial conversion of starting 5-aryl-4-nitropyrazoles 5.2.1, only an 
inseparable mixture of products was observed.  
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Being motivated by recent works of Baran and coworkers,149f,258 on the next stage of the study 
numerous trials were made to overcome this problem applying well-defined Minisci 
reaction.259 Therefore, under various conditions the starting 4-nitropyrazoles were treated with 
different aromatic carboxylic acids and boronic acids. However, in this case as well, all 
attempts to perform the desired arylation by Minisci reaction experienced a failure; in most of 
the cases were observed inseparable mixtures of undefined nature.  
Fortunately, after some further examinations it was found that the excess of CuI can initiate 
the desired C(3)-H arylation. Thus, it was possible to demonstrate that the starting N-
substituted 4-nitropyrazoles 5.1.3 can be successfully arylated at both possible positions in 
one step using 6 equivalents of CuI (instead of 1.2 equivalents), which leads to the formation 
of 3,5-diaryl-4-nitropyrazoles 5.2.2a,b in good yields (Scheme 5.2.2).  
Alternatively, the preparation of unsymmetrically arylated pyrazoles 5.2.2c,d was possible 
utilising the reaction of C(5)-H arylation product 4-nitropyrazole 5.2.1k with corresponding 
aryl bromides in the presence of 4 equivalents of CuI. Noteworthy, the synthesis of 
symmetrically arylated pyrazoles can be performed in one-pot; nonetheless, the consecutive 
procedure was more effective (Scheme 5.2.2).  
 
5.3. Exploration of Further Transformations of Nitro Group 
 
After the development of efficient and regioselective Ni- and Pd-catalyzed direct C-H 
arylation methodologies for both feasible positions of 4-nitropyrazoles, next the chemical 
versatility of nitro group was explored. Accordingly, in this part of the work the simple 
reduction of nitro group was tested first (Scheme 5.3.1).  
 
 
Scheme 5.3.1. Reduction of arylated 4-nitropyrazoles. 
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It was found that unlike corresponding arylated nitroimidazoles (Chapter 4.4, Scheme 4.4.1), 
the Pd-catalyzed reduction of arylated 4-nitropyrazoles 5.2.1u,z represents a useful approach 
for the synthesis of arylated 4-aminopyrazoles 5.3.1a,b which are difficult to access by other 
methods.  
The reaction was carried out using Pd/C as catalyst, under hydrogen atmosphere, in distilled 
technical MeOH at ambient temperatures for 5 hours. In case of 4-nitropyrazoles the overall 
outcome of the reaction was well predictable; namely, two examples of arylated 4-
aminopyrazole were isolated in 83% and 88% yields respectively (Scheme 5.3.1).  
Subsequently, when the Pd-catalyzed reduction of arylated 4-nitropyrazoles 5.2.1a,b,c was 
performed in the presence of an excess of formalin (37% solution in the water, stabilized by 
MeOH), the anticipated N,N-dimethylamines 5.3.2a-c were obtained in good yields (Scheme 
5.3.1).  
 
 
Scheme 5.3.2. Preparation of pyrazolo[4,3-c]isoquinolines. 
 
Additionally, in the course of further examinations it was possible to show that the Pd-
catalyzed reduction of C-H arylation products, which bear an ortho carbonyl functional group 
5.2.1e,q,s,t,ä, leads to the formation of pyrazolo[4,3-c]isoquinoline system (Scheme 5.3.2). In 
this case probably in situ generated reduction product amine undergoes a subsequent 
intramolecular cyclocondensation with carbonyl group giving rise to the aromatic 
isoquinoline system. The reaction has general character for arylated 4-nitropyrazoles which 
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contain an ortho carbonyl group at phenyl ring. Namely, the Pd-catalyzed reduction of 
suitable 4-nitropyrazoles in MeOH, under hydrogen atmosphere at ambient temperature leads 
to the formation of corresponding pyrazolo[4,3-c]isoquinolines 5.3.3a-e in 88-94% yields 
(Scheme 5.3.2).  
Noteworthy, the reduction product pyrazolo[4,3-c]isoquinolines 5.3.3 demonstrated 
significant fluorescent properties. As depicted in the Figure 5.3.1, at first were considered the 
solutions of pyrazolo[4,3-c]isoquinolines in chloroform, then the solutions of most fluorescent 
pyrazolo[4,3-c]isoquinoline 5.3.3a in different solvents (2 mg from each pyrazolo[4,3-
c]isoquinoline was dissolved in 1 mL of corresponding solvent). Empirical considerations 
indicated that compound 5.3.3a demonstrates the strongest fluorescent properties in acidic 
solutions which may become an object of further physicochemical investigations (Figure 
5.3.1).  
 
 
Figure 5.3.1. Fluorescent properties of pyrazolo[4,3-c]isoquinolines 5.3.3a,b,d,e. 
 
5.4. Possible Mechanisms of C-H Arylation and Further Experiments 
 
The regioselectivity of Pd-catalyzed direct C(5)-H arylation of 4-nitropyrazoles can be 
explained by an assumption that the catalyst coordinated by the nitro group initiates the C(5)-
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H bond cleavage via concerted metalation-deprotonation (CMD), as illustrated in Scheme 
5.4.1 (A) (similar considerations are equally applicable for Ni). This hypothesis is strongly 
supported by numerous theoretical calculations and practical observations.130,131,133-136,197 
Based on the explanation of the reduced reactivity of C(4)-H bond of imidazoles towards Pd-
catalyzed C-H arylation,251 the low reactivity of C(3)-H bond of 4-nitropyrazoles can be the 
result of electronic repulsion between the electron lone pair on the N-(2) atom of pyrazole and 
the C-Pd bond (Scheme 5.4.1, B). In this regard, intermediate (C) should be more favourable.  
 
 
Scheme 5.4.1. Proposed mechanistic explanation of the regioselectivity. 
 
On the other hand, 1-phenyl-1H-pyrazoles have a tendency to form thermodynamically stable 
five-membered metallacycles via coordination of the catalyst by N-(2) atom of pyrazole and 
subsequent cyclometalation (D).167,168 This path may result in direct C-H functionalization of 
phenyl ring attached to the N-(1) atom of model pyrazole.153 In this regard, we assume that 
the high levels of reactivity of Pd(Ni)/Cu catalytic system towards selective C(5)-H arylation 
could be a result of coordination of the N-(2) atom of pyrazole ring to Cu(I) that would 
prevent the N-bound coordination mode of the pyrazole substrates with Pd or Ni (A, D, E). 
This assumption is supported by the obtained observations during the course of optimization 
of reaction conditions. Namely, in the absence of CuI we observed a product corresponding to 
C-H arylation at both pyrazole and phenyl rings 5.2.1' (Table 5.2.1, entry 1).  
Based on these considerations we assume that the mechanism of the reaction is very much 
similar to the mechanism for C(5)-H arylation of 4-nitroimidazoles (Chapter 4.5, Scheme 
4.5.2). That is to say, the catalytic cycle starts with oxidative addition of aryl bromide to the 
catalyst Pd(0) delivering Ar-Pd(II)-Br complex (Scheme 5.4.2, A, similar considerations are 
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equally true for Ni). In the next step of the process the product of oxidative addition 
undergoes a ligand exchange reaction with potassium pivalate which is more soluble in the 
solvent than K2CO3 (B). Subsequently, the Ar-Pd(II)-OPiv species first coordinates to the 
nitro group of pyrazole which is followed by a carboxylate-assisted C-H bond cleavage via 
concerted metalation-deprotonation (C, D). This process is accompanied by regeneration of 
PivOH and PivOK (E, F). Finally, the reductive elimination of catalyst Pd(0) leads to the 
formation of desired arylated 4-nitropyrazole and regeneration of components of catalytic 
cycle (Scheme 5.4.2, G).  
 
 
Scheme 5.4.2. Possible mechanism of Pd-catalyzed C(5)-H arylation of 4-nitropyrazoles. 
 
Concerning the Pd-catalyzed C(3)-H arylation of 4-nitropyrazoles, we assume that a 
cooperative action of Pd and Cu may enable the direct C-H activation via appropriate cuprate 
of pyrazole (Scheme 5.4.1, F). Noteworthy, Cu(I) salts alone can initiate the direct C-H 
arylation of different heteroarenes;200q,202f,252 nevertheless, in the absence of Pd-catalyst the 5-
aryl-4-nitropyrazoles were fully recovered without any conversion. In this respect, recently 
made DFT calculations by Fu and coworkers, regarding the impact of formation of the Ar-Cu 
species on concerted C-H activation, fully supports the assumption of cooperative action of 
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Pd and Cu.252g Accordingly, the coordination of Cu to the N-(2) atom of pyrazole ring may 
increase the C(3)-H acidity due to the enhanced inductive effects (Scheme 5.4.3, A). This may 
be followed by the base induced cupration of pyrazole ring (B). Further, the pyrazole can be 
transferred from Ar-Cu species to the electrophilic Ar1-Pd(II)-Hal species via transmetallation 
(D, C). The final step of catalytic cycle constitutes the reductive elimination of arylated 4-
nitropyrazole with regeneration of catalytically active Pd(0) complex (E). Noteworthy, the 
final steps of the process are very much similar to the Pd-catalyzed cross-coupling reaction of 
arylcopper(I) reagents with aryl halides developed by Nilsson and coworkers (Chapter 2.1, 
Scheme 2.1.16, M = Cu).109a,110  
 
 
Scheme 5.4.3. Possible mechanism of C(3)-H arylation of 5-aryl-4-nitropyrazoles. 
 
With the aim to obtain more insights into the directing effect of nitro group on TM-catalyzed 
C-H arylation of 4-nitropyrazoles, the model pyrazole 5.1.3h was synthesized applying the 
Cu-induced Ullmann arylation of simple unprotected 1H-pyrazole.237k Subsequently, the 
pyrazole 5.1.3h was subjected to the optimal Pd-catalyzed reaction conditions (Scheme 5.4.4). 
In this respect, perhaps unsurprisingly, an inseparable mixture of products was observed along 
with some quantities of starting pyrazole; all attempts to isolate and characterize any product 
of the reaction were unsuccessful. Noteworthy, the recent works of Doucet and coworkers on 
Pd-catalyzed direct C-H arylation of unfunctionalized N-substituted pyrazoles revealed on 
similar reactivities of C(4)-H and C(5)-H bonds of pyrazoles, whereas the C(3)-H bond 
usually remained intact.140e,144b,d,h These results along with our findings clearly show the 
crucial effect of nitro group on the selectivity and efficiency of the reaction.  
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Scheme 5.4.4. Exploration of directing ability of nitro group. 
 
On the next stage of the work, in order to get more insights into the reaction pattern, under 
optimized reaction conditions, the model 4-nitropyrazole 5.1.3c was treated with two 
electronically different aryl bromides, namely with 1-bromo-3-methoxybenzene and 1-bromo-
3-nitrobenzene (Scheme 5.4.5, A). The aim of the competitive experiment was the 
identification of comparable reactivities of electronically different aryl bromides in Pd-
catalyzed direct C-H arylation of 4-nitropyrazoles.  
 
 
Scheme 5.4.5. The competitive experiments between 4-nitropyrazoles and aryl bromides. 
 
The GC-MS studies of the reaction mixture indicated the preference of electron-deficient aryl 
bromides over aryl bromides with electron-donating groups (Scheme 5.4.5, A). In particular, 
it was possible to detect the product 5.2.1ö corresponding to C-H arylation by 1-bromo-3-
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nitrobenzene in 88% yield (GC-MS yield). In addition, the GC-MS showed only traces of the 
product corresponding to C-H arylation by 1-bromo-3-methoxybenzene 5.2.1ö'.  
The related competitive experiment between various 4-nitropyrazoles (5.1.3c, 5.1.3g) and 
electron-deficient 1-bromo-3-nitrobenzene revealed that the N-(1) substituent of pyrazole ring 
has no influence on the outcome of the reaction (Scheme 5.4.5, B). In particular, a mixture of 
both arylated 4-nitropyrazoles was observed with almost similar quantities (GC-MS studies).  
 
5.5. Structure Identification 
 
The structures of synthesized compounds were mainly established by NMR, IR spectroscopy 
and mass spectrometry. Noteworthy, in all arylated 4-nitropyrazoles the aryl groups do not 
possess bulky functional groups near pyrazole ring which indicates on free rotation around 
newly formed Ar-Ar C-C bond and absence of atropisomers (at room temperature).1e,f,253  
In the 1H NMR spectra of starting N-substituted 4-nitropyrazoles 5.1.3 the singlets of CH 
bonds of pyrazole ring appears at 8.03-8.50 ppm and 8.71-9.56 ppm (DMSO-d6). In the 
products of C-H arylation 5.2.1-5.2.2 at least one of singlets disappear; instead of this, the 
number of aromatic signals increases (Figure 5.5.1, 5.5.2). In all C(5)-H arylation products 
5.2.1a-ä, the C(3)-H bond appears as a singlet at 8.17-8.40 ppm (CDCl3) (Figure 5.5.1).  
 
 
Figure 5.5.1. Observations from NMR experiments. 
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Figure 5.5.2. Comparison of 1H NMR spectra of starting 4-nitropyrazoles 5.1.3f,g and 
corresponding C-H arylation products 5.2.1g, 5.2.2c. 
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The typical signals of CH2 groups of N-alkyl substituents appears at range 0.7-5.3 ppm. In 
particular, the triplets of CH2 groups of phenethyl functionality were detected at 3.0-3.1 ppm 
(CH2Ph) and 4.1-4.2 ppm (NCH2) (DMSO-d6) with a coupling constant 
3J = 6.1-7.0 Hz 
(Figure 5.5.1, 5.2.1w-y). The Me and CH2 groups of n-butyl functionality appear at 0.7 ppm 
(NCH2CH2CH2CH3), 1.0 ppm (NCH2CH2CH2CH3), 1.6 ppm (NCH2CH2CH2CH3) and 3.9 
ppm (NCH2CH2CH2CH3) respectively (DMSO-d6) (Figure 5.5.1, 5.2.1p,q). The multiplets of 
phenoxyethyl CH2 groups were seen at 4.2-4.3 ppm (DMSO-d6) (Figure 5.5.1, 5.2.1z,ä). The 
singlet of Me group of p-methylbenzyl functionality along with the singlet of benzyl CH2 
group appears at 2.2 ppm and 5.2-5.3 ppm respectively (DMSO-d6) (Figure 5.5.1, 5.2.1r-v). 
Accordingly, the singlet of Me group of N-p-tolyl functionality was detected at 2.3 ppm 
(CDCl3); the aromatic protons of N-p-tolyl functionality appear at 7.0-7.2 ppm as doublets 
with a coupling constant 3J = 8.5 Hz (CDCl3) (Figure 5.5.1, 5.2.1a-j). The singlet of Me group 
of N-Me functionality was seen at 3.7-3.8 ppm (DMSO-d6) (Figure 5.5.1, 5.2.1k-o). The 
broad singlet of NH2 group of reduction products 5.3.1 was detected at 2.9-3.1 ppm (CDCl3). 
The singlet of NMe2 group of reduction products 5.3.2 appears at 2.5 ppm (CDCl3). 
Additionally, the singlet of C(5)-H bond of pyridine ring of reduction product pyrazolo[4,3-
c]isoquinolines 5.3.3 was detected at range 8.9-9.1 ppm (DMSO-d6). Besides, in the 
13C NMR 
spectra of synthesized compounds the Me and CH2 groups as well as typical quartets of CF3 
group (1J = 262-272 Hz, CDCl3) were observed. In the 
19F NMR spectra CF3 group appears 
from -62.8 to -62.9 ppm (CDCl3).  
Furthermore, in the IR spectra of arylated 4-nitropyrazoles the N-O stretching vibrations of 
NO2 group (medium intensity) were observed at 1480-1554 cm
-1 (asymmetrical) and 1320-
1358 cm-1 (symmetrical). On the other hand, in the IR spectra of reduction products the 
typical peaks of stretching vibrations of NO2 group disappeared; instead of these, the two N-H 
stretches (2920-3321 cm-1) of amino group along with C-N stretch (1238 cm-1) were 
observed.  
 
Compound Crystal structure Structure 
5.2.1n 
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Compound Crystal structure Structure 
5.2.1v 
 
 
5.2.2c 
  
5.2.1'' 
  
5.3.1c 
  
5.3.2c 
 
 
Table 5.5.1. Crystal structures of compounds 5.2.1n,v, 5.2.1'', 5.2.2c, 5.3.1c and 5.3.2c. 
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The structures of compounds 5.2.1n,v, 5.2.1'', 5.2.2c, 5.3.1c and 5.3.2c were confirmed by X-
ray single crystal analyses (Table 5.5.1). Thus, the regioselectivity of TM-catalyzed direct C-
H arylation was independently proved by X-ray analysis.  
 
6. Direct C-H Arylation of Fused 3-Nitropyridines 
 
6.1. Preparation of Starting Fused 3-Nitropyridines 
 
Inspired by previous results on Pd(Ni)-catalyzed direct C-H arylation of 4-nitroimidazoles 
(Chapter 4)236 and 4-nitropyrazoles (Chapter 5),254 we started the present project on TM-
catalyzed direct C-H arylation in the range of fused 3-nitropyridines (Scheme 6.1.1, 6.1.2),260 
which represent an important class of purine-like compounds.234  
Accordingly, the starting fused 3-nitropyridines 6.1.3a-m were prepared utilizing the reaction 
of suitable electron-excessive aminoheterocycles and anilines 6.1.2 with the enolate of 
nitromalonaldehyde 6.1.1 (Scheme 6.1.1).261 The reaction was performed in DMF under inert 
atmosphere, at 100oC for 12 hours using TMSCl as water scavenger;256 thus, it was possible 
to prepare the desired fused 3-nitropyridines from good to excellent yields.  
 
 
Scheme 6.1.1. Preparation of starting fused 3-nitropyridines. 
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In order to extend the substrate scope and applicability of the work, a number of other nitro-
substituted heteroarenes were designed and synthesized (6.1.5 and 6.1.7) following the 
methodology previously developed by us (Scheme 6.1.2).262 In particular, utilizing the 
reaction of 3-nitrochromone with various binucleophiles, it was possible to prepare a number 
of nitro-substituted heteroarenes in good yields; the examples include fused pyridines, 
pyrazoles and isoxazole. As it was shown previously,262 the reactions can be performed 
applying two distinct acidic procedures as depicted in Scheme 6.1.2.  
 
 
Scheme 6.1.2. Preparation of starting nitro-substituted heteroarenes from 3-nitrochromone. 
 
Noteworthy, these systems are difficult to access by other methodologies due to the electron-
deficient nature of pyridines; thus, the developed procedures are of special value.  
 
6.2. C-H Arylation of Fused 3-Nitropyridines: Scope and Limitations 
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With the set of fused 3-nitropyridines in hand, further, the TM-catalyzed direct C-H arylation 
of these systems was explored. As a model compound pyrazolo[3,4-b]pyridine derivative 
6.1.3a was chosen. This is another interesting substrate, since it has several directing groups 
and potentially activatable C-H bonds. During the optimization of reaction conditions a 
number of parameters were thoroughly examined. Some of representative trials are depicted 
on Table 6.2.1.  
 
 
Entry Catalyst Ligand Additive 1 Additive 2 Base Solvent oC % of 6.2.1aa 
1 Pd(PPh3)4 - - PivOH K2CO3 DMF 130 - 
2 Pd(OAc)2 Cy3PxHBF4 CuI PivOH K2CO3 DMF 130 48 
3 Pd(OAc)2 - CuI PivOH K2CO3 DMF 130 52 
4 Pd(OAc)2 - CuI PivOH Cs2CO3 DMF 130 43 
5 Pd(OAc)2 - CuI - Cs2CO3 DMF 130 12 
6 Pd(OAc)2 - CuI - K2CO3 DMF 130 15 
7 Pd(OAc)2 - CuI Ph3CCO2H K2CO3 DMF 130 40 
8 Pd(OAc)2 - CuI PivOH K3PO4 DMF 130 8 
9 Pd(OAc)2 - CuI - KOtBu DMF 130 - 
10 Pd(OAc)2 - Ag2CO3 PivOH K2CO3 DMF 130 27 
11 Pd(OAc)2 - CuI+Ag2CO3 PivOH K2CO3 DMF 130 - 
12 Pd(OAc)2 - AuCl PivOH K2CO3 DMF 130 - 
13 - - CuI PivOH K2CO3 DMF 130 - 
14 Pd(OAc)2 - CuI PivOH K2CO3 DMA 130 50 
15 Pd(OAc)2 - CuI PivOH K2CO3 toluene 100 - 
16 Pd(OAc)2 - CuI - K2CO3 TFA 100 - 
17 PdCl2(PPh3)2 - CuI PivOH K2CO3 DMF 130 77 
18 NiCl2(PPh3)2 - CuI PivOH K2CO3 DMF 130 43 
19 RuCl3xH2O Cy3PxHBF4 CuI PivOH K2CO3 DMA 160 - 
20 [Ru(p-cymene)Cl2]2 - - or CuI PivOH K2CO3 DMA 160 - 
21 [Rh(cod)Cl]2 - - or CuI PivOH K2CO3 DMA 160 - 
22 [Rh(OAc)2]2 - - or CuI PivOH K2CO3 DMA 160 - 
23 IrCl3xH2O Cy3PxHBF4 - or CuI PivOH K2CO3 DMA 160 - 
Table 6.2.1. Optimization of reaction conditions; a isolated yields. 
 
On the basis of previous results,236,254 the Pd-based catalysts with CuI as an additive were 
considered to be the starting point in this study. Gratifyingly, pilot experiments indicated that 
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indeed the Pd/CuI system is rather efficient for direct γ-C-H arylation of the pyridine ring 
(Table 6.2.1, entries 2-8, 14, 17). In particular, the best catalyst for direct C-H arylation of 
model pyrazolo[3,4-b]pyridine derivative 6.1.3a turned to be PdCl2(PPh3)2; the desired 
product 6.2.1a was isolated in 77% yield as a single regioisomer (entry 17). Further research 
showed that this regioisomer (6.2.1a) is the main product of C-H arylation of pyrazolo[3,4-
b]pyridine derivative 6.1.3a within the range of tested conditions.  
Further experiments showed that the addition of monodentate phosphine ligands as well as 
bidentate ligands such as 1,10-phenanthroline have no real impact on the outcome of the 
reaction (entries 2 and 3). Meanwhile, it should be noted that the use of the salts of coinage 
metals such as CuI and Ag2CO3 in stoichiometric amounts was crucial; in these cases only 
one regioisomer was observed. Otherwise the conversion of starting pyrazolo[3,4-b]pyridine 
derivative 6.1.3a was significantly reduced; in addition traces of 6.2.1'' were detected (Table 
6.2.1). Interestingly, the use of Lewis acids like CuI or Ag2CO3 blocks the formation of this 
regioisomer. However, the mixture of CuI and Ag2CO3 produced an intensive reduction of Ag 
and oxidation of Cu without any conversion of reactants (entry 11). Exploration of other 
parameters showed that the best base for the reaction is the K2CO3/PivOH system; the 
replacement of K2CO3 by other salts of alkali metals and/or replacement of PivOH by other 
carboxylic acids decreased the yields of C-H arylation (entries 4-9). On the other hand, the 
reaction can be effectively performed at 130oC in DMF (entry 17, 77%) and DMA (entry 14, 
50%); however, the use of other solvents such as toluene and TFA turned to be ineffective 
(entries 15, 16). Afterwards, aiming to obtain another regioisomer and/or the same product 
with better yields, a number of other transition metal based catalysts were studied; however, 
the results were quite unsatisfactory (entries 19-23). In this respect, during further 
examinations it was found that among other transition metals the Ni-based catalysts are also 
effective under otherwise identical conditions, providing the desired C-H arylation product 
6.2.1a in 43% yield (entry 18). Nevertheless, in this case as well the conversion of starting 
pyrazolo[3,4-b]pyridine derivative 6.1.3a and overall yield of the reaction was reduced. After 
the optimization of reaction conditions, next the scope and limitations of the reaction with 
respect to the aryl halide coupling partners were examined (Scheme 6.2.1). In this context, the 
results were quite similar to those observed ones for the previous heterocyclic systems 
(Chapters 4 and 5). Namely, pyrazolo[3,4-b]pyridine derivative 6.1.3a readily react with 
electron-rich and electron-deficient aryl bromides, as well as heteroaryl bromides, giving rise 
to the corresponding γ-arylated pyrazolo[3,4-b]pyridines 6.2.1a-o from good to excellent 
yields. Particularly, as for the previous cases in this case as well a number of functional 
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groups including F (6.2.1c), NO2 (6.2.1d), CF3 (6.2.1e), CN (6.2.1f), Ac (6.2.1g), formyl 
(6.2.1i,j) and OMe (6.2.1h,j) were well tolerated under the optimized reaction conditions. At 
the same time, the use of aryl iodides resulted in the formation of a great amount of 
symmetrical biaryls via homocoupling of aryl iodides induced by CuI.53 Together with this, 
under optimized reaction conditions aryl chlorides were not active enough; although, for 
electron-deficient 2-chloropyrimidine it was possible to isolate the corresponding 
heteroarylation product 6.2.1n in 48% yield. Besides, for 5-bromothiophene-2-carboxylic 
acid, the Pd-catalyzed γ-C-H arylation reaction was accompanied by CuI induced 
decarboxylation85d,f,i,186 leading to the arylation product 6.2.1o in 28% yield.  
 
 
Scheme 6.2.1. Scope of the reaction with respect to aryl halides. 
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Notably, the Ni-based catalyst was also active with the range of aryl bromides 
(6.2.1b,e,f,g,k,l) leading to the formation of suitable γ-arylated pyrazolo[3,4-b]pyridine 
derivatives in moderate yields (Scheme 6.2.1).  
Once the scope of the reaction towards aryl halide coupling partners was established, it was 
decided to switched on the examination of the scope of fused 3-nitropyridines. In this regard, 
it was discovered that the reaction has general character. Particularly, under otherwise similar 
conditions numerous fused 3-nitropyridines were successfully coupled with different aryl 
bromides giving rise to the corresponding γ-arylated fused 3-nitropyridines in good yields. 
That is, 1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 6.1.3b, 6-nitro-1H-
imidazo[4,5-b]pyridine-2(3H)-thione derivatives 6.1.3d,e and 6-nitrothiazolo[4,5-b]pyridine 
derivative 6.1.3f react uneventfully with appropriate aryl bromides producing the 
corresponding γ-C-H arylation products 6.2.2a-g in good yields (Scheme 6.2.2). Notably, in 
these cases as well the γ-C-H arylation product was the only observed regioisomer. Besides, 
the reactions can be catalyzed by NiCl2(PPh3)2 (6.2.2a,c); however, with a lower efficiency.  
 
 
Scheme 6.2.2. Scope of the reaction with respect to fused 3-nitropyridines. 
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From the target fused 3-nitropyridines, pyrrolo[2,3-b]pyridine derivative 6.1.3h stands out 
because of two potentially activatable C-H bonds and directing groups. In fact indoles and 
derivatives are one of the most extensively studied and reactive systems towards TM-
catalyzed C-H activation.170b,181g Besides, the nitrile group is known to direct the TM-
catalyzed C-H activation reactions.221b,263 Thus, in the process of Pd-catalyzed C-H arylation 
of pyrrolo[2,3-b]pyridine derivative 6.1.3h, perhaps unsurprisingly, the C-H arylation 
occurred simultaneously at both pyridine and pyrrole rings (Scheme 6.2.3).  
 
 
Scheme 6.2.3. Scope of the reaction with respect to pyrrolo[2,3-b]pyridine derivative 6.1.3h. 
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As a result two regioisomers were isolated, corresponding to the C(2)-H and C(4)-H arylation 
products 6.2.3a-h (Scheme 6.2.3). Further exploration of the reaction showed that both C(2)-
H and C(4)-H bonds of pyrrolo[2,3-b]pyridine 6.1.3h are approximately equally active 
towards Pd-catalyzed C-H arylation. Particularly, the use of only 1 equivalent of aryl bromide 
led to a mixture of regioisomers without full conversion of the reactant 6.1.3h. Moreover, the 
reduction of quantities of aryl bromide coupling partner as well as further modifications of the 
reaction conditions did not affect on the regioselectivity of the reaction, or even in some 
cases, vice versa, the conversion of starting pyrrolo[2,3-b]pyridine 6.1.3h decreased 
significantly. After some examinations it was found that quite applicable yields for both 
regioisomers can be achieved using similar conditions to those used ones for other fused 3-
nitropyridines. Additionally, in order to avoid the double arylation and/or disastrous mixtures 
of products, no more than 2 equivalents of aryl bromide should be used.  
On the next stage of the work an attempt was made to arylate α-position of fused 3-
nitropyridines (see also Table 6.2.1, 6.2.1'). Nevertheless, despite numerous efforts on 
development of a practical approach to α-C-H arylated fused 3-nitropyridines, all trials were 
unsuccessful. Although, a number of procedures were thoroughly examined, in most cases we 
obtained complex mixtures of undefined nature and/or poor conversion of reactants. Thereby, 
to overcome this problem and further extend the substrate scope of the work, it was decided to 
examine previously synthesized fused 3-nitropyridines 6.1.5 (Scheme 6.1.2), which already 
possess an aryl substituent at the α-position of pyridine core.  
Noteworthy, the synthesized fused 3-nitropyridines 6.1.5 bear a hydroxy group which 
potentially can be subjected to a TM-catalyzed C-O cross-coupling reaction;47,264 
nevertheless, the reaction of the model fused 3-nitropyridine 6.1.5a and 4-bromotoluene under 
standard conditions for C-H activation gave an unexpected result (Scheme 6.2.4). In spite of a 
complex mixture of products, it was possible to isolate a pure compound, which proved to be 
the structure 6.2.5b. Further exploration of the reaction parameters showed that the reaction 
consists a two-step domino process:265 initially occurs an intramolecular aromatic 
nucleophilic substitution of nitro group by hydroxy group which is followed by Pd-catalyzed 
C-H arylation (Scheme 6.2.4). This assumption was verified by isolation and characterization 
of intermediate 6.2.4; further treatment of intermediate 6.2.4 with aryl bromide and other 
reaction components resulted in the final arylation products 6.2.5 in good yields. It was 
discovered that the initial step of the domino reaction can occur in the absence of catalyst. 
Moreover, we excluded reaction components successively to find that CuI and PivOH do not 
play decisive roles in this transformation and just base (K2CO3) can initiate the cyclisation.  
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Scheme 6.2.4. The domino nitro group substitution-C-H arylation reaction; i: ArBr (4 equiv.), 
PdCl2(PPh3)2 (5 mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), K2CO3 (2.3 equiv.), DMF, under 
argon, 130oC, 16h; ii: K2CO3 (1.3 equiv.), DMF, under argon, 130
oC, 16h; iii: ArBr (4 equiv.), 
PdCl2(PPh3)2 (5 mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), K2CO3 (1.3 equiv.), DMF, under 
argon, 130oC, 16h. 
 
Inspired by these findings, next, the intramolecular nucleophilic substitution of nitro group 
was performed in a wide range of substrates; in most cases the reaction went uneventful 
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leading to corresponding furo[3,2-b]pyridine derivatives 6.2.4a-f from good to excellent 
yields. The only systems which were unreactive and/or unstable under basic conditions were 
pyrazoles 5.1.7a,b and isoxazole 5.1.7c (Scheme 6.2.4). With the set of fused furo[3,2-
b]pyridine derivatives 6.2.4a-f in hand, the C-H arylation at the pyridine ring was examined. 
In general it was possible to demonstrate that arylated fused furo[3,2-b]pyridines 6.2.5 can be 
prepared either in one-pot or consecutively. Interestingly, the Pd-catalyzed C-H arylation of 
starting fused 3-nitropyridines 6.1.5 as well as fused furo[3,2-b]pyridines 6.2.4 can occur 
effectively under the standard conditions which were found to be optimal for previous 
systems (6.1.3). Thus, applying elaborated one-pot and consecutive procedures, a number of 
arylated fused furo[3,2-b]pyridines 6.2.5a-d were prepared in good yields. Not surprisingly, 
the consecutive synthesis of arylated fused furo[3,2-b]pyridines was more effective (Scheme 
6.2.4).  
 
6.3. Exploration of Further Transformations of Nitro Group 
 
On the next stage of the work, in order to fully demonstrate the synthetic capacity of this 
methodology, the chemical versatility of the directing group was explored. For this purpose, 
initially the simple reduction of nitro group was examined (Scheme 6.3.1). Thus, it was 
possible to show that the Pd-catalyzed reduction of the γ-C-H arylation products of fused 3-
nitropyridines (6.2.1, 6.2.2) represents a useful approach for the synthesis of arylated fused 3-
aminopyridines 6.3.1a-c which are difficult to access by other methods. The reaction was 
conducted in distilled technical MeOH under normal pressure of H2 using Pd/C (10 mol%) as 
catalyst at ambient temperatures; accordingly, the corresponding 3-aminopyridines were 
isolated in 75-84% yields (Scheme 6.3.1).  
Besides, it was discovered that the Pd-catalyzed reduction of nitro group in the presence of an 
excess of formaldehyde affords corresponding fused N,N-dimethylaminopyridine 6.3.2a in 
58% yield. Additionally, the Pd-catalyzed reduction of C-H arylation product 6.2.1i which 
bear a carbonyl functional group led to the formation of isoquinoline system 6.3.3a in 65% 
yield (Scheme 6.3.1). Remarkably, when the reduction of C-H arylation product 6.2.1a was 
performed using stoichiometric amounts of formalin (1.5 equivalents), the reduction was 
followed by isoquinoline ring formation to give 6.3.3a in 46% yield (Scheme 6.3.1). The new 
pathway of the reaction can be explained by an assumption that the reduction of nitro group in 
the presence of stoichiometric amounts of formalin generates an imine which further 
undergoes a Pd-catalyzed intramolecular hydroarylation followed by aromatisation to form 
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the isoquinoline core. To the best of our knowledge, similar transformations were not 
observed previously. However, related TM-catalyzed intermolecular hydroarylation of imines 
is a rapidly growing area in the field of C-H activation.150p,s,178b,266 Detailed exploration of 
possible mechanism and further applications of the reaction is underway in our group.  
Furthermore, it was possible to transfer the nitro group to bromo substituent (85%) using a 
semi-one-pot procedure on the basis of modified Sandmeyer halogenation (Scheme 6.3.2).267 
The synthesis of brominated fused pyridine 6.3.4 allowed us to perform some other well-
known TM-catalyzed C-C bond forming reactions.261 Namely, the pyrazolo[3,4-b]pyridine 
system was incorporateed with arenes, alkynes and olefins using Suzuki-Miyaura,86-88 
Sonogashira268 and Mizoroki-Heck269 cross-coupling reactions respectively.  
 
 
Scheme 6.3.1. Reduction of nitro group; * in the brackets on red is the yield of reduction of 
compound 6.2.1i. 
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Firstly, the Suzuki-Miyaura reaction was considered as an efficient approach for incorporation 
of various arenes in the β-position of the model pyrazolo[3,4-b]pyridine. Thus, it was found 
that brominated pyrazolo[3,4-b]pyridine 6.3.4 readily undergo the Pd-catalyzed arylation with 
the set of diverse boronic acids giving rise to corresponding β-arylated pyrazolo[3,4-
b]pyridines 6.3.5a-f in 87-95% yields (Scheme 6.3.2).  
 
 
Scheme 6.3.2. Further transformations of nitro group through cross-coupling reactions; i: Ar-
B(OH)2 (1.5 equiv.), PdCl2(PPh3)2 (2 mol%), K2CO3 (2 equiv.), 1,4-dioxane, under argon, 
90oC, 8h; ii: Acetylene (2 equiv.), PdCl2(PPh3)2 (2 mol%), CuI (5 mol%), TEA (1.3 equiv.), 
DMF, under argon, 120oC, 8h; iii: Alkene (3 equiv.), PdCl2(PPh3)2 (4 mol%), TEA (4 equiv.), 
DMF, under argon, 140oC, 14h. 
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Meanwhile, all attempts to shorten the synthetic pathway to β-arylated fused pyridines by 
usage of appropriate diazonium salt,85c,k instead of aryl bromide, were unsuccessful. 
Although, it was possible to perform the Pd-catalyzed couplings with corresponding 
diazonium salt, the yields never exceeded 30% due to numerous side processes. Concerning 
the Sonogashira cross-coupling, it was discovered that the brominated pyrazolo[3,4-
b]pyridine 6.3.4 can be readily coupled with a commercially available acetylene under the 
standard conditions for Sonogashira reaction.268 Namely, conducting the reaction in DMF at 
120oC, using PdCl2(PPh3)2/CuI catalytic system and TEA as base, suitable pyrazolo[3,4-
b]pyridine derivative 6.3.6a was obtained in 85% yield (Scheme 6.3.2). Eventually, the 
olefination of model pyrazolo[3,4-b]pyridine 6.3.4 was performed utilising the Pd-catalyzed 
reaction with appropriate olefins in DMF at 140oC applying TEA as base. In this way, three 
examples of alkenylated pyrazolo[3,4-b]pyridines 6.3.7a-c were prepared in 65-71% yields.  
 
6.4. Possible Mechanisms of C-H Arylation and Further Experiments 
 
The regioselectivity of the reaction might be explained by the assumption that the free 
electron pair of the N atom of pyridine shields the α-position which manifests by the 
electronic repulsion between the electron lone pair of the N atom and the C-Pd bond (Scheme 
6.4.1, A).221b Thus, intermediate (B) should be more favourable. On the other hand, pyridine 
and derivatives have a tendency to form a non-productive N-bound coordination mode with 
metal centres; thus, poisoning the catalyst (structure C or D in Scheme 6.4.1, similar 
considerations are equally applicable for Ni).167,168 In this respect, the protection of the N 
atom by conversion to N-oxides136,147c,g,200d,j and N-iminopyridinium ylides147a,b,h has allowed 
the development of several TM-catalyzed C(2)-H transformations of pyridines.  
 
 
Scheme 6.4.1. Proposed mechanistic explanation of the regioselectivity. 
 
On this basis, supposedly the high levels of reactivity of the Pd(Ni)/CuI catalytic system could 
be a result of the strong coordination of the N atom of the pyridine ring to Cu(I) that would 
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prevent the N-bound coordination mode of the pyridine substrates with Pd or Ni (C, D). 
Noteworthy, very recently two research groups found that the coordination of a strong and 
bulky Al-based Lewis acid with the N atom of pyridine ring not only activates the pyridine 
ring but also favours C(4)-H functionalization.146h,i Hence, under these circumstances, we 
suppose that the carboxylate assisted γ-C-H bond cleavage of fused 3-nitropyridines could 
take place, if the appropriate orientation between the nitro group of the pyridine and Pd (Ni) is 
assembled (structure E, Scheme 6.4.1).  
 
 
Scheme 6.4.2. Possible mechanism of Pd-catalyzed γ-C-H arylation of fused 3-nitropyridines. 
 
Based on these considerations, we assume that the mechanism of the reaction is very much 
similar to the mechanisms presented in Chapters 4.5 and 5.4 (Schemes 4.5.2 and 5.4.2). Thus, 
the catalytic cycle starts with oxidative addition of aryl bromide to the catalyst Pd(0) 
delivering Ar-Pd(II)-Br complex (Scheme 6.4.2, A, similar considerations are equally true for 
Ni). Subsequently, the product of oxidative addition undergoes a ligand exchange reaction 
with potassium pivalate which is more soluble in the solvent (DMF) than K2CO3 (B). On the 
next stage of the process the Ar-Pd(II)-OPiv species first coordinates to the nitro group of 
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fused 3-nitropyridine which is followed by γ-C-H bond cleavage via carboxylate assisted 
concerted metalation-deprotonation (C, D). This process is followed by regeneration of 
PivOH and PivOK (E, F). Eventually, the reductive elimination of catalyst leads to the 
formation of desired γ-arylated fused 3-nitropyridine and regeneration of components of 
catalytic cycle (Scheme 6.4.2, G).  
Aiming to shed light on the directing effect of nitro group and to obtain additional insights 
into the reaction mechanism, the substrates 6.4.3a-c,270 6.3.3a and 6.3.4a261 were subjected to 
the standard TM-catalyzed reaction conditions (Scheme 6.4.3). However, to our astonishment, 
the initial testings with model pyrazolo[3,4-b]pyridines, bearing a polar CN270a 6.4.3a or 
CO2Et
270b 6.4.3b substituents instead of nitro group, experienced a failure; substrates 6.4.3a 
and 6.4.3b were recovered completely. The same reactivity pattern was observed for 
unsubstituted pyrazolo[3,4-b]pyridine 6.4.3c.270c Additionally, pyrazolo[3,4-b]pyridines 
bearing a non-coordinating p-tolyl 6.3.3a and CC-Ar 6.3.4a substituents under otherwise 
identical conditions did not cause the γ-C-H arylation. In particular, pyrazolo[3,4-b]pyridine 
6.3.3a was fully recovered; though, for pyrazolo[3,4-b]pyridine 6.3.4a we observed some 
conversion resulting in the formation of a mixture of undefined nature, which might be the 
result of degradation due to the reactivity of the triple bond under TM-catalyzed conditions.  
 
 
Scheme 6.4.3. Exploration of directing ability of nitro group; i: ArBr (4 equiv.), PdCl2(PPh3)2 
(5 mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), K2CO3 (1.3 equiv.), DMF, under argon, 
130oC, 16h; ii: ArBr (4 equiv.), NiCl2(PPh3)2 (5 mol%), CuI (1.2 equiv.), PivOH (0.3 equiv.), 
K2CO3 (1.3 equiv.), DMF, under argon, 130
oC, 16h. 
 
Noteworthy, in previous reports on imidazo[4,5-b]pyridines and related heteroannulated 
pyridines, our colleagues235 and others139a,b,h,144f demonstrated that as a rule the pyridine ring 
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remains intact under typical C-H activation protocols if the nitro group is replaced by H or 
electron-withdrawing CF3 group.  
 
 
 
Scheme 6.4.4. The competitive experiments between nitro-substituted heteroarenes. 
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In addition, Yu and coworkers found that the Pd-catalyzed ''innate'' C-H arylation of 
unprotected simple pyridines leads to a mixture of isomers (C3/C4/C2) with predominant 
C(3)-H selectivity.135 Notably, in the work starting pyridines were used as solvent, otherwise 
the yields of arylation were significantly reduced which indicates the importance of directing 
groups on efficient C-H arylation of pyridine and derivatives.  
Eventually, we conducted several competitive experiments between various nitro-substituted 
arenes used in the work (Scheme 6.4.4, A-D). The aim of the study was the identification of 
comparable reactivities of nitroarenes in Pd-catalyzed direct C-H arylation. Accordingly, the 
Pd-catalyzed competitive C-H arylation of two distinct fused 3-nitropyridines was explored 
(Scheme 6.4.4, A). The GC-MS studies of the reaction mixture indicated on the preference of 
pyrido[2,3-d]pyrimidine derivative 6.1.3b over pyrazolo[3,4-b]pyridine derivative 6.1.3a. In 
particular, a mixture of both arylated fused 3-nitropyridines was observed in 6.2.1d : 6.2.2h = 
1 : 2 ratio (GC-MS studies). The related competitive experiment between pyrazolo[3,4-
b]pyridine derivative 6.1.3a and 4-nitropyrazole 5.1.3c revealed that 4-nitropyrazoles are far 
more reactive towards Pd-catalyzed C-H arylation than fused 3-nitropyridines (Scheme 6.4.4, 
B). Thus, we observed the arylated 4-nitropyrazole 5.2.1ö in 76% yield and only traces of 
arylated fused 3-nitropyridine 6.2.1d (GC-MS studies). Similarly, the competitive experiment 
between pyrazolo[3,4-b]pyridine derivative 6.1.3a and 4-nitroimidazole 4.1.3f revealed that 
4-nitroimidazoles are also more reactive than fused 3-nitropyridines (Scheme 6.4.4, C). 
Finally, the competitive experiment between 4-nitropyrazole 5.1.3c and 4-nitroimidazole 
4.1.3f gave a mixture of corresponding arylation products in 71% and 15% yields respectively 
(Scheme 6.4.4, D, GC-MS yields). Hence, from studied nitroarenes 4-nitropyrazoles are the 
most reactive heterocyclic systems towards Pd-catalyzed direct C-H arylation.  
 
6.5. Structure Identification 
 
The structures of synthesized compounds were mainly established by NMR, IR spectroscopy 
and mass spectrometry. Noteworthy, in all arylated fused 3-nitropyridines the aryl groups do 
not possess bulky functional groups near pyridine ring which indicates on free rotation around 
newly formed Ar-Ar C-C bond and absence of atropisomers (at room temperature).1e,f,253  
In the 1H NMR spectra of starting fused 3-nitropyridines 6.1.3 the γ- and α-CH bonds of 
pyridine ring appears at 7.62-8.90 ppm and 8.86-9.43 ppm (DMSO-d6) as doublets with 
coupling constant 4J = 2.1-2.5 Hz (Figure 6.5.1). In the products of C-H arylation 6.2.1-6.2.3 
the doublet corresponding to the γ-CH bond disappear, the doublet corresponding to the α-CH 
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bond turns to a singlet (9.25-9.42 ppm, DMSO-d6); in addition, the number of aromatic 
signals increases (Figure 6.5.1, 6.5.2).  
 
 
Figure 6.5.1. Observations from NMR experiments. 
 
Accordingly, the singlet of α-CH bond of arylated pyrazolo[3,4-b]pyridines 6.2.1a-o appears 
at range 9.27-9.42 ppm (DMSO-d6); the singlet of 3-Me group of arylated pyrazolo[3,4-
b]pyridines was seen at 1.73-2.09 ppm (DMSO-d6) (Figure 6.5.1). Similarly, for arylated 
pyrido[2,3-d]pyrimidines 6.2.2a-d the singlets of α-CH bond and NMe groups were seen at 
9.25-9.37 ppm, 3.64-3.68 ppm and 3.15-3.16 ppm respectively (DMSO-d6) (Figure 6.5.1). 
The typical singlets of α-CH bonds of arylated imidazo[4,5-b]pyridines 6.2.2e,f and 
thiazolo[4,5-b]pyridine derivative 6.2.2g appear at 8.58-8.86 ppm (CDCl3) and 9.06 ppm 
(DMSO-d6) respectively. Additionally, the singlets of NMe group of arylated imidazo[4,5-
b]pyridines 6.2.2e,f and NMe2 group of thiazolo[4,5-b]pyridine derivative 6.2.2g were 
detected at 2.82-2.89 ppm (CDCl3) and 3.21 ppm (DMSO-d6) respectively (Figure 6.5.1). In 
C(2)-H arylated pyrrolo[2,3-b]pyridines 6.2.3b,e,g,h the γ- and α-CH bonds of pyridine core 
appear as doublets at range 8.84-8.87 ppm and 9.33-9.36 ppm with a coupling constant 4J = 
2.4-2.6 Hz (CDCl3). On the other hand, in C(4)-H arylated pyrrolo[2,3-b]pyridines 
6.2.3a,c,d,f the CH bonds of pyrrole and pyridine rings appear as singlets at range 8.02-8.80 
ppm and 9.11-9.23 ppm respectively (CDCl3). The tert-butyl group of arylated pyrrolo[2,3-
b]pyridines 6.2.3 appears as a singlet at range 1.70-1.87 ppm (CDCl3) (Figure 6.5.1).  
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Figure 6.5.2. Comparison of 1H NMR spectra of starting fused 3-nitropyridines 6.1.3a,b and 
corresponding C-H arylation products 6.2.1a, 6.2.2c. 
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The singlet of γ-CH bond of pyridine core in furo[3,2-b]pyridine derivatives 6.2.4a-f was seen 
at 7.98-8.78 ppm (DMSO-d6); in corresponding C-H arylation products 6.2.5a-d the singlet 
disappeared. The broad singlet of NH2 group of reduction products 6.3.1a-c was detected at 
4.20-4.31 ppm (CDCl3).  
Besides, in the 13C NMR spectra of pyrido[2,3-d]pyrimidines 6.2.2a-d and imidazo[4,5-
b]pyridines 6.2.2e,f the carbonyl groups and thione (C=S) were detected at 152.9-153.4 ppm, 
158.9-159.5 ppm (DMSO-d6) and 147.8 ppm (CDCl3) respectively. In addition, the typical 
quartets of CF3 group were observed (
1J = 240-274 Hz, DMSO-d6). In the 
19F NMR spectra 
CF3 group appears from -60.9 to -62.8 ppm (DMSO-d6).  
Furthermore, in the IR spectra of arylated fused 3-nitropyridines 6.2.1-6.2.3 the N-O 
stretching vibrations of NO2 group (medium intensity) were observed at 1430-1590 cm
-1 
(asymmetrical) and 1290-1358 cm-1 (symmetrical). On the other hand, in the IR spectra of 
reduction products 6.3.1 the typical peaks of stretching vibrations of NO2 group disappeared; 
instead of these the two N-H stretches (3330-3442 cm-1) of amino group along with C-N 
stretch (1280-1290 cm-1) were observed. In addition, in the IR spectra of pyrrolo[2,3-
b]pyridines 6.2.3 and pyrido[2,3-d]pyrimidines 6.2.2a-d the typical peaks of stretching 
vibrations of CN and carbonyl groups were observed at ranges 2223-2228 cm-1 and 1660-
1722 cm-1 respectively (from medium to strong intensity).  
 
Compound Crystal structure Structure 
6.2.1a 
 
 
6.2.1h 
  
  
91 
Compound Crystal structure Structure 
6.2.1l 
 
 
6.2.2d 
 
 
6.2.3h 
 
 
6.2.4b 
 
 
6.2.4d 
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Compound Crystal structure Structure 
6.3.1c 
 
 
Table 6.5.1. Crystal structures of compounds 6.2.1a,h,l, 6.2.2d, 6.2.3h, 6.2.4b,d and 6.3.1c. 
 
The structures of compounds 6.2.1a,h,l, 6.2.2d, 6.2.3h, 6.2.4b,d and 6.3.1c were confirmed 
by X-ray single crystal analyses (Table 6.5.1). Thus, the regioselectivity of TM-catalyzed 
direct C-H arylation was independently proved by X-ray analysis.  
 
7. Exploration of Other Nitroarenes Towards Direct C-H Arylation 
 
To extend our methodology, a number of variously substituted nitroarenes were synthesized 
and studied applying the conditions developed for previous systems. Among others, 3-nitro-
2H-chromen-2-one 7.1a,271 3-nitro-4H-chromen-4-one 7.1b,262 5-nitropyrimidine derivatives 
7.1c-e,272 4-nitroisoxazole 7.1f,273 methyl 4-nitrofuran-2-carboxylate 7.1g274 (Figure 7.1) as 
well as some of fused 3-nitropyridines 6.1.3i,j and quinolines 6.1.3k-m261 (Scheme 6.1.1) 
were unreactive and/or unstable in our typical reaction protocol.  
 
 
Figure 7.1. The list of nitroarenes explored in the work. 
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Gratifyingly, in contrast to these unsuccessful trials, further experiments showed that 1-
methyl-4-nitro-1H-pyrrole-2-carbonitrile 7.1h275 and commercially available 2-nitrothiophene 
7.1i under otherwise identical conditions are prone to react with suitable aryl bromides 
leading to the formation of corresponding biaryls 7.2a-c in good yields (Scheme 7.1). In all 
cases, the product of the arylation of the β-C-H bond to the nitro group was the only observed 
regioisomer. Further optimization of reaction conditions and exploration of new methods for 
TM-catalyzed C-H activation of nitroarenes will be studied in our ongoing research program.  
 
 
Scheme 7.1. Scope of the reaction with respect to other nitroarenes. 
 
8. Summary and Outlook 
 
In conclusion, the TM-catalyzed C-H arylation of a broad range of nitro-substituted 
heteroarenes was studied in detail (Scheme 8.1). Namely, in case of 4-nitroimidazoles it was 
possible to arylate the C(5)-H and C(2)-H bonds regioselectively. For arylation of position 4 
of imidazole ring an efficient Pd-catalyzed Suzuki-Miyaura cross-coupling reaction of 4-
bromo-5-nitroimidazoles was developed. In addition, it was possible to demonstrate that the 
yields of Suzuki-Miyaura cross-coupling reaction of 5-bromo-4-nitroimidazoles were slightly 
lower in comparison to the yields obtained for similar compounds in direct C(5)-H arylation.  
In case of 4-nitropyrazoles the reactions proceeded with exclusive C(5)-H regioselectivity; 
however, additional experiments showed that the C(5)-H arylation products can be further 
arylated at position 3 of pyrazole ring in the presence of an excess of CuI.  
In case of purine-like fused 3-nitropyridines we were successful with pyrazolo[3,4-b]pyridine, 
pyrido[2,3-d]pyrimidine, imidazo[4,5-b]pyridine, thiazolo[4,5-b]pyridine and pyrrolo[2,3-
b]pyridine derivatives. In all cases except pyrrolo[2,3-b]pyridine derivative, the main 
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regioisomer appeared to be the γ-C-H arylation product. For the pyrrolo[2,3-b]pyridine 
derivative, it was possible to show that the positions 2 and 4 are almost equally active.  
 
 
 
Scheme 8.1. Scope of the work. 
 
The scope of the reactions with respect to the aryl halide coupling partner as well as for nitro-
substituted heteroarenes was examined. For all systems the C-H arylation can be performed 
by two different d-metals, namely Pd and Ni, using CuI as additive. The use of Pd-based 
catalysts proved to give better yields than Ni. Furthermore, it was possible to optimize the 
reaction conditions, so that only stoichiometric amounts of coupling partners can be used. The 
competitive experiments showed that aryl bromides with an electron-withdrawing group are 
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much more reactive than the respective aryl bromides with an electron-donating group. 
Besides, the competitive experiments between different nitro-substituted heteroarenes showed 
that 4-nitropyrazoles are the most reactive heterocyclic system towards Pd-catalyzed direct C-
H arylation.  
Additionally, it was discovered that among others, nitropyrrole derivatives and 2-
nitrothiophene under otherwise identical conditions are prone to react with suitable aryl 
bromides leading to the formation of corresponding biaryls. Many other nitro-substituted 
heteroarenes were also examined; nevertheless, the results were unsatisfactory.  
Within the course of study the multipurpose nature of nitro group as directing group was 
demonstrated (Scheme 8.1). In particular, via reduction of nitro group in different conditions 
it was possible to prepare various aminoarenes, N,N-dimethylamino arenes and isoquinolines 
fused with different heteroarenes. It was possible to perform a domino nitro group 
substitution-C-H arylation reaction which leads to the formation of benzofuran derivatives. 
Eventually, we could transform the nitro group to bromo substituent, using a semi-one-pot 
procedure, which allowed us to perform some further C-C bond forming reactions via cross-
coupling reactions.  
A mechanistic explanation of results was proposed. The developed methods show a number 
of advantages, including high experimental simplicity, catalyst efficiency, functional group 
compatibility, low cost of the catalytic system and starting materials.  
Regarding the future development of the field, it is difficult to predict anything since 15 years 
ago nobody really knew about C-H activation (Chapter 2.2, Figure 2.2.1); nevertheless, 
especially during the last four years the field of TM-catalyzed direct C-H transformations has 
been growing enormously (Chapter 2.2, Figure 2.2.1). A number of crucial chemical 
transformations were and will be modified to corresponding efficient direct C-H 
transformations; thus, making the synthesis of targeted substances less time consuming and 
inexpensive.  
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Appendix 
 
A.1. Experimental Section  
 
A.1.1. Equipment  
 
1H NMR Spectroscopy: Bruker AM 250, Bruker ARX 300, Bruker ARX 500; δ = 0.00 ppm 
for tetramethylsilane; δ = 7.25 ppm for (CDCl3); δ = 2.50 ppm for DMSO-d6. 
Characterization of the signals: s = singlet, d = doublet, dd = doublet of doublets, ddd = 
doublet of doublet of doublets, t = triplet, dt = double of triplet, q = quartet, quint = quintet, m 
= multiplet, br = broad. Spectra were evaluated according to first order rules. All coupling 
constants are indicated as (J).  
 
13C NMR Spectroscopy: Bruker AM 250, (62.9 MHz); Bruker ARX 300, (75 MHz), Bruker 
ARX 500, (125 MHz); Ref: δ = 77.00 ppm for CDCl3; δ = 39.7 ppm for DMSO-d6. The 
multiplicity of the carbon atoms was determined by the DEPT 135 and APT technique (APT 
= Attached Proton Test) and quoted as Me, CH2, CH and C for primary, secondary, tertiary 
and quaternary carbon atoms, respectively. Characterization of the signal: q = quartet. The 
multiplicity of the signals was determined by the DEPT and/or the APT recording 
technologies.  
 
Mass Spectrometry (MS): AMD MS40, AMD 402 (AMD Intectra), Varian MAT CH 7, 
MAT 731.  
 
High Resolution Mass Spectrometry (HRMS): Finnigan MAT 95 or Varian MAT 311; 
Bruker FT CIR, AMD 402 (AMD Intectra).  
 
Infrared Spectroscopy (IR): Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 
460, Nicolet 360 Smart rbit (ATR); KBr, KAP, Nujol, and ATR; Abbreviations for signal 
allocations: w = weak, m = medium, s = strong.  
 
X-ray Crystal Structure Analysis: Bruker X8Apex Diffractometer with CCD-Kamera (Mo - 
100 Kα and graphite monochromator, λ = 0.71073 Å).  
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Melting Points: Micro heating table HMK 67/1825 Kuestner (Büchi apparatus); Melting 
points are uncorrected.  
 
Column Chromatography: Chromatography was performed over Merck silica gel 60 (0,063 
- 0,200 mm, 70 - 230 mesh) as normal and/or over silica gel 60 (0,040 - 0,063 mm, 200 -400 
mesh) as flash chromatography. All solvents were distilled before use.  
 
Thin Layer Chromatography (TLC): Merck DC finished aluminum foils silica gel 60 F254 
and Macherey finished foils Alugram® Sil G/UV254. Detection under UV light at 254 nm 
and/or 366 nm without dipping reagent, as well as with vanillin-sulfuric acid reagent (1 mL 
vanillin in 100 mL stock solution of 85% methanol, 14% acetic acid and 1% sulfuric acid).  
 
Chemicals and work technique: All solvents for using were distilled by standard methods.  
Most of the starting chemicals are standard, commercially available from Merck®, Aldrich®, 
Arcos® and others.  
 
A.1.2. General procedures and spectroscopic data  
 
General Procedure for the Synthesis of N-Substituted Imidazoles by Alkylation. 
Synthesis of Compounds 4.1.3a-i, 4.1.6a-c, and 4.1.7a-c. The corresponding imidazole (1 
equiv.) and K2CO3 (3 equiv.) successively were weighed in air and placed in a Schlenk flask 
equipped with a magnetic stir bar, which then was capped with a rubber septum. The reaction 
vessel was evacuated and back filled with argon. The dry DMF (8 mL for 10 mmol of 
imidazole) and corresponding alkyl bromide (1.3 equiv.) were added via syringe, and the 
reaction was heated to 90°C for 8h. Upon completion, the reaction was cooled to room 
temperature and concentrated under vacuum. The crude mass was washed with water, which 
was extracted with chloroform. Finally, the organic phase was dried (Na2SO4), filtered, and 
evaporated to dryness, or (if necessary) the residue was purified by column chromatography 
typically using heptane/ethyl acetate mixtures to provide the desired alkylated product.  
 
General Procedure for Direct C-H Arylation of N-Substituted 4-Nitroimidazoles. 
Synthesis of Compounds 4.2.1a-t and 4.2.5a. The corresponding N-substituted 4-
nitroimidazole 4.1.3b,c,e-g or 4.2.4c (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), 
(CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (or NiCl2(PPh3)2) (0.05 equiv.) successively 
  
98 
were weighed in air and placed in a Schlenk flask equipped with a magnetic stir bar, which 
then was capped with a rubber septum. The reaction vessel was evacuated and back filled 
with argon (three times). The dry DMA (8 mL for 1 mmol of N-substituted 4-nitroimidazole) 
and aryl bromide (2 equiv.) were added via syringe (in the case of solid aryl bromide, first it 
was dissolved in dry DMA under inert atmosphere), and the reaction was heated to 130°C for 
14h. Upon completion, the reaction was cooled to room temperature and concentrated under 
vacuum. The residue was purified by column chromatography typically using heptane/ethyl 
acetate mixtures to provide the desired arylated product.  
 
General Procedure for Pd-Catalyzed Intramolecular Dehydrogenative Twofold C-H 
Cross-Coupling Reaction. Synthesis of Compounds 4.2.2a-c. The corresponding N-
substituted 4-nitro-imidazole 4.1.3c,e,f (1 equiv.), Ag2CO3 (1.2 equiv.), K2CO3 (1.3 equiv.), 
(CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively were weighed in air 
and placed in a Schlenk flask, equipped with a magnetic stir bar, which then was capped with 
a rubber septum. The reaction vessel was evacuated and back filled with argon (three times). 
The dry DMA (8 mL for 1 mmol of N-substituted 4-nitroimidazole) was added via a syringe, 
and the reaction was heated to 130°C for 14h. Upon completion, the reaction was cooled to 
room temperature and concentrated under vacuum. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for Direct C-H Arylation of 2,5-Unsubstituted 4-Nitroimidazole. 
Synthesis of Compounds 4.2.3a-c. The corresponding N-substituted 4-nitroimidazole 4.1.3d 
(1 equiv.), CuI (1.2 equiv.), K2CO3 (2.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 
(0.05 equiv.) successively were weighed in air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon (three times). The dry DMA (8 mL for 1 mmol of N-
substituted 4-nitroimidazole) and aryl bromide (2.5 equiv.) were added via syringe (in the 
case of solid aryl bromide, first it was dissolved in dry DMA under inert atmosphere), and the 
reaction was heated to 130°C for 14h. Upon completion, the reaction was cooled to room 
temperature and concentrated under vacuum. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired arylated 
product.  
 
General Procedure for Regioselective C(5)-H Arylation of 2,5-Unsubstituted 4-
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Nitroimidazole. Synthesis of Compounds 4.2.4a-c. The corresponding N-substituted 4-
nitroimidazole 4.1.3d (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 
equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively were weighed in air and placed in a 
Schlenk flask, equipped with a magnetic stir bar, which then was capped with a rubber 
septum. The reaction vessel was evacuated and back filled with argon (three times). The dry 
DMA (8 mL for 1 mmol of N-substituted 4-nitroimidazole) and aryl bromide (1.1 equiv.) 
were added via syringe (in case of solid aryl bromide, first it was dissolved in dry DMA under 
inert atmosphere), and the reaction was heated to 130oC for 14h. Upon completion, the 
reaction was cooled to room temperature and concentrated under vacuum. The residue was 
purified by column chromatography typically using heptane/ethyl acetate mixtures to provide 
the desired arylated product.  
 
General Procedure for Pd-Catalyzed Suzuki-Miyaura Cross-Coupling Reaction of 5(4)-
Bromo-4(5)-nitroimidazoles. Synthesis of Compounds 4.3.1a-f and 4.3.2a-e. The 
corresponding 5(4)-bromo-4(5)-nitroimidazole 4.1.6 or 4.1.7 (1 equiv.), arylboronic acid (1.3 
equiv.), and Pd(PPh3)4 (0.10 equiv.) successively were weighed in air and placed in a Schlenk 
flask (under the flow of argon), equipped with a magnetic stir bar, which then was set with 
reflux and capped with a rubber septum. The toluene/MeOH (5 : 1) system (8 mL for 1 mmol 
of 5(4)-bromo-4(5)-nitroimidazole) and 2 M aqueous K2CO3 (1 mL for 1 mmol of starting 
nitroimidazole) were added via syringe (under the flow of argon), and the reaction mixture 
was refluxed for 5h in inert atmosphere (argon balloon). Upon completion, the reaction was 
cooled to room temperature and concentrated under vacuum. The residue was purified by 
column chromatography typically using heptane/ethyl acetate mixtures to provide the desired 
arylated product.  
 
General Procedure for Reduction of Arylated Nitroimidazoles Containing a Carbonyl 
Group. Synthesis of Compounds 4.4.3a-e. To a Schlenk flask equipped with a magnetic stir 
bar and filled with corresponding arylated nitroimidazole 4.2.1t, 4.3.1a,b, 4.3.2a,e (1 equiv.) 
was added 10% Pd/C (0.1 equiv.). The flask was fitted with a rubber septum and then held 
under vacuum for 3min; it was then filled with MeOH (25 mL for 1 mmol of arylated 
nitroimidazole) and hydrogen. Holding under vacuum was repeated one more time, and after 
sequential filling with hydrogen, the reaction mixture was stirred for 5h under H2 atmosphere 
(H2 balloon). After the reaction was stopped, the mixture was filtered through a Celite pad. 
The filtrate was evaporated to dryness and purified by column chromatography typically 
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using heptane/ethyl acetate mixtures to provide the desired product.  
 
Competitive Experiment Between Imidazole 4.1.3c and Electronically Different Aryl 
Bromides. Synthesis of Compound 4.2.1u. The corresponding N-substituted 4-
nitroimidazole 4.1.3c (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 
equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively were weighed in air and placed in a 
Schlenk flask, equipped with a magnetic stir bar, which then was capped with a rubber 
septum. The reaction vessel was evacuated and back filled with argon (three times). The dry 
DMA (8 mL for 1 mmol of N-substituted 4-nitroimidazole) and aryl bromides (from each 1 
equiv.) were added via syringe (in case of solid aryl bromide, first it was dissolved in dry 
DMA under inert atmosphere), and the reaction was heated to 130°C for 14h. Upon 
completion, the reaction was cooled to room temperature and concentrated under vacuum. 
The residue was purified by column chromatography typically using heptane/ethyl acetate 
mixtures.  
 
Competitive Experiment Between Two Various Imidazoles. Synthesis of Compounds 
4.2.1u and 4.2.1w. The corresponding N-substituted 4-nitroimidazoles 4.1.3c and 4.1.3g 
(from each 1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and 
PdCl2(PPh3)2 (0.05 equiv.) successively were weighed in air and placed in a Schlenk flask, 
equipped with a magnetic stir bar, which then was capped with a rubber septum. The reaction 
vessel was evacuated and back filled with argon (three times). The dry DMA (8 mL for 2 
mmol of N-substituted 4-nitroimidazoles) and aryl bromide (1.1 equiv.) were added via 
syringe (in the case of solid aryl bromide, first it was dissolved in dry DMA under inert 
atmosphere), and the reaction was heated to 130°C for 14h. Upon completion, the reaction 
was cooled to room temperature and concentrated under vacuum. The mixture of compounds 
4.2.1u and 4.2.1w was purified by column chromatography typically using heptane/ethyl 
acetate mixtures.  
 
1-Ethyl-2-methyl-4-nitro-1H-imidazole (4.1.3a).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), bromoethane (1.41 g, 13 mmol) and K2CO3 (4.14 g, 30 mmol) in 
8 mL DMF, the product 4.1.3a was isolated as a white solid (1.271 g, 
82%). Mp: 64-65°C.  
1H NMR (300 MHz, CDCl3): δ = 1.46 (t, 3H, 3J = 7.0 Hz, CH2CH3), 2.42 (s, 3H, Me), 3.96 (t, 
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2H, 3J = 7.0 Hz, CH2CH3), 7.69 (s, 1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 13.0, 15.5 (Me), 42.0 (CH2), 118.9 (CH), 144.4 (C).  
MS (GC, 70 eV): m/z (%) = 155 (M+, 61), 83 (20), 56 (41), 43 (100).  
HRMS (EI): calcd for C6H9N3O2 (M
+) 155.06893, found 155.06894.  
IR (ATR, cm-1): ν̃ = 3108 (w), 1532 (s), 1495 (m), 1453 (w), 1423 (m), 1399 (s), 1332 (s), 
1292 (s), 1259 (s), 1190 (w), 1149 (m), 1082 (m), 1034 (w), 991 (m), 964 (m), 835 (s), 803 
(m), 757 (s), 681 (s), 639 (w).  
 
1-Butyl-2-methyl-4-nitro-1H-imidazole (4.1.3b).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), 1-bromobutane (1.78 g, 13 mmol) and K2CO3 (4.14 g, 30 mmol) 
in 8 mL DMF, the product 4.1.3b was isolated as a white solid (1.610 g, 
88%). Mp: 55-57°C.  
1H NMR (300 MHz, CDCl3): δ = 0.83 (t, 3H, 3J = 6.7 Hz, CH2CH2CH2CH3), 1.18-1.31 (m, 
2H, CH2CH2CH2CH3), 1.56-1.70 (m, 2H, CH2CH2CH2CH3), 2.29 (s, 3H, Me), 3.81 (t, 2H, 
3J 
= 7.3 Hz, CH2CH2CH2CH3), 7.59 (s, 1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 12.7, 13.1 (Me), 19.3, 31.9, 46.6 (CH2), 119.5 (CH), 144.4, 
145.9 (C).  
MS (GC, 70 eV): m/z (%) = 183 (M+, 58), 168 (21), 141 (64), 43 (100).  
HRMS (EI): calcd for C8H13N3O2 (M
+) 183.10023, found 183.100133.  
IR (ATR, cm-1): ν̃ = 3119 (w), 2960 (m), 2874 (w), 1531 (s), 1496 (m), 1466 (s), 1379 (m), 
1330 (s), 1290 (s), 1261 (s), 1186 (m), 1135 (m), 1095 (m), 994 (m), 827 (s), 757 (s), 682 (m), 
663 (m).  
 
2-Methyl-4-nitro-1-phenethyl-1H-imidazole (4.1.3c).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), (2-bromoethyl)benzene (2.40 g, 13 mmol) and K2CO3 (4.14 g, 
30 mmol) in 8 mL DMF, the product 4.1.3c was isolated as a white solid 
(2.150 g, 93%). Mp: 111-113°C.  
1H NMR (300 MHz, CDCl3): δ = 2.08 (s, 3H, Me), 3.07 (t, 2H, 3J = 6.8 
Hz, CH2), 4.24 (t, 2H, 
3J = 6.8 Hz, CH2), 7.00-7.03 (m, 2H, CHAr), 7.16-7.17 (m, 1H, CHAr), 
7.23-7.30 (m, 3H, CHAr), 7.48 (s, 1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 11.8 (Me), 37.2, 49.8 (CH2), 119.1, 127.5, 128.4 (CH), 
128.6, 128.9 (C), 129.0, 135.9, 136.0 (CH), 147.9 (C).  
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MS (GC, 70 eV): m/z (%) = 231 (M+, 40), 105 (25), 91 (100).  
HRMS (EI): calcd for C12H13N3O2 (M
+) 231.10023, found 231.100263.  
IR (ATR, cm-1): ν̃ = 3115 (w), 1516 (m), 1481 (s), 1438 (m), 1404 (m), 1377 (s), 1333 (s), 
1286 (s), 1159 (w), 1124 (m), 1048 (w), 1015 (w), 982 (m), 863 (m), 822 (s), 751 (s), 698 (s), 
654 (s), 621 (w), 564 (m).  
 
4-Nitro-1-phenethyl-1H-imidazole (4.1.3d).  
Starting from 4(5)-nitro-1H-imidazole 4.1.1b (1.13 g, 10 mmol), (2-
bromoethyl)benzene (2.40 g, 13 mmol) and K2CO3 (4.14 g, 30 mmol) in 8 mL 
DMF, the product 4.1.3d was isolated as a white solid (1.736 g, 80%). Mp: 
81-83°C.  
1H NMR (300 MHz, CDCl3): δ = 3.07 (t, 2H, 3J = 6.9 Hz, CH2), 4.24 (t, 2H, 
3J = 6.9 Hz, CH2), 7.00-7.03 (m, 2H, CHAr), 7.17 (d, 1H, 
4J = 1.4 Hz, imidazole), 7.21-7.27 
(m, 3H, CHAr), 7.58 (d, 1H, 
4J = 1.4 Hz, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 37.2, 49.8 (CH2), 119.1, 127.5, 128.4 (CH), 128.6, 128.9 
(C), 129.1, 135.9 (CH), 136.0, 147.9 (C).  
MS (GC, 70 eV): m/z (%) = 217 (M+, 40), 105 (25), 91 (100).  
HRMS (EI): calcd for C11H11N3O2 (M
+) 217.22394, found 217.22396.  
IR (ATR, cm-1): ν̃ = 3115 (w), 1516 (m), 1481 (s), 1438 (m), 1404 (m), 1377 (m), 1333 (s), 
1286 (s), 1159 (w), 1124 (m), 1079 (w), 1048 (w), 982 (m), 932 (w), 863 (m), 822 (s), 751 (s), 
698 (s), 672 (m), 654 (s), 564 (m).  
 
2-Methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazole (4.1.3e).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), (3-bromopropyl)benzene (2.59 g, 13 mmol) and K2CO3 (4.14 g, 
30 mmol) in 8 mL DMF, the product 4.1.3e was isolated as a white solid 
(1.911 g, 78%). Mp: 82-84°C.  
1H NMR (300 MHz, CDCl3): δ = 2.17-2.29 (m, 2H, CH2), 2.42 (s, 3H, 
Me), 2.77 (t, 2H, 3J = 7.4 Hz, CH2), 3.97 (t, 2H, 
3J = 7.4 Hz, CH2), 7.22-
7.24 (m, 2H, CHAr), 7.31-7.43 (m, 3H, CHAr), 7.74 (s, 1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 13.0 (Me), 31.3, 32.3, 46.3 (CH2), 119.4, 126.7, 128.2, 
128.8 (CH), 139.4, 144.7, 146.5 (C).  
MS (GC, 70 eV): m/z (%) = 245 (M+, 34), 141 (100), 117 (25), 91 (76), 43 (68).  
HRMS (EI): calcd for C13H15N3O2 (M
+) 245.11588, found 245.11586.  
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IR (ATR, cm-1): ν̃ = 3104 (w), 3023 (w), 1531 (s), 1494 (s), 1464 (m), 1454 (m), 1419 (m), 
1401 (m), 1358 (s), 1326 (s), 1289 (s), 1233 (w), 4498 (w), 1143 (m), 1039 (w), 991 (m), 910 
(w), 833 (s), 747 (s), 698 (s), 681 (m), 641 (w), 618 (w), 591 (w), 572 (m).  
 
2-Methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazole (4.1.3f).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), (2-bromoethoxy)benzene (2.61 g, 13 mmol) and K2CO3 (4.14 g, 
30 mmol) in 8 mL DMF, the product 4.1.3f was isolated as a white solid 
(2.198 g, 89%). Mp: 100-101°C.  
1H NMR (300 MHz, CDCl3): δ = 2.48 (s, 3H, Me), 4.24-4.30 (m, 4H, 
2×CH2), 6.80-6.83 (m, 2H, CHAr), 6.93-6.98 (m, 1H, CHAr), 7.22-7.27 (m, 2H, CHAr), 7.81 (s, 
1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 13.1 (Me), 46.5, 66.1 (CH2), 114.3, 120.2, 121.8, 129.6 
(CH), 145.2, 146.4, 157.4 (C).  
MS (GC, 70 eV): m/z (%) = 247 (M+, 100), 120 (60), 107 (72), 77 (73).  
HRMS (EI): calcd for C12H13N3O3 (M
+) 247.09514, found 247.09556.  
IR (ATR, cm-1): ν̃ = 3118 (w), 1588 (w), 1531 (m), 1495 (m), 1469 (m), 1385 (m), 1329 (s), 
1290 (s), 1237 (s), 1161 (m), 1079 (m), 1050 (m), 993 (m), 907 (m), 827 (m), 787 (m), 753 
(s), 690 (s), 678 (m), 617 (w), 599 (m), 568 (w).  
 
1-(4-Methylbenzyl)-2-methyl-4-nitro-1H-imidazole (4.1.3g).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), 1-(bromomethyl)-4-methylbenzene (2.40 g, 13 mmol) and 
K2CO3 (4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.3g was isolated 
as a white solid (1.917 g, 83%). Mp: 104-105°C.  
1H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H, Me), 2.38 (s, 3H, Me), 5.03 (s, 2H, CH2), 7.02 
(d, 2H, 3J = 8.1 Hz, CHAr), 7.18 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.60 (s, 1H, imidazole).  
13C NMR (62.9 MHz, CDCl3): δ = 13.3, 21.1 (Me), 50.8 (CH2), 120.0, 127.3, 130.1 (CH), 
130.7, 139.0, 145.0, 146.4 (C).  
MS (GC, 70 eV): m/z (%) = 231 (M+, 11), 105 (100).  
HRMS (EI): calcd for C12H13N3O2 (M
+) 231.10023, found 231.10038.  
IR (ATR, cm-1): ν̃ = 3099 (w), 1533 (s), 1493 (m), 1462 (m), 145 (w), 1396 (s), 1350 (m), 
1329 (s), 1314 (m), 1286 (s), 1226 (m), 1141 (m), 1036n (w), 993 (m), 833 (m), 756 (s), 681 
(s), 662 (m), 616 (w), 574 (m).  
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1-(2-Brombenzyl)-2-methyl-4-nitro-1H-imidazole (4.1.3h).  
Starting from 2-methyl-4(5)-nitro-1H-imidazole 4.1.1a (1.27 g, 10 
mmol), 1-bromo-2-(bromomethyl)benzene (3.25 g, 13 mmol) and 
K2CO3 (4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.3h was 
isolated as a brown solid (2.449 g, 83%). Mp: 91-92°C.  
1H NMR (300 MHz, CDCl3): δ = 2.43 (s, 3H, Me), 5.15 (s, 2H, 
CH2), 6.95 (dd, 1H, 
3J = 7.6 Hz, 4J = 1.7 Hz, CHAr), 7.24-7.34 (m, 2H, CHAr), 7.56 (s, 1H, 
CHAr), 7.64 (dd, 1H, 
3J = 7.8 Hz, 4J = 1.3 Hz, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.3 (Me), 51.0 (CH2), 119.8 (CH), 123.3 (C), 128.5, 
129.2, 130.8 (CH), 133.1 (C), 133.7 (CH), 145.2, 146.5 (C).  
MS (GC, 70 eV): m/z (%) = 296 (M+, 9), 296 (1), 295 (10), 171 (100), 169 (97), 90 (34), 89 
(32).  
HRMS (EI): calcd for C11H10N3O2Br (M
+) 296.12000, found 296.12012.  
IR (ATR, cm-1): ν̃ = 3127 (w), 1588 (w), 1532 (s), 1493 (s), 1438 (m), 1413 (m), 1380 (m), 
1358 (m), 1324 (m), 1291 (s), 1268 (s), 1142 (m), 1127 (m), 1030 (m), 992 (m), 943 (w), 829 
(m), 783 (m), 752 (s), 659 (m).  
 
2-Methyl-1-(3-phenylpropyl)-1H-imidazole (4.1.3i).  
Starting from 2-methyl-1H-imidazole (0.82 g, 10 mmol), (3-
bromopropyl)benzene (2.59 g, 13 mmol) and K2CO3 (4.14 g, 30 mmol) in 8 
mL DMF, the product 4.1.3i was isolated as a white viscous oil (0.821 g, 
41%).  
1H NMR (300 MHz, CDCl3): δ = 2.02-2.12 (m, 2H, CH2), 2.32 (s, 3H, Me), 
2.64 (t, 2H, 3J = 7.4 Hz, CH2), 3.82 (t, 2H, 
3J = 7.2 Hz, CH2), 6.81-6.82 (m, 
1H, imidazole), 6.91-6.92 (m, 1H, imidazole), 7.13-7.32 (m, 5H, CHAr).  
13C NMR (75.4 MHz, CDCl3): δ = 13.0 (Me), 32.0, 32.6, 45.3 (CH2), 119.0, 126.4, 127.0, 
128.3, 128.6 (CH), 140.4, 144.4, (C).  
MS (GC, 70 eV): m/z (%) = 200 (M+, 50), 117 (17), 117 (25), 96 (76), 91 (45).  
HRMS (ESI): calcd for C13H16N2 (M+H) 201.13862, found 201.13866.  
IR (ATR, cm-1): ν̃ = 3034 (w), 2928 (w), 1589 (w), 1531 (m), 1492 (m), 1423 (m), 1349 (w), 
1277 (w), 1232 (w), 1153 (w), 1095 (w), 1045 (w), 926 (w), 857 (w), 768 (s), 738 (s), 704 (s), 
669 (s), 619 (w), 577 (m).  
 
5-Bromo-2-methyl-4-nitro-1-phenethyl-1H-imidazole (4.1.6a).  
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Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (2-bromoethyl)benzene (2.40 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.6a was isolated as a 
brown solid (1.767 g, 57%). Mp: 127-129°C.  
1H NMR (300 MHz, CDCl3): δ = 2.01 (s, 3H, Me), 3.02 (t, 2H, 3J = 7.0 
Hz, CH2), 4.18 (t, 2H, 
3J = 7.0 Hz, CH2), 6.98-7.01 (m, 2H, CHAr), 7.25-7.27 (m, 3H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.5 (Me), 35.6, 48.0 (CH2), 104.2 (C), 127.5, 128.7, 129.1 
(CH), 136.0, 145.3 (C).  
MS (GC, 70 eV): m/z (%) = 309 (M+, 4), 230 (100), 213 (50), 105 (70), 91 (99), 77 (35).  
HRMS (EI): calcd for C12H12N3BrO2 (M
+) 309.01074, found 309.010864.  
IR (ATR, cm-1): ν̃ = 2927 (w), 1724 (w), 1632 (w), 1599 (w), 1537 (w), 1515 (s), 1476 (m), 
1453 (m), 1381 (s), 1281 (s), 1239 (m), 1181 (w), 1153 (m), 1082 (w), 1040 (m), 1013 (m), 
930 (w), 899 (w), 842 (m), 759 (m), 750 (s), 673 (m), 634 (m), 570 (m).  
 
5-Bromo-2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazole (4.1.6b).  
Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (2-bromoethoxy)benzene (2.61 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.6b was isolated as a 
brown solid (1.891 g, 58%). Mp: 93-95°C.  
1H NMR (300 MHz, CDCl3): δ = 2.63 (s, 3H, Me), 4.28 (t, 2H, 3J = 5.0 
Hz, CH2), 4.44 (t, 2H, 
3J = 5.0 Hz, CH2), 6.81-6.85 (m, 2H, CHAr), 6.95-7.02 (m, 1H, CHAr), 
7.25-7.31 (m, 2H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 14.3 (Me), 45.8, 65.3 (CH2), 104.4 (C), 114.0, 121.6, 129.5 
(CH), 146.2, 157.3 (C).  
MS (GC, 70 eV): m/z (%) = 325 (M+, 1), 246 (100), 107 (15), 77 (31).  
HRMS (ESI): calcd for C12H12N3BrO3 (M+H) 326.01348, found 326.0141.  
IR (ATR, cm-1): ν̃ = 2931 (w), 1587 (w), 1526 (s), 1494 (s), 1466 (m), 1376 (m), 1336 (s), 
1279 (m), 1244 (s), 1157 (w), 1080 (m), 1057 (m), 1038 (m), 916 (m), 882 (w), 842 (m), 788 
(m), 753 (s), 687 (s), 603 (m).  
 
5-Bromo-2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazole (4.1.6c).  
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Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (3-bromopropyl)benzene (2.59 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.6c was isolated as a 
brown solid (1.782 g, 55%). Mp: 62-64°C.  
1H NMR (300 MHz, CDCl3): δ = 2.01-2.12 (m, 2H, CH2), 2.37 (s, 3H, 
Me), 2.72 (t, 2H, 3J = 7.5 Hz, CH2), 3.93-3.98 (m, 2H, CH2), 7.16-7.34 
(m, 5H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.9 (Me), 30.7, 32.5, 45.7 (CH2), 104.5 (C), 126.6, 128.1, 
128.7 (CH), 139.4, 144.6 (C).  
MS (GC, 70 eV): m/z (%) = 323 (M+, 1), 244 (24), 198 (100), 117 (18), 91 (64).  
HRMS (EI): calcd for C13H14N3BrO2 (M
+) 323.02639, found 323.02638.  
IR (ATR, cm-1): ν̃ = 1519 (s), 1479 (m), 1384 (s), 1334 (s), 1285 (s), 1254 (s), 1173 (w), 1148 
(m), 1084 (w), 1028 (m), 907 (w), 867 (m), 834 (m), 752 (m), 718 (s), 693 (s), 670 (m), 631 
(w).  
 
4-Bromo-2-methyl-5-nitro-1-phenethyl-1H-imidazole (4.1.7a).  
Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (2-bromoethyl)benzene (2.40 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.7a was isolated as a 
brown solid (0.960 g, 31%). Mp: 125-127°C.  
1H NMR (300 MHz, CDCl3): δ = 2.01 (s, 3H, Me), 3.03 (t, 2H, 3J = 7.0 
Hz, CH2), 4.49 (t, 2H, 
3J = 7.0 Hz, CH2), 7.02-7.05 (m, 2H, CHAr), 7.27-7.29 (m, 3H, CHAr).  
13C NMR (62.96 MHz, CDCl3): δ = 13.6 (Me), 36.4, 49.2 (CH2), 120.8 (C), 127.4, 128.7, 
129.0 (CH), 136.4, 149.1 (C).  
MS (GC, 70 eV): m/z (%) = 309 (M+, 1), 263 (44), 184 (100), 104 (72), 91 (76), 77 (41).  
HRMS (EI): calcd for C12H12N3BrO2 (M
+) 309.01074, found 309.011022.  
IR (ATR, cm-1): ν̃ = 2931 (w), 1526 (s), 1497 (w), 1462 (m), 1415 (m), 1384 (m), 1357 (s), 
1332 (s), 1275 (w), 1249(s), 1192 (m), 1175 (s), 1085 (w), 1032 (w), 1002 (m), 852 (w), 830 
(s), 802 (w), 755 (s), 741 (m), 704 (s), 686 (m), 671 (m), 630 (w), 610 (w), 563 (m).  
 
4-Bromo-2-methyl-5-nitro-1-(2-phenoxyethyl)-1H-imidazole (4.1.7b).  
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Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (2-bromoethoxy)benzene (2.61 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.7b was isolated as a 
brown solid (1.239 g, 38%). Mp: 100-102°C.  
1H NMR (300 MHz, CDCl3): δ = 2.60 (s, 3H, Me), 4.29 (t, 2H, 3J = 5.0 
Hz, CH2), 4.70 (t, 2H, 
3J = 5.0 Hz, CH2), 6.76-6.80 (m, 2H, CHAr), 6.92-6.98 (m, 1H, CHAr), 
7.22-7.28 (m, 2H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 14.6 (Me), 47.2, 66.3 (CH2), 114.1 (CH), 121.2 (C), 121.7, 
129.6 (CH), 150.4, 157.5 (C).  
MS (GC, 70 eV): m/z (%) = 325 (M+, 5), 263 (44), 281 (85), 232 (71), 200 (56), 107 (26), 77 
(100).  
HRMS (EI): calcd for C12H12N3BrO3 (M+H) 326.01348, found 326.0141.  
IR (ATR, cm-1): ν̃ = 2930 (w), 1586 (w), 1516 (s), 1488 (m), 1454 (s), 1413 (s), 1355 (s), 
1329 (s), 1235 (s), 1172 (s), 1083 (m), 1063 (m), 1022 (m), 912 (m), 890 (w), 829 (m), 758 
(s), 693 (s), 632 (w), 591 (m).  
 
4-Bromo-2-methyl-5-nitro-1-(3-phenylpropyl)-1H-imidazole (4.1.7c).  
Starting from 5(4)-bromo-2-methyl-4(5)-nitro-1H-imidazole 4.1.5 (2.06 
g, 10 mmol), (3-bromopropyl)benzene (2.59 g, 13 mmol) and K2CO3 
(4.14 g, 30 mmol) in 8 mL DMF, the product 4.1.7c was isolated as a 
brown solid (1.296 g, 40%). Mp: 50-52°C.  
1H NMR (300 MHz, CDCl3): δ = 1.94-2.06 (m, 2H, CH2), 2.24 (s, 3H, 
Me), 2.64 (t, 2H, 3J = 7.5 Hz, CH2), 4.18 (t, 2H, 
3J = 7.5 Hz, CH2), 
7.09-7.25 (m, 5H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.7 (Me), 31.0, 32.4, 46.8 (CH2), 120.3 (C), 126.3, 128.0, 
128.5 (CH), 139.5, 148.4 (C).  
MS (GC, 70 eV): m/z (%) = 323 (M+, 1), 277 (52), 198 (50), 175 (32), 117 (51), 91 (100).  
HRMS (ESI): Calcd for C13H15N3BrO2 (M+H) 324.03422. Found 324.03456.  
IR (ATR, cm-1): ν̃ = 1514 (s), 1495 (m), 1452 (s), 1409 (s), 1378 (m), 1343 (s), 1250 (s), 1230 
(s), 1170 (s), 1032 (m), 910 (w), 885 (w), 830 (s), 765 (s), 745 (s), 721 (s), 695 (s), 643 (w), 
585 (w).  
 
5-(4-(Trifluoromethyl)phenyl)-2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazole 
(4.2.1a).  
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Starting from 2-methyl-4-nitro-1-(3-phenylpropyl)-1H-
imidazole 4.1.3e (0.245 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.450 g, 2 mmol), (1-iodo-3-
(trifluoromethyl)benzene (0.544 g, 2 mmol)), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 
g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, 
the product 4.2.1a was isolated as a green solid (0.373 g, 96%Pd), (0.276 g, 71%Ar-I). Mp: 118-
120°C.  
1H NMR (300 MHz, DMSO-d6): δ = 1.77-1.87 (m, 2H, CH2), 2.31 (s, 3H, Me), 2.71-2.77 (m, 
2H, CH2), 3.99-4.05 (m, 2H, CH2), 65.8-6.88 (m, 2H, CHAr), 7.19-7.22 (m, 3H, CHAr), 7.62-
7.77 (m, 3H, CHAr), 7.88-7.91 (m, 1H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -62.7 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.4 (Me), 31.3, 32.4, 44.2 (CH2), 123.5 (q, 1J = 274.3 
Hz, CF3), 126.7 (CH), 126.8 (q, 
3J = 8 Hz, C), 127.9 (CH), 128.4 (C), 128.7, 129.5 (CH), 
130.2 (C), 131.3 (q, 2J = 32.8 Hz, CCF3), 133.5 (CH), 139.1, 143.5, 143.9 (C).  
MS (GC, 70 eV): m/z (%) = 389 (M+, 100), 285 (12), 211 (20), 198 (39), 178 (11), 117 (11), 
91 (55).  
HRMS (EI): calcd for C20H18N3O2F3 (M
+) 389.13456, found 389.13444.  
IR (ATR, cm-1): ν̃ = 2956 (w), 1602 (w), 1573 (w), 1533 (w), 1504 (s), 1437 (m), 1402 (m), 
1331 (s), 1291 (s), 1245 (m), 1222 (w), 1190 (m), 1163 (m), 1120 (s), 1081 (s), 1020 (w), 930 
(w), 872 (m), 804 (m), 778 (w), 750 (m), 732 (m), 698 (s), 674 (m), 565 (m).  
 
2-Methyl-4-nitro-5-(3-nitrophenyl)-1-(3-phenylpropyl)-1H-imidazole (4.2.1b).  
Starting from 2-methyl-4-nitro-1-(3-phenylpropyl)-1H-
imidazole 4.1.3e (0.245 g, 1 mmol), 1-bromo-3-nitrobenzene 
(0.404 g, 2 mmol), (1-iodo-3-nitrobenzene (0.498 g, 2 
mmol)), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 
(0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMA, the product 4.2.1b was isolated as a green solid (0.296 g, 81%Pd), (0.157 g, 48%Ni), 
(0.216 g, 59%Ar-I). Mp: 164-166°C.  
1H NMR (300 MHz, DMSO-d6): δ = 1.69-1.79 (m, 2H, CH2), 2.41-2.46 (m, 5H, Me, CH2), 
3.72-3.78 (m, 2H, CH2), 6.94-6.97 (m, 2H, CHAr), 7.06-7.17 (m, 3H, CHAr), 7.74-7.80 (m, 
1H, CHAr), 7.92-7.95 (m, 1H, CHAr), 8.33-8.37 (m, 2H, CHAr).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 13.0 (Me), 30.3, 31.5, 43.7 (CH2), 124.5, 124.9, 125.8, 
127.9, 128.1 (CH), 129.4, 130.1 (C), 130.2, 137.0 (CH), 140.1, 142.7, 144.3, 147.6 (C).  
MS (GC, 70 eV): m/z (%) = 366 (M+, 47), 175 (25), 117 (18), 91 (100).  
HRMS (EI): calcd for C19H18N4O4 (M
+) 366.37062, found 366.37064.  
IR (ATR, cm-1): ν̃ = 3060 (w), 1526 (s), 1504 (m), 1441 (w), 1402 (w), 1349 (s), 1290 (s), 
1242 (m), 1099 (m), 1018 (w), 932 (w), 890 (w), 861 (w), 814 (m), 755 (s), 733 (m), 694 (s), 
668 (m), 578 (w).  
 
2-(2-Methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazol-5-yl)benzaldehyde (4.2.1c).  
Starting from 2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazole 
4.1.3e (0.245 g, 1 mmol), 2-bromobenzaldehyde (0.370 g, 2 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMA, the product 4.2.1c was isolated as a yellow 
solid (0.314 g, 90%Pd). Mp: 126-128°C.  
1H NMR (300 MHz, CDCl3): δ = 1.71-1.82 (m, 2H, CH2), 2.40 (s, 3H, Me), 2.44 (t, 2H, 3J = 
7.3 Hz, CH2), 3.47-3.71 (m, 2H, CH2), 6.88-6.92 (m, 2H, CHAr), 7.11-7.18 (m, 2H, CHAr), 
7.27-7.31 (m, 1H, CHAr), 7.37-7.55 (m, 1H, CHAr), 7.66-7.74 (m, 2H, CHAr), 7.94-8.00 (m, 
1H, CHAr), 9.85 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 30.9, 32.3, 44.2 (CH2), 126.4, 127.9 (CH), 
128.3 (C), 128.6, 130.7 (CH), 131.7 (C), 131.9, 132.1, 134.0, 135.1 (CH), 139.2, 143.6 (C), 
190.4 (CH).  
MS (GC, 70 eV): m/z (%) = 349 (M+, 1), 303 (100), 91 (44).  
HRMS (ESI): calcd for C20H20N3O3 (M+H) 350.14992, found 350.15086.  
IR (ATR, cm-1): ν̃ = 1683 (s), 1599 (w), 1564 (w), 1542 (m), 1490 (s), 1453 (m), 1398 (m), 
1353 (m), 1337 (s), 1294 (s), 1269 (m), 1254 (m), 1225 (m), 1197 (m), 1120 (w), 1032 (w), 
1005 (w), 978 (w), 850 (m), 823 (m), 764 (m), 738 (s), 698 (s), 671 (s), 614 (m), 540 (m).  
 
4,5-Dimethoxy-2-(2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazol-5-yl)benzaldehyde 
(4.2.1d).  
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Starting from 2-methyl-4-nitro-1-(3-phenylpropyl)-1H-
imidazole 4.1.3e (0.245 g, 1 mmol), 2-bromo-4,5-
dimethoxybenzaldehyde (0.490 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMA, the product 4.2.1d was isolated as a yellow solid 
(0.360 g, 88%Pd). Mp: 165-167°C.  
1H NMR (300 MHz, DMSO-d6): δ = 1.77-1.82 (m, 2H, CH2), 2.41-2.51 (m, 5H, Me, CH2), 
3.56-3.72 (m, 2H, CH2), 3.87 (s, 3H, OMe), 4.02 (s, 3H, OMe), 6.67 (s, 1H, CHAr), 6.89-6.92 
(m, 3H, CHAr), 7.17-7.19 (m, 2H, CHAr), 7.46 (br s, 1H, CHAr), 9.63 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.6 (Me), 30.3, 31.5, 43.8 (CH2), 55.7, 56.2 (OMe), 
111.5, 113.8 (CH), 123.3, 125.8 (C), 127.9, 128.1, 128.8 (CH), 129.6 (C), 131.4, 131.5 (CH), 
132.0, 140.2, 143.4, 144.3, 149.7, 153.2 (C), 190.0 (CHO).  
MS (GC, 70 eV): m/z (%) = 409 (M+, 1), 363 (100), 91 (25).  
HRMS (ESI): calcd for C22H24N3O5 (M+H) 410.17105, found 410.17082.  
IR (ATR, cm-1): ν̃ = 2938 (w), 1681 (m), 1591 (m), 1514 (s), 1494 (m), 1441 (m), 1397 (m), 
1352 (m), 1329 (m), 1268 (s), 1227 (m), 1145 (s), 1100 (m), 1021 (m), 866 (w), 824 (w), 749 
(m), 699 (s), 641 (w), 586 (m), 540 (w).  
 
5-(3-(Trifluoromethyl)phenyl)-2-methyl-4-nitro-1-phenethyl-1H-imidazole (4.2.1e).  
Starting from 2-methyl-4-nitro-1-phenethyl-1H-imidazole 
4.1.3c (0.231 g, 1 mmol), 1-bromo-3-(trifluoromethyl)benzene 
(0.450 g, 2 mmol), (1-iodo-3-(trifluoromethyl)benzene (0.544 
g, 2 mmol)), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
(NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1e 
was isolated as a green solid (0.368 g, 98%Pd), (0.274 g, 73%Ni), (0.281 g, 75%Ar-I). Mp: 164-
166°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.31 (s, 3H, Me), 2.71-2.77 (m, 2H, CH2), 3.99-4.05 (m, 
2H, CH2), 6.58-6.88 (m, 2H, CHAr), 7.19-7.22 (m, 3H, CHAr), 7.62-7.77 (m, 3H, CHAr), 7.88-
7.91 (m, 1H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -61.03 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.9 (Me), 34.8, 46.0 (CH2), 123.8 (q, 1J = 271 Hz, 
CF3), 126.3, 126.8, 127.0, 128.5, 128.5 (CH), 129.3 (q, 
2J = 31 Hz, CCF3), 129.7 (CH), 131.0 
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(C), 134.0 (CH), 137.0, 142.6, 144.4 (C).  
MS (GC, 70 eV): m/z (%) = 375 (M+, 94), 105 (100), 91 (80).  
HRMS (EI): calcd for C19H16N3O2F3 (M
+) 375.11891, found 375.11871.  
IR (ATR, cm-1): ν̃ = 1565 (w), 1533 (w), 1498 (m), 1440 (w), 1388 (w), 1354 (m), 1329 (s), 
1308 (s), 1288 (s), 1254 (m), 1224 (w), 1201 (w), 1167 (m), 1117 (s), 1073 (s), 1020 (w), 935 
(m), 900 (w), 856 (m), 806 (s), 755 (m), 698 (s), 672 (m), 649 (w).  
 
5-(2-Methyl-4-nitro-1-phenethyl-1H-imidazol-5-yl)pyrimidine (4.2.1f).  
Starting from 2-methyl-4-nitro-1-phenethyl-1H-imidazole 4.1.3c 
(0.231 g, 1 mmol), 5-bromopyrimidine (0.318 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1f was 
isolated as a yellow solid (0.247 g, 80%Pd), (0.163 g, 53%Ni). Mp: 183-185°C.  
1H NMR (300 MHz, CDCl3): δ = 2.45 (s, 3H, Me), 2.86 (t, 2H, 3J = 6.4 Hz, CH2), 4.10 (t, 2H, 
3J = 6.4 Hz, CH2), 6.76-6.78 (m, 2H, CHAr), 7.22-7.32 (m, 3H, CHAr), 8.37 (s, 2H, CHAr), 
9.29 (s, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.5 (Me), 35.9, 46.3 (CH2), 122.7, 125.5 (C), 127.8, 
128.5, 129.2 (CH), 131.9, 135.3, 144.2, 145.2 (C), 157.4, 158.9 (CH).  
MS (GC, 70 eV): m/z (%) = 309 (M+, 98), 105 (90), 91 (100), 77 (33).  
HRMS (EI): calcd for C16H15N5O2 (M
+) 309.12203, found 309.12208.  
IR (ATR, cm-1): ν̃ = 2920 (w), 1609 (w), 1549 (w), 1505 (s), 1453 (w), 1408 (s), 1342 (s), 
1298 (m), 1253 (m), 1187 (m), 1119 (w), 997 (m), 919 (m), 865 (m), 754 (m), 724 (s), 705 
(s), 665 (m), 625 (s), 564 (m).  
 
2-(2-Methyl-4-nitro-1-phenethyl-1H-imidazol-5-yl)benzaldehyde (4.2.1g).  
Starting from 2-methyl-4-nitro-1-phenethyl-1H-imidazole 4.1.3c 
(0.231 g, 1 mmol), 2-bromobenzaldehyde (0.370 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1g was 
isolated as a yellow solid (0.322 g, 96%Pd), (0.218 g, 65%Ni). Mp: 162-164°C.  
1H NMR (300 MHz, CDCl3): δ = 2.26 (s, 3H, Me), 2.70 (t, 2H, 3J = 7.1 Hz, CH2), 3.72-3.81 
(m, 1H, CH2), 3.96-4.06 (m, 2H, CH2), 6.78-6.81 (m, 2H, CHAr), 7.11-7.13 (m, 1H, CHAr), 
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7.17-7.22 (m, 2H, CHAr), 7.42-7.53 (m, 2H, CHAr), 7.62-7.73 (m, 1H, CHAr), 8.00-8.03 (m, 
1H, CHAr), 9.81 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 36.0, 46.5 (CH2), 127.4 (CH), 128.4 (C), 128.6, 
129.0, 130.6, 131.7, 132.1 (CH), 133.9, 135.1, 136.1 (C), 190.4 (CH).  
MS (GC, 70 eV): m/z (%) = 335 (M+, 1), 289 (100), 105 (39), 91 (15), 77 (14).  
HRMS (ESI): calcd for C19H18N3O3 (M+H) 336.13427, found 336.1346.  
IR (ATR, cm-1): ν̃ = 1695 (m), 1599 (w), 1531 (m), 1496 (s), 1437 (m), 1384 (m), 1319 (s), 
1293 (s), 1270 (m), 1236 (s), 1201 (m), 1120 (w), 1092 (w), 1003 (w), 931 (w), 850 (m), 824 
(m), 757 (s), 702 (s), 673 (m), 569 (m).  
 
5-(2-Chloro-5-(trifluoromethyl)phenyl)-2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-
imidazole (4.2.1h).  
Starting from 2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazole 
4.1.3f (0.247 g, 1 mmol), 2-bromo-1-chloro-4-
(trifluoromethyl)benzene (0.520 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1h was 
isolated as a green solid (0.318 g, 30%Pd). Mp: 180-181°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, Me), 3.93-4.19 (m, 4H, 2×CH2), 6.69-6.72 
(m, 2H, CHAr), 6.94-6.98 (m, 1H, CHAr), 7.21-7.26 (m, 2H, CHAr), 7.67-7.76 (m, 3H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -62.5 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.9 (Me), 44.7, 65.6 (CH2), 114.1, 121.9 (CH), 123.4 
(q, 1J = 273 Hz, CF3), 127.5, 128.1 (C), 128.5 (q, 
3J = 4 Hz, CH), 129.3 (q, 3J = 4 Hz, CH), 
129.7 (CH), 130.2 (C), 130.8 (CH), 138.9, 144.1, 145.5, 157.4 (C).  
MS (GC, 70 eV): m/z (%) = 425 (M+, 16), 390 (59), 360 (100), 77 (39).  
HRMS (ESI): calcd for C19H16N3O3F3Cl (M+H) 426.08249, found 426.08249.  
IR (ATR, cm-1): ν̃ = 1738 (w), 1673 (w), 1588 (w), 1532 (w), 1504 (s), 1406 (m), 1329 (s), 
1285 (m), 1239 (s), 1168 (s), 1121 (s), 1078 (s), 1017 (m), 918 (m), 859 (m), 814 (m), 791 
(m), 753 (s), 689 (m), 605 (w), 535 (m).  
 
4,5-Dimethoxy-2-(2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazol-5-yl)benzaldehyde 
(4.2.1i).  
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Starting from 2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-
imidazole 4.1.3f (0.247 g, 1 mmol), 2-bromo-4,5-
dimethoxybenzaldehyde (0.490 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 
g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, 
the product 4.2.1i was isolated as a yellow solid (0.333 g, 81%Pd). Mp: 141-143°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.56 (s, 3H, Me), 3.85 (s, 3H, OMe), 3.93 (s, 3H, OMe), 
3.96-4.26 (m, 4H, 2×CH2), 6.73 (d, 2H, 
3J = 8.0 Hz, CHAr), 6.91 (t, 1H, 
3J = 7.1 Hz, CHAr), 
7.19-7.25 (m, 3H, CHAr), 7.56 (s, 1H, CHAr), 9.67 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.0 (Me), 43.6 (CH2), 55.2, 55.8 (OMe), 65.2 (CH2), 
110.7, 113.7, 120.5 (CH), 123.0, 127.9, 128.1, 128.3, 128.9 (C), 129.4 (CH), 143.2, 144.6, 
149.3, 152.7, 157.1 (C), 189.4 (CHO).  
MS (GC, 70 eV): m/z (%) = 411 (M+, 1), 365 (100), 77 (18).  
HRMS (ESI): calcd for C21H22N3O6 (M+H) 412.15031, found 412.15044.  
IR (ATR, cm-1): ν̃ = 2933 (w), 1737 (w), 1678 (m), 1586 (m), 1537 (m), 1495 (s), 1445 (m), 
1398 (m), 1353 (m), 1329 (m), 1283 (s), 1222 (s), 1155 (s), 1119 (m), 1036 (m), 1016 (m), 
882 (s), 856 (m), 815 (m), 743 (s), 691 (m), 585 (m).  
 
2-(2-Methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazol-5-yl)benzaldehyde (4.2.1j).  
Starting from 2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazole 
4.1.3f (0.247 g, 1 mmol), 2-bromobenzaldehyde (0.370 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMA, the product 4.2.1j was isolated as a yellow solid (0.263 
g, 75%Pd). Mp: 148-150°C.  
1H NMR (300 MHz, CDCl3): δ = 2.57 (s, 3H, Me), 3.96-4.24 (m, 4H, 2×CH2), 6.70-6.74 (m, 
2H, CHAr), 6.88-6.93 (m, 1H, CHAr), 7.19-7.25 (m, 2H, CHAr), 7.59-7.64 (m, 1H, CHAr), 7.77-
7.89 (m, 2H, CHAr), 8.10 (dd, 1H, 
3J = 7.3 Hz, 4J = 1.2 Hz, CHAr), 9.86 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 44.1, 65.6 (CH2), 114.2, 121.0, 128.7, 129.4 
(CH), 130.6 (C), 130.7, 131.4, 131.5, 132.0, 134.2 (CH), 135.0, 143.3, 145.2, 157.5 (C), 194.8 
(CHO).  
MS (GC, 70 eV): m/z (%) = 351 (M+, 1), 305 (21), 44 (100). 
HRMS (EI): calcd for C19H17N3O4 (M
+) 351.35598, found 351.35599.  
IR (ATR, cm-1): ν̃ = 2927 (w), 1690 (m), 1600 (m), 1565 (w), 1538 (w), 1496 (s), 1396 (m), 
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1353 (m), 1330 (s), 1293 (m), 1269 (m), 1230 (s), 1179 (m), 1119 (w), 1085 (m), 1051 (m), 
962 (w), 908 (w), 886 (w), 849 (m), 828 (m), 757 (s), 721 (m), 692 (s), 670 (m), 631 (w), 592 
(w), 539 (m).  
 
1-(4-Methylbenzyl)-2-methyl-4-nitro-5-(phenanthren-10-yl)-1H-imidazole (4.2.1k).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 9-bromophenanthrene 
(0.514 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
(NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 
8 mL DMA, the product 4.2.1k was isolated as a dark brown viscous oil (0.258 g, 80%Pd), 
(0.162 g, 40%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3H, Me), 2.39 (s, 3H, Me), 4.62 (d, 1H, 3J = 15.0 
Hz, CH2), 4.84 (d, 1H, 
3J = 15.0 Hz, CH2), 6.55 (d, 2H, 
3J = 7.9 Hz, CHAr), 6.86 (d, 2H, 
3J = 
7.9 Hz, CHAr), 7.36-7.67 (m, 7H, CHAr), 8.60 (t, 2H, 
3J = 9.8 Hz, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.7, 18.4, 20.9 (Me), 48.1 (CH2), 126.3, 127.0, 129.5 
(CH), 130.7, 131.7 (C), 134.2 (CH), 137.1, 137.9, 143.4, 144.1, 144.7 (C) 149.9 (CH).  
MS (GC, 70 eV): m/z (%) = 407 (M+, 53), 105 (100).  
HRMS (EI): calcd for C26H21N3O2 (M
+) 407.16283, found 407.16301.  
IR (ATR, cm-1): ν̃ = 1537 (m), 1504 (s), 1446 (m), 1385 (m), 1336(s), 1293 (s), 1222 (m), 
1124 (w), 1018 (m), 933 (w), 859 (s), 796 (s), 766 (m), 756 (m), 719 (m), 665 (m), 624 (m), 
594 (w).  
 
3-(1-(4-Methylbenzyl)-2-methyl-4-nitro-1H-imidazol-5-yl)benzaldehyde (4.2.1l).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-imidazole 
4.1.3g (0.231 g, 1 mmol), 2-bromobenzaldehyde (0.370 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMA, the product 4.2.1l was isolated as a yellow solid (0.285 g, 85%Pd). Mp: 139-141°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.21 (s, 3H, Me), 2.39 (s, 3H, Me), 4.88-5.03 (m, 2H, 
CH2), 6.74 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.03 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.48-7.51 (m, 1H, 
CHAr), 7.72-7.77 (m, 2H, CHAr), 7.95-7.99 (m, 1H, CHAr), 9.73 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.4, 20.5 (Me), 47.6 (CH2), 126.4, 127.5 (CH), 128.4 
(C), 129.1, 129.5, 130.5 (CH), 130.6 (C), 130.9, 131.5 (CH), 132.0 (C), 134.0, 134.7 (CH), 
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137.0, 143.4, 144.8 (C), 191.4 (CHO).  
MS (GC, 70 eV): m/z (%) = 335 (M+, 1), 105 (100).  
HRMS (ESI): calcd for C19H18N3O3 (M+H) 336.13427, found 336.1342.  
IR (ATR, cm-1): ν̃ = 2841 (w), 2751 (w), 1699 (m), 1601 (w), 1568 (w) 1533 (m), 1494 (s), 
1435 (m), 1397 (m), 1377 (s), 1328 (s), 1288 (s), 1249 (s), 1199 (m), 1121 (m), 1036 (w), 
1003 (w), 859 (m), 813 (s), 785 (s), 765 (s), 723 (m), 670 (m), 610 (m), 541 (s).  
 
1-(4-Methylbenzyl)-5-(3-(trifluoromethyl)phenyl)-2-methyl-4-nitro-1H-imidazole 
(4.2.1m).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.450 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), 
CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMA, the product 4.2.1m was isolated as a green solid (0.368 g, 92%Pd), (0.191 g, 62%Ni). 
Mp: 152-154°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.31 (s, 3H, Me), 2.43 (s, 3H, Me), 4.90 (s, 2H, CH2), 
6.71 (d, 2H, 3J = 6.0 Hz, CHAr), 7.45 (d, 2H, 
3J = 6.0 Hz, CHAr), 7.45-7.56 (m, 3H, CHAr), 
7.68-7.71 (m, 1H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -62.9 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.7, 21.0 (Me), 48.2 (CH2), 123.4 (q, 1J = 273.2 Hz, 
CF3), 125.7 (CH), 126.7 (q, 
3J = 4.1 Hz, CH), 127.1 (q, 3J = 4.1 Hz, CH), 128.2 (C), 129.3 
(CH), 129.9 (C), 130.7 (CH), 131.1 (q, 2J = 32.6 Hz, CCF3), 131.3 (C), 133.5 (CH), 138.4, 
143.5, 144.7 (C).  
MS (GC, 70 eV): m/z (%) = 375 (M+, 10), 105 (100).  
HRMS (EI): calcd for C19H16N3O2F3 (M
+) 375.11891, found 375.11887.  
IR (ATR, cm-1): ν̃ = 1538 (m), 1499 (m), 1429 (w), 1399 (m), 1328 (s), 1288 (s), 1252 (m), 
1184 (m), 1164 (s), 1111 (s), 1076 (s), 1024 (m), 926 (m), 857 (m), 812 (m), 796 (s), 766 (m), 
726 (m), 700 (m), 663 (m), 644 (w), 599 (w).  
 
5-(1-(4-Methylbenzyl)-2-methyl-4-nitro-1H-imidazol-5-yl)pyrimidine (4.2.1n).  
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Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-imidazole 
4.1.3g (0.231 g, 1 mmol), 5-bromopyrimidine (0.318 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1n was isolated as a yellow solid 
(0.253 g, 82%Pd), (0.157 g, 51%Ni). Mp: 183-185°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.25 (s, 3H, Me), 2.39 (s, 3H, Me), 5.14 (s, 2H, CH2), 
6.82 (d, 2H, 3J = 8.1 Hz, CHAr), 7.10 (d, 2H, 
3J = 8.1 Hz, CHAr), 8.84 (s, 2H, CHAr), 9.25 (s, 
1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.2, 20.6 (Me), 47.5 (CH2), 123.0 (C), 126.1 (CH), 
126.8 (C), 128.6, 129.4, 131.4, 131.5 (CH), 132.0, 137.1, 143.8, 145.5 (C), 157.7, 158.7 (CH).  
MS (GC, 70 eV): m/z (%) = 309 (M+, 10), 105 (100).  
HRMS (EI): calcd for C16H15N5O2 (M
+) 309.12203, found 309.12176.  
IR (ATR, cm-1): ν̃ = 2965 (w), 1551 (w), 1529 (w), 1501 (s), 1432 (m), 1401 (m), 1339 (s), 
1299 (m), 1271 (m), 1189 (m), 1120 (m), 1002 (m), 917 (w), 858 (m), 789 (m), 756 (w), 723 
(s), 694 (m), 665 (m), 628 (m), 537 (m).  
 
1-(4-Methylbenzyl)-5-(4-methoxyphenyl)-2-methyl-4-nitro-1H-imidazole (4.2.1o).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 1-bromo-4-
methoxybenzene (0.374 g, 2 mmol), (1-iodo-4-
methoxybenzene (0.468 g, 2 mmol)), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1o was isolated as a 
yellow viscous oil (0.226 g, 67%Pd), (0.155 g, 46%Ar-I).  
1H NMR (300 MHz, CDCl3): δ = 2.29 (s, 3H, Me), 2.33 (s, 3H, Me), 3.79 (s, 3H, OMe), 4.91 
(s, 2H, CH2), 6.75 (d, 2H, 
3J = 7.6 Hz, CHAr), 6.90 (d, 2H, 
3J = 8.5 Hz, CHAr), 7.09 (d, 2H, 
3J 
= 7.6 Hz, CHAr), 7.19 (d, 2H, 
3J = 8.5 Hz, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.8, 21.0 (Me), 47.8 (CH2), 55.3 (OMe), 114.2 (CH), 
115.4, 119.0 (C), 125.8, 128.7, 129.8, 130.1, 131.6 (CH), 133.1, 138.1, 143.2, 144.1, 160.8 
(C).  
MS (GC, 70 eV): m/z (%) = 337 (M+, 32), 105 (100).  
HRMS (EI): calcd for C19H19N3O3 (M
+) 337.14209, found 337.14203.  
IR (ATR, cm-1): ν̃ = 2926 (w), 1666 (w), 1613 (w), 1506 (s), 1441 (w), 1335 (s), 1288 (s), 
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1247 (s), 1176 (s), 1110 (w), 1032 (m), 856 (s), 797 (m), 717 (m), 669 (w), 620 (w), 596 (m), 
529 (m).  
 
1-(4-Methylbenzyl)-5-(2-fluorophenyl)-2-methyl-4-nitro-1H-imidazole (4.2.1p).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-imidazole 
4.1.3g (0.231 g, 1 mmol), 1-bromo-2-fluorobenzene (0.350 g, 2 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) 
in 8 mL DMA, the product 4.2.1p was isolated as a green solid 
(0.166 g, 51%Pd). Mp: 115-117°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.26 (s, 3H, Me), 2.34 (s, 3H, Me), 4.82-4.99 (m, 2H, 
CH2), 6.72 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.05 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.09-7.22 (m, 3H, 
CHAr), 7.39-7.46 (m, 1H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -111.23 (CF).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.4, 20.8 (Me), 48.0 (CH2), 115.2 (d, 3J = 15.4 Hz, C), 
115.9 (d, 2J = 22.2 Hz, CH), 124.3 (d, J = 4.1 Hz, C), 125.8 (CH), 126.5 (C), 129.5, 131.1, 
131.5, 132.1, 132.3 (CH), 137.9, 143.9, 144.9 (C), 159.3 (d, 1J = 249.7 Hz, CF).  
MS (GC, 70 eV): m/z (%) = 325 (M+, 21), 105 (100).  
HRMS (ESI): calcd for C18H17N3O2F (M+H) 326.12993, found 326.13006.  
IR (ATR, cm-1): ν̃ = 1532 (m), 1495 (s), 1444 (m), 1397 (m), 1378 (m), 1328 (s), 1288 (m), 
1269 (m), 1251 (m), 1221 (m), 1116 (w), 1095 (w), 1007 (w), 863 (w), 840 (m), 808 (s), 765 
(s), 716 (m), 665 (m), 607 (m).  
 
2-Methyl-5-(2-methyl-1-(4-methylbenzyl)-4-nitro-1H-imidazol-5-yl)pyridine (4.2.1q).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 2-bromo-5-methylpyridine 
(0.344 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1q was 
isolated as a yellow viscous oil (0.220 g, 54%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.25 (s, 3H, Me), 2.36 (s, 6H, Me), 5.16 (s, 2H, CH2), 6.76 
(d, 2H, 3J = 8.0 Hz, CHAr), 7.02 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.45 (d, 1H, 
3J = 8.0 Hz, CHAr), 
7.53-7.56 (m, 1H, CHAr), 8.51 (s, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.7, 18.4, 20.6 (Me), 48.0 (CH2), 126.3, 127.1, 129.5 
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(CH), 130.8, 131.8, 134.2 (C), 137.1 (CH), 137.9, 143.5, 144.1, 144.8 (C), 150.0 (CH).  
MS (GC, 70 eV): m/z (%) = 322 (M+, 10), 305 (100), 263 (34), 146 (26), 119 (23), 105 (52).  
HRMS (EI): calcd for C18H18N4O2 (M
+) 322.14243, found 322.14228.  
IR (ATR, cm-1): ν̃ = 1733 (w), 1668 (w), 1564 (w), 1497 (s), 1441 (m), 1384 (m), 1336 (s), 
1282 (m), 1226 (w), 1136 (m), 1039 (w), 901 (m), 864 (w), 839 (w), 810 (w), 749 (s), 725 (s), 
616 (m).  
 
1-(4-Methylbenzyl)-5-(3-methoxyphenyl)-2-methyl-4-nitro-1H-imidazole (4.2.1r).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 1-bromo-3-
methoxybenzene (0.374 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 
g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 
g, 1.3 mmol) in 8 mL DMA, the product 4.2.1r was isolated as a yellow solid (0.263 g, 
78%Pd), (0.145 g, 43%Ni). Mp: 146-148°C.  
1H NMR (300 MHz, CDCl3): δ = 2.31 (s, 3H, Me), 2.35 (s, 3H, Me), 3.67 (s, 3H, OMe), 4.91 
(s, 2H, CH2), 6.75-6.77 (m, 3H, CHAr), 6.84-6.87 (m, 1H, CHAr), 6.95-6.99 (m, 1H, CHAr), 
7.09-7.12 (m, 2H, CHAr), 7.29-7.34 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.8, 21.0 (Me), 47.9 (CH2), 55.2 (OMe), 115.4, 115.9, 
122.2, 125.8 (CH), 128.3 (C), 129.7, 129.8 (CH), 131.8, 132.8, 138.1, 144.2, 159.5 (C).  
MS (GC, 70 eV): m/z (%) = 337 (M+, 24), 105 (100).  
HRMS (EI): calcd for C19H19N3O3 (M
+) 337.14209, found 337.14198.  
IR (ATR, cm-1): ν̃ = 2919 (w), 1589 (m), 1568 (m), 1536 (m), 1503 (s), 1451 (m), 1398 (s), 
1344 (s), 1292 (s), 1223 (s), 1180 (m), 1125 (m), 1039 (m), 1016 (m), 897 (m), 873 (m), 829 
(m), 786 (s), 765 (m), 706 (m), 689 (m), 665 (m), 555 (w).  
 
1-(3-(2-Methyl-1-(4-methylbenzyl)-4-nitro-1H-imidazol-5-yl)phenyl)ethanone (4.2.1s).  
Starting from 2-methyl-1-(4-methylbenzyl)-4-nitro-1H-
imidazole 4.1.3g (0.231 g, 1 mmol), 1-(3-
bromophenyl)ethanone (0.398 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMA, the product 4.2.1s was isolated as a yellow solid (0.251 g, 72%Pd). Mp: 173-174°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.23 (s, 3H, Me), 2.34 (s, 3H, Me), 2.49 (s, 3H, Me), 
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5.03 (s, 2H, CH2), 6.80 (d, 2H, 
3J = 7.5 Hz, CHAr), 7.09 (d, 2H, 
3J = 7.5 Hz, CHAr), 7.58-7.70 
(m, 2H, CHAr), 7.91 (br s, 1H, CHAr), 8.01-8.05 (m, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.2, 20.5, 26.6 (Me), 47.3 (CH2), 126.0 (CH), 128.0 
(C), 129.0, 129.1, 129.3, 130.0 (CH), 132.2, 132.4 (C), 134.8 (CH), 136.8, 136.9, 142.7, 144.4 
(C), 197.2 (CO).  
MS (GC, 70 eV): m/z (%) = 349 (M+, 8), 105 (100).  
HRMS (EI): calcd for C20H19N3O3 (M
+) 349.14209, found 349.14266.  
IR (ATR, cm-1): ν̃ = 2921 (w), 1683 (s), 1564 (w), 1535 (w), 1501 (s), 1424 (w), 1396 (m), 
1335 (s), 1274 (s), 1231 (s), 1122 (w), 1020 (w), 958 (w), 904 (w), 796 (m), 766 (m), 693 (m), 
588 (m).  
 
2-(1-Butyl-2-methyl-4-nitro-1H-imidazol-5-yl)-4,5-dimethoxybenzaldehyde (4.2.1t).  
Starting from 1-butyl-2-methyl-4-nitro-1H-imidazole 4.1.3b 
(0.183 g, 1 mmol), 2-bromo-4,5-dimethoxybenzaldehyde 
(0.490 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.1t was 
isolated as a brown solid (0.295 g, 85%Pd). Mp: 212-214°C.  
1H NMR (300 MHz, DMSO-d6): δ = 0.67 (t, 3H, 3J = 7.3 Hz, CH2CH2CH2CH3), 1.04-1.17 
(m, 2H, CH2CH2CH2CH3), 1.33-1.42 (m, 2H, CH2CH2CH2CH3), 2.46 (s, 3H, Me), 3.61-3.82 
(m, 2H, CH2CH2CH2CH3), 3.85 (s, 3H, OMe), 3.92 (s, 3H, OMe), 7.19 (s, 1H, CHAr), 7.58 (s, 
1H, CHAr), 9.70 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.1, 13.2 (Me), 18.9, 31.1, 44.2 (CH2), 55.7, 56.3 
(OMe), 111.6, 114.5 (CH), 123.5, 128.2, 129.6, 132.0, 143.4, 149.8, 153.2 (C), 189.9 (CHO).  
MS (GC, 70 eV): m/z (%) = 347 (M+, 1), 303 (100), 91 (44).  
HRMS (ESI): calcd for C17H21N3O5 (M+H) 348.1554, found 348.1560.  
IR (ATR, cm-1): ν̃ = 2957 (w), 1666 (m), 1582 (m), 1498 (s), 1447 (w), 14023 (m), 1351 (m), 
1291 (m), 1276 (s), 1222 (s), 1132 (s), 1132 (s), 1077 (m), 1019 (m), 978 (w), 889 (m), 859 
(w), 814 (m), 749 (m), 720 (m), 698 (m), 585 (m), 539 (m).  
 
3-Methyl-1-nitro-6,7-dihydro-5H-benzo[c]imidazo[1,5-a]azepine (4.2.2a).  
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Starting from 2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazole 
4.1.3e (0.245 g, 1 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
Ag2CO3 (0.331 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.2a was 
isolated as a yellow viscous oil (0.199 g, 82%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.23 (t, 2H, 3J = 6.8 Hz, CH2), 2.48 (s, 3H, Me), 2.64 (t, 2H, 
3J = 6.6 Hz, CH2), 3.76 (br s, 2H, CH2), 7.27-7.31 (m, 1H, CHAr), 7.38-7.42 (m, 2H, CHAr), 
7.74-7.78 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.1 (Me), 29.9, 30.8, 42.5 (CH2), 126.9 (CH), 127.3 (C), 
129.0, 130.5, 131.5 (CH), 132.2, 138.3, 142.3 (C).  
MS (GC, 70 eV): m/z (%) = 243 (M+, 100), 212 (11), 156 (22), 144 (45), 128 (31), 116 (66).  
HRMS (EI): calcd for C13H13N3O2 (M
+) 243.10023, found 243.10027.  
IR (ATR, cm-1): ν̃ = 2922 (w), 2854 (w), 1577 (w), 1562 (w), 1529 (m), 1494 (s), 1454 (m), 
1399 (m), 1380 (m), 1329 (s), 1316 (s), 1279 (s), 1238 (m), 1120 (w), 1025 (w), 1004 (m), 
956 (w), 855 (s), 822 (m), 772 (m), 757 (s), 722 (m), 690 (m), 665 (m).  
 
3-Methyl-1-nitro-5,6-dihydroimidazo[5,1-a]isoquinoline (4.2.2b).  
Starting from 2-methyl-4-nitro-1-phenethyl-1H-imidazole 4.1.3c 
(0.231 g, 1 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), Ag2CO3 
(0.331 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 
g, 1.3 mmol) in 8 mL DMA, the product 4.2.2b was isolated as a 
yellow solid (0.222 g, 97%Pd). Mp: 151-152°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.40 (s, 3H, Me), 3.09 (t, 2H, 3J = 6.6 Hz, CH2), 4.08 (t, 
2H, 3J = 6.8 Hz, CH2), 7.36-7.44 (m, 2H, CHAr), 8.25-8.29 (m, 2H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.6 (Me), 28.4, 40.8 (CH2), 124.2 (C), 127.0, 127.4, 
128.2, 129.9 (CH), 134.8, 142.9 (C).  
MS (GC, 70 eV): m/z (%) = 229 (M+, 85), 159 (15), 140 (34), 130 (100), 115 (41), 103 (29).  
HRMS (EI): calcd for C12H11N3O2 (M
+) 229.08458, found 229.08425.  
IR (ATR, cm-1): ν̃ = 2957 (w), 1741 (w), 1610 (w), 1531 (m), 1480 (m), 1403 (m), 1375 (m), 
1344 (m), 1309 (w), 1269 (s), 1066 (m), 1131 (m), 1043 (m), 1002 (m), 937 (m), 845 (s), 780 
(s), 761 (s), 700 (m), 683 (m), 650 (m).  
 
3-Methyl-1-nitro-5,6-dihydrobenzo[f]imidazo[1,5-d][1,4]-oxazepine (4.2.2c).  
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Starting from 2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazole 
4.1.3f (0.247 g, 1 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
Ag2CO3 (0.331 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMA, the product 4.2.2c was 
isolated as a yellow viscous oil (0.186 g, 76%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.51 (s, 3H, Me), 4.01 (t, 2H, 3J = 5.9 Hz, CH2), 4.49 (t, 2H, 
3J = 5.9 Hz, CH2), 7.20 (dd, 1H, 
3J = 8.0 Hz, 4J = 1.1 Hz, CHAr), 7.31 (dt, 1H, 
3J = 7.6 Hz, 4J 
= 1.3 Hz, CHAr), 7.47 (dt, 1H, 
3J = 7.6 Hz, 4J = 1.9 Hz, CHAr), 7.84 (dd, 1H, 
3J = 7.8 Hz, 4J = 
1.7 Hz, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.0 (Me), 42.7, 73.8 (CH2), 121.8 (CH), 122.6 (C), 125.0 
(CH), 130.1 (C), 132.1, 132.2 (CH), 142.0, 153.3 (C).  
MS (GC, 70 eV): m/z (%) = 245 (M+, 100).  
HRMS (EI): calcd for C12H11N3O3 (M
+) 245.08004, found 245.08010.  
IR (ATR, cm-1): ν̃ = 2881 (w), 1743 (w), 1531 (m), 1504 (m), 1450 (m), 1402 (m), 1380 (m), 
1329 (s), 1275 (s), 1231 (m), 1145 (w), 1109 (w), 1043 (m), 884 (w), 837 (m), 799 (m), 753 
(m), 663 (w).  
 
2,5-Bis(4-methoxyphenyl)-4-nitro-1-phenethyl-1H-imidazole (4.2.3a).  
Starting from 4-nitro-1-phenethyl-1H-
imidazole 4.1.3d (0.217 g, 1 mmol), 1-bromo-
4-methoxybenzene (0.374 g, 2.5 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 
g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.320 g, 2.3 mmol) in 8 mL DMA, the product 4.2.3a was isolated as a yellow solid 
(0.249 g, 58%Pd). Mp: 153-155°C.  
1H NMR (300 MHz, CDCl3): δ = 2.47-2.51 (m, 2H, CH2), 3.04 (s, 3H, OMe), 3.85 (s, 3H, 
OMe), 4.16 (t, 2H, 3J = 7.2 Hz, CH2), 6.64-6.67 (m, 2H, CHAr), 7.07-7.17 (m, 7H, CHAr), 
7.32-7.34 (m, 2H, CHAr), 7.55 (d, 2H, 
3J = 9.0 Hz, CHAr). 
13C NMR (62.9 MHz, CDCl3): δ = 34.5, 46.7 (CH2), 55.2, 55.3 (OMe), 114.0, 114.2 (CH), 
119.3, 121.4 (C), 126.7, 128.3, 128.5, 130.4, 131.7 (CH), 133.6, 136.7, 143.2, 145.4, 160.2, 
160.3 (C).  
MS (GC, 70 eV): m/z (%) = 429 (M+, 100), 135 (27), 105 (60).  
HRMS (EI): calcd for C25H23N3O4 (M
+) 429.46782, found 429.46784.  
IR (ATR, cm-1): ν̃ = 1613 (m), 1575 (w), 1505 (m), 1489 (m), 1454 (m), 1379 (m), 1341 (m), 
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1289 (m), 1245 (s), 1171 (s), 1110 (m), 1020 (m), 861 (m), 833 (s), 797 (m), 739 (s), 697 (s), 
645 (m), 535 (m).  
 
4,4′-(4-Nitro-1-phenethyl-1H-imidazole-2,5-diyl)dibenzonitrile (4.2.3b).  
Starting from 4-nitro-1-phenethyl-1H-imidazole 
4.1.3d (0.217 g, 1 mmol), 4-bromobenzonitrile 
(0.455 g, 2.5 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 
0.3 mmol) and K2CO3 (0.320 g, 2.3 mmol) in 8 mL 
DMA, the product 4.2.3b was isolated as a brown solid (0.264 g, 63%Pd). Mp: 224-226°C.  
1H NMR (300 MHz, CDCl3): δ = 2.46 (t, 2H, 3J = 6.8 Hz, CH2), 4.15 (t, 2H, 3J = 6.8 Hz, 
CH2), 6.47-6.50 (m, 2H, CHAr), 7.05-7.19 (m, 3H, CHAr), 7.25-7.29 (m, 2H, CHAr), 7.55-7.58 
(m, 2H, CHAr), 7.69-7.74 (m, 4H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 35.9, 47.5 (CH2), 114.1, 114.3, 117.8 (C), 127.7, 128.3, 
129.1, 129.6, 131.1 (CH), 131.4 (C), 131.6 (CH), 132.6 (C), 132.6 (CH), 132.9, 135.1, 144.5, 
144.9 (C).  
MS (GC, 70 eV): m/z (%) = 419 (M+, 86), 389 (22), 128 (22), 105 (100), 91 (62).  
HRMS (ESI): calcd for C25H18N5O2 (M+H) 420.1455, found 420.14487.  
IR (ATR, cm-1): ν̃ = 2233 (m), 1514 (s), 1480 (m), 1453 (w), 1393 (m), 1346 (s), 1308 (m), 
1260 (m), 1181 (w), 1078 (w), 1007 (w), 918 (w), 858 (m), 845 (s), 754 (m), 746 (m), 699 (s), 
659 (m), 557 (s), 549 (s).  
 
2,5-Bis(3-(trifluoromethyl)phenyl)-4-nitro-1-phenethyl-1H-imidazole (4.2.3c).  
Starting from 4-nitro-1-phenethyl-1H-imidazole 
4.1.3d (0.217 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.562 g, 2.5 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 
1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.320 g, 2.3 mmol) in 8 mL DMA, the product 4.2.3c was isolated as a yellow solid (0.308 g, 
61%Pd). Mp: 184-185°C.  
1H NMR (300 MHz, CDCl3): δ = 2.53 (t, 2H, 3J = 6.7 Hz, CH2), 4.20 (t, 2H, 3J = 6.7 Hz, 
CH2), 6.54-6.57 (m, 2H, CHAr), 7.10-7.20 (m, 3H, CHAr), 7.46-7.53 (m, 2H, CHAr), 7.62-7.82 
(m, 6H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -62.7 (CF3).  
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13C NMR: due to bed solubility it was not possible to measure.  
MS (GC, 70 eV): m/z (%) = 505 (M+, 51), 173 (14), 145 (13), 105 (100), 91 (24).  
HRMS (EI): calcd for C25H17N3O2F6 (M
+) 505.12195, found 505.12226.  
IR (ATR, cm-1): ν̃ = 1568 (w), 1505 (s), 1456 (w), 1381 (w), 1325 (s), 1311 (s), 1240 (m), 
1167 (s), 1120 (s), 1072 (s), 923 (m), 900 (m), 851 (m), 811 (m), 795 (s), 751 (m), 728 (w), 
715 (m), 695 (s), 671 (m), 648 (m).  
 
4-(4-Nitro-1-phenethyl-1H-imidazol-5-yl)benzonitrile (4.2.4a).  
Starting from 4-nitro-1-phenethyl-1H-imidazole 4.1.3d (0.217 
g, 1 mmol), 4-bromobenzonitrile (0.200 g, 1.1 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.180 g, 1.3 mmol) in 
8 mL DMA, the product 4.2.4a was isolated as a yellow solid 
(0.267 g, 84%Pd). Mp: 131-133°C.  
1H NMR (300 MHz, CDCl3): δ = 2.90 (t, 2H, 3J = 6.8 Hz, CH2), 4.07 (t, 2H, 3J = 6.8 Hz, 
CH2), 6.82-6.85 (m, 2H, CHAr), 7.18-7.29 (m, 3H, CHAr), 7.43-7.67 (m, 3H, CHAr), 7.72-7.74 
(m, 2H, CHAr).  
13C NMR (125.7 MHz, CDCl3): δ = 37.0, 47.6 (CH2), 113.8 (CH), 118.0 (C), 127.5 (CH), 
128.2 (C), 128.4, 128.5 (CH), 128.7 (C), 128.8, 129.1, 129.7 (CH), 130.3, 130.7 (C), 131.0, 
132.4, 132.6 (CH), 133.0 (C).  
MS (GC, 70 eV): m/z (%) = 318 (M+, 83), 105 (56), 91 (100).  
HRMS (EI): calcd for C18H14N4O2 (M
+) 318.11113, found 318.111300.  
IR (ATR, cm-1): ν̃ = 2233 (m), 1574 (w), 1514 (s), 1496 (s), 1437 (m), 1405 (w), 1337 (s), 
1275 (m), 1226 (m), 1190 (m), 1112 (m), 1028 (w), 1000 (m), 933 (w), 845 (s), 748 (s), 720 
(m), 697 (s), 655 (s), 566 (m), 541 (s).  
 
5-(4-Nitro-1-phenethyl-1H-imidazol-5-yl)pyrimidine (4.2.4b).  
Starting from 4-nitro-1-phenethyl-1H-imidazole 4.1.3d (0.217 g, 1 
mmol), 5-bromopyrimidine (0.175 g, 1.1 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 
0.3 mmol) and K2CO3 (0.180 g, 1.3 mmol) in 8 mL DMA, the 
product 4.2.4b was isolated as a yellow solid (0.242 g, 82%Pd). Mp: 
137-139°C.  
1H NMR (300 MHz, CDCl3): δ = 2.90 (t, 2H, 3J = 6.6 Hz, CH2), 4.20 (t, 2H, 3J = 6.6 Hz, 
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CH2), 6.94-6.97 (m, 2H, CHAr), 7.21-7.23 (m, 2H, CHAr), 7.57-7.63 (m, 1H, CHAr), 8.07 (s, 
1H, CHAr), 8.74 (s, 2H, CHAr), 9.31 (s, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 35.8, 47.0 (CH2), 122.3, 126.2 (C), 126.8, 128.6, 128.8, 
131.4, 131.5 (CH), 136.9 (C), 137.5 (CH), 144.5 (C) 157.7, 158.8 (CH).  
MS (GC, 70 eV): m/z (%) = 295 (M+, 38), 278 (12), 105 (40), 91 (100), 77 (27).  
HRMS (EI): calcd for C15H13N5O2 (M
+) 295.10638, found 295.10607.  
IR (ATR, cm-1): ν̃ = 3127 (w), 1714 (w), 1599 (w), 1552 (m), 1495 (s), 1454 (m), 1408 (m), 
1371 (s), 1333 (s), 1266 (s), 1223 (m), 1189 (m), 1156 (m), 1119 (m), 1080 (w), 996 (m), 913 
(w), 864 (w), 831 (s), 760 (s), 725 (s), 702 (s), 652 (m), 628 (s), 588 (w), 566 (m), 539 (s).  
 
4-Nitro-5-(3-nitrophenyl)-1-phenethyl-1H-imidazole (4.2.4c).  
Starting from 4-nitro-1-phenethyl-1H-imidazole 4.1.3d (0.217 
g, 1 mmol), 1-bromo-3-nitrobenzene (0.222 g, 1.1 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.180 g, 1.3 mmol) in 
8 mL DMA, the product 4.2.4c was isolated as a yellow solid 
(0.220 g, 65%Pd). Mp: 128-130°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.85 (t, 2H, 3J = 6.7 Hz, CH2), 4.13 (t, 2H, 3J = 6.7 Hz, 
CH2), 6.89-6.92 (m, 2H, CHAr), 7.17-7.19 (m, 3H, CHAr), 7.74-7.81 (m, 2H, CHAr), 8.03 (br s, 
1H, CHAr), 8.09 (br s, 1H, CHAr), 8.35-8.37 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 35.7, 46.9 (CH2), 124.5, 125.2, 126.7, 128.4 (CH), 128.4 
(C), 128.5, 128.8 (CH), 130.0 (C), 130.1, 131.5 (CH), 132.0 (C), 136.7, 136.8 (CH), 137.0, 
147.7 (C).  
MS (GC, 70 eV): m/z (%) = 338 (M+, 70), 105 (46), 91 (100).  
HRMS (EI): calcd for C17H14N4O4 (M
+) 338.10096, found 338.10087.  
IR (ATR, cm-1): ν̃ = 3126 (w), 1526 (s), 1496 (s), 1436 (m), 1383 (w), 1345 (s), 1296 (s), 
1249 (w), 1212 (m), 1158 (m), 1103 (m), 1028 (w), 1004 (m), 902 (m), 829 (s), 763 (m), 731 
(s), 692 (s), 647 (s), 538 (s).  
 
2-(4-Nitro-5-(3-nitrophenyl)-1-phenethyl-1H-imidazol-2-yl)benzaldehyde (4.2.5a).  
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Starting from 4-nitro-5-(3-nitrophenyl)-1-phenethyl-
1H-imidazole 4.2.4c (0.338 g, 1 mmol), 2-
bromobenzaldehyde (0.370 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.180 g, 1.3 mmol) in 
8 mL DMA, the product 4.2.5a was isolated as a 
yellow solid (0.345 g, 78%Pd). Mp: 152-154°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.84 (t, 2H, 3J = 6.6 Hz, CH2), 3.98 (t, 2H, 3J = 6.6 Hz, 
CH2), 6.52-6.55 (m, 2H, CHAr), 7.04-7.15 (m, 3H, CHAr), 7.33-7.36 (m, 1H, CHAr), 7.61-7.74 
(m, 4H, CHAr), 7.96-7.99 (m, 1H, CHAr), 8.12-8.13 (m, 1H, CHAr), 8.30-8.34 (m, 1H, CHAr), 
9.90 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 35.8, 47.1 (CH2), 123.9, 124.8, 125.4, 127.5, 127.6, 138.4 
(CH), 128.7 (C), 129.0, 130.0 (CH), 130.2 (C) 131.2 (CH), 132.0 (C), 134.0, 134.9, 135.1 
(CH), 135.6 (C), 136.4 (CH), 144.2, 144.6, 148.2 (C), 190.9 (CHO).  
MS (GC, 70 eV): m/z (%) = 442 (M+, 70), 310 (77), 264 (22), 105 (100).  
HRMS (ESI): calcd for C24H18N4O5 (M+H) 443.1350, found 443.13495.  
IR (ATR, cm-1): ν̃ = 3084 (w), 2858 (w), 1693 (m), 1600 (w), 1525 (s), 1470 (m), 1453 (m), 
1389 (m), 1346 (s), 1246 (m), 1196 (m), 1137 (w), 1078 (w), 906 (w), 876 (w), 829 (m), 776 
(m), 739 (s), 698 (s), 573 (w).  
 
2-(2-Methyl-4-nitro-1-phenethyl-1H-imidazol-5-yl)benzaldehyde (4.3.1a).  
Starting from 5-bromo-2-methyl-4-nitro-1-phenethyl-1H-
imidazole 4.1.6a (0.310 g, 1 mmol), (2-formylphenyl)boronic acid 
(0.195 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.1a 
was isolated as a yellow solid (0.208 g, 62%). Mp: 162-164°C.  
1H NMR (300 MHz, CDCl3): δ = 2.26 (s, 3H, Me), 2.70 (t, 2H, 3J = 7.1 Hz, CH2), 3.72-3.81 
(m, 1H, CH2), 3.96-4.06 (m, 2H, CH2), 6.78-6.81 (m, 2H, CHAr), 7.11-7.13 (m, 1H, CHAr), 
7.17-7.22 (m, 2H, CHAr), 7.42-7.53 (m, 2H, CHAr), 7.62-7.73 (m, 1H, CHAr), 8.00-8.03 (m, 
1H, CHAr), 9.81 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 36.0, 46.5 (CH2), 127.4 (CH), 128.4 (C), 128.6, 
129.0, 130.6, 131.7, 132.1 (CH), 133.9, 135.1, 136.1 (C), 190.4 (CH).  
MS (GC, 70 eV): m/z (%) = 335 (M+, 1), 289 (100), 105 (39), 91 (15), 77 (14).  
HRMS (ESI): calcd for C19H18N3O3 (M+H) 336.13427, found 336.1346.  
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IR (ATR, cm-1): ν̃ = 1695 (m), 1599 (w), 1531 (m), 1496 (s), 1437 (m), 1384 (m), 1319 (s), 
1293 (s), 1270 (m), 1236 (s), 1201 (m), 1120 (w), 1092 (w), 1003 (w), 931 (w), 850 (m), 824 
(m), 757 (s), 702 (s), 673 (m), 569 (m).  
 
2-(2-Methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazol-5-yl)benzaldehyde (4.3.1b).  
Starting from 5-bromo-2-methyl-4-nitro-1-(3-phenylpropyl)-1H-
imidazole 4.1.6c (0.324 g, 1 mmol), (2-formylphenyl)boronic acid 
(0.195 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.1b 
was isolated as a yellow solid (0.196 g, 56%). Mp: 126-128°C.  
1H NMR (300 MHz, CDCl3): δ = 1.71-1.82 (m, 2H, CH2), 2.40 (s, 
3H, Me), 2.44 (t, 2H, 3J = 7.3 Hz, CH2), 3.47-3.71 (m, 2H, CH2), 6.88-6.92 (m, 2H, CHAr), 
7.11-7.18 (m, 2H, CHAr), 7.27-7.31 (m, 1H, CHAr), 7.37-7.55 (m, 1H, CHAr), 7.66-7.74 (m, 
2H, CHAr), 7.94-8.00 (m, 1H, CHAr), 9.85 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 30.9, 32.3, 44.2 (CH2), 126.4, 127.9 (CH), 
128.3 (C), 128.6, 130.7 (CH), 131.7 (C), 131.9, 132.1, 134.0, 135.1 (CH), 139.2, 143.6 (C), 
190.4 (CH).  
MS (GC, 70 eV): m/z (%) = 349 (M+, 1), 303 (100), 91 (44).  
HRMS (ESI): calcd for C20H20N3O3 (M+H) 350.14992, found 350.15086.  
IR (ATR, cm-1): ν̃ = 1683 (s), 1599 (w), 1564 (w), 1542 (m), 1490 (s), 1453 (m), 1398 (m), 
1353 (m), 1337 (s), 1294 (s), 1269 (m), 1254 (m), 1225 (m), 1197 (m), 1120 (w), 1032 (w), 
1005 (w), 978 (w), 850 (m), 823 (m), 764 (m), 738 (s), 698 (s), 671 (s), 614 (m), 540 (m).  
 
2-(2-Methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazol-5-yl)benzaldehyde (4.3.1c).  
Starting from 5-bromo-2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-
imidazole 4.1.6b (0.326 g, 1 mmol), (2-formylphenyl)boronic acid 
(0.195 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.1c 
was isolated as a yellow solid (0.240 g, 68%). Mp: 148-150°C.  
1H NMR (300 MHz, CDCl3): δ = 2.57 (s, 3H, Me), 3.96-4.24 (m, 4H, 2×CH2), 6.70-6.74 (m, 
2H, CHAr), 6.88-6.93 (m, 1H, CHAr), 7.19-7.25 (m, 2H, CHAr), 7.59-7.64 (m, 1H, CHAr), 7.77-
7.89 (m, 2H, CHAr), 8.10 (dd, 1H, 
3J = 7.3 Hz, 4J = 1.2 Hz, CHAr), 9.86 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 44.1, 65.6 (CH2), 114.2, 121.0, 128.7, 129.4 
(CH), 130.6 (C), 130.7, 131.4, 131.5, 132.0, 134.2 (CH), 135.0, 143.3, 145.2, 157.5 (C), 194.8 
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(CHO).  
MS (GC, 70 eV): m/z (%) = 351 (M+, 1), 305 (21), 44 (100). 
HRMS (EI): calcd for C19H17N3O4 (M
+) 351.35598, found 351.35599.  
IR (ATR, cm-1): ν̃ = 2927 (w), 1690 (m), 1600 (m), 1565 (w), 1538 (w), 1496 (s), 1396 (m), 
1353 (m), 1330 (s), 1293 (m), 1269 (m), 1230 (s), 1179 (m), 1119 (w), 1085 (m), 1051 (m), 
962 (w), 908 (w), 886 (w), 849 (m), 828 (m), 757 (s), 721 (m), 692 (s), 670 (m), 631 (w), 592 
(w), 539 (m).  
 
1-(2-(2-Methyl-4-nitro-1-(2-phenoxyethyl)-1H-imidazol-5-yl)phenyl)ethanone (4.3.1d).  
Starting from 5-bromo-2-methyl-4-nitro-1-(2-phenoxyethyl)-1H-
imidazole 4.1.6b (0.326 g, 1 mmol), (2-acetylphenyl)boronic acid 
(0.213 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.1d 
was isolated as a yellow viscous oil (0.233 g, 37%).  
1H NMR (300 MHz, CDCl3): δ = 2.11 (s, 3H, Me), 2.49 (s, 3H, Me), 2.70-2.76 (m, 2H, CH2), 
3.69-3.79 (m, 1H, CH2), 3.94-4.12 (m, 1H, CH2), 6.89-6.97 (m, 2H, CHAr), 7.04-7.07 (m, 1H, 
CHAr), 7.18-7.24 (m, 3H, CHAr), 7.51-7.62 (m, 2H, CHAr), 7.89-7.92 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.1, 27.8 (Me), 35.4, 46.7 (CH2), 127.0 (C), 128.5, 128.6, 
128.7, 129.3 (CH), 129.3 (C), 130.1, 131.4, 131.8 (CH), 132.6, 136.8, 138.9, 143.9, 199.3 (C).  
MS (GC, 70 eV): m/z (%) = 365 (M+, 1), 319 (100).  
HRMS (ESI): calcd for C20H20N3O4 (M+H) 366.14483, found 366.14499.  
IR (ATR, cm-1): ν̃ = 1699 (m), 1601 (w), 1531 (m), 1496 (s), 1442 (m), 1384 (m), 1319 (s), 
1293 (s), 1275 (m), 1236 (s), 1205 (m), 1120 (w), 1092 (w), 1000 (w), 931 (w), 852 (s), 824 
(m), 759 (m), 702 (s), 673 (m), 569 (m).  
 
2-Methyl-4-nitro-1-phenethyl-5-(4-(trifluoromethyl)phenyl)-1H-imidazole (4.3.1e).  
Starting from 5-bromo-2-methyl-4-nitro-1-phenethyl-1H-
imidazole 4.1.6a (0.310 g, 1 mmol), (4-
(trifluoromethyl)phenyl)boronic acid (0.247 g, 1.3 mmol), 
Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. K2CO3 (1 mL) in 
8 mL Toluene/MeOH (5:1), the product 4.3.1e was isolated as 
a green solid (0.326 g, 87%). Mp: 155-156°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.17 (s, 3H, Me), 3.10 (t, 2H, 3J = 7.1 Hz, CH2), 4.52 (t, 
2H, 3J = 7.1 Hz, CH2), 7.08-7.11 (m, 2H, CHAr), 7.27-7.31 (m, 3H, CHAr), 7.69 (d, 2H, 
3J = 
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8.0 Hz, CHAr), 7.87 (d, 2H, 
3J = 8.0 Hz, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -62.8 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.8 (Me), 36.5, 48.8 (CH2), 124.8 (q, 1J = 270.5 Hz, 
CF3), 125.0 (q, 
4J = 3.7 Hz, CHCCF3), 127.5, 128.8, 129.1, 130.0 (CH), 131.3 (q, 
2J = 33.2 
Hz, CCF3), 134.9, 136.5, 141.9, 148.7 (C).  
MS (GC, 70 eV): m/z (%) = 375 (M+, 10), 329 (100), 105 (58), 91 (49), 77 (26).  
HRMS (EI): calcd for C19H16N3O2F3 (M
+) 375.11891, found 375.11984.  
IR (ATR, cm-1): ν̃ = 1714 (w), 1558 (w), 1506 (w), 1468 (m), 1359 (m), 1317 (s), 1186 (m), 
1108 (s), 1067 (s), 1018 (m), 848 (s), 746 (s), 701 (s), 661 (w), 593 (m).  
 
5-(4-Tert-Butylphenyl)-2-methyl-4-nitro-1-phenethyl-1H-imidazole (4.3.1f).  
Starting from 5-bromo-2-methyl-4-nitro-1-phenethyl-1H-
imidazole 4.1.6a (0.310 g, 1 mmol), (4-(tert-
butyl)phenyl)boronic acid (0.232 g, 1.3 mmol), Pd(PPh3)4 
(0.115 g, 0.10 mmol) and 2M aq. K2CO3 (1 mL) in 8 mL 
Toluene/MeOH (5:1), the product 4.3.1f was isolated as a 
yellow viscous oil (0.258 g, 71%).  
1H NMR (300 MHz, CDCl3): δ = 1.38 (s, 9H, tBu), 2.55 (s, 3H, Me), 2.70 (t, 2H, 3J = 7.2 Hz, 
CH2), 3.97 (t, 2H, 
3J = 7.2 Hz, CH2), 6.76-6.80 (m, 2H, CHAr), 7.19-7.21 (m, 5H, CHAr), 7.50 
(d, 2H, 3J = 8.5 Hz, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.3 (Me), 31.2 (tBu), 34.9 (CtBu), 36.2, 46.4 (CH2), 
124.1 (C), 125.8, 127.3, 128.6, 129.0, 129.7 (CH), 132.5, 136.3, 143.7, 153.2 (C).  
MS (GC, 70 eV): m/z (%) = 363 (M+, 100), 348 (89), 244 (15), 115 (11), 105 (97), 91 (28), 77 
(27).  
HRMS (ESI): calcd for C22H26N3O2 (M+H) 364.20195, found 364.2019.  
IR (ATR, cm-1): ν̃ = 2960 (w), 1575 (w), 1544 (w), 1504 (s), 1452 (m), 1398 (m), 1383 (s), 
1331 (s), 1294 (s), 1248 (s), 1201 (w), 1100 (w), 1048 (w), 1029 (w), 1003 (m), 867 (s), 832 
(m), 769 (m), 744 (s), 698 (s), 669 (m), 629 (w), 577 (m), 558 (m).  
 
2-(2-Methyl-5-nitro-1-phenethyl-1H-imidazol-4-yl)benzaldehyde (4.3.2a).  
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Starting from 4-bromo-2-methyl-5-nitro-1-phenethyl-1H-imidazole 
4.1.7a (0.310 g, 1 mmol), (2-formylphenyl)boronic acid (0.195 g, 
1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. K2CO3 (1 
mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.2a was isolated 
as a brown viscous oil (0.262 g, 78%).  
1H NMR (300 MHz, CDCl3): δ = 2.06 (s, 3H, Me), 3.07 (t, 2H, 3J = 
6.8 Hz, CH2), 4.53 (t, 2H, 
3J = 6.8 Hz, CH2), 7.06-7.09 (m, 1H, CHAr), 7.24-7.27 (m, 1H, 
CHAr), 7.41-7.44 (m, 2H, CHAr), 7.46-7.51 (m, 2H, CHAr), 7.54-7.56 (m, 1H, CHAr), 7.64-7.67 
(m, 1H, CHAr) 7.95 (dd, 1H, 
3J = 7.5 Hz, 4J = 1.47 Hz, CHAr), 9.91 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 13.6 (Me), 36.3, 48.5 (CH2), 127.3 (CH), 128.3 (C), 128.5 
(CH), 128.7 (C), 128.9 (CH), 129.1 (C), 129.4 (CH), 130.9 (C), 131.8, 132.0, 133.2 (CH), 
134.4, 136.5 (C), 190.8 (CHO).  
MS (GC, 70 eV): m/z (%) = 335 (M+, 100).  
HRMS (ESI): calcd for C19H18N3O3 (M+H) 336.13427, found 336.13499.  
IR (ATR, cm-1): ν̃ = 1697 (m), 1600 (w), 1531 (m), 1496 (s), 1440 (m), 1384 (m), 1319 (s), 
1293 (s), 1271 (m), 1236 (s), 1201 (m), 1120 (w), 1092 (w), 1005 (w), 931 (w), 850 (m), 825 
(m), 757 (s), 700 (s), 673 (m), 569 (m).  
 
1-(2-(2-Methyl-5-nitro-1-phenethyl-1H-imidazol-4-yl)phenyl)ethanone (4.3.2b).  
Starting from 4-bromo-2-methyl-5-nitro-1-phenethyl-1H-imidazole 
4.1.7a (0.310 g, 1 mmol), (2-acetylphenyl)boronic acid (0.213 g, 1.3 
mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. K2CO3 (1 mL) 
in 8 mL Toluene/MeOH (5:1), the product 4.3.2b was isolated as a 
red solid (0.265 g, 76%). Mp: 123-125°C.  
1H NMR (300 MHz, CDCl3): δ = 2.00 (s, 3H, Me), 2.56 (s, 3H, Me), 
3.07 (t, 2H, 3J = 6.6 Hz, CH2), 4.50 (t, 2H, 
3J = 6.6 Hz, CH2), 7.14-
7.16 (m, 2H, CHAr), 7.25-7.34 (m, 3H, CHAr), 7.45-7.56 (m, 3H, CHAr), 7.77-7.80 (m, 1H, 
CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4, 27.6 (Me), 36.3, 48.4 (CH2), 126.9, 128.0, 128.7, 
128.8, 128.9, 131.0, 131.1 (CH), 131.9, 133.3, 136.7, 138.7, 145.1, 149.0, 199.6 (C).  
MS (GC, 70 eV): m/z (%) = 349 (M+, 1), 303 (100), 199 (17), 105 (71).  
HRMS (ESI): calcd for C20H20N3O3 (M+H) 350.14992, found 350.15029.  
IR (ATR, cm-1): ν̃ = 1694 (s), 1549 (m), 1498 (m), 1462 (s), 1418 (s), 1353 (s), 1327 (s), 1308 
(s), 1249 (s), 1186 (s), 998 (w), 836 (m), 779 (m), 754 (s), 701 (s), 633 (w), 593 (s).  
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4-(4-Fluorophenyl)-2-methyl-5-nitro-1-phenethyl-1H-imidazole (4.3.2c).  
Starting from 4-bromo-2-methyl-5-nitro-1-phenethyl-1H-
imidazole 4.1.7a (0.310 g, 1 mmol), (4-fluorophenyl)boronic acid 
(0.182 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.2c 
was isolated as a brown viscous oil (0.238 g, 73%).  
1H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3H, Me), 3.08 (t, 2H, 3J 
= 7.4 Hz, CH2), 4.52 (t, 2H, 
3J = 7.4 Hz, CH2), 7.08-7.15 (m, 4H, CHAr), 7.26-7.31 (m, 3H, 
CHAr), 7.75-7.80 (m, 2H, CHAr).  
19F NMR (235 MHz, DMSO-d6): δ = -110.8 (CF).  
13C NMR (62.9 MHz, CDCl3): δ = 13.6 (Me), 36.5, 48.7 (CH2), 115.2 (d, 3J = 20 Hz, CH), 
127.4 (CH), 127.5 (C), 128.8, 129.0 (CH), 131.7 (d, 3J = 8 Hz, CH), 136.6, 142.9, 148.5 (C), 
163.4 (d, 1J = 249.9 Hz, CF).  
MS (GC, 70 eV): m/z (%) = 325 (M+, 30), 279 (100), 238 (15), 133 (14), 105 (48), 91 (40) 77 
(19).  
HRMS (ESI): calcd for C18H17FN3O2 (M+H) 326.12993, found 326.13008.  
IR (ATR, cm-1): ν̃ = 1499 (w), 1456 (w), 1409 (w), 1376 (w), 1351 (w), 1329 (m), 1312 (m), 
1261 (w), 1219 (m), 1183 (m), 1156 (m), 1083 (m), 1016 (m), 841 (s), 795 (s), 759 (s), 708 
(s), 643 (w), 593 (m).  
 
2-Methyl-4-(3,5-dimethylphenyl)-5-nitro-1-phenethyl-1H-imidazole (4.3.2d).  
Starting from 4-bromo-2-methyl-5-nitro-1-phenethyl-1H-
imidazole 4.1.7a (0.310 g, 1 mmol), (3,5-
dimethylphenyl)boronic acid (0.195 g, 1.3 mmol), Pd(PPh3)4 
(0.115 g, 0.10 mmol) and 2M aq. K2CO3 (1 mL) in 8 mL 
Toluene/MeOH (5:1), the product 4.3.2d was isolated as a 
brown viscous oil (0.252 g, 75%).  
1H NMR (300 MHz, CDCl3): δ = 2.09 (s, 3H, Me), 2.33 (s, 
6H, 2xMe), 3.05 (t, 2H, 3J = 7.0 Hz, CH2), 4.46 (t, 2H, 
3J = 7.0 Hz, CH2), 7.02-7.09 (m, 3H, 
CHAr), 7.22-7.32 (m, 5H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 13.8 (Me), 21.3 (2xMe), 36.6, 48.6 (CH2), 125.0, 127.1 
(C), 127.3, 128.7, 128.8, 129.0 (CH), 131.3 (C), 131.4 133.8, 136.8 (CH), 137.6, 138.0, 144.4, 
148.3 (C).  
MS (GC, 70 eV): m/z (%) = 335 (M+, 64), 305 (14), 289 (90), 233 (22), 160 (15), 132 (24), 
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115 (27), 105 (100), 91 (57), 77 (42).  
HRMS (ESI): calcd for C20H22N3O2 (M+H) 336.17065, found 336.17099.  
IR (ATR, cm-1): ν̃ = 2959 (w), 1602 (w), 1537 (w), 1501 (m), 1454 (m), 1417 (s), 1376 (w), 
1354 (s), 1323 (s), 1245 (m), 1178 (s), 1085 (w), 1031 (w), 903 (w), 892 (w), 854 (m), 816 
(m), 752 (s), 700 (s), 656 (w), 632 (m), 571 (w), 536 (w).  
 
2-(2-Methyl-5-nitro-1-(2-phenoxyethyl)-1H-imidazol-4-yl)-benzaldehyde (4.3.2e).  
Starting from 4-bromo-2-methyl-5-nitro-1-(2-phenoxyethyl)-1H-
imidazole 4.1.7b (0.326 g, 1 mmol), (2-formylphenyl)boronic acid 
(0.195 g, 1.3 mmol), Pd(PPh3)4 (0.115 g, 0.10 mmol) and 2M aq. 
K2CO3 (1 mL) in 8 mL Toluene/MeOH (5:1), the product 4.3.2e 
was isolated as a brown viscous oil (0.281 g, 80%).  
1H NMR (300 MHz, CDCl3): δ = 2.66 (s, 3H, Me), 4.38 (t, 2H, 3J 
= 4.8 Hz, CH2), 4.76 (t, 2H, 
3J = 4.8 Hz, CH2), 6.82-6.86 (m, 2H, CHAr), 6.95-7.00 (m, 1H, 
CHAr), 7.25-7.30 (m, 2H, CHAr), 7.50-7.66 (m, 3H, CHAr), 7.98 (dd, 1H, 
3J = 7.4 Hz, 4J = 1.1 
Hz, CHAr), 9.92 (s, 1H, CHO).  
13C NMR (62.9 MHz, CDCl3): δ = 14.6 (Me), 46.7, 66.5 (CH2), 114.2, 121.6, 128.8, 129.6, 
131.0, 133.2, 134.5 (CH), 141.6, 150.2, 157.7 (C), 190.9 (CHO).  
MS (GC, 70 eV): m/z (%) = 351 (M+, 1), 305 (100), 183 (24), 77 (46).  
HRMS (ESI): calcd for C19H18N3O4 (M+H) 352.121914, found 352.121963.  
IR (ATR, cm-1): ν̃ = 1693 (m), 1598 (m), 1491 (s), 1459 (m), 1413 (s), 1354 (m), 1323 (s), 
1296 (m), 1240 (s), 1186 (s), 1082 (m), 1062 (m), 912 (m), 823 (m), 770 (s), 751 (s), 696 (m), 
677 (m), 637 (m), 610 (m).  
 
1-Butyl-7,8-dimethoxy-2-methyl-1H-imidazo[4,5-c]isoquinoline (4.4.3a).  
Starting from 2-(1-butyl-2-methyl-4-nitro-1H-imidazol-5-yl)-
4,5-dimethoxybenzaldehyde 4.2.1t (0.347 g, 1 mmol), Pd/C 
(0.030 g, 0.10 mmol) and H2 balloon in 25 mL MeOH, the 
product 4.4.3a was isolated as a brown viscous oil (0.203 g, 
68%).  
1H NMR (300 MHz, DMSO-d6): δ = 0.71 (t, 3H, 3J = 7.1 Hz, CH2CH2CH2CH3), 1.09-1.15 
(m, 2H, CH2CH2CH2CH3), 1.42-1.44 (m, 2H, CH2CH2CH2CH3), 2.54 (s, 3H, Me), 3.66-3.84 
(m, 2H, CH2CH2CH2CH3), 3.90 (s, 3H, OMe), 3.97 (s, 3H, OMe), 7.23 (s, 1H, CHAr), 7.62 (s, 
1H, CHAr), 9.74 (s, 1H, isoquinoline).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 13.1, 13.2 (Me), 18.9, 31.1, 44.2 (CH2), 55.7, 56.3 
(OMe), 111.5, 114.5 (CH), 123.5, 128.2, 129.6, 143.4, 144.3, 149.8, 153.2 (C), 189.9 (CH).  
MS (GC, 70 eV): m/z (%) = 299 (M+, 100).  
HRMS (EI): calcd for C17H21N3O2 (M
+) 299.36754, found 299.36755.  
IR (ATR, cm-1): ν̃ = 2933 (w), 1665 (m), 1582 (m), 1498 (s), 1448 (m), 1351 (s), 1291 (m), 
1267 (s), 1059 (w), 1132 (s), 1077 (s), 1019 (s), 978 (w), 889 (m), 859 (m), 814 (m), 749 (m), 
675 (w), 639 (w), 585 (m).  
 
2-Methyl-1-phenethyl-1H-imidazo[4,5-c]isoquinoline (4.4.3b).  
Starting from 2-(2-methyl-4-nitro-1-phenethyl-1H-imidazol-5-
yl)benzaldehyde 4.2.1g (0.335 g, 1 mmol), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 4.4.3b was 
isolated as a brown solid (0.186 g, 65%). Mp: 262-264°C.  
1H NMR (300 MHz, CDCl3): δ = 2.12 (s, 3H, Me), 3.20 (br s, 2H, 
CH2), 4.70 (br s, 2H, CH2), 6.88-6.91 (m, 2H, CHAr), 7.22-7.25 (m, 3H, CHAr), 7.52 (t, 1H, 
3J 
= 7.3 Hz, CHAr), 7.66 (t, 1H, 
3J = 7.3 Hz, CHAr), 7.79 (d, 1H, 
3J = 8.3 Hz, CHAr), 8.11 (d, 1H, 
3J = 7.8 Hz, 4J = 0.8 Hz, CHAr), 8.68 (s, 1H, isoquinoline).  
13C NMR (62.9 MHz, CDCl3): δ = 13.4 (Me), 36.0, 47.9 (CH2), 120.9, 118.8 (CH), 119.4, 
122.9, 126.2 (C), 126.3, 126.9, 127.5, 128.7, 128.8, 129.1, 132.1 (CH), 136.4, 143.1, 151.4 
(C).  
MS (GC, 70 eV): m/z (%) = 287 (M+, 81), 196 (100), 128 (36).  
HRMS (EI): calcd for C19H17N3 (M
+) 287.14170, found 287.14121.  
IR (ATR, cm-1): ν̃ = 2999 (w), 1526 (m), 1499 (m), 1454 (m), 1414 (m), 1362 (m), 1337 (m), 
1304 (s), 1228 (m), 1190 (m), 1135 (m), 994 (m), 928 (w), 885 (m), 804 (w), 775 (s), 752 (s), 
670 (s), 665 (m), 649 (m), 619 (s), 569 (m).  
 
2-Methyl-1-(3-phenylpropyl)-1H-imidazo[4,5-c]isoquinoline (4.4.3c).  
Starting from 2-(2-methyl-4-nitro-1-(3-phenylpropyl)-1H-imidazol-
5-yl)benzaldehyde 4.2.1c (0.349 g, 1 mmol), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 4.4.3c was 
isolated as a yellow solid (0.222 g, 74%). Mp: 126-128°C.  
1H NMR (300 MHz, CDCl3): δ = 2.07 (br s, 2H, CH2), 2.51 (s, 3H, 
Me), 2.70 (t, 2H, 3J = 6.6 Hz, CH2), 4.28 (br s, 2H, CH2), 7.10-7.15 
(m, 2H, CHAr), 7.17-7.35 (m, 6H, CHAr), 7.57-7.59 (m, 1H, CHAr), 8.52 (s, 1H, isoquinoline).  
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13C NMR (62.9 MHz, CDCl3): δ = 13.8 (Me), 31.2, 32.8, 45.1 (CH2), 118.6 (CH), 119.0 (C), 
124.3, 124.4 (CH), 125.8 (C), 128.5, 128.7, 129.6, 130.3 (CH), 139.9 (C), 148.3 (CH), 150.3, 
150.4 (C).  
MS (GC, 70 eV): m/z (%) = 301 (M+, 100), 196 (39), 182 (39), 169 (15), 128 (24), 91 (29).  
HRMS (EI): calcd for C20H19N3 (M
+) 301.15735, found 301.15740.  
IR (ATR, cm-1): ν̃ = 1578 (w), 1529 (m), 1503 (m), 1454 (m), 1415 (m), 1309 (s), 1284 (m), 
1231 (m), 1189 (s), 1127 (m), 1044 (w), 991 (m), 903 (m), 829 (w), 776 (m), 754 (s), 702 (s), 
669 (m), 654 (s), 577 (s).  
 
2-Methyl-3-phenethyl-3H-imidazo[4,5-c]isoquinoline (4.4.3d).  
Starting from 2-(2-methyl-5-nitro-1-phenethyl-1H-imidazol-4-
yl)benzaldehyde 4.3.2a (0.335 g, 1 mmol), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 4.4.3d was 
isolated as a red solid (0.195 g, 68%). Mp: 138-140°C.  
1H NMR (300 MHz, CDCl3): δ = 2.24 (s, 3H, Me), 3.20 (t, 2H, 3J 
= 6.8 Hz, CH2), 4.56 (t, 2H, 
3J = 6.8 Hz, CH2), 6.97-7.00 (m, 2H, 
CHAr), 7.20-7.24 (m, 3H, CHAr), 7.51-7.57 (m, 1H, CHAr), 7.75-7.80 (m, 1H, CHAr), 8.07 (d, 
1H, 3J = 8.3 Hz, CHAr), 8.51 (dd, 1H, 
3J = 8.3 Hz, 4J = 0.8 Hz, CHAr), 8.95 (s, 1H, 
isoquinoline).  
13C NMR (62.9 MHz, CDCl3): δ = 13.8 (Me), 36.2, 44.7 (CH2), 120.9, 124.8 (CH), 126.3 (C), 
126.9, 128.4, 128.7, 128.9 (CH), 129.4 (C), 130.4, 132.0, 132.2 (CH), 138.0, 142.4 (C), 146.5 
(CH), 149.8 (C).  
MS (GC, 70 eV): m/z (%) = 287 (M+, 79), 196 (72), 183 (100), 128 (33), 116 (24), 77 (16).  
HRMS (ESI): calcd for C19H18N3 (M+H) 288.14952, found 288.14934.  
IR (ATR, cm-1): ν̃ = 2971 (w), 1630 (m), 1572 (m), 1491 (w), 1453 (m), 1436 (m), 1360 (s), 
1225 (m), 1118 (m), 1024 (m), 1003 (m), 895 (w), 796 (w), 751 (s), 694 (s), 665 (m), 580 (m). 
 
2-Methyl-3-(2-phenoxyethyl)-3H-imidazo[4,5-c]isoquinoline (4.4.3e).  
Starting from 2-(2-methyl-5-nitro-1-(2-phenoxyethyl)-1H-
imidazol-4-yl)benzaldehyde 4.3.2e (0.351 g, 1 mmol), Pd/C (0.030 
g, 0.10 mmol) and H2 balloon in 25 mL MeOH, the product 4.4.3e 
was isolated as a brown viscous oil (0.188 g, 62%).  
1H NMR (300 MHz, CDCl3): δ = 2.83 (s, 3H, Me), 4.39 (t, 2H, 3J 
= 5.2 Hz, CH2), 4.74 (t, 2H, 
3J = 5.2 Hz, CH2), 6.78-6.81 (m, 2H, 
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CHAr), 6.87-6.92 (m, 1H, CHAr), 7.18-7.23 (m, 2H, CHAr), 7.49-7.54 (m, 1H, CHAr), 7.73-7.79 
(m, 1H, CHAr), 8.03 (d, 1H, 
3J = 8.3 Hz, CHAr), 8.50 (dd, 1H, 
3J = 8.3 Hz, 4J = 0.7 Hz, CHAr), 
8.90 (s, 1H, isoquinoline).  
13C NMR(62.9 MHz, CDCl3): δ = 14.6 (Me), 42.5, 66.3 (CH2), 114.2, 120.8, 121.2, 124.9 
(CH), 126.3 (C), 128.3 (CH), 128.7 (C), 129.5, 130.5 (CH), 142.3 (C), 146.4 (CH), 150.5, 
158.0 (C).  
MS (GC, 70 eV): m/z (%) = 303 (M+, 26), 183 (100).  
HRMS (ESI): calcd for C19H18N3O (M+H) 304.14444, found 304.14427.  
IR (ATR, cm-1): ν̃ = 2928 (w), 1724 (w), 1633 (w), 1597 (m), 1496 (m), 1458 (m), 1438 (m), 
1403 (m), 1358 (s), 1291 (m), 1237 (s), 1176 (m), 1082 (m), 1059 (m), 996 (m), 890 (m), 748 
(s), 690 (s), 668 (s), 577 (m).  
 
5-(3-(Nitrophenyl)-2-methyl-4-nitro-1-phenethyl-1H-imidazole (4.2.1u).  
Starting from 2-methyl-4-nitro-1-phenethyl-1H-imidazole 
4.1.3c (0.231 g, 1 mmol), 1-bromo-3-nitrobenzene (0.202 g, 
1 mmol), 1-bromo-3-methoxybenzene (0.187 g, 1 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMA, the product 4.2.1u was isolated as a green solid (0.290 g, 82%Pd). Mp: 
132-133°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.31 (s, 3H, Me), 2.74 (d, 2H, 3J = 7.0 Hz, CH2), 4.07 (d, 
2H, 3J = 7.0 Hz, CH2), 6.84-6.88 (m, 2H, CHAr), 7.15-7.17 (m, 3H, CHAr), 7.75-7.77 (m, 2H, 
CHAr), 8.04-8.05 (m, 1H, CHAr), 8.33-8.36 (m, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.9 (Me), 34.9, 46.0 (CH2), 124.3, 125.3, 126.7, 
128.4, 128.6, 128.8 (CH), 129.1 (C), 130.1, 131.5 (CH), 132.0 (C), 136.7 (CH), 137.0, 142.6, 
144.6, 147.7 (C).  
MS (GC, 70 eV): m/z (%) = 352 (M+, 100), 105 (85), 91 (80).  
HRMS (EI): calcd for C18H16N4O4 (M
+) 352.34404, found 352.34406.  
IR (ATR, cm-1): ν̃ = 3056 (w), 1520 (s), 1494 (m), 1402 (w), 1342 (s), 1291 (s), 1247 (m), 
1162 (w), 1120 (w), 1086 (w), 1019 (w), 929 (w), 884 (w), 856 (s), 837 (w), 810 (w), 767 (w), 
745 (s), 735 (s), 693 (s), 667 (m), 566 (w), 540 (m).  
 
General Procedure for the Synthesis of 4-Nitropyrazoles by Alkylation. Synthesis of 
Compounds 5.1.3a-e: Corresponding 4-nitro-1H-pyrazole 5.1.1 (1 equiv.) and K2CO3 (2.3 
 
  
135 
equiv.) successively were weighed to air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon. The dry DMF (8 mL for 10 mmol of 4-nitro-1H-
pyrazole) and corresponding alkyl bromide 5.1.2 (1.3 equiv.) were added via a syringe, and 
the reaction was heated to 90°C for 8h. Upon completion, the reaction was cooled to room 
temperature and concentrated under vacuum. The crude mass was washed with water, which 
was extracted with chloroform afterward. Finally, the organic phase was dried (Na2SO4), 
filtered, and evaporated to dryness, or (if necessary) the residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired 
alkylated product.  
 
General Procedure for the Synthesis of 4-Nitropyrazoles by Cyclocondensation. 
Synthesis of Compounds 5.1.3f,g: Corresponding hydrazine 5.1.5 (1 equiv.) and 
nitromalonaldehyde 5.1.4 (1.5 equiv.) were placed in a pressure tube under the flow of dry 
argon and dissolved in dry DMF (10 mL for 10 mmol of hydrazine) containing TMSCl (10 
equiv.). The mixture was heated at 120°C for 6h. Then the solution was evaporated under 
reduced pressure. The residue was purified by column chromatography typically using 
heptane/ethyl acetate mixtures to provide the desired 4-nitropyrazole.  
 
General Procedure for Direct C(5)-H Arylation of 4-Nitropyrazoles. Synthesis of 
Compounds 5.2.1a-ä: Corresponding 4-nitropyrazole 5.1.3 (1 equiv.), CuI (1.2 equiv.), 
K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (or NiCl2(PPh3)2) (0.05 
equiv.) successively were weighed to air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon (three times). The dry DMF (8 mL for 1 mmol of 4-
nitropyrazole) and aryl bromide (4 equiv.) were added via a syringe (in the case of solid aryl 
bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction was 
heated to 120°C for 16h. Upon completion, the reaction was cooled to room temperature and 
concentrated under vacuum. The residue was purified by column chromatography typically 
using heptane/ethyl acetate mixtures to provide the desired arylated product.  
 
General Procedure for Synthesis of Compounds 5.2.1′ and 5.2.1′′: Corresponding 4-
nitropyrazole 5.1.3g (1 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and 
PdCl2(PPh3)2 (0.05 equiv.) successively were weighed to air and placed in a Schlenk flask, 
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equipped with a magnetic stir bar, which then was capped with a rubber septum. The reaction 
vessel was evacuated and back filled with argon (three times). The dry DMF (8 mL for 1 
mmol of 4-nitropyrazole) and aryl bromide (4 equiv.) were added via a syringe (in the case of 
solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction 
was heated to 120°C for 16h. Upon completion, the reaction was cooled to room temperature 
and concentrated under vacuum. The residue was purified by column chromatography 
typically using heptane/ethyl acetate mixtures.  
 
General Procedure for One-Pot Double C-H Arylation of 4-Nitropyrazoles. Synthesis of 
Compounds 5.2.2a,b: Corresponding 4-nitropyrazole 5.1.3 (1 equiv.), CuI (6 equiv.), K2CO3 
(2.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively were 
weighed to air and placed in a Schlenk flask, equipped with a magnetic stir bar, which then 
was capped with a rubber septum. The reaction vessel was evacuated and back filled with 
argon (three times). The dry DMF (8 mL for 1 mmol of 4-nitropyrazole) and aryl bromide (6 
equiv.) were added via a syringe (in the case of solid aryl bromide, first it was dissolved in 
dry DMF under inert atmosphere), and the reaction was heated to 120°C for 16h. Upon 
completion, the reaction was cooled to room temperature and concentrated under vacuum. 
The residue was purified by column chromatography typically using heptane/ethyl acetate 
mixtures to provide the desired arylated product.  
 
General Procedure for C-H Arylation of the Third Position of 4-Nitropyrazoles. 
Synthesis of Compounds 5.2.2a-d: Corresponding 4-nitro-5-arylpyrazole 5.2.1 (1 equiv.), 
CuI (4 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 
equiv.) successively were weighed to air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon (three times). The dry DMF (8 mL for 1 mmol of 4-
nitro-5-arylpyrazole) and aryl bromide (4 equiv.) were added via a syringe (in the case of 
solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction 
was heated to 120°C for 16h. Upon completion, the reaction was cooled to room temperature 
and concentrated under vacuum. The residue was purified by column chromatography 
typically using heptane/ethyl acetate mixtures to provide the desired arylated product.  
 
General Procedure for Reduction of 4-Nitropyrazoles. Synthesis of Compounds 5.3.1a,b 
and 5.3.3a-e: To a Schlenk flask equipped with a magnetic stir bar and filled with 
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corresponding 4-nitro-5-arylpyrazole 5.2.1 (1 equiv.) was added 10% Pd/C (0.1 equiv.). The 
flask was fitted with a rubber septum and then held under vacuum for 3min, after that, it was 
filled with MeOH (25 mL for 1 mmol of 4-nitropyrazole) and hydrogen. Holding under 
vacuum was repeated one more time, and after sequential filling with hydrogen, the reaction 
mixture was stirred for 5h under H2 atmosphere (H2 balloon). After the reaction was stopped, 
the mixture was filtered through a Celite pad, and the filtrate was evaporated to dryness or (if 
necessary) was purified by column chromatography typically using heptane/ethyl acetate 
mixtures to provide the desired product.  
 
General Procedure for Reduction of 4-Nitropyrazoles with Formaldehyde. Synthesis of 
Compounds 5.3.2a-c: To a Schlenk flask equipped with a magnetic stir bar and filled with 
corresponding 4-nitro-5-arylpyrazole 5.2.1 (1 equiv.) was added 10% Pd/C (0.1 equiv.). The 
flask was fitted with a rubber septum and then held under vacuum for 3min, after that, it was 
filled with MeOH (25 mL for 1 mmol of 4-nitropyrazole), formaldehyde solution (6 equiv., 37 
wt % in H2O, contains 10-15% methanol as stabilizer), and hydrogen. Holding under vacuum 
was repeated one more time, and after sequential filling with hydrogen, the reaction mixture 
was stirred for 5h under H2 atmosphere (H2 balloon). After the reaction was stopped, the 
mixture was filtered through Celite pad and filtrate was evaporated to dryness or (if 
necessary) was purified by column chromatography typically using heptane/ethyl acetate 
mixtures to provide the desired product.  
 
Competitive Experiment Between Pyrazole 5.1.3c and Electronically Different Aryl 
Bromides. The corresponding N-substituted 4-nitropyrazole 5.1.3c (1 equiv.), CuI (1.2 
equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) 
successively were weighed in air and placed in a Schlenk flask, equipped with a magnetic stir 
bar, which then was capped with a rubber septum. The reaction vessel was evacuated and 
back filled with argon (three times). The dry DMF (8 mL for 1 mmol of N-substituted 4-
nitropyrazole) and aryl bromides (from each 1 equiv.) were added via syringe (in case of solid 
aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction was 
heated to 120°C for 16h. After the reaction was stopped, the mixture was filtered through 
Celite pad and the filtrate was submitted to GC/MS analysis.  
 
Competitive Experiment Between Two Various Pyrazoles. The corresponding N-
substituted 4-nitropyrazoles 5.1.3c and 5.1.3g (from each 1 equiv.), CuI (1.2 equiv.), K2CO3 
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(1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively were 
weighed in air and placed in a Schlenk flask, equipped with a magnetic stir bar, which then 
was capped with a rubber septum. The reaction vessel was evacuated and back filled with 
argon (three times). The dry DMF (8 mL for 2 mmol of N-substituted 4-nitropyrazoles) and 
aryl bromide (1.1 equiv.) were added via syringe (in the case of solid aryl bromide, first it was 
dissolved in dry DMF under inert atmosphere), and the reaction was heated to 120°C for 16h. 
After the reaction was stopped, the mixture was filtered through Celite pad and the filtrate 
was submitted to GC/MS analysis.  
 
1-Butyl-4-nitro-1H-pyrazole (5.1.3a).  
Starting from 4-nitro-1H-pyrazole 5.1.1 (1.13 g, 10 mmol), 1-bromobutane 
(1.78 g, 13 mmol) and K2CO3 (3.20 g, 23 mmol) in 8 mL DMF, the product 
5.1.3a was isolated as a brown solid (1.42 g, 84%). Mp: 92-93°C.  
1H NMR (250 MHz, DMSO-d6): δ = 0.88 (t, 3H, 3J = 7.4 Hz, 
CH2CH2CH2CH3), 1.18-1.27 (m, 2H, CH2CH2CH2CH3), 1.72-1.84 (m, 2H, 
CH2CH2CH2CH3), 4.17 (t, 2H, 
3J = 7.2 Hz, CH2CH2CH2CH3), 8.24 (s, 1H, pyrazole), 8.90 (s, 
1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.2 (Me), 18.9, 31.1, 52.0 (CH2), 130.3 (CH), 134.7 
(C), 135.4 (CH).  
MS (GC, 70 eV): m/z (%) = 169 (M+, 9), 126 (100), 114 (10), 97 (25), 80 (14), 52 (53), 41 
(80).  
HRMS (ESI): calcd for C7H11N3O2 (M+H) 170.0924, found 170.09227.  
IR (ATR, cm-1): ν̃ = 3112 (m), 2931 (m), 2868 (w), 1502 (s), 1458 (m), 1405 (s), 1368 (w), 
1304 (s), 1191 (w), 1129 (m), 999 (m), 957 (w), 892 (m), 817 (s), 754 (s), 659 (w), 599 (m), 
560 (m).  
 
4-Nitro-1-phenethyl-1H-pyrazole (5.1.3b).  
Starting from 4-nitro-1H-pyrazole 5.1.1 (1.13 g, 10 mmol), (2-
bromoethyl)benzene (2.40 g, 13 mmol) and K2CO3 (3.20 g, 23 mmol) in 8 mL 
DMF, the product 5.1.3b was isolated as a white solid (1.93 g, 89%). Mp: 128-
130°C.  
1H NMR (250 MHz, DMSO-d6): δ = 3.14 (d, 2H, 3J = 7.2 Hz, CH2), 4.43 (d, 
2H, 3J = 7.0 Hz, CH2), 7.14-7.31 (m, 5H, CHAr), 8.25 (s, 1H, pyrazole), 8.75 (s, 
1H, pyrazole).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 35.1, 53.4 (CH2), 126.6, 128.4, 128.6, 130.4 (CH), 
134.6 (C), 135.5 (CH), 137.5 (C).  
MS (GC, 70 eV): m/z (%) = 217 (M+, 1), 104 (100), 91 (75), 77 (20), 65 (28), 52 (23), 41 
(10).  
HRMS (EI): calcd for C11H11N3O2 (M
+) 217.08458, found 217.08471.  
IR (ATR, cm-1): ν̃ = 3104 (m), 3030 (w), 2931 (w), 1529 (m), 1498 (s), 1453 (m), 1408 (s), 
1327 (m), 1299 (s), 1146 (w), 1005 (m), 966 (w), 880 (m), 817 (m), 756 (s), 726 (s), 697 (s), 
601 (m), 572 (m), 546 (m).  
 
4-nitro-1-(3-phenylpropyl)-1H-pyrazole (5.1.3c).  
Starting from 4-nitro-1H-pyrazole 5.1.1 (1.13 g, 10 mmol), (3-
bromopropyl)benzene (2.60 g, 13 mmol) and K2CO3 (3.20 g, 23 mmol) in 8 
mL DMF, the product 5.1.3c was isolated as a white viscous oil (2.01 g, 87%).  
1H NMR (250 MHz, CDCl3): δ = 2.16-2.31 (m, 2H, CH2), 2.62-2.70 (m, 2H, 
CH2), 4.13 (t, 
3J = 7.1 Hz, CH2), 7.14-7.34 (m, 5H, CHAr), 8.06-8.10 (m, 2H, 
pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 30.9, 32.4, 52.6 (CH2), 126.1, 128.3, 128.5, 
128.7 (CH), 135.8 (C), 140.0 (CH), 140.5 (C).  
MS (GC, 70 eV): m/z (%) = 231 (M+, 11), 126 (41), 117 (100), 103 (16), 91 (89), 65 (38), 41 
(14).  
HRMS (EI): calcd for C12H13N3O2 (M
+) 231.10023, found 231.10023.  
IR (ATR, cm-1): ν̃ = 3115 (w), 3024 (w), 2923 (w), 1601 (w), 1496 (s), 1446 (m), 1410 (s), 
1365 (m), 1301 (s), 1143 (w), 1031 (w), 1000 (m), 956 (m), 884 (m), 816 (s), 779 (m), 739 
(s), 697 (s), 601 (m), 554 (m).  
 
4-Nitro-1-(2-phenoxyethyl)-1H-pyrazole (5.1.3d).  
Starting from 4-nitro-1H-pyrazole 5.1.1 (1.13 g, 10 mmol), (2-
bromoethoxy)benzene (2.61 g, 13 mmol) and K2CO3 (3.20 g, 23 mmol) in 8 
mL DMF, the product 5.1.3d was isolated as a white solid (2.16 g, 93%). Mp: 
127-128°C.  
1H NMR (250 MHz, DMSO-d6): δ = 4.15 (d, 2H, 3J = 5.3 Hz, CH2), 4.34 (d, 
2H, 3J = 5.3 Hz, CH2), 6.64-6.71 (m, 3H, CHAr), 6.98-7.05 (m, 2H, CHAr), 8.03 
(s, 1H, pyrazole), 8.71 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 52.0, 65.4 (CH2), 114.5, 121.0, 131.0 (CH), 134.9 (C), 
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135.7 (CH), 157.8 (C).  
MS (GC, 70 eV): m/z (%) = 233 (M+, 16), 140 (35), 120 (85), 107 (14), 94 (47), 77 (100), 65 
(58).  
HRMS (EI): calcd for C11H11N3O3 (M
+) 233.07949, found 233.07995.  
IR (ATR, cm-1): ν̃ = 3118 (m), 3040 (w), 2919 (w), 1598 (w), 1527 (m), 1478 (s), 1435 (m), 
1416 (m), 1360 (w), 1321 (m), 1296 (s), 1244 (s), 1136 (w), 1079 (m), 1000 (m), 869 (m), 
818 (s), 745 (s), 682 (s), 609 (s), 552 (m).  
 
1-(4-Methylbenzyl)-4-nitro-1H-pyrazole (5.1.3e).  
Starting from 4-nitro-1H-pyrazole 5.1.1 (1.13 g, 10 mmol), 1-(bromomethyl)-
4-methylbenzene (2.41 g, 13 mmol) and K2CO3 (3.20 g, 23 mmol) in 8 mL 
DMF, the product 5.1.3e was isolated as a white solid (1.81 g, 83%). Mp: 112-
113°C.  
1H NMR (250 MHz, DMSO-d6): δ = 2.27 (s, 3H, Me), 5.34 (s, 2H, CH2), 7.14-
7.25 (m, 4H, CHAr), 8.25 (s, 1H, pyrazole), 9.00 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.6 (Me), 55.6 (CH2), 128.0, 129.2, 130.3 (CH), 
132.2, 132.7, 135.0 (C), 135.8, 137.5 (CH).  
MS (GC, 70 eV): m/z (%) = 217 (M+, 26), 105 (100), 91 (11), 79 (23), 65 (11), 52 (16), 39 
(15).  
HRMS (EI): calcd for C11H11N3O2 (M
+) 217.08458, found 217.08410.  
IR (ATR, cm-1): ν̃ = 3130 (w), 2962 (w), 1558 (w), 1503 (s), 1423 (m), 1403 (s), 1325 (m), 
1291 (m), 1163 (w), 1114 (m), 1000 (m), 926 (w), 866 (m), 812 (s), 755 (s), 694 (w), 590 (m), 
554 (m).  
 
1-Methyl-4-nitro-1H-pyrazole (5.1.3f).  
Starting from methylhydrazine (0.460 g, 10 mmol), enolate of 
nitromalonaldehyde 5.1.4 (2.08 g, 15 mmol) and TMSCl (10.86 g, 100 mmol) 
in 10 mL DMF, the product 5.1.3f was isolated as a yellow solid (1.02 g, 81%). 
Mp: 96-97°C.  
1H NMR (250 MHz, DMSO-d6): δ = 3.91 (s, 3H, Me), 8.22 (s, 1H, pyrazole), 
8.83 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 39.6 (Me), 130.9 (CH), 134.8 (C), 135.4 (CH).  
MS (GC, 70 eV): m/z (%) = 127 (M+, 33), 97 (14), 52 (18), 46 (10), 42 (100), 38 (19), 30 
(25).  
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HRMS (EI): calcd for C4H5N3O2 (M
+) 127.03763, found 127.03757.  
IR (ATR, cm-1): ν̃ = 3112 (m), 2962 (w), 1720 (w), 1529 (m), 1505 (s), 1447 (m), 1400 (s), 
1310 (s), 1191 (w), 1130 (m), 1068 (w), 999 (m), 885 (s), 819 (s), 753 (s), 692 (w), 684 (m), 
591 (s), 548 (m).  
 
4-Nitro-1-p-tolyl-1H-pyrazole (5.1.3g).  
Starting from p-tolylhydrazine (1.22 g, 10 mmol), enolate of 
nitromalonaldehyde 5.1.4 (2.08 g, 15 mmol) and TMSCl (10.86 g, 100 mmol) 
in 10 mL DMF, the product 5.1.3g was isolated as a brown solid (1.76 g, 87%). 
Mp: 98-99°C.  
1H NMR (250 MHz, DMSO-d6): δ = 2.35 (s, 3H, Me), 7.34 (d, 2H, 3J = 8.4 Hz, 
CHAr), 7.81 (d, 2H, 
3J = 8.4 Hz, CHAr), 8.50 (s, 1H, pyrazole), 9.56 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.5 (Me), 119.3, 127.7, 130.0 (CH), 136.1 (C), 136.7 
(CH), 137.9 (C).  
MS (GC, 70 eV): m/z (%) = 203 (M+, 100), 142 (10), 128 (24), 118 (34), 103 (12), 91 (73), 65 
(49), 51 (24).  
HRMS (EI): calcd for C10H9N3O2 (M
+) 203.06893, found 203.06907.  
IR (ATR, cm-1): ν̃ = 3130 (m), 3035 (w), 2924 (w), 1902 (w), 1503 (s), 1405 (s), 1348 (w), 
1312 (s), 1236 (w), 1170 (m), 1107 (w), 1025 (w), 1002 (m), 947 (m), 886 (m), 810 (s), 750 
(s), 657 (w), 594 (m), 563 (m).  
 
4-Nitro-1,5-di-p-tolyl-1H-pyrazole (5.2.1a).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 1-bromo-4-methylbenzene (0.684 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 
0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 5.2.1a was isolated as a brown viscous oil (0.246 g, 83%Pd), (0.132 g, 45%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H, Me), 2.37 (s, 3H, Me), 7.05-7.12 (m, 4H, 
CHAr), 7.20 (br s, 4H, CHAr), 8.36 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1, 21.5 (Me), 123.4 (C), 125.1, 128.5, 129.2, 130.2, 
130.4 (CH), 133.7, 136.2 (C), 137.4 (CH), 138.8, 140.3, 141.0 (C).  
MS (GC, 70 eV): m/z (%) = 293 (M+, 100), 249 (11), 246 (15), 209 (13), 208 (21), 91 (39), 89 
(11), 65 (28).  
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HRMS (ESI): calcd for C17H16N3O2 (M+H) 294.1237, found 294.12351.  
IR (ATR, cm-1): ν̃ = 3041 (w), 1557 (w), 1505 (s), 1388 (s), 1321 (s), 1178 (w), 1112 (w), 
1020 (w), 945 (w), 875 (w), 827 (s), 763 (s), 698 (m), 629 (w), 592 (m).  
 
5-(4-Methoxyphenyl)-4-nitro-1-p-tolyl-1H-pyrazole (5.2.1b).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 
1 mmol), 1-bromo-4-methoxybenzene (0.748 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 
0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 5.2.1b was isolated as a brown viscous oil (0.188 g, 61%Pd), (0.123 g, 40%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.32 (s, 3H, Me), 3.81 (s, 3H, OMe), 6.86-6.89 (m, 2H, 
CHAr), 7.05-7.12 (m, 4H, CHAr), 7.20-7.23 (m, 2H, CHAr), 8.35 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 55.3 (OMe), 114 (CH), 118.3 (C), 125.1, 129.9, 
131.9 (CH), 133.2, 136.2 (C), 137.4 (CH), 138.8, 140.8, 160.8 (C).  
MS (GC, 70 eV): m/z (%) = 309 (M+, 100), 224 (11), 91 (21), 65 (14).  
HRMS (ESI): calcd for C17H16N3O3 (M+H) 310.11862, found 310.11868.  
IR (ATR, cm-1): ν̃ = 3021 (w), 1611 (m), 1558 (w), 1506 (s), 1455 (m), 1392 (s), 1324 (s), 
1291 (m), 1250 (m), 1176 (s), 1113 (w), 1026 (m), 1014 (m), 954 (m), 862 (w), 842 (s), 821 
(s), 762 (s), 713 (w), 615 (m), 595 (m).  
 
4-(4-Nitro-1-p-tolyl-1H-pyrazol-5-yl)benzonitrile (5.2.1c).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 4-bromobenzonitrile (0.728 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1c was 
isolated as a brown viscous oil (0.258 g, 85%Pd), (0.152 g, 50%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H, Me), 7.01 (d, 2H, 3J = 8.3 Hz, CHAr), 7.12 (d, 
2H, 3J = 8.3 Hz, CHAr), 7.42 (d, 2H, 
3J = 8.6 Hz, CHAr), 7.64 (d, 2H, 
3J = 8.6 Hz, CHAr), 8.35 
(s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21 (Me), 113.8, 117.8 (C), 125.1, 127.8, 129.9, 131.2, 
132.0, 132.8 (CH), 134.0, 135.3 (C), 137.3 (CH), 138.6, 139.6, 143.4 (C).  
MS (GC, 70 eV): m/z (%) = 304 (M+, 100), 303(13), 257 (16), 219 (10) 91 (35), 65 (20).  
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HRMS (ESI): calcd for C17H13N4O2 (M+H) 305.1033, found 305.10312.  
IR (ATR, cm-1): ν̃ = 3042 (w), 1557 (w), 1508 (s), 1455 (m), 1390 (s), 1322 (s), 1200 (w), 
1179 (w), 1112 (w) 1007 (w), 955 (m), 909 (m), 820 (s), 728 (s), 649 (m), 630 (w), 595 (m), 
552 (s).  
 
5-(3-(Trifluoromethyl)phenyl)-4-nitro-1-p-tolyl-1H-pyrazole (5.2.1d).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 1-bromo-3-(trifluoromethyl)benzene (0.900 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1d was 
isolated as a brown viscous oil (0.256 g, 74%Pd), (0.156 g, 45%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.32 (s, 3H, Me), 7.04 (d, 2H, 3J = 8.5 Hz, CHAr), 7.12 (d, 
2H, 3J = 8.5 Hz, CHAr), 7.49-7.56 (m, 3H, CHAr), 7.66-7.70 (m, 1H, CHAr), 8.38 (s, 1H, 
pyrazole).  
19F NMR (282 MHz, CDCl3): δ = -62.9 (CF3).  
13C NMR (75.5 MHz, CDCl3): δ = 21 (Me), 123.4 (q, 1J = 262 Hz, CF3), 126.7 (q, 3J = 4 Hz, 
CHCCF3), 127.5 (q, 
3J = 4 Hz, CHCCF3), 129.0, 129.8, 130.0, 130.9 (CH), 131.0 (q, 
2J = 33 
Hz, CCF3), 133.8 (CH), 134.0, 135.5 (C), 137.3 (CH), 139.1, 139.5 (C).  
MS (GC, 70 eV): m/z (%) = 347 (M+, 100), 300 (16), 346 (14), 262 (11), 91 (25), 65 (14).  
HRMS (EI): calcd for C17H12N3O2F3 (M
+) 347.08761, found 347.08784.  
IR (ATR, cm-1): ν̃ = 3043 (w), 1556 (w), 1505 (s), 1391 (s), 1311(s), 1266 (m), 1124 (s), 1073 
(s), 1024 (m), 904 (m), 868 (w), 830 (s), 699 (s), 646 (m), 529 (m).  
 
4,5-Dimethoxy-2-(4-nitro-1-p-tolyl-1H-pyrazol-5-yl)benzaldehyde (5.2.1e).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 2-bromo-4,5-dimethoxybenzaldehyde (0.980 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 5.2.1e was isolated as a 
brown viscous oil (0.176 g, 48%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.31 (s, 3H, Me), 3.82 (s, 3H, OMe), 3.97 (s, 3H, OMe), 
6.72 (s, 1H, CHAr), 7.02-7.10 (m, 4H, CHAr), 7.41 (s, 1H, CHAr), 8.41 (s, 1H, pyrazole), 9.66 
(s, 1H, CHO).  
 
 
  
144 
13C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 56.2 (OMe), 56.4 (OMe), 111.3, 113.5 (CH), 
122.7 (C), 124.7 (CH), 128.5 (C), 129.8 (CH), 135.7 (C), 137.2 (CH), 137.9, 139.3, 150.6, 
153.4 (C), 188.1 (CH).  
MS (GC, 70 eV): m/z (%) = 367 (M+, 16), 367 (16), 350 (12), 322 (34), 321 (100), 309 (12), 
308 (15), 305 (13), 277 (13), 91 (22), 65 (17).  
HRMS (ESI): calcd for C19H18N3O5 (M+H) 368.1241, found 368.12386.  
IR (ATR, cm-1): ν̃ = 3010 (w), 1683 (m), 1592 (w), 1557 (w), 1505 (s), 1456 (m), 1394 (s), 
1316 (s), 1281 (s), 1221 (m), 1163 (m), 1118 (s), 1016 (s), 976 (w), 875 (m) 817 (s), 785 (m), 
763 (w), 746 (m), 716 (w), 629 (w), 584 (w).  
 
4-Nitro-5-phenyl-1-p-tolyl-1H-pyrazole (5.2.1f).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), bromobenzene (0.628 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) 
in 8 mL DMF, the product 5.2.1f was isolated as a brown viscous oil 
(0.206 g, 74%Pd), (0.106 g, 38%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.32 (s, 3H, Me), 7.04-7.11 (m, 4H, CHAr), 7.27-7.31 (m, 
2H, CHAr), 7.34-7.43 (m, 3H, CHAr), 8.37 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 125.1 (CH), 126.6 (C), 128.5, 129.6, 130.0, 
130.4 (CH), 136.1 (C), 137.4 (CH), 138.9, 140.8 (C).  
MS (GC, 70 eV): m/z (%) = 279 (M+, 100), 279 (100), 235 (11), 232 (16), 194 (14), 91 (34), 
89 (11), 65 (23).  
HRMS (ESI): calcd for C16H14N3O2 (M+H) 280.10805, found 280.10789.  
IR (ATR, cm-1): ν̃ = 3056 (w), 1606 (w), 1556 (w), 1504 (s), 1446 (m), 1386 (s), 1322 (s), 
1184 (m), 1116 (w), 1069 (w), 1034 (w), 1007 (w), 949 (m), 915 (m), 861 (m) 821 (s), 754 
(s), 709 (m), 690 (s), 646 (m), 594 (m), 528 (s).  
 
5-(2-Fluorophenyl)-4-nitro-1-p-tolyl-1H-pyrazole (5.2.1g).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 1-bromo-2-fluorobenzene (0.700 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 
1.3 mmol) in 8 mL DMF, the product 5.2.1g was isolated as a brown 
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viscous oil (0.130 g, 44%Pd), (0.056 g, 19%Ni).  
1H NMR (300 MHz, DMSO-d6): δ = 2.29 (s, 3H, Me), 7.16-7.22 (m, 4H, CHAr), 7.23-7.35 
(m, 2H, CHAr), 7.46-7.59 (m, 2H, CHAr), 8.69 (s, 1H, pyrazole).  
19F NMR (282 MHz, DMSO-d6): δ = -112.7 (CF).  
13C NMR (75.5 MHz, DMSO-d6): δ = 20.5 (Me), 114.6 (d, J = 14 Hz, C), 115.7 (d, J = 24 Hz, 
CH), 124.6 (d, J = 3 Hz, CH), 125.0, 129.6, 132.2 (CH), 133.0 (d, J = 8 Hz, CH), 134.7 (d, J 
= 79 Hz, CF), 135.5 (C), 137.2 (CH), 139.1, 157.6, 160.9 (C).  
MS (GC, 70 eV): m/z (%) = 297 (M+, 100), 132 (17), 91 (66), 65 (44).  
HRMS (ESI): calcd for C16H12N3O2F (M+H) 298.09863, found 298.09895.  
IR (ATR, cm-1): ν̃ = 2923 (w), 1711 (w), 1623 (w), 1559 (w), 1507 (s), 1460 (m), 1392 (s), 
1324 (s), 1265 (w), 1224 (m), 1178 (w), 1109 (w), 1035 (w), 957 (w), 866 (w), 815 (s), 757 
(s), 710 (w), 646 (w), 595 (w), 550 (w).  
 
2-(4-Nitro-1-p-tolyl-1H-pyrazol-5-yl)pyrimidine (5.2.1h).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 2-bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1h was 
isolated as a yellow solid (0.123 g, 44%Pd). Mp: 204-206°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.28 (s, 3H, Me), 7.15-7.23 (m, 4H, CHAr), 7.65 (t, 1H, 
3J = 4.9 Hz, CHAr), 8.69 (s, 1H, pyrazole), 8.96 (d, 2H, 
3J = 4.9 Hz, pyrimidine).  
13C NMR (62.9 MHz, DMSO-d6): δ =20.5 (Me), 122.0, 124.3, 129.8 (CH), 134.2, 135.6 (C), 
136.7 (CH), 138.2, 139.1, 155.8 (C), 158.1 (CH).  
MS (GC, 70 eV): m/z (%) = 281 (M+, 50), 264 (77), 234 (100), 91 (41).  
HRMS (EI): calcd for C14H11N5O2 (M
+) 281.09073, found 281.09078.  
IR (ATR, cm-1): ν̃ = 1558 (w), 1512 (s), 1465 (m), 1394 (s), 1324 (s), 1288 (m), 1218 (w), 
1176 (w), 1099 (w), 1042 (w), 988 (w), 960 (m), 868 (w), 818 (s), 758 (m), 732 (w), 709 (m), 
667 (w), 650 (w), 625 (m), 596 (m), 534 (m).  
 
3-(4-Nitro-1-p-tolyl-1H-pyrazol-5-yl)pyridine (5.2.1i).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 3-bromopyridine (0.632 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 
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8 mL DMF, the product 5.2.1i was isolated as a brown viscous oil (0.235 g, 84%Pd), (0.092g, 
33%Ni).  
1H NMR (300 MHz, CDCl3): δ = 2.32 (s, 3H, Me), 7.04 (d, 2H, 3J = 8.5 Hz, CHAr), 7.12 (d, 
2H, 3J = 8.5 Hz, CHAr),7.32-7.36 (m, 1H, pyridine), 7.67-7.71 (m, 1H, pyridine), 8.39 (s, 1H, 
pyrazole) 8.47 (s, 1H, pyridine), 8.64 (d, 3J = 4.02 Hz,1H, pyridine).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 123.2, 125.3, 130.0 (CH), 134.4, 135.5 (C), 
137.5 (CH), 137.6 (C), 138.1 (CH), 139.6 (C), 150.5, 150.7 (CH).  
MS (GC, 70 eV): m/z (%) = 280 (M+, 100), 280 (100), 279 (70), 236 (16), 234 (14), 233 (52), 
232 (17), 220 (11), 195 (11), 91 (33), 65 (26).  
HRMS (ESI): calcd for C15H13N4O2 (M+H) 281.1033, found 281.1033.  
IR (ATR, cm-1): ν̃ = 3054 (w), 1599 (w), 1549 (w), 1494 (s), 1471 (m), 1392 (s), 1318 (s), 
1192 (m), 1179 (w), 1110 (w), 1031 (m), 1005 (w), 955 (m), 920 (w), 861 (m) 824 (s), 761 
(s), 706 (s), 620 (m), 533 (s).  
 
5-(4-Nitro-1-p-tolyl-1H-pyrazol-5-yl)pyrimidine (5.2.1j).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 5-bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1j was 
isolated as a brown viscous oil (0.230 g, 82%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.35 (s, 3H, Me), 7.05 (d, 2H, 3J = 8.5 Hz, CHAr), 7.17 (d, 
2H, 3J = 8.5 Hz, CHAr), 8.42 (s, 1H, pyrazole), 8.68 (s, 2H, pyrimidine), 9.22 (s, 1H, 
pyrimidine).  
13C NMR (75.5 MHz, CDCl3): δ = 21.2 (Me), 122.1 (C), 125.5, 130.3 (CH), 134.4, 134.7, 
135.0 (C), 137.6 (CH), 140.3 (C), 157.8, 159.1 (CH).  
MS (GC, 70 eV): m/z (%) = 281 (M+, 100), 280 (16), 264 (26), 237 (22), 235 (13), 234 (68), 
221 (12), 207 (18), 91 (49), 65 (33).  
HRMS (EI): calcd for C14H11N5O2 (M
+) 281.09073, found 281.09048.  
IR (ATR, cm-1): ν̃ = 3046 (w), 1598 (w), 1556 (m), 1495 (s), 1463 (m), 1396 (s), 1320 (s), 
1286 (m), 1212 (m), 1165 (w), 1111 (w), 1039 (w), 1002 (w), 957 (m), 918 (w), 862 (w) 825 
(s), 762 (s), 743 (w), 723 (s), 628 (s), 539 (m).  
 
1-Methyl-4-nitro-5-(3-nitrophenyl)-1H-pyrazole (5.2.1k).  
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Starting from 1-methyl-4-nitro-1H-pyrazole 5.1.3f (0.127 g, 1 
mmol), 1-bromo-3-nitrobenzene (0.808 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 
0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 5.2.1k was isolated as a brown solid (0.235 g, 95%Pd). 
Mp: 126-128°C.  
1H NMR (300 MHz, DMSO-d6): δ = 3.73 (s, 3H, Me), 7.85-7.95 (m, 1H, CHAr), 8.05-8.09 
(m, 1H, CHAr), 8.41-8.45 (m, 2H, CHAr, pyrazole), 8.53-8.54 (m, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 38.1 (Me), 125.0, 125.2 (CH), 128.2 (C), 130.2 (CH), 
132.4 (C), 135.9, 136.7 (CH), 138.8, 147.8, 162.3 (C).  
MS (GC, 70 eV): m/z (%) = 248 (M+, 100), 163 (26), 117 (52).  
HRMS (EI): calcd for C10H8N4O4 (M
+) 248.05401, found 248.05381.  
IR (ATR, cm-1): ν̃ = 3068 (w), 1673 (w), 1526 (m), 1505 (m), 1472 (m), 1388 (m), 1349 (s), 
1322 (m), 1239 (m) 1172 (w), 1087 (m), 979 (w), 919 (w), 826 (m), 758 (m), 726 (m), 694 
(m), 675 (m), 640 (m), 592 (w).  
 
5-(3-Methoxyphenyl)-1-methyl-4-nitro-1H-pyrazole (5.2.1l).  
Starting from 1-methyl-4-nitro-1H-pyrazole 5.1.3f (0.127 g, 1 
mmol), 1-bromo-3-methoxybenzene (0.748 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMF, the product 5.2.1l was isolated as a yellow viscous oil 
(0.193 g, 83%Pd).  
1H NMR (250 MHz, CDCl3): δ = 3.73 (s, 3H, NMe), 3.84 (s, 3H, OMe), 6.89-6.95 (m, 2H, 
CHAr), 7.05-7.09 (m, 1H, CHAr), 7.44 (t, 1H, 
3J = 7.5 Hz, CHAr), 8.17 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 38.0 (NMe), 55.4 (OMe), 115.3, 115.9, 121.7 (CH), 127.7 
(C), 130.0, 136.3 (CH), 141.3, 159.7 (C).  
MS (GC, 70 eV): m/z (%) = 233 (M+, 100), 148 (30), 133 (30), 115 (30), 95 (76).  
HRMS (EI): calcd for C11H11N3O3 (M
+) 233.07949, found 233.07921.  
IR (ATR, cm-1): ν̃ = 2923 (w), 1582 (w), 1555 (w), 1499 (m), 1465 (m), 1390 (m), 1348 (m), 
1323 (s), 1285 (m), 1257 (m), 1208 (m), 1168 (m), 1044 (m), 1021 (m), 975 (w), 824 (s), 786 
(m), 761 (m), 737 (m), 691 (m), 640 (w).  
 
5-(4-Methoxyphenyl)-1-methyl-4-nitro-1H-pyrazole (5.2.1m).  
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Starting from 1-methyl-4-nitro-1H-pyrazole 5.1.3f (0.127 g, 
1 mmol), 1-bromo-4-methoxybenzene (0.748 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 
0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 5.2.1m was isolated as a brown solid (0.144 g, 62%Pd), (0.051 g, 22%Ni). Mp: 67-
68°C.  
1H NMR (300 MHz, DMSO-d6): δ = 3.70 (s, 3H, NMe), 3.85 (s, 3H, OMe), 7.09 (d, 2H, 3J = 
8.6 Hz, CHAr), 7.50 (d, 2H, 
3J = 8.6 Hz, CHAr), 8.35 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 37.9 (NMe), 55.3 (OMe), 114.0 (CH), 118.1 (C), 131.6 
(CH), 132.2 (C), 136.0 (CH), 141.1, 160.5 (C).  
MS (GC, 70 eV): m/z (%) = 233 (M+, 100), 148 (25), 133 (28), 101 (15).  
HRMS (ESI): calcd for C11H12N3O3 (M+H) 234.08732, found 234.08738.  
IR (ATR, cm-1): ν̃ = 2837 (w), 1609 (m), 1575 (w), 1505 (s), 1459 (m), 1440 (m), 1391 (s), 
1321 (s), 1297 (m), 1259 (s), 1175 (s), 1111 (m), 1034 (m), 970 (m), 945 (w), 867 (m), 834 
(s), 798 (m), 762 (s), 696 (w), 642 (m), 615 (m), 586 (s), 530 (m).  
 
1-(3-(1-Methyl-4-nitro-1H-pyrazol-5-yl)phenyl)ethanone (5.2.1n).  
Starting from 1-methyl-4-nitro-1H-pyrazole 5.1.3f (0.127 g, 1 
mmol), 1-(3-bromophenyl)ethanone (0.796 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMF, the product 5.2.1n was isolated as a brown solid 
(0.198 g, 78%Pd). Mp: 109-111°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, COMe), 3.71 (s, 3H, Me), 7.70-7.75 (m, 1H, 
CHAr), 7.83-7.87 (m, 1H, CHAr), 8.12-8.17 (m, 2H, CHAr), 8.41 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 26.8, 38.0 (Me), 127.1 (C), 129.1, 129.7, 129.8 (CH), 
132.6 (C), 134.5, 136.0 (CH), 137.0, 140.3, 197.4 (C).  
MS (GC, 70 eV): m/z (%) = 245 (M+, 37), 230 (100), 43 (42).  
HRMS (EI): calcd for C12H11N3O3 (M
+) 245.07949, found 245.07931.  
IR (ATR, cm-1): ν̃ = 3064 (w), 1678 (s), 1605 (m), 1552 (w), 1483 (s), 1423 (m), 1392 (s), 
1220 (s), 1169 (m), 1037 (w), 962 (w), 944 (w), 860 (m), 828 (s), 802 (s), 761 (s), 693 (m), 
588 (m).  
 
 
 
  
149 
5-(1-Methyl-4-nitro-1H-pyrazol-5-yl)pyrimidine (5.2.1o).  
Starting from 1-methyl-4-nitro-1H-pyrazole 5.1.3f (0.127 g, 1 mmol), 
5-bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1o was 
isolated as a brown solid (0.188 g, 92%Pd). Mp: 177-179°C.  
1H NMR (300 MHz, DMSO-d6): δ = 3.82 (s, 3H, Me), 8.47 (s, 1H, pyrazole), 9.11 (s, 2H, 
pyrimidine), 9.37 (s, 1H, pyrimidine).  
13C NMR (62.9 MHz, DMSO-d6): δ = 38.3 (Me), 122.0 (C), 128.6, 131.4 (CH), 131.9, 135.4 
(C), 136.1, 157.8, 159.1 (CH).  
MS (GC, 70 eV): m/z (%) = 205 (M+, 100), 175 (27), 161 (25), 134 (42), 120 (31), 79 (27), 62 
(78).  
HRMS (EI): calcd for C8H7N5O2 (M
+) 205.05943, found 205.05932.  
IR (ATR, cm-1): ν̃ = 2961 (w), 1713 (w), 1674 (w), 1598 (w), 1556 (m), 1496 (m), 1471 (m), 
1392 (s), 1320 (s), 1248 (m), 1193 (m), 1154 (m), 1119 (m), 1052 (w), 999 (w), 972 (m), 920 
(m), 878 (m), 828 (m), 761 (m), 716 (s), 694 (m), 641 (m), 628 (m), 594 (m), 539 (s).  
 
1-Butyl-4-nitro-5-p-tolyl-1H-pyrazole (5.2.1p).  
Starting from 1-butyl-4-nitro-1H-pyrazole 5.1.3a (0.169 g, 1 
mmol), 1-bromo-4-methylbenzene (0.684 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 
8 mL DMF, the product 5.2.1p was isolated as a yellow solid 
(0.215 g, 83%Pd). Mp: 163-164°C.  
1H NMR (300 MHz, DMSO-d6): δ = 0.73 (t, 3H, 3J = 7.7 Hz, CH2CH2CH2CH3), 1.05-1.17 
(m, 2H, CH2CH2CH2CH3), 1.59-1.68 (m, 2H, CH2CH2CH2CH3), 2.41 (s, 3H, Me), 3.93 (t, 
3H, 3J = 6.7 Hz, CH2CH2CH2CH3), 7.35-7.42 (m, 4H, CHAr), 8.38 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.2 (Me), 18.7 (CH2), 21.0 (Me), 30.9, 49.4 (CH2), 
123.5 (C), 129.2, 129.6 (CH), 132.2 (C), 136.17 (CH), 139.8, 141.3 (C).  
MS (GC, 70 eV): m/z (%) = 259 (M+, 17), 227 (100).  
HRMS (ESI): calcd for C14H18N3O2 (M+H) 260.13935, found 260.13948.  
IR (ATR, cm-1): ν̃ = 3126 (w), 2953 (w), 2232 (m), 1555 (w), 1500 (s), 1496 (m), 1396 (s), 
1320 (s), 1251 (m), 1195 (m), 1113 (w), 1027 (w), 983 (w), 880 (w), 846 (s), 763 (s), 685 (w), 
595 (w), 569 (m), 548 (s).  
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2-(1-Butyl-4-nitro-1H-pyrazol-5-yl)benzaldehyde (5.2.1q).  
Starting from 1-butyl-4-nitro-1H-pyrazole 5.1.3a (0.169 g, 1 mmol), 
2-bromobenzaldehyde (0.740 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1q 
was isolated as a brown viscous oil (0.174 g, 64%Pd).  
1H NMR (250 MHz, DMSO-d6): δ = 0.70 (t, 3H, 3J = 7.2 Hz, 
CH2CH2CH2CH3), 1.05-1.17 (m, 2H, CH2CH2CH2CH3), 1.53-1.64 (m, 2H, CH2CH2CH2CH3), 
3.78-3.85 (m, 2H, CH2CH2CH2CH3), 7.61-7.64 (m, 1H, CHAr), 7.86-7.90 (m, 2H, CHAr), 
8.15-8.18 (m, 1H, CHAr), 8.44 (s, 1H, pyrazole), 9.92 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.1 (Me), 18.7, 30.6, 49.5 (CH2), 126.6 (C), 131.2, 
131.4 (CH), 132.2 (C), 132.7 (CH), 133.0 (C), 134.3 (CH), 134.5 (C), 136.0 (CH), 139.3 (C), 
192.0 (CHO).  
MS (GC, 70 eV): m/z (%) = 273 (M+, 1), 227 (100), 183 (18), 171 (55), 129 (29), 115 (23), 
102 (26).  
HRMS (EI): calcd for C14H15O3N3 (M
+) 273.11079, found 273.11081.  
IR (ATR, cm-1): ν̃ = 3391 (w), 2958 (w), 1703 (m), 1599 (w), 1558 (w), 1500 (s), 1461 (m), 
1401 (s9, 1321 (s), 1271 (m), 1242 (m), 1197 (m), 1023 (w), 845 (w), 826 (s), 758 (s), 605 
(w).  
 
1-(4-Methylbenzyl)-4-nitro-5-(3-nitrophenyl)-1H-pyrazole (5.2.1r).  
Starting from 1-(4-methylbenzyl)-4-nitro-1H-pyrazole 5.1.3e 
(0.217 g, 1 mmol), 1-bromo-3-nitrobenzene (0.808 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMF, the product 5.2.1r was isolated as a yellow solid (0.246 
g, 73%Pd). Mp: 157-158°C.  
1H NMR (300 MHz, CDCl3): δ = 2.30 (s, 3H, Me), 5.13 (s, 2H, CH2), 6.86 (d, 2H, 3J = 7.9 
Hz, CHAr), 7.08 (d, 2H, 
3J = 7.9 Hz, CHAr), 7.56-7.60 (m, 1H, CHAr), 7.67 (t, 1H, 
3J = 8.0 Hz, 
CHAr), 8.08-8.10 (m, 1H, CHAr), 8.26 (s, 1H, pyrazole), 8.36-8.40 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1 (Me), 54.8 (CH2), 125.0, 125.1, 127.3 (CH), 128.3 
(C), 129.7, 129.9 (CH), 131.5, 133.9 (C), 135.9, 136.5 (CH), 138.7, 148.1 (C).  
MS (GC, 70 eV): m/z (%) = 338 (M+, 1), 105 (100).  
HRMS (EI): calcd for C17H14N4O4 (M
+) 338.10096, found 338.10021.  
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IR (ATR, cm-1): ν̃ = 3117 (w), 2919 (w), 1620 (w), 1565 (w), 1530 (s), 1498 (s), 1477 (s), 
1453 (m), 1400 (s), 1344 (s), 1322 (s), 1247 (m), 1184 (m), 1085 (w), 1035 (w), 1006 (w), 
900 (m), 871 (m), 829 (s), 773 (s), 740 (s), 696 (m), 680 (m), 651 (w), 607 (m), 534 (w).  
 
2-(1-(4-Methylbenzyl)-4-nitro-1H-pyrazol-5-yl)benzaldehyde (5.2.1s).  
Starting from 1-(4-methylbenzyl)-4-nitro-1H-pyrazole 5.1.3e (0.217 
g, 1 mmol), 2-bromobenzaldehyde (0.740 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
5.2.1s was isolated as a yellow viscous oil (0.215 g, 67%Pd).  
1H NMR (300 MHz, DMSO-d6): δ = 2.22 (s, 3H, Me), 5.05-5.06 (m, 
2H, CH2), 6.81 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.03 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.51-7.54 (m, 1H, 
CHAr), 7.81-7.84 (m, 2H, CHAr), 8.06-8.09 (m, 1H, CHAr), 8.47 (s, 1H, pyrazole), 9.73 (s, 1H, 
CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.6 (Me), 53.7 (CH2), 126.6 (C), 127.5, 128.9, 131.1, 
131.3 (CH), 132.1 (C), 132.2 (CH), 133.6 (C), 134.1 (CH), 134.4 (C), 136.1 (CH), 137.2, 
139.4 (C), 191.4 (CHO).  
MS (GC, 70 eV): m/z (%) = 321 (M+, 100), 77 (18).  
HRMS (ESI): calcd for C18H15N3O3 (M+H) 322.11862, found 322.11825.  
IR (ATR, cm-1): ν̃ = 3129 (w), 1706 (s), 1564 (m), 1497 (s), 1459 (m), 1399 (s), 1350 (m), 
1321 (s), 1295 (m), 1268 (m), 1244 (m), 1195 (m), 1133 (w), 1042 (w), 1021 (w), 922 (w), 
879 (w), 831 (s), 811 (m), 781 (s), 762 (s), 732 (m), 667 (m), 602 (m), 534 (m).  
 
2-(1-(4-Methylbenzyl)-4-nitro-1H-pyrazol-5-yl)-4,5-dimethoxybenzaldehyde (5.2.1t).  
Starting from 1-(4-methylbenzyl)-4-nitro-1H-pyrazole 
5.1.3e (0.217 g, 1 mmol), 2-bromo-4,5-
dimethoxybenzaldehyde (0.980 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 
mL DMF, the product 5.2.1t was isolated as a yellow solid 
(0.205 g, 54%Pd). Mp: 68-69°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.28 (s, 3H, Me), 3.82 (s, 3H, OMe), 3.90 (s, 3H, OMe), 
5.34 (s, 2H, CH2), 7.16-7.24 (m, 4H, CHAr), 7.32 (d, 2H, 
4J = 3.9 Hz, CHAr), 8.25 (s, 1H, 
CHAr), 9.0 (s, 1H, pyrazole), 10.07 (s, 1H, CHO).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 20.7 (Me), 55.6 (CH2), 55.7, 56.5 (OMe), 110.5, 116.0 
(CH), 119.3, 125.7 (C), 128.0, 129.2, 130.4 (CH), 132.7 (C), 135.8 (CH), 137.5, 148.6, 154.5 
(C), 190.2 (CHO).  
MS (GC, 70 eV): m/z (%) = 381 (M+, 58), 335 (34), 105 (100).  
HRMS (EI): calcd for C20H19N3O5 (M
+) 381.13192, found 381.13183.  
IR (ATR, cm-1): ν̃ = 1667 (m), 1584 (m), 1504 (s), 1470 (m), 1444 (m), 1385 (m), 1340 (w), 
1311 (w), 1269 (s), 1217 (m), 1154 (s), 1041 (m), 1014 (m), 979 (m), 866 (s), 811 (s), 756 
(m), 737 (s), 654 (m), 588 (s), 555 (m).  
 
5-(1-(4-Methylbenzyl)-4-nitro-1H-pyrazol-5-yl)pyrimidine (5.2.1u).  
Starting from 1-(4-methylbenzyl)-4-nitro-1H-pyrazole 5.1.3e (0.217 
g, 1 mmol), 5-bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
5.2.1u was isolated as a yellow solid (0.230 g, 78%Pd). Mp: 106-
108°C.  
1H NMR (250 MHz, DMSO-d6): δ = 2.25 (s, 3H, Me), 5.31 (s, 2H, CH2), 6.90 (d, 2H, 3J = 8.3 
Hz, CHAr), 7.09 (d, 2H, 
3J = 8.3 Hz, CHAr), 8.54 (s, 1H, pyrimidine), 8.94 (s, 2H, pyrimidine), 
9.33 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.6 (Me), 53.9 (CH2), 122.0 (C), 127.2, 129.2 (CH), 
132.2, 134.0, 135.6 (C), 136.5 (CH), 137.3 (C), 157.5, 159.2 (CH).  
MS (GC, 70 eV): m/z (%) = 295 (M+, 78), 105 (100), 77 (28).  
HRMS (EI): calcd for C15H13N5O2 (M
+) 295.10638, found 295.10704.  
IR (ATR, cm-1): ν̃ = 3128 (w), 1599 (w), 1549 (m), 1514 (m), 1470 (m), 1441 (w), 1399 (s), 
1354 (m), 1324 (m), 1260 (m), 1187 (m), 1009 (w), 1055 (w), 987 (w), 913 (w), 870 (m), 824 
(m), 772 (m), 757 (s), 722 (s), 629 (m), 612 (s), 538 (m).  
 
3-(1-(4-Methylbenzyl)-4-nitro-1H-pyrazol-5-yl)pyridine (5.2.1v).  
Starting from 1-(4-methylbenzyl)-4-nitro-1H-pyrazole 5.1.3e (0.217 
g, 1 mmol), 3-bromopyridine (0.632 g, 4 mmol), PdCl2(PPh3)2 (0.035 
g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1v 
was isolated as a yellow solid (0.244 g, 83%Pd). Mp: 113-115°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.24 (s, 3H, Me), 5.21 (s, 2H, 
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CH2), 6.87 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.08 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.54-7.58 (m, 1H, 
CHAr), 7.92-7.96 (m, 1H, CHAr), 8.50 (s, 1H, pyrazole), 8.65-8.73 (m, 2H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.6 (Me), 53.5 (CH2), 123.5, 127.1, 129.1 (CH), 
132.4, 133.4 (C), 136.5 (CH), 137.2 (C), 137.7 (CH), 138.6 (C), 149.8, 151.0 (CH).  
MS (GC, 70 eV): m/z (%) = 294 (M+, 84), 105 (100).  
HRMS (EI): calcd for C16H14N4O2 (M
+) 294.11113, found 294.11093.  
IR (ATR, cm-1): ν̃ = 2918 (w), 1602 (w), 1573 (w), 1552 (w), 1498 (s), 1466 (m), 1400 (s), 
1355 (w), 1324 (s), 1258 (m); 1190 (m), 1101 (w), 1029 (m), 996 (m), 873 (w), 839 (m), 813 
(m), 798 (s), 763 (m), 708 (m), 614 (m).  
 
5-(3-(Trifluoromethyl)phenyl)-4-nitro-1-phenethyl-1H-pyrazole (5.2.1w).  
Starting from 4-nitro-1-phenethyl-1H-pyrazole 5.1.3b (0.217 g, 1 
mmol), 1-bromo-3-(trifluoromethyl)benzene (0.900 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, 
the product 5.2.1w was isolated as a yellow viscous oil (0.281 g, 
78%Pd).  
1H NMR (250 MHz, DMSO-d6): δ = 3.04 (d, 2H, 3J = 6.3 Hz, CH2), 
4.14 (d, 2H, 3J = 6.3 Hz, CH2), 6.81-6.85 (m, 2H, CHAr), 7.17-7.22 (m, 3H, CHAr), 7.34-7.38 
(m, 2H, CHAr), 7.67 (t, 1H, 
3J = 7.9 Hz, CHAr), 7.88 (d, 1H, 
3J = 8.0 Hz, CHAr), 8.52 (s, 1H, 
pyrazole).  
19F NMR (282 MHz, DMSO-d6): δ = -61.0 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 34.9, 51.3 (CH2), 123.7 (q, 1J = 272 Hz, CF3), 126.4 (q, 
3J = 4 Hz, CH), 126.7 (CH), 126.8 (q, 3J = 4 Hz, CH), 127.3 (C), 128.5 (CH), 129.0 (q, 2J = 
32 Hz, CCF3), 129.6 (CH), 132.5 (C), 133.8, 136.5 (CH), 137.4, 140.1 (C).  
MS (GC, 70 eV): m/z (%) = 361 (M+, 1), 104 (100), 91 (24).  
HRMS (ESI): calcd for C18H15N3O2F3 (M+H) 362.11109, found 362.11081.  
IR (ATR, cm-1): ν̃ = 1558 (w), 1506 (s), 1462 (m), 1399 (m), 1309 (s), 1245 (m), 1163 (s), 
1123 (s), 1096 (m), 1074 (s), 1028 (m), 932 (w), 902 (m), 869 (m), 829 (s), 809 (m), 758 (s), 
700 (s), 645 (w), 593 (m), 558 (m).  
 
4-Nitro-5-(3-nitrophenyl)-1-phenethyl-1H-pyrazol (5.2.1x).  
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Starting from 4-nitro-1-phenethyl-1H-pyrazole 5.1.3b (0.217 g, 1 
mmol), 1-bromo-3-nitrobenzene (0.808 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1x was isolated 
as a brown viscous oil (0.321 g, 95%Pd), (0.169g, 50%Ni).  
1H NMR (300 MHz, DMSO-d6): δ = 3.13 (t, 2H, 3J = 6.1 Hz, 
CH2), 4.16 (t, 2H, 
3J = 6.1 Hz, CH2), 6.73-6.78 (m, 2H, CHAr), 6.95-6.99 (m, 1H, CHAr), 7.15-
7.28 (m, 3H, CHAr), 7.51 (t, 1H, 
3J = 8.0 Hz, CHAr), 7.62 (t, 1H, 
4J = 1.4 Hz, CHAr), 8.26-8.31 
(m, 2H, CHAr, pyrazole).  
13C NMR (75.5 MHz, DMSO-d6): δ = 35.9, 51.9 (CH2), 124.8, 127.4 (CH), 127.9 (C), 128.6, 
128.9, 129.6, 135.5 (CH), 136.7 (C), 136.8 (CH), 139.6, 148.0 (C).  
MS (GC, 70 eV): m/z (%) = 338 (M+, 1), 104 (100), 91 (29).  
HRMS (ESI): calcd for C17H14N4O4 (M+H) 339.109, found 339.109.  
IR (ATR, cm-1): ν̃ = 2923 (w), 1559 (w), 1525 (s), 1499 (s), 1455 (m), 1398 (s), 1346 (s), 
1322 (s), 1254 (m), 1178 (m), 1098 (w), 1077 (w), 1030 (w), 978 (w), 904 (w), 871 (m), 825 
(s), 736 (s), 697 (s), 647 (m), 560 (m).  
 
5-(4-Nitro-1-phenethyl-1H-pyrazol-5-yl)pyrimidine (5.2.1y).  
Starting from 4-nitro-1-phenethyl-1H-pyrazole 5.1.3b (0.217 g, 1 
mmol), 5-bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 5.2.1y was 
isolated as a yellow viscous oil (0.256 g, 87%Pd).  
1H NMR (300 MHz, DMSO-d6): δ = 3.05 (d, 2H, 3J = 7.0 Hz, CH2), 
4.25 (d, 2H, 3J = 7.0 Hz, CH2), 6.86-6.89 (m, 2H, CHAr), 7.18-7.23 
(m, 3H, CHAr), 8.47 (s, 2H, pyrimidine), 8.57 (s, 1H, pyrazole), 9.29 (s, 1H, pyrimidine).  
13C NMR (75.5 MHz, CDCl3): δ = 35.1, 51.6 (CH2), 121.6 (C), 126.8, 128.6 (CH), 133.2, 
135.8 (C), 136.7 (CH), 137.3 (C), 157.2, 159.0 (CH).  
MS (GC, 70 eV): m/z (%) = 295 (M+, 1), 104 (100), 91 (45).  
HRMS (ESI): calcd for C15H14N5O2 (M+H) 296.1142, found 296.11452.  
IR (ATR, cm-1): ν̃ = 2929 (w), 2223 (m), 1599 (w), 1550 (m), 1499 (s), 1465 (m), 1399 (s), 
1322 (s), 1263 (m), 1178 (m), 1077 (w), 1031 (w), 974 (w), 915 (w), 867 (w), 826 (s), 748 
(m), 724 (m), 701 (s), 627 (m), 561 (w).  
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3-(4-Nitro-1-(2-phenoxyethyl)-1H-pyrazol-5-yl)pyridine (5.2.1z).  
Starting from 4-nitro-1-(2-phenoxyethyl)-1H-pyrazole 5.1.3d (0.233 
g, 1 mmol), 3-bromopyridine (0.632 g, 4 mmol), PdCl2(PPh3)2 (0.035 
g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 
8 mL DMF, the product 5.2.1z was isolated as a brown viscous oil 
(0.282 g, 91%Pd), (0.130g, 42%Ni).  
1H NMR (250 MHz, DMSO-d6): δ = 4.32 (br s, 4H, 2xCH2), 6.81-
6.94 (m, 3H, CHAr), 7.21-7.27 (m, 2H, CHAr), 7.55-7.66 (m, 2H, CHAr), 8.13 (br s, 1H, CHAr), 
8.51 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, DMSO-d6): δ = 49.4, 65.3 (CH2), 114.2, 120.9, 128.5, 128.7, 129.4 
(CH), 131.3 (C), 131.4, 131.9 (CH), 133.1 (C), 136.7 (CH), 157.5 (C).  
MS (GC, 70 eV): m/z (%) = 310 (M+, 22), 217 (51), 170 (16), 120 (100), 77 (66).  
HRMS (EI): calcd for C16H14N4O3 (M
+) 310.10604, found 310.10655.  
IR (ATR, cm-1): ν̃ = 3076 (w), 1598 (w), 1552 (w), 1496 (s), 1405 (m), 1361 (w), 1321 (m), 
1272 (w), 1248 (m), 1178 (w), 1151 (w), 1082 (w), 1048 (w), 1011 (w), 995 (w), 906 (w), 830 
(m), 753 (s), 708 (m), 693 (s), 615 (m), 539 (w).  
 
2-(4-Nitro-1-(2-phenoxyethyl)-1H-pyrazol-5-yl)benzaldehyde (5.2.1ä).  
Starting from 4-nitro-1-(2-phenoxyethyl)-1H-pyrazole 5.1.3d (0.233 
g, 1 mmol), 2-bromobenzaldehyde (0.740 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
5.2.1ä was isolated as a yellow solid (0.219 g, 65%Pd). Mp: 98-100°C.  
1H NMR (250 MHz, DMSO-d6): δ = 4.21-4.28 (m, 4H, 2xCH2), 6.75-
6.78 (m, 2H, CHAr), 6.87-6.93 (m, 1H, CHAr), 7.19-7.26 (m, 2H, 
CHAr), 7.64-7.67 (m, 1H, CHAr), 7.81-7.91 (m, 2H, CHAr), 9.51 (s, 1H, pyrazole), 9.89 (s, 1H, 
CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 49.4, 65.2 (CH2), 114.2, 121.0 (CH), 127.0 (C), 129.4, 
131.1, 131.4, 131.6 (CH), 133.4 (C), 134.1 (CH), 136.5 (CH), 140.0, 157.6 (C), 191.7 (CHO).  
MS (GC, 70 eV): m/z (%) = 337 (M+, 1), 231 (100), 146 (65), 120 (43), 75 (63).  
HRMS (ESI): calcd for C18H15N3O4 (M+H) 338.11353, found 338.11364.  
IR (ATR, cm-1): ν̃ = 1713 (w), 1600 (w), 1553 (w), 1497 (s), 1475 (m), 1394 (m), 1320 (s), 
1234 (s), 1159 (m), 1079 (m), 1045 (m), 1002 (m), 897 (w), 869 (m), 823 (s), 795 (m), 748 
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(s), 683 (m), 610 (m), 577 (m), 533 (m).  
 
(Z)-2-nitro-3-(p-tolyl)-3-(p-tolylamino)acrylonitrile (5.2.1′′).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 5.1.3g (0.203 g, 1 
mmol), 1-bromo-4-methylbenzene (0.684 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), Cy3PxHBF4 (0.044 g, 0.12 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 5.2.1′′ was isolated as a yellow 
solid (0.088 g, 30%Pd). Mp: 171-173°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.19 (s, 3H, Me), 2.27 (s, 
3H, Me), 6.95-7.04 (m, 4H, CHAr), 7.19 (d, 2H, 
3J = 8.0 Hz, 
CHAr), 7.35 (d, 2H, 
3J = 8.0 Hz, CHAr), 12.07 (s, 1H, NH).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.4, 20.9 (Me), 104.1, 114.0 (C), 126.0, 126.1 (CH), 
127.2 (C), 128.5, 129.1, 129.2 (CH), 134.5, 136.8, 141.0 (C).  
MS (GC, 70 eV): m/z (%) = 293 (M+, 100).  
HRMS (ESI): calcd for C17H16N3O2 (M+H) 294.1237, found 293.12375.  
IR (ATR, cm-1): ν̃ = 3208 (w), 2920 (w), 2217 (w), 1707 (w), 1590 (m), 1559 (s), 1506 (s), 
1426 (m), 1362 (m), 1324 (w), 1274 (s), 1195 (s), 1159 (s), 1111 (m), 1020 (m), 955 (w), 818 
(s), 765 (m), 719 (m), 700 (m), 665 (w), 572 (w).  
 
1-(4',5-dimethyl-[1,1'-biphenyl]-2-yl)-4-nitro-5-(p-tolyl)-1H-pyrazole (5.2.1′).  
Starting from 4-nitro-1-(p-tolyl)-1H-pyrazole 
5.1.3g (0.203 g, 1 mmol), 1-bromo-4-
methylbenzene (0.684 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
Cy3PxHBF4 (0.044 g, 0.12 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 5.2.1′ was 
isolated as a yellow viscous oil (0.046 g, 
12%Pd).  
1H NMR (300 MHz, CDCl3): δ = 2.44 (s, 3H, Me), 2.50 (s, 3H, Me), 2.53 (s, 3H, Me), 7.20-
7.40 (m, 10H, CHAr), 7.73-7.76 (m, 2H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 21.1, 21.4, 21.5 (Me), 124.1 (C), 125.2 (CH), 127.5 (C), 
128.9, 129.1, 129.3, 129.6, 130.1 (CH), 136.2, 138.6, 139.3, 140.1, 142.1, 147.8 (C).  
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MS (GC, 70 eV): m/z (%) = 383 (M+, 100), 233 (20), 219 (13), 208 (43), 202 (25), 91 (45), 65 
(29).  
HRMS (EI): calcd for C24H21N3O2 (M
+) 383.16338, found 383.16340.  
IR (ATR, cm-1): ν̃ = 3027 (w), 2917 (w), 2860 (w), 1615 (w), 1558 (w), 1508 (s), 1426 (m), 
1355 (s), 1270 (w), 1182 (w) 1116 (w), 1019 (w), 967 (w), 829 (s), 743 (m), 650 (w), 535 
(m).  
 
4-Nitro-3,5-bis(3-nitrophenyl)-1-phenethyl-1H-pyrazole (5.2.2a).  
Starting from 4-nitro-1-phenethyl-1H-pyrazole 
5.1.3b (0.217 g, 1 mmol)one-pot, (4-nitro-5-(3-
nitrophenyl)-1-phenethyl-1H-pyrazole 5.2.1x 
(0.338 g, 1 mmol))consecutive, 1-bromo-3-
nitrobenzene (1.21 g, 6 mmol)one-pot, (1-bromo-3-
nitrobenzene (0.808 g, 4 mmol))consecutive, 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (1.14 g, 6 mmol)
one-pot, (CuI (0.762 g, 4 
mmol))consecutive, PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.320 g, 2.3 mmol)
one-pot, (K2CO3 
(0.179 g, 1.3 mmol))consecutive, in 8 mL DMF, the product 5.2.2a was isolated as a yellow solid 
(0.220 g, 48%one-pot), (0.284 g, 62%consecutive). Mp: 148-150°C.  
1H NMR (250 MHz, CDCl3): δ = 3.18 (t, 2H, 3J = 6.4 Hz, CH2), 4.21 (t, 2H, 3J = 6.4 Hz, 
CH2), 6.80-6.84 (m, 2H, CHAr), 7.07-7.11 (m, 1H, CHAr), 7.19-7.32 (m, 3H, CHAr), 7.56 (t, 
1H, 3J = 8.0 Hz, CHAr), 7.69 (t, 2H, 
3J = 8.0 Hz, CHAr), 7.74 (t, 1H, 
4J = 1.7 Hz, CHAr), 8.06-
8.10 (m, 2H, CHAr), 8.30-8.38 (m, 1H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 34.9, 51.2 (CH2), 123.2, 123.5, 123.8, 124.1, 126.5 (CH), 
127.1 (C), 127.6, 128.0, 128.3, 128.8 (CH), 131.0 (C), 134.4, 134.5 (CH), 135.6, 140.6, 144.7, 
147.1, 147.2 (C).  
MS (GC, 70 eV): m/z (%) = 459 (M+, 1), 104 (100).  
HRMS (EI): calcd for C23H17N5O6 (M
+) 459.11733, found 459.11773.  
IR (ATR, cm-1): ν̃ = 2923 (w), 1525 (s), 1499 (s), 1477 (m), 1455 (m), 1398 (s), 1346 (s), 
1322 (s), 1254 (m), 1178 (m), 1098 (w), 1077 (w), 1030 (w), 978 (w), 931 (w), 904 (w), 871 
(m), 825 (s), 736 (s), 697 (s), 676 (s), 647 (m), 607 (w), 560 (m).  
 
1-(4-Methylbenzyl)-4-nitro-3,5-bis(3-nitrophenyl)-1H-pyrazole (5.2.2b).  
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Starting from 1-(4-methylbenzyl)-4-nitro-1H-
pyrazole 5.1.3e (0.217 g, 1 mmol)one-pot, (1-(4-
methylbenzyl)-4-nitro-5-(3-nitrophenyl)-1H-
pyrazole 5.2.1r (0.338 g, 1 mmol))consecutive, 1-
bromo-3-nitrobenzene (1.21 g, 6 mmol)one-pot, 
(1-bromo-3-nitrobenzene (0.808 g, 4 
mmol))consecutive, PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (1.14 g, 6 mmol)
one-pot, (CuI (0.762 
g, 4 mmol))consecutive, PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.320 g, 2.3 mmol)
one-pot, 
(K2CO3 (0.179 g, 1.3 mmol))
consecutive, in 8 mL DMF, the product 5.2.2b was isolated as a 
yellow solid (0.243 g, 53%one-pot), (0.312 g, 68%consecutive). Mp: 131-132°C.  
1H NMR (250 MHz, CDCl3): δ = 2.31 (s, 3H, Me), 5.18 (s, 2H, CH2), 6.90 (d, 2H, 3J = 8.0 
Hz, CHAr), 7.09 (d, 2H, 
3J = 8.0 Hz, CHAr), 7.59-7.74 (m, 3H, CHAr), 8.04-8.14 (m, 2H, 
CHAr), 8.31-8.44 (m, 2H, CHAr), 8.62-8.64 (m, 1H, CHAr).  
13C NMR: due to bed solubility it was not possible to measure.  
MS (GC, 70 eV): m/z (%) = 459 (M+, 62), 105 (100).  
HRMS (EI): calcd for C23H17N5O6 (M
+) 459.11733, found 459.11682.  
IR (ATR, cm-1): ν̃ = 3086 (w), 2922 (s), 2852 (w), 1620 (w), 1524 (s), 1454 (m), 1345 (s), 
1244 (w), 1201 (w), 1097 (m), 1041 (w), 909 (m), 870 (w), 842 (m), 808 (m), 736 (s), 677 (s), 
570 (w).  
 
3-(4-(Trifluoromethyl)phenyl)-1-methyl-4-nitro-5-(3-nitrophenyl)-1H-pyrazole (5.2.2c).  
Starting from 1-methyl-4-nitro-5-(3-
nitrophenyl)-1H-pyrazole 5.2.1k (0.248 g, 1 
mmol), 1-bromo-4-(trifluoromethyl)benzene 
(0.900 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.762 g, 4 mmol), PivOH (0.030 g, 
0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol), in 8 
mL DMF, the product 5.2.2c was isolated as a white solid (0.333 g, 85%consecutive). Mp: 202-
204°C.  
1H NMR (300 MHz, CDCl3): δ = 3.81 (s, 3H, Me), 7.71-7.77 (m, 2H, CHAr), 7.78-7.93 (m, 
4H, CHAr), 8.35-8.36 (m, 1H, CHAr), 8.44 (dt, 1H, 
3J = 7.1 Hz, 4J = 2.5 Hz, CHAr).  
19F NMR (282 MHz, CDCl3): δ = -62.8 (CF3).  
13C NMR (62.9 MHz, CDCl3): δ = 38.3 (Me), 124.0 (q, 1J = 272 Hz, CF3), 124.9 (CH), 125.2 
(C), 125.2, 125.3, 125.4 (CH), 128.6 (C), 129.6, 130.2 (CH), 131.4 (q, 2J = 33 Hz, CH), 133.6 
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(C), 135.7 (CH), 140.6, 146.3, 148.4 (C).  
MS (GC, 70 eV): m/z (%) = 392 (M+, 100), 373 (16), 316 (14), 174 (28), 163 (40), 117 (40).  
HRMS (EI): calcd for C17H11N4O4F3 (M
+) 392.07269, found 392.07271.  
IR (ATR, cm-1): ν̃ = 3087 (w), 1525 (m), 1505 (m), 1451 (m), 1350 (s), 1321 (s), 1239 (m), 
1191 (w), 1166 (m), 1108 (s), 1063 (s), 1013 (m), 964 (w), 916 (m), 877 (w), 849 (s), 815 
(m), 800 (m), 769 (w), 731 (s), 697 (s), 678 (m), 656 (m), 647 (m), 595 (m).  
 
3-(1-Methyl-4-nitro-5-(3-nitrophenyl)-1H-pyrazol-3-yl)pyridine (5.2.2d).  
Starting from 1-methyl-4-nitro-5-(3-nitrophenyl)-1H-
pyrazole 5.2.1k (0.248 g, 1 mmol), 3-bromopyridine 
(0.632 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
CuI (0.762 g, 4 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol), in 8 mL DMF, the product 
5.2.2d was isolated as a brown solid (0.201 g, 62%consecutive). Mp: 202-204°C.  
1H NMR (300 MHz, CDCl3): δ = 3.77 (s, 3H, NMe), 7.57-7.63 (m, 1H, CHAr), 7.74-7.76 (m, 
2H, CHAr), 7.96-7.99 (m, 1H, CHAr), 8.25-8.31 (m, 2H, CHAr), 8.38-8.42 (m, 1H, CHAr), 8.54 
(t, 1H, 4J = 1.9 Hz, CHAr).  
13C NMR: due to bed solubility it was not possible to measure.  
MS (GC, 70 eV): m/z (%) = 325 (M+, 100), 163 (23), 117 (25).  
HRMS (EI): calcd for C15H11N5O4 (M
+) 325.0811, found 325.08113.  
IR (ATR, cm-1): ν̃ = 3098 (w), 2929 (w), 1620 (w), 1524 (s), 1503 (m), 1454 (m), 1379 (w), 
1346 (s), 1235 (m), 1087 (m), 1002 (w), 901 (m), 840 (m), 799 (m), 768 (w), 737 (s), 720 (m), 
696 (s), 673 (m), 646 (m).  
 
1-(2-Phenoxyethyl)-5-(pyridin-3-yl)-1H-pyrazol-4-amine (5.3.1a).  
Starting from 3-(4-nitro-1-(2-phenoxyethyl)-1H-pyrazol-5-
yl)pyridine 5.2.1z (0.310 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol) and 
H2 balloon in 25 mL MeOH, the product 5.3.1a was isolated as a 
brown viscous oil (0.246 g, 88%).  
1H NMR (300 MHz, CDCl3): δ = 2.99-3.14 (br s, 2H, NH2), 4.21-
4.35 (m, 4H, 2xCH2), 6.66-6.70 (m, 2H, CHAr), 6.82-6.88 (m, 1H, 
CHAr), 7.12-7.19 (m, 3H, CHAr), 7.34-7.39 (m, 1H, CHAr), 7.74-7.77 
(m, 1H, CHAr).  
13C NMR (75.5 MHz, CDCl3): δ = 49.1, 66.6 (CH2), 114.4, 121.2, 123.8 (CH), 125.9, 127.6, 
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128.2 (C), 129.5, 131.3, 137.4, 149.3, 150.4 (CH) 158.1 (C).  
MS (GC, 70 eV): m/z (%) = 280 (M+, 100), 173 (34), 160 (81), 105 (28), 77 (30).  
HRMS (EI): calcd for C16H16N4O (M
+) 280.13186, found 280.13186.  
IR (ATR, cm-1): ν̃ = 3321 (w), 2929 (w), 1666 (w), 1597 (m), 1494 (m), 1460 (w), 1411 (m), 
1370 (m), 1291 (w), 1238 (s), 1172 (m), 1081 (w), 1054 (m), 1003 (w), 959 (w), 903 (w), 814 
(m), 789 (w), 753 (s), 711 (s), 690 (s), 618 (m).  
 
1-(4-Methylbenzyl)-5-(pyrimidin-5-yl)-1H-pyrazol-4-amine (5.3.1b).  
Starting from 5-(1-(4-methylbenzyl)-4-nitro-1H-pyrazol-5-
yl)pyrimidine 5.2.1u (0.295 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol) 
and H2 balloon in 25 mL MeOH, the product 5.3.1b was isolated as a 
brown viscous oil (0.220 g, 83%).  
1H NMR (300 MHz, CDCl3): δ = 2.19 (br s, 5H, NH2, Me), 5.08 (s, 
2H, CH2), 6.74 (d, 2H, 
3J = 8.0 Hz, CHAr), 6.95 (d, 2H, 
3J = 8.0 Hz, 
CHAr), 7.17 (s, 1H, pyrazole), 8.52 (s, 2H, pyrimidine), 9.08 (s, 1H, pyrimidine).  
13C NMR (62.9 MHz, CDCl3): δ = 21.0 (Me), 54.1 (CH2), 123.7, 124.6 (C), 126.5 (CH) 
129.1, 129.5, 131.0 (CH), 133.8, 137.7 (C), 156.9 (CH), 158.0 (C).  
MS (GC, 70 eV): m/z (%) = 265 (M+, 87), 105 (100).  
HRMS (EI): calcd for C15H15N5 (M
+) 265.13220, found 265.13228.  
IR (ATR, cm-1): ν̃ = 2922 (w), 1682 (w), 1545 (m), 1515 (m), 1406 (s), 1315 (m), 1187 (m), 
1119 (w), 1038 (w), 998 (m), 912 (w), 793 (s), 752 (m), 724 (s), 657 (m), 627 (s).  
 
5-(4-Methoxyphenyl)-N,N-dimethyl-1-p-tolyl-1H-pyrazol-4-amine (5.3.2a).  
Starting from 5-(4-methoxyphenyl)-4-nitro-1-(p-tolyl)-1H-
pyrazole 5.2.1b (0.309 g, 1 mmol), CH2O (0.180 g, 6 mmol 
(37 wt % in H2O)), Pd/C (0.030 g, 0.10 mmol) and H2 
balloon in 25 mL MeOH, the product 5.3.2a was isolated as 
an orange viscous oil (0.273 g, 89%).  
1H NMR (300 MHz, CDCl3): δ = 2.30 (s, 3H, Me), 2.56 (s, 6H, NMe2), 3.80 (s, 3H, OMe), 
6.84 (d, 2H, 3J = 8.5 Hz, CHAr), 7.06 (br s, 4H, CHAr), 7.20 (d, 2H, 
3J = 8.5 Hz, CHAr), 7.51 
(s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21.0 (Me), 44.7 (NMe2), 55.2 (OMe), 113.8 (CH), 123.0 
(C), 124.8, 129.2 (CH) 131.2 (C), 131.2 (CH), 131.6, 136.6, 136.9, 138.1, 159.2 (C).  
MS (GC, 70 eV): m/z (%) = 307 (M+, 100), 307 (100), 306 (10), 224 (40), 146 (13), 132 (19), 
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91 (18), 65 (13).  
HRMS (ESI): calcd for C16H15N3O2 (M+H) 308.17600, found 308.17655.  
IR (ATR, cm-1): ν̃ = 3011 (w), 1614 (w), 1565 (w), 1513 (s), 1456 (m), 1384 (m), 1287 (w), 
1245 (s), 1176 (m), 1086 (w), 1035 (m), 962 (s), 926 (w), 813 (s), 740 (w) 661 (m), 631 (m), 
576 (m), 528 (m).  
 
4-(4-(Dimethylamino)-1-p-tolyl-1H-pyrazol-5-yl)benzonitrile (5.3.2b).  
Starting from 4-(4-nitro-1-(p-tolyl)-1H-pyrazol-5-
yl)benzonitrile 5.2.1c (0.304 g, 1 mmol), CH2O (0.180 g, 6 
mmol (37 wt % in H2O)), Pd/C (0.030 g, 0.10 mmol) and H2 
balloon in 25 mL MeOH, the product 5.3.2b was isolated as 
an orange viscous oil (0.257 g, 85%).  
1H NMR (300 MHz, CDCl3): δ = 2.33 (s, 3H, Me), 2.56 (s, 6H, NMe2), 7.02 (d, 2H, 3J = 8.3 
Hz, CHAr), 7.10 (d, 2H, 
3J = 8.3 Hz, CHAr), 7.42 (d, 2H, 
3J = 8.3 Hz, CHAr), 7.56 (d, 2H, 
3J = 
8.3 Hz, CHAr), 7.57 (s, 1H, pyrazole).  
13C NMR (75.5 MHz, CDCl3): δ = 21.1 (Me), 44.9 (NMe2), 111.2, 118.6 (C), 125.1, 129.6 
(CH), 130.0 (C), 130.2, 131.8, 132.0 (CH), 135.2, 137,6. 138,1 (C).  
MS (GC, 70 eV): m/z (%) = 302 (M+, 100), 303 (23), 302 (100), 301 (13), 276 (11), 260 (10), 
219 (34), 146 (12), 132 (20), 91 (25), 65 (14).  
HRMS (ESI): calcd for C19H19N4 (M+H) 303.1610, found 303.16064.  
IR (ATR, cm-1): ν̃ = 2942 (w), 2777 (w), 1558 (w), 1513 (s), 1452 (w), 1411 (w), 1382 (m), 
1312 (w), 1232 (w), 1180 (w), 1149 (w), 1086 (w), 1031 (w), 1015 (w), 961 (m), 926 (w), 818 
(s), 771 (w), 729 (w), 700 (w), 660 (w), 629 (w), 593 (w), 573 (w).  
 
N,N-Dimethyl-1,5-di-p-tolyl-1H-pyrazol-4-amine (5.3.2c).  
Starting from 4-nitro-1,5-di-p-tolyl-1H-pyrazole 5.2.1a 
(0.293 g, 1 mmol), CH2O (0.180 g, 6 mmol (37 wt % in 
H2O)), Pd/C (0.030 g, 0.10 mmol) and H2 balloon in 25 mL 
MeOH, the product 5.3.2c was isolated as an orange viscous 
oil (0.250 g, 86%).  
1H NMR (300 MHz, CDCl3): δ = 2.30 (s, 3H, Me), 2.33 (s, 3H, Me), 2.56 (s, 6H, NMe2), 
6.99-7.21 (m, 8H, CHAr), 7.49 (s, 1H, pyrazole).  
13C NMR (62.9 MHz, CDCl3): δ = 21.0 (Me), 21.3 (Me), 44.8 (NMe2), 124.8 (CH), 127.7 (C), 
129.0, 129.2, 129.9, 131.2 (CH) 131.7, 136.6, 136.7, 138.0, 138.1 (C).  
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MS (GC, 70 eV): m/z (%) = 291 (M+, 100), 291 (100), 290 (10), 276 (11), 208 (36), 146 (11), 
132 (20), 91 (19), 65 (11).  
HRMS (ESI): calcd for C19H22N3 (M+H) 292.17355, found 292.18126.  
IR (ATR, cm-1): ν̃ = 2946 (w), 1558 (w), 1515 (m), 1556 (w), 1420 (w), 1382 (m), 1327 (s), 
1271 (w), 1230 (w), 1175 (m), 1148 (m), 1121 (s), 1095 (m), 1073 (m), 1031 (m), 971 (m), 
926 (m), 908 (m), 810 (s), 717 (m), 702 (m), 694 (m), 658 (m), 582 (m).  
 
7,8-Dimethoxy-1-p-tolyl-1H-pyrazolo[4,3-c]isoquinoline (5.3.3a).  
Starting from 4,5-dimethoxy-2-(4-nitro-1-(p-tolyl)-1H-
pyrazol-5-yl)benzaldehyde 5.2.1e (0.367 g, 1 mmol), Pd/C 
(0.030 g, 0.10 mmol) and H2 balloon in 25 mL MeOH, the 
product 5.3.3a was isolated as a gray solid (0.297 g, 93%). 
Mp: 180-182°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.46 (s, 3H, Me), 3.51 (s, 3H, OMe), 3.92 (s, 3H, OMe), 
6.83 (s, 1H, CHAr), 7.48 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.54 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.73 (s, 
1H, CHAr), 8.45 (s, 1H, pyrazole), 8.95 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.8 (Me), 55.0, 55.7 (OMe), 100.8, 108.6 (CH), 117.6, 
122.7 (C), 126.9, 127.9 (CH), 129.8 (C), 135.3 (CH), 135.9, 138.1, 138.9 (C), 147.9 (CH), 
149.3, 151.8 (C).  
MS (GC, 70 eV): m/z (%) = 319 (M+, 100).  
HRMS (EI): calcd for C19H17N3O2 (M
+) 319.13153, found 319.13144.  
IR (ATR, cm-1): ν̃ = 2905 (w), 1622 (w), 1518 (w), 1492 (s), 1455 (m), 1437 (m), 1385 (m), 
1295 (w), 1258 (s), 1205 (m), 1174 (m), 1137 (s), 1084 (m), 944 (m), 925 (m), 865 (m), 824 
(s), 796 (s), 713 (m), 664 (w), 630 (w), 573 (m), 563 (m).  
 
1-(2-Phenoxyethyl)-1H-pyrazolo[4,3-c]isoquinoline (5.3.3b).  
Starting from 2-(4-nitro-1-(2-phenoxyethyl)-1H-pyrazol-5-
yl)benzaldehyde 5.2.1ä (0.337 g, 1 mmol), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 5.3.3b was 
isolated as a yellow solid (0.254 g, 88%). Mp: 117-119°C.  
1H NMR (300 MHz, DMSO-d6): δ = 4.51 (t, 2H, 3J = 5.3 Hz, CH2), 
5.24 (t, 2H, 3J = 5.3 Hz, CH2), 6.68-6.72 (m, 2H, CHAr), 6.82-6.88 
(m, 1H, CHAr), 7.13-7.20 (m, 1H, CHAr), 7.78-7.83 (m, 1H, CHAr), 7.93-7.99 (m, 1H, CHAr), 
8.29-8.32 (m, 1H, CHAr), 8.37 (s, 1H, pyrazole), 9.07 (s, 1H, Py).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 51.5, 66.8 (CH2), 114.2, 120.8, 122.0 (CH), 122.6, 
126.8 (C), 127.3 (CH), 128.1 (C), 129.3, 129.4, 130.8, 134.2 (CH), 136.3 (C), 149.4 (CH), 
157.9 (C).  
MS (GC, 70 eV): m/z (%) = 289 (M+, 24), 196 (26), 182 (31), 169 (100), 128 (51), 77 (47).  
HRMS (ESI): calcd for C18H16N3O (M+H) 290.12879, found 290.1288.  
IR (ATR, cm-1): ν̃ = 3033 (w), 1622 (w), 1588 (m), 1531 (w), 1496 (m), 1445 (m), 1416 (m), 
1350 (w), 1286 (m), 1241 (s), 1133 (w), 1061 (m), 1021 (w), 950 (m), 906 (m), 827 (m), 789 
(m), 741 (s), 686 (s), 592 (m), 574 (s).  
 
1-(4-Methylbenzyl)-7,8-dimethoxy-1H-pyrazolo[4,3-c]isoquinoline (5.3.3c).  
Starting from 4,5-dimethoxy-2-(1-(4-methylbenzyl)-4-nitro-
1H-pyrazol-5-yl)benzaldehyde 5.2.1t (0.381 g, 1 mmol), 
Pd/C (0.030 g, 0.10 mmol) and H2 balloon in 25 mL MeOH, 
the product 5.3.3c was isolated as a gray solid (0.300 g, 
90%). Mp: 168-170°C.  
1H NMR (250 MHz, CDCl3): δ = 2.27 (s, 3H, Me), 3.77 (s, 
3H, OMe), 4.00 (s, 3H, OMe), 5.96 (s, 2H, CH2), 6.97 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.08 (d, 2H, 
3J = 8.1 Hz, CHAr), 7.28 (s, 1H, CHAr), 7.38 (s, 1H, CHAr), 8.34 (s, 1H, pyrazole), 8.87 (s, 1H, 
Py).  
13C NMR (75.5 MHz, CDCl3): δ = 21.0 (Me), 56.0 (OMe), 56.1 (CH2), 56.3 (OMe), 101.9, 
108.2 (CH), 118.8, 122.7 (C), 125.7, 128.4 (CH), 128.5 (C), 129.8, 132.0 (CH), 132.1 (C), 
133.8 (CH), 133.9, 135.9, 137.7 (C), 147.4 (CH), 149.4, 152.8 (C).  
MS (GC, 70 eV): m/z (%) = 333 (M+, 100), 105 (72).  
HRMS (EI): calcd for C20H19N3O2 (M
+) 333.14718, found 333.14682.  
IR (ATR, cm-1): ν̃ = 2920 (w), 1622 (w), 1582 (w), 1495 (m), 1436 (m), 1405 (m), 1265 (m), 
1191 (m), 1154 (s), 1117 (s), 1072 (m), 1016 (m), 926 (m), 850 (m), 803 (m), 783 (m), 753 
(m), 719 (s), 693 (s), 575 (m), 538 (s).  
 
1-(4-Methylbenzyl)-1H-pyrazolo[4,3-c]isoquinoline (5.3.3d).  
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Starting from 2-(1-(4-methylbenzyl)-4-nitro-1H-pyrazol-5-
yl)benzaldehyde 5.2.1s (0.321 g, 1 mmol), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 5.3.3d was 
isolated as a yellow solid (0.256 g, 94%). Mp: 163-164°C.  
1H NMR (300 MHz, DMSO-d6): δ = 2.18 (s, 3H, Me), 6.06 (s, 2H, 
CH2), 6.98 (d, 2H, 
3J = 8.4 Hz, CHAr), 7.07 (d, 2H, 
3J = 8.4 Hz, 
CHAr), 7.69-7.75 (m, 1H, CHAr), 7.80-7.86 (m, 1H, CHAr), 8.25-8.32 (m, 2H, CHAr), 8.43 (s, 
1H, pyrazole), 9.08 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 20.5 (Me), 55.1 (CH2), 121.5 (CH), 122.2 (C), 126.1 
(CH), 126.7 (C), 127.2, 129.3, 131.1, 134.0 (CH), 134.1, 136.6, 136.7 (C), 149.5 (CH).  
MS (GC, 70 eV): m/z (%) = 273 (M+, 75), 105 (100).  
HRMS (ESI): calcd for C18H16N3 (M+H) 274.13387, found 274.13397.  
IR (ATR, cm-1): ν̃ = 3129 (w), 1621 (w), 1531 (w), 1512 (w), 1474 (w), 1415 (m), 1349 (m), 
1309 (m), 1179 (w), 11052 (w), 1063 (m), 1019 (w), 994 (w), 952 (w), 927 (w), 889 (m), 836 
(m), 793 (s), 759 (s), 734 (m), 698 (m), 615 (w), 578 (s).  
 
1-Butyl-1H-pyrazolo[4,3-c]isoquinoline (5.3.3e).  
Starting from 2-(1-butyl-4-nitro-1H-pyrazol-5-yl)benzaldehyde 
5.2.1q (0.273 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol) and H2 balloon 
in 25 mL MeOH, the product 5.3.3e was isolated as a yellow solid 
(0.209 g, 93%). Mp: 137-139°C.  
1H NMR (250 MHz, CDCl3): δ = 0.98 (t, 3H, 3J = 7.5 Hz, 
CH2CH2CH2CH3), 1.39-1.54 (m, 2H, CH2CH2CH2CH3), 1.93-2.05 (m, 2H, CH2CH2CH2CH3), 
4.80 (t, 2H, 3J = 7.5 Hz, CH2CH2CH2CH3), 7.69-7.76 (m, 1H, CHAr), 7.87-7.93 (m, 1H, 
CHAr), 8.15-8.18 (m, 1H, CHAr), 8.26-8.30 (m, 2H, pyrazole, CHAr), 9.03 (s, 1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 13.7 (Me), 19.9, 31.9, 52.8 (CH2), 121.1 (CH), 123.5 (C), 
127.1, 129.8, 131.3, 133.6 (CH), 136.1, 147.6, 149.0 (C).  
MS (GC, 70 eV): m/z (%) = 225 (M+, 20), 182 (100), 169 (35), 128 (28).  
HRMS (EI): calcd for C14H15N3 (M
+) 225.12605, found 225.12597.  
IR (ATR, cm-1): ν̃ = 2955 (w), 2930 (w), 2205 (w), 2063 (m), 1958 (m), 1463 (m), 1412 (m), 
1346 (m), 1313 (w), 1275 (m), 1232 (w), 1086 (w), 1053 (m), 978 (m), 930 (m), 875 (m), 859 
(m), 781 (s), 743 (s), 700 (s), 596 (w), 569 (s).  
 
General Procedure for the Synthesis of Fused 3-Nitropyridines by Cyclocondensation. 
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Synthesis of Compounds 6.1.3a-m: Corresponding aminoheterocycle or aniline 6.1.2 (1 
equiv.) and nitromalonaldehyde 6.1.1 (1.5 equiv.) were placed in a pressure tube under the 
flow of dry argon and dissolved in dry DMF (10 mL for 10 mmol of aminoheterocycle or 
aniline) containing TMSCl (10 equiv.). The mixture was heated at 100°C for 12h. Then the 
solution was evaporated under reduced pressure. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired fused 3-
nitropyridines.  
 
General Procedure for Preparation of Starting Fused 3-Nitropyridines from 3-
Nitrochromone. Synthesis of compounds 6.1.5a-d,f and 6.1.7a-c: The corresponding 3-
nitrochromone 6.1.4 (1 equiv.) and the nucleophile 6.1.2, 6.1.6 (appropriate amino 
heterocyclic, 3-aminocrotononitrile, corresponding substituted hydrazine, hydroxylamine 
hydrochloride) (1.2 equiv.) were dissolved in acetic acid (20 mL for 10 mmol of 3-
nitrochromone). The mixture was heated under reflux under an inert atmosphere for 8h. Then 
the solution was evaporated under reduced pressure. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for the Synthesis of Compound 6.1.5e: Corresponding aniline 6.1.2 
(1.2 equiv.) and 3-nitrochromone 6.1.4 (1 equiv.) were placed in a pressure tube under the 
flow of dry argon and dissolved in dry DMF (10 mL for 10 mmol of 3-nitrochromone) 
containing TMSCl (10 equiv.). The mixture was heated at 100°C for 12h. Then the solution 
was evaporated under reduced pressure. The residue was purified by column chromatography 
typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for TM-catalyzed γ-C-H Arylation of Fused 3-Nitropyridines. 
Synthesis of Compounds 6.2.1a-o and 6.2.2a-g: The corresponding fused 3-nitropyridine 
6.1.3 (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.) and 
PdCl2(PPh3)2 (or NiCl2(PPh3)2) (0.05 equiv.) were weighed in air and placed successively in a 
Schlenk flask equipped with a magnetic stir bar, which was capped with a rubber septum. The 
reaction vessel was evacuated and back-filled with argon (three times). Dry DMF (8 mL for 1 
mmol of fused 3-nitropyridine) and aryl bromide (4 equiv.) were added with a syringe (in case 
of solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the 
reaction mixture was heated to 130oC for 16h. Afterwards, the reaction mixture was cooled to 
room temperature and concentrated under vacuum. The residue was purified by column 
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chromatography typically using heptane/ethyl acetate mixtures to provide the desired arylated 
product.  
 
General Procedure for Pd-catalyzed C-H Arylation of Pyrrolo[2,3-b]pyridine Derivative. 
Synthesis of Compounds 6.2.3a-h: The corresponding pyrrolo[2,3-b]pyridine derivative 
6.1.3h (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.) and 
PdCl2(PPh3)2 (0.05 equiv.) were weighed in air and placed successively into a Schlenk flask 
equipped with a magnetic stir bar, which was capped with a rubber septum. The reaction 
vessel was evacuated and back-filled with argon (three times). Dry DMF (8 mL for 1 mmol of 
pyrrolo[2,3-b]pyridine derivative) and aryl bromide (2 equiv.) were added with a syringe (in 
case of solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the 
reaction was heated to 130oC for 16h. Upon completion, the reaction was cooled to room 
temperature and concentrated under vacuum. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired arylated 
product.  
 
General Procedure for Intramolecular Aromatic Nucleophilic Substitution of Nitro 
Group by Hydroxy Group. Synthesis of Compounds 6.2.4a-f: The corresponding fused 3-
nitropyridine 6.1.5 (1 equiv.) and K2CO3 (1.3 equiv.) were weighed in air and placed 
successively into a Schlenk flask equipped with a magnetic stir bar, which was capped with a 
rubber septum. The reaction vessel was evacuated and back-filled with argon. Dry DMF (8 
mL for 1 mmol of fused 3-nitropyridine) was added with a syringe, and the reaction mixture 
was heated to 130oC for 16h. Upon completion, the reaction was cooled to room temperature 
and concentrated under vacuum. The residue was purified by column chromatography 
typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for One-Pot Pd-catalyzed Domino Nitro Group Substitution-C-H 
Arylation Reaction. Synthesis of Compounds 6.2.5a-c: The corresponding fused 3-
nitropyridine 6.1.5 (1 equiv.), CuI (1.2 equiv.), K2CO3 (2.3 equiv.) and (CH3)3CCO2H (0.3 
equiv.) were weighed in air and placed successively into a Schlenk flask equipped with a 
magnetic stir bar, which was capped with a rubber septum. The reaction vessel was evacuated 
and back-filled with argon (three times). Dry DMF (8 mL for 1 mmol of fused 3-
nitropyridine) was added with a syringe, and the reaction mixture was heated to 130oC for 6h. 
Afterwards, the reaction was cooled to room temperature. Successively, PdCl2(PPh3)2 (0.05 
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equiv.) and aryl bromide (4 equiv.) were weighed in air, dissolved in dry DMF under inert 
atmosphere and added with a syringe to the reaction mixture. The reaction vessel was 
evacuated and back-filled with argon, and the reaction mixture was heated to 130oC for 10h. 
Upon completion, the reaction was cooled to room temperature and concentrated under 
vacuum. The residue was purified by column chromatography typically using heptane/ethyl 
acetate mixtures to provide the desired arylated product.  
 
General Procedure for Pd-catalyzed C-H Arylation of Furo[3,2-b]pyridine Derivatives. 
Synthesis of Compounds 6.2.5a-d: The corresponding fused furo[3,2-b]pyridine derivative 
6.2.4 (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.) and 
PdCl2(PPh3)2 (0.05 equiv.) were weighed in air and placed successively into a Schlenk flask 
equipped with a magnetic stir bar, which was capped with a rubber septum. The reaction 
vessel was evacuated and back-filled with argon (three times). Dry DMF (8 mL for 1 mmol of 
furo[3,2-b]pyridine derivative) and aryl bromide (4 equiv.) were added with a syringe (in case 
of solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the 
reaction was heated to 130oC for 16h. Upon completion, the reaction was cooled to room 
temperature and concentrated under vacuum. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired arylated 
product.  
 
General Procedure for Reduction of Arylated Fused 3-Nitropyridines. Synthesis of 
Compounds 6.3.1a-c and 6.3.3a: To a Schlenk flask equipped with a magnetic stir bar and 
filled with the corresponding arylated fused 3-nitropyridine 6.2.1b,l,i or 6.2.2c (1 equiv.) was 
added 10% Pd/C (0.1 equiv.). The flask was fitted with a rubber septum and then held under 
vacuum for 3min before it was filled with MeOH (25 mL for 1 mmol of arylated fused 3-
nitropyridine) and H2. Holding under vacuum was repeated one more time, and after 
sequential filling with H2, the reaction mixture was stirred for 5h under a H2 atmosphere (H2 
balloon). Afterwards, the reaction mixture was filtered through a Celite pad, and the filtrate 
was evaporated to dryness or (if necessary) purified by column chromatography typically 
using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for Reduction of Arylated Fused 3-Nitropyridine 6.2.1e with 
Formaldehyde. Synthesis of Compound 6.3.2a: To a Schlenk flask equipped with a 
magnetic stir bar and filled with the arylated fused 3-nitropyridine 6.2.1e (1 equiv.) was added 
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10% Pd/C (0.1 equiv.). The flask was fitted with a rubber septum and held under vacuum for 
3min before it was filled with MeOH (25 mL for 1 mmol of arylated fused 3-nitropyridine), 
formaldehyde solution (6 equiv., 37 wt% in H2O, contains 10-15% methanol as stabiliser), 
and H2. Holding under vacuum was repeated one more time, and after sequential filling with 
H2, the reaction mixture was stirred for 5h under a H2 atmosphere (H2 balloon). Afterwards, 
the reaction mixture was filtered through a Celite pad, and the filtrate was evaporated to 
dryness. The residue was purified by column chromatography typically using heptane/ethyl 
acetate mixtures to provide the desired product.  
 
General Procedure for the Synthesis of Compound 6.3.3a from Arylated Fused 3-
Nitropyridine 6.2.1a and Formaldehyde: To a Schlenk flask equipped with a magnetic stir 
bar and filled with the arylated fused 3-nitropyridine 6.2.1a (1 equiv.) was added 10% Pd/C 
(0.1 equiv.). The flask was fitted with a rubber septum and held under vacuum for 3min 
before it was filled with MeOH (25 mL for 1 mmol of arylated fused 3-nitropyridine), 
formaldehyde solution (1.5 equiv., 37 wt% in H2O, contains 10-15% methanol as stabiliser), 
and H2. Holding under vacuum was repeated one more time, and after sequential filling with 
H2, the reaction mixture was stirred for 5h under a H2 atmosphere (H2 balloon). Afterwards, 
the reaction mixture was filtered through Celite pad, and filtrate was evaporated to dryness. 
The residue was purified by column chromatography typically using heptane/ethyl acetate 
mixtures to provide the desired product.  
 
General Procedure for Semi-One-Pot Transfer of Nitro Group to Bromo Substituent. 
Synthesis of Compound 6.3.4: To a Schlenk flask equipped with a magnetic stir bar and 
filled with pyrazolo[3,4-b]pyridine derivative 6.1.3a (1 equiv.) was added 10% Pd/C (0.1 
equiv.). The flask was fitted with a rubber septum and then held under vacuum for 3min 
before it was filled with MeOH (25 mL for 1 mmol of pyrazolo[3,4-b]pyridine derivative) and 
H2. Holding under vacuum was repeated one more time, and after sequential filling with H2, 
the reaction mixture was stirred for 5h under a H2 atmosphere (H2 balloon). Afterwards, the 
reaction mixture was filtered through a Celite pad, and the filtrate was evaporated to dryness. 
The crude mass was dissolved in dry acetonitrile (5 mL for 1 mmol of corresponding amine) 
under inert atmosphere. The resulting solution was slowly added over a period of 5min to the 
three necked round bottom flask containing dry CuBr2 (1.2 equiv.), solution of tert-butyl 
nitrite (1.5 equiv.) in dry acetonitrile (40 mL), and equipped with a reflux condenser, addition 
funnel or solid inlet tube, and a gas outlet tube. After complete gas evolution, the reaction 
  
169 
mixture was poured into 200 mL of 20% aqueous hydrochloric acid and extracted with ether. 
The organic layer was washed with 20% aqueous hydrochloric acid. The resulting ether 
solution was dried over anhydrous MgSO4 and evaporated to dryness. The residue was 
purified by column chromatography typically using heptane/ethyl acetate mixtures to provide 
the desired product.  
 
General Procedure for Suzuki-Miyaura Reaction of Fused 3-Bromopyridine. Synthesis 
of Compounds 6.3.5a-f: Corresponding fused 3-bromopyridine 6.3.4 (1 equiv.), appropriate 
boronic acid (1.5 equiv.), K2CO3 (2 equiv.) and PdCl2(PPh3)2 (0.02 equiv.) were weighed in 
air and placed successively into a pressure tube under the flow of argon and dissolved in dry 
1,4-dioxane (4 mL for 1 mmol of fused 3-bromopyridine). The mixture was heated at 90°C 
for 8h. Then the solution was evaporated under reduced pressure. The residue was purified by 
column chromatography typically using heptane/ethyl acetate mixtures to provide the desired 
product.  
 
General Procedure for Sonogashira Reaction of Fused 3-Bromopyridine. Synthesis of 
Compound 6.3.6a: Corresponding fused 3-bromopyridine 6.3.4 (1 equiv.), appropriate 
acetylene (2 equiv.), TEA (1.3 equiv.) and PdCl2(PPh3)2 (0.02 equiv.) were weighed in air and 
placed successively into a pressure tube under the flow of argon and dissolved in dry DMF (4 
mL for 1 mmol of fused 3-bromopyridine). The mixture was heated at 120°C for 8h. Then the 
solution was evaporated under reduced pressure. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
General Procedure for Mizoroki-Heck Reaction of Fused 3-Bromopyridine. Synthesis of 
Compounds 6.3.7a-c: Corresponding fused 3-bromopyridine 6.3.4 (1 equiv.), appropriate 
alkene (3 equiv.), TEA (4 equiv.) and PdCl2(PPh3)2 (0.04 equiv.) were weighed in air and 
placed successively into a pressure tube under the flow of argon and dissolved in dry DMF (4 
mL for 1 mmol of fused 3-bromopyridine). The mixture was heated at 140°C for 14h. Then 
the solution was evaporated under reduced pressure. The residue was purified by column 
chromatography typically using heptane/ethyl acetate mixtures to provide the desired product.  
 
Competitive Experiment Between Two Various Fused 3-Nitropyridines. The 
corresponding fused 3-nitropyridines 6.1.3a and 6.1.3b (from each 1 equiv.), CuI (1.2 equiv.), 
K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) successively 
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were weighed in air and placed in a Schlenk flask, equipped with a magnetic stir bar, which 
then was capped with a rubber septum. The reaction vessel was evacuated and back filled 
with argon (three times). The dry DMF (8 mL for 2 mmol of fused 3-nitropyridines) and aryl 
bromide (1.1 equiv.) were added via syringe (in the case of solid aryl bromide, first it was 
dissolved in dry DMF under inert atmosphere), and the reaction was heated to 130°C for 16h. 
After the reaction was stopped, the mixture was filtered through Celite pad and the filtrate 
was submitted to GC/MS analysis.  
 
Competitive Experiment Between Fused 3-Nitropyridine and 4-Nitropyrazole. The 
corresponding fused 3-nitropyridine 6.1.3a and 4-nitropyrazole 5.1.3c (from each 1 equiv.), 
CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 
equiv.) successively were weighed in air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon (three times). The dry DMF (8 mL for 2 mmol of 
starting heterocycles) and aryl bromide (1.1 equiv.) were added via syringe (in the case of 
solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction 
was heated to 130°C for 16h. After the reaction was stopped, the mixture was filtered through 
Celite pad and the filtrate was submitted to GC/MS analysis.  
 
Competitive Experiment Between Fused 3-Nitropyridine and 4-Nitroimidazole. The 
corresponding fused 3-nitropyridine 6.1.3a and 4-nitroimidazole 4.1.3f (from each 1 equiv.), 
CuI (1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 
equiv.) successively were weighed in air and placed in a Schlenk flask, equipped with a 
magnetic stir bar, which then was capped with a rubber septum. The reaction vessel was 
evacuated and back filled with argon (three times). The dry DMF (8 mL for 2 mmol of 
starting heterocycles) and aryl bromide (1.1 equiv.) were added via syringe (in the case of 
solid aryl bromide, first it was dissolved in dry DMF under inert atmosphere), and the reaction 
was heated to 130°C for 16h. After the reaction was stopped, the mixture was filtered through 
Celite pad and the filtrate was submitted to GC/MS analysis.  
 
Competitive Experiment Between 4-Nitropyrazole and 4-Nitroimidazole. The 
corresponding 4-nitropyrazole 5.1.3c and 4-nitroimidazole 4.1.3f (from each 1 equiv.), CuI 
(1.2 equiv.), K2CO3 (1.3 equiv.), (CH3)3CCO2H (0.3 equiv.), and PdCl2(PPh3)2 (0.05 equiv.) 
successively were weighed in air and placed in a Schlenk flask, equipped with a magnetic stir 
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bar, which then was capped with a rubber septum. The reaction vessel was evacuated and 
back filled with argon (three times). The dry DMF (8 mL for 2 mmol of starting heterocycles) 
and aryl bromide (1.1 equiv.) were added via syringe (in the case of solid aryl bromide, first it 
was dissolved in dry DMF under inert atmosphere), and the reaction was heated to 130°C for 
16h. After the reaction was stopped, the mixture was filtered through Celite pad and the 
filtrate was submitted to GC/MS analysis.  
 
3-Methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.1.3a).  
Starting from 3-methyl-1-phenyl-1H-pyrazol-5-amine (1.73 g, 10 
mmol), enolate of nitromalonaldehyde (2.08 g, 15 mmol) and TMSCl 
(10.86 g, 100 mmol) in 10 mL DMF, the product 6.1.3a was isolated as 
a yellow solid (2.24 g, 88%). Mp: 130-132oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.71 (s, 3H, Me), 7.32-7.38 (m, 1H, CHAr), 7.51-7.56 
(m, 2H, CHAr), 8.18-8.21 (m, 2H, CHAr), 8.90 (d, 1H, 
4J = 2.5 Hz, Py), 9.43 (d, 1H, 4J = 2.5 
Hz, Py).  
13C NMR (75.5 MHz, CDCl3): δ = 12.5 (Me), 116.0 (C), 121.3, 126.3, 126.9, 129.2 (CH), 
138.4, 139.2 (C), 145.0 (CH), 145.2, 151.2 (C).  
MS (GC, 70 eV): m/z (%) = 254 (M+, 100), 208 (14), 167 (12), 140 (12), 77 (15).  
HRMS (ESI): calcd for C13H10N4O2 (M+H) 255.08765, found 255.08749.  
IR (ATR, cm-1): ν̃ = 3078 (w), 1593 (m), 1522 (m), 1504 (m), 1476 (m), 1437 (m), 1383 (w), 
1350 (m), 1328 (s), 1265 (m), 1160 (w), 1123 (m), 1030 (w), 1011 (w), 962 (w), 933 (w), 914 
(w), 790 (m), 772 (s), 752 (s), 689 (s), 671 (m), 656 (m), 595 (s).  
 
1,3-Dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (6.1.3b).  
Starting from 6-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 
(1.55 g, 10 mmol), enolate of nitromalonaldehyde (2.08 g, 15 
mmol) and TMSCl (10.86 g, 100 mmol) in 10 mL DMF, the 
product 6.1.3b was isolated as a white solid (2.15 g, 91%). Mp: 
202-204oC.  
1H NMR (300 MHz, CDCl3): δ = 3.51 (s, 3H, Me), 3.78 (s, 3H, Me), 9.20 (d, 1H, 4J = 2.7 Hz, 
Py), 9.46 (d, 1H, 4J = 2.7 Hz, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 28.9, 30.4 (Me), 110.0 (C), 133.5 (CH), 140.0 (C), 149.7 
(CH), 150.7, 153.7, 159.7 (C).  
MS (GC, 70 eV): m/z (%) = 236 (M+, 100), 208 (11), 124 (53), 78 (11).  
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HRMS (ESI): calcd for C9H8N4O4 (M+H) 237.0618, found 237.0622.  
IR (ATR, cm-1): ν̃ = 3059 (w), 2923 (w), 2853 (w), 1722 (w), 1666 (m), 1591 (s), 1536 (m), 
1471 (m), 1412 (m), 1376 (m), 1334 (s), 1280 (s), 1163 (m), 1097 (s), 1005 (m), 981 (m), 949 
(m), 910 (w), 829 (m), 796 (s), 751 (s), 733 (s), 711 (m), 675 (m), 580 (m).  
 
3-Cyclohexyl-1-methyl-6-nitro-1H-imidazo[4,5-b]pyridine-2(3H)-thione (6.1.3d).  
Starting from 4-amino-3-cyclohexyl-1-methyl-1H-imidazole-
2(3H)-thione (2.11 g, 10 mmol), enolate of nitromalonaldehyde 
(2.08 g, 15 mmol) and TMSCl (10.86 g, 100 mmol) in 10 mL 
DMF, the product 6.1.3d was isolated as a yellow solid (2.31 g, 
79%). Mp: 198-200oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.24-1.50 (m, 6H, CH2Cy), 1.63-1.66 (m, 2H, CH2Cy), 
1.77-1.80 (m, 2H, CH2Cy), 2.89-2.96 (m, 1H, CHCy), 3.45 (s, 3H, Me), 7.62 (d, 1H, 
4J = 2.11 
Hz, Py), 8.86 (d, 1H, 4J = 2.11 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 24.7, 25.5 (CH2), 31.4 (Me), 33.4 (CH2), 64.7 (CH), 
106.7 (CH), 125.8 (C), 136.7 (CH), 137.3, 143.1, 155.1 (C).  
MS (GC, 70 eV): m/z (%) = 292 (M+, 43), 263 (16), 249 (100), 237 (13), 203 (20).  
HRMS (EI): calcd for C13H16O2N4S (M
+) 292.09885, found 292.099655.  
IR (ATR, cm-1): ν̃ = 3097 (w), 2922 (s), 2852 (s), 1732 (w),1647 (s),1583 (m),1519 (s),1448 
(s),1430 (s),1395 (m),1336 (s), 1285 (s), 1261 (s), 1218 (m), 1147 (s), 1106 (s), 1076 (s), 
1013 (m), 970 (s), 916 (s), 892 (m), 871 (m), 822 (s), 795 (m), 743 (s), 600 (s).  
 
1-Methyl-6-nitro-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione (6.1.3e).  
Starting from 4-amino-1-methyl-3-phenyl-1H-imidazole-2(3H)-
thione (2.05 g, 10 mmol), enolate of nitromalonaldehyde (2.08 g, 15 
mmol) and TMSCl (10.86 g, 100 mmol) in 10 mL DMF, the 
product 6.1.3e was isolated as a red solid (2.38 g, 83%). Mp: 260-
262oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.86 (s, 3H, Me), 7.51-7.65 (m, 5H, CHAr), 8.78 (d, 1H, 
4J = 2.3 Hz, Py), 9.05 (d, 1H, 4J = 2.3 Hz, Py).  
13C NMR (75.5 MHz, CDCl3): δ = 31.6 (Me), 111.9 (CH), 126.2 (C), 128.5, 129.2, 129.3 
(CH), 134.0 (C), 137.0 (CH), 141.0, 148.7, 173.8 (C).  
MS (GC, 70 eV): m/z (%) = 286 (M+, 100), 239 (45), 224 (12), 77 (12).  
HRMS (EI): calcd for C13H10N2O2S (M
+) 286.05190, found 286.051426.  
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IR (ATR, cm-1): ν̃ = 3021 (w), 1597 (w), 1567 (w), 1536 (m), 1486 (w), 1444 (w),1414 
(w),1393 (w), 1322 (m),1283 (s), 1248 (m), 1127 (m), 1061 (m), 950 (m), 938 (m), 900 (m), 
771 (s), 744 (m), 719 (m), 657 (m), 631 (m), 564 (m).  
 
N,N-Dimethyl-6-nitrothiazolo[4,5-b]pyridin-2-amine (6.1.3f).  
Starting from N2,N2-dimethylthiazole-2,4-diamine 
hydrochloride (1.79 g, 10 mmol), enolate of 
nitromalonaldehyde (2.08 g, 15 mmol) and TMSCl (10.86 g, 
100 mmol) in 10 mL DMF, the product 6.1.3f was isolated as a yellow viscous oil (1.70 g, 
76%).  
1H NMR (300 MHz, DMSO-d6): δ = 3.27 (s, 6H, 2xMe), 9.05 (d, 1H, 4J = 2.6 Hz, Py), 9.12 
(d, 1H, 4J = 2.6 Hz, Py).  
13C NMR: due to bed solubility it was not possible to measure.  
MS (EI, 70 eV): m/z (%) = 224 (M+, 67), 209 (100), 181 (35), 163 (21), 108 (14).  
HRMS (EI): calcd for C8H8O2N4S (M
+) 224.03680, found 224.03686.  
IR (ATR, cm-1): ν̃ = 3048 (w), 2967 (w), 1582 (w), 1563 (m), 1484 (m), 1438 (m), 1384 (m), 
1309 (m), 1290 (m), 1239 (s), 1107 (s), 1066 (m), 1054 (m), 1028 (m), 937 (m), 801 (w), 769 
(s), 744 (m), 707 (w), 636 (m).  
 
1-(Tert-butyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6.1.3h).  
Starting from 5-amino-1-(tert-butyl)-1H-pyrrole-3-carbonitrile (1.63 
g, 10 mmol), enolate of nitromalonaldehyde (2.08 g, 15 mmol) and 
TMSCl (10.86 g, 100 mmol) in 10 mL DMF, the product 6.1.3h was 
isolated as an orange solid (2.27 g, 93%). Mp: 218-220oC.  
1H NMR (300 MHz, CDCl3): δ = 1.79 (s, 9H, tBu), 8.00 (s, 1H, 
pyrrole), 8.82 (d, 1H, 4J = 2.6 Hz, Py), 9.24 (d, 1H, 4J = 2.5 Hz, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 29.1 (tBu), 59.9, 86.0, 113.7, 120.3 (C), 124.1, 136.6 
(CH), 140.0 (C), 140.1 (CH), 148.7 (C).  
MS (GC, 70 eV): m/z (%) = 244 (M+, 24), 188 (100), 142 (28).  
HRMS (ESI): calcd for C12H13N4O2 (M+H) 245.1033, found 245.1032.  
IR (ATR, cm-1): ν̃ = 3167 (w), 2974 (w), 2222 (s), 1604 (m), 1575 (m), 1515 (s), 1414 (m), 
1333 (s), 1292 (s), 1196 (s), 1119 (m), 912 (m), 776 (m), 744 (m), 660 (m), 619 (m).  
 
6-(2-Hydroxyphenyl)-2-methyl-5-nitropyridine-3-carbonitrile (6.1.5f).  
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Starting from 3-nitro-4H-chromen-4-one 6.1.4 (1.91 g, 10 mmol) 
and 3-aminobut-2-enenitrile (0.985 g, 12 mmol) in 20 mL AcOH, 
the product 6.1.5f was isolated as a yellow solid (2.12 g, 83%). Mp: 
182-183oC.  
1H NMR (300 MHz, CDCl3): δ = 2.90 (s, 3H, Me), 6.92-6.98 (m, 1H, CHAr), 7.02 (dd, 1H, 3J 
= 8.4 Hz, 4J = 0.9 Hz, CHAr), 7.29 (dd, 1H, 
3J = 8.0 Hz, 4J = 1.5 Hz, CHAr), 7.38-7.44 (m, 1H, 
CHAr), 8.34 (s, 1H, Py), 9.77 (s, 1H, OH).  
13C NMR (62.9 MHz, CDCl3): δ = 23.7 (Me), 107.1 (CN), 114.6, 117.8 (C), 118.4, 120.7, 
129.4, 134.0, 136.9 (CH), 142.8, 153.4, 157.0, 163.0 (C).  
MS (GC, 70eV): m/z (%) = 255 (M+, 45), 209 (100).  
HRMS (EI): calcd for C13H9N3O3 (M
+) 255.06384, found 255.06358.  
IR (ATR, cm-1): ν̃ = 3330 (m), 2246 (m), 1596 (m), 1549 (m), 1522 (s), 1456 (m), 1348 (m), 
1301 (m), 1241 (m), 1119 (m), 1094 (m), 1026 (w), 936 (m), 846 (m), 819 (m), 758 (s), 620 
(m).  
 
2-(1-Methyl-4-nitro-1H-pyrazol-5-yl)phenol (6.1.7a).  
Starting from 3-nitro-4H-chromen-4-one 6.1.4 (1.91 g, 10 mmol) and 
methylhydrazine (0.553 g, 12 mmol) in 20 mL AcOH, the product 6.1.7a 
was isolated as a yellow viscous oil (1.55 g, 71%).  
1H NMR (300 MHz, CDCl3): δ = 3.92 (s, 3H, Me), 6.83-6.90 (m, 2H, 
CHAr), 7.23-7.29 (m, 2H, CHAr), 8.81 (s, 1H, pyrazole), 9.69 (s, 1H, OH).  
13C NMR (75.5 MHz, CDCl3): δ = 37.6 (Me), 115.4, 118.2, 118.6, 130.1, 130.3, 131.8 (CH), 
133.1, 144.1, 155.8 (C).  
MS (EI, 70eV): m/z (%) = 219 (M+, 86), 173 (100), 145 (44).  
HRMS (ESI): calcd for C10H10N3O3 (M+H) 220.07167, found 220.07180.  
IR (ATR, cm-1): ν̃ = 3129 (m), 1616 (w), 1491 (s), 1391 (m), 1325 (s), 1256 (s), 1194 (m), 
1111 (m), 821 (s), 752 (s), 692 (m).  
 
2-(4-Nitro-1-phenyl-1H-pyrazol-5-yl)phenol (6.1.7b).  
Starting from 3-nitro-4H-chromen-4-one 6.1.4 (1.91 g, 10 mmol) and 
phenylhydrazine (1.28 g, 12 mmol) in 20 mL AcOH, the product 
6.1.7b was isolated as a brown solid (2.59 g, 92%). Mp: 165-167oC.  
1H NMR (300 MHz, DMSO-d6): δ = 6.80 (dt, 1H, 3J = 7.5 Hz, 4J = 0.9 
Hz, CHAr), 6.87 (dd, 1H, 
3J = 8.3 Hz, 4J = 0.7 Hz, CHAr), 7.16 (dd, 1H, 
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3J = 7.7 Hz, 4J = 1.7 Hz, CHAr), 7.24-7.31 (m, 3H, CHAr), 7.36-7.41 (m, 3H, CHAr), 8.61 (s, 
1H, pyrazole), 10.02 (s, 1H, OH).  
13C NMR (75.5 MHz, DMSO-d6): δ = 113.8 (C), 115.7, 119.0, 124.9, 128.8, 129.0, 131.1, 
131.8 (CH), 134.1 (C), 137.1 (CH), 138.5, 139.1, 155.6 (C).  
MS (GC, 70eV): m/z (%) = 281 (M+, 45), 235 (100), 77 (49).  
HRMS (EI): calcd for C15H11N3O3 (M
+) 281.07949, found 281.07944.  
IR (ATR, cm-1): ν̃ = 3134 (m), 1724 (w), 1614 (w), 1558 (w), 1516 (s), 1496 (m), 1452 (m), 
1328 (s), 1153(m), 1110 (m), 1038 (w), 965 (m), 910 (w), 867 (w), 824 (s), 758 (s), 686 (s), 
626 (m).  
 
2-(4-Nitroisoxazol-5-yl)phenol (6.1.7c).  
Starting from 3-nitro-4H-chromen-4-one 6.1.4 (1.91 g, 10 mmol) and 
hydroxylamine hydrochloride (0.834 g, 12 mmol) in 20 mL AcOH, the 
product 6.1.7c was isolated as a brown solid (1.19 g, 58%). Mp: 119-
120oC.  
1H NMR (300 MHz, DMSO): δ = 7.38-7.46 (m, 2H, CHAr), 7.69-7.75 
(m, 1H, CHAr), 7.99-8.02 (m, 1H, CHAr), 9.61 (br. s, 2H, CH oxazole, OH).  
13C NMR (62.9 MHz, DMSO): δ = 116.5 (CH), 116.8, 122.0 (C), 125.4, 125.9, 134.1 (CH), 
151.2, 162.7, 167.3 (C).  
MS (EI, 70eV): m/z (%) = 206 (M+, 100), 159 (58), 148 (17), 120 (75), 104 (20), 92 (33).  
HRMS (EI): calcd for C9H6N2O4 (M
+) 206.03221, found 206.03178.  
IR (ATR, cm-1): ν̃ = 3376 (m), 3094 (m), 1623 (m), 1607 (m), 1533 (w), 1465 (m), 1282 (s), 
1221 (s), 1037 (m), 918 (w), 866 (w), 749 (s), 639 (s).  
 
3-Methyl-5-nitro-1,4-diphenyl-1H-pyrazolo[3,4-b]pyridine (6.2.1a).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), bromobenzene (0.628 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1a was 
isolated as a yellow solid (0.254 g, 77%Pd), (0.142 g, 43%Ni). Mp: 
135-137oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.90 (s, 3H, Me), 7.38-7.43 (m, 1H, CHAr), 7.47-7.51 
(m, 2H, CHAr), 7.55-7.62 (m, 5H, CHAr), 8.14-8.17 (m, 2H, CHAr), 9.29 (s, 1H, Py).  
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13C NMR (62.9 MHz, DMSO-d6): δ = 13.9 (Me), 114.8 (C), 121.1, 126.8, 128.0, 128.3, 129.2, 
129.3, 132.0 (CH), 138.0, 139.8, 141.5, 145.2 (C), 149.8 (CH).  
MS (GC, 70eV): m/z (%) = 330 (M+, 100), 283 (17), 243 (10), 77 (21).  
HRMS (EI): calcd for C19H14N4O2 (M
+) 330.11113, found 330.111158.  
IR (ATR, cm-1): ν̃ = 2925 (w), 1579 (m), 1562 (m), 1521 (s), 1438 (m), 1337 (s), 1300 (s), 
1153 (m), 1115 (m), 1028 (m), 928 (w), 901 (w), 796 (m), 758 (S), 701 (s), 988 (s), 629 (m), 
555 (m).  
 
3-Methyl-5-nitro-1-phenyl-4-p-tolyl-1H-pyrazolo[3,4-b]pyridine (6.2.1b).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 1-bromo-4-methylbenzene (0.684 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 
0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1b was 
isolated as a brown solid (0.186 g, 54%Pd), (0,120 g, 35%Ni). Mp: 170-
172oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.94 (s, 3H, Me), 2.43 (s, 3H, Me), 7.38-7.43 (m, 5H, 
CHAr), 7.56-7.63 (m, 2H, CHAr), 8.14-8.17 (m, 2H, CHAr), 9.26 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.2, 20.9 (Me), 114.9 (C), 121.2, 126.7, 128.0, 129.3 
(CH), 138.0, 138.8, 140.1, 141.5, 145.2 (C), 145.7 (CH), 149.8 (C).  
MS (GC, 70eV): m/z (%) = 344 (M+, 100), 77 (18).  
HRMS (EI): calcd for C20H16N4O2 (M
+) 344.12678, found 344.126555.  
IR (ATR, cm-1): ν̃ = 1575 (m), 1556 (m), 1506 (s), 1439 (m), 1299 (m), 1153 (w), 1114 (m), 
1023 (w), 976 (w), 933 (w), 906 (w), 846 (w), 820 (m), 784 (m), 762 (s), 688 (s), 667 (s), 619 
(m), 604 (m).  
 
4-(2-Fluorophenyl)-3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.2.1c).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 1-bromo-2-fluorobenzene (0.700 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMF, the product 6.2.1c was isolated as a yellow solid (0.209 g, 
60%Pd). Mp: 187-189oC.  
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1H NMR (300 MHz, DMSO-d6): δ = 1.99 (s, 3H, Me), 7.40-7.51 (m, 3H, CHAr), 7.56-7.71 
(m, 4H, CHAr), 8.15 (d, 2H, 
3J = 7.7 Hz, CHAr), 9.38 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -115.0 (CF).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.5 (Me), 114.7 (C), 115.6 (d, J = 20.6 Hz, CH), 119.7 
(d, J = 16.4 Hz, C), 121.4, 124.7, 127.0, 129.3, 130.4 (CH), 132.1 (d, J = 7.0 Hz, CH), 135.3, 
137.8, 139.6, 144.9 (C), 146.3 (CH), 150.0 (C), 158.4 (d, 1J = 248.4 Hz, CF).  
MS (GC, 70eV): m/z (%) = 348 (M+, 100), 77 (22).  
HRMS (EI): calcd for C19H13N4O2F (M
+) 348.10171, found 348.101769.  
IR (ATR, cm-1): ν̃ = 1622 (w), 1581 (m), 1565 (s), 1500 (s), 1440 (s), 1385 (w), 1339 (s) 1307 
(s), 1235 (m), 1215 (m), 1157 (m), 1111 (m), 1031 (m), 978 (w), 850 (m), 790 (m), 751 (s), 
689 (s), 630 (s), 559 (m).  
 
3-Methyl-5-nitro-4-(3-nitrophenyl)-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.2.1d).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 1-bromo-3-nitrobenzene (0.808 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, 
the product 6.2.1d was isolated as a yellow solid (0.233 g, 62%Pd). 
Mp: 210-212oC.  
1H NMR (300 MHz, CDCl3): δ = 1.99 (s, 3H, Me), 7.36-7.43 (m, 1H, 
CHAr), 7.52-7.60 (m, 2H, CHAr), 7.69-7.80 (m, 2H, CHAr), 8.15-8.20 (m, 2H, CHAr), 8.28-8.29 
(m, 1H, CHAr), 8.41-8.46 (m, 1H, CHAr), 9.34 (s, 1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 14.6 (Me), 121.7 (CH), 123.0 (C), 124.2, 127.2, 129.3, 
129.7, 133.7 (CH), 134.4, 138.1, 144.7 (C), 146.1 (CH).  
MS (GC, 70eV): m/z (%) = 375 (M+, 100).  
HRMS (EI): calcd for C19H13N5O4 (M
+) 375.09621, found 375.09617.  
IR (ATR, cm-1): ν̃ = 3077 (w), 1594 (m), 1564 (m), 1533 (s), 1505 (s), 1438 (m), 1390 (w), 
1346 (s), 1330 (s), 1232 (w), 1154 (m), 1118 (m), 1104 (m), 1075 (w), 1032 (w), 991 (w), 927 
(w), 897 (w), 883 (w), 832 (w), 810 (w), 788 (m), 753 (m), 731 (s), 688 (s), 667 (m), 657 (m), 
632 (m), 566 (w).  
 
4-(2-(Trifluoromethyl)phenyl)-3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
(6.2.1e).  
 
  
178 
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 1-bromo-3-(trifluoromethyl)benzene (0.900 
g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 
g, 0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1e was 
isolated as a yellow solid (0.330 g, 83%Pd), (0.247 g, 62%Ni). Mp: 
145-146oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.87 (s, 3H, Me), 7.40-7.45 (m, 1H, CHAr), 7.59-7.64 
(m, 2H, CHAr), 7.79-7.88 (m, 2H, CHAr), 7.95-8.01 (m, 2H, CHAr), 8.15-8.18 (m, 2H, CHAr), 
9.40 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -61.0 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.0 (Me), 115.0 (C), 121.2 (CH), 125.9 (C), 126.9 (q, 
1J = 240.0 Hz, CF3), 127.0, 129.4, 129.5, 132.2 (CH), 133.6, 137.9, 139.2 (C), 139.4 (q, 
2J = 
40.0 Hz, CCF3), 140.1, 145.1 (C), 146.3 (CH), 150.0 (C).  
MS (GC, 70eV): m/z (%) = 398 (M+, 100), 77 (18).  
HRMS (EI): calcd for C20H13N4O2F3 (M
+) 398.09851, found 398.097866.  
IR (ATR, cm-1): ν̃ = 1595 (m), 1581 (m), 1563 (m), 1526 (m), 1506 (s), 1434 (m), 1324 (s), 
1307 (s), 1260 (s), 1169 (m), 1153 (s), 1121 (s), 1074 (s), 985 (m), 909 (w), 862 (w), 789 (m), 
780 (m), 752 (s), 714 (m), 703 (m), 687 (s), 654 (m), 608 (m).  
 
4-(3-Methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)benzonitrile (6.2.1f).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 4-bromobenzonitrile (0.728 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1f was 
isolated as a yellow solid (0.302 g, 85%Pd), (0,188 g, 53%Ni). Mp: 
170-172oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.89 (s, 3H, Me), 7.42 (tt, 1H, 3J = 7.4 Hz, 4J = 1.0 Hz, 
CHAr), 7.58-7.64 (m, 2H, CHAr), 7.75-7.79 (m, 2H, CHAr), 8.05-8.08 (m, 2H, CHAr), 8.14-8.18 
(m, 2H, CHAr), 9.39 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.1 (Me), 112.0, 114.5, 118.4 (C), 121.2, 128.0, 129.1, 
129.4, 132.2, 133.0 (CH), 137.6, 137.8, 138.8, 140.1, 145.1 (C), 146.3 (CH), 149.9 (C).  
MS (GC, 70eV): m/z (%) = 355 (M+, 100), 77 (21).  
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HRMS (EI): calcd for C20H13N5O2 (M
+) 355.10638, found 355.105826.  
IR (ATR, cm-1): ν̃ = 2228 (m), 1581 (m), 1556 (m), 1523 (m), 1504 (s), 1436 (m), 1336 (s), 
1304 (s), 1152 (m), 1115 (m), 1084 (m), 1020 (w), 937 (w), 908 (w), 834 (m), 788 (s), 762 
(s), 688 (s), 664 (m), 639 (m), 553 (m).  
 
1-(3-(3-Methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)phenyl)ethanone 
(6.2.1g).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-
b]pyridine 6.1.3a (0.254 g, 1 mmol), 1-(3-bromophenyl)ethanone 
(0.796 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), 
(NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMF, the product 6.2.1g was isolated as a brown solid (0.242 g, 
65%Pd), (0.119 g, 32%Ni). Mp: 172-174oC.  
1H NMR (250 MHz, CDCl3): δ = 1.96 (s, 3H, Me), 2.66 (s, 3H, Me), 7.34-7.41 (m, 1H, 
CHAr), 7.52-7.70 (m, 4H, CHAr), 7.97-7.98 (m, 1H, CHAr), 8.11-8.20 (m, 3H, CHAr), 9.28 (s, 
1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 14.5, 26.7 (Me), 115.2 (C), 121.7, 127.0, 127.6, 128.9, 
129.2, 129.3, 132.3 (CH), 133.1, 137.1, 138.3, 139.3, 140.8, 145.2 (C), 145.9 (CH), 150.5 (C), 
197.0 (C=O).  
MS (GC, 70eV): m/z (%) = 372 (M+, 100), 313 (64), 241 (72), 209 (45), 113 (52), 77 (95).  
HRMS (ESI): calcd for C21H17N4O3 (M+H) 373.12952, found 373.12909.  
IR (ATR, cm-1): ν̃ = 1682 (m), 1575 (m), 1559 (m), 1521 (m), 1488 (m), 1338 (s), 1309 (m), 
1280 (m), 1247 (m), 1221 (m), 1155 (m), 1118 (m), 1083 (m), 1018 (w), 962 (m), 856 (w), 
799 (m), 785 (m), 763 (s), 693 (m), 645 (m), 607 (m), 588 (m), 555 (m).  
 
4-(4-Methoxyphenyl)-3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.2.1h).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 1-bromo-4-methoxybenzene (0.748 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMF, the product 6.2.1h was isolated as a yellow solid (0.249 g, 
68%Pd). Mp: 168-170oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.00 (s, 3H, Me), 3.86 (s, 3H, 
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OMe), 7.11-7.14 (m, 2H, CHAr), 7.38-7.46 (m, 3H, CHAr), 7.57-7.62 (m, 2H, CHAr), 8.15-8.18 
(m, 2H, CHAr), 9.25 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.3 (Me), 55.2 (OMe), 113.8 (CH), 115.0 (C), 121.1 
(CH), 123.5 (C), 126.7, 129.3, 129.6 (CH), 138.0, 140.4, 141.3, 145.2 (C), 145.7 (CH), 149.8, 
160.0 (C).  
MS (GC, 70eV): m/z (%) = 360 (M+, 100).  
HRMS (EI): calcd for C20H16N4O3 (M
+) 360.12169, found 360.12119.  
IR (ATR, cm-1): ν̃ = 1606 (m), 1576 (m), 1509 (m), 1440 (m), 1340 (m), 1303 (m), 1253 (m), 
1177 (m), 1030 (m), 840 (m), 785 (m), 765 (m), 689 (m), 607 (m).  
 
2-(3-Methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)benzaldehyde (6.2.1i).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 2-bromobenzaldehyde (0.740 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, 
the product 6.2.1i was isolated as a brown solid (0.215 g, 60%Pd). 
Mp: 148-150oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.73 (s, 3H, Me), 7.39-7.44 (m, 1H, CHAr), 7.53-7.63 
(m, 3H, CHAr), 7.83-7.90 (m, 2H, CHAr), 8.17-8.21 (m, 3H, CHAr), 9.42 (s, 1H, Py), 9.94 (s, 
1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.4 (Me), 115.0 (C), 121.1, 126.8, 129.2, 129.3, 130.0, 
132.7 (CH), 133.0, 133.5, 134.0, 137.9, 138.9, 141.2, 145.1 (C), 146.3 (CH), 150.0 (C), 192.6 
(CHO).  
MS (GC, 70eV): m/z (%) = 358 (M+, 27), 312 (100), 77 (24).  
HRMS (EI): calcd for C20H14N4O3 (M
+) 358.10604, found 358.105910.  
IR (ATR, cm-1): ν̃ = 2857 (w), 2759 (w), 1699 (s), 1581 (m), 1560 (s), 1507 (s), 1492 (s), 
1440 (m), 1339 (s), 1300 (s), 1264 (m), 1200 (m), 1155 (m), 1115 (m), 1012 (w), 929 (w), 
862 (m), 818 (m), 792 (m), 762 (s), 705 (s), 695 (s), 668 (m), 625 (s), 555 (m).  
 
4,5-Dimethoxy-2-(3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridin-4-
yl)benzaldehyde (6.2.1j).  
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Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 2-bromo-4,5-dimethoxybenzaldehyde 
(0.980 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 
1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.1j was isolated as a brown 
solid (0.217 g, 52%Pd). Mp: 80-82oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.86 (s, 3H, Me), 3.84 (s, 3H, 
OMe), 3.97 (s, 3H, OMe), 7.20 (s, 1H, CHAr), 7.40-7.45 (m, 1H, CHAr), 7.59-7.64 (m, 2H, 
CHAr), 7.70 (s, 1H, CHAr), 8.17-8.20 (m, 2H, CHAr), 9.41 (s, 1H, Py), 9.74 (s, 1H, CHO).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.5 (Me), 55.8, 56.3 (OMe), 112.4, 113.1 (CH), 115.5 
(C), 126.7, 126.8 (CH), 126.8, 127.7 (C), 129.3 (CH), 137.9, 139.5, 140.5, 145.4 (C), 146.2 
(CH), 149.1, 149.9, 153.1 (C), 190.6 (CHO).  
MS (GC, 70eV): m/z (%) = 418 (M+, 14), 372 (100).  
HRMS (ESI): calcd for C22H19N4O5 (M+H) 419.1350, found 419.1346.  
IR (ATR, cm-1): ν̃ = 1682 (m), 1594 (m), 1558 (m), 1505 (s), 1440 (m), 1337 (s), 1304 (m), 
1277 (s), 1220 (m), 1163 (m), 1124 (s), 1075 (m), 1003 (m), 869 (w), 781 (m), 757 (s), 685 
(m).  
 
3-Methyl-5-nitro-1-phenyl-4-(pyridin-3-yl)-1H-pyrazolo[3,4-b]pyridine (6.2.1k).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 3-bromopyridine (0.632 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 
mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1k was 
isolated as a yellow solid (0.222 g, 67%Pd), (0.119 g, 36%Ni). Mp: 
151-153oC.  
1H NMR (300 MHz, CDCl3): δ = 2.00 (s, 3H, Me), 7.35-7.41 (m, 1H, CHAr), 7.52-7.58 (m, 
3H, CHAr), 7.73-7.76 (m, 1H, CHAr), 8.16-8.20 (m, 2H, CHAr), 8.74-8.99 (br. m, 2H, Py), 9.31 
(s, 1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 14.7 (Me), 115.4 (C), 121.7, 127.1, 129.3, 135.4 (CH), 
138.2, 139.4 (C), 145.1 (CH), 145.9, 150.4 (C).  
MS (GC, 70eV): m/z (%) = 331 (M+, 100), 284 (21).  
HRMS (EI): calcd for C18H13N5O2 (M
+) 331.10638, found 331.10624.  
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IR (ATR, cm-1): ν̃ = 2921 (w), 1595 (m), 1574 (m), 1557 (s), 1506 (s), 1444 (s), 1333 (s), 
1305 (s), 1234 (w), 1192 (w), 1152 (m), 1119 (m), 1088 (m), 1046 (w), 1023 (m), 978 (w), 
942 (m), 913 (w), 845 (w), 808 (m), 785 (m), 765 (s), 716 (s), 693 (s), 655 (m), 638 (m), 616 
(m), 554 (m).  
 
3-Methyl-4-(5-methylpyridin-2-yl)-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.2.1l).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 2-bromo-5-methylpyridine (0.688 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 
0.05 mmol)), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.1l was 
isolated as a brown solid (0.276 g, 80%Pd), (0.166 g, 48%Ni). Mp: 153-
155oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.96 (s, 3H, Me), 2.44 (s, 3H, Me), 7.38-7.43 (m, 1H, 
CHAr), 7.56-7.66 (m, 3H, CHAr), 7.84-7.87 (m, 1H, CHAr), 8.14-8.17 (m, 2H, CHAr), 8.60 (s, 
1H, Py), 9.31 (s, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.2, 17.8 (Me), 114.3 (C), 121.2, 123.7, 126.8, 129.3 
(CH), 133.8 (C), 137.1 (CH), 137.9, 139.2, 139.9, 144.9 (C), 146.0 (CH), 148.0 (C), 149.7 
(CH), 150.3 (C).  
MS (GC, 70eV): m/z (%) = 345 (M+, 49), 328 (61), 298 (100), 193 (11), 77 (26).  
HRMS (EI): calcd for C19H15N5O2 (M
+) 345.12203, found 345.121980.  
IR (ATR, cm-1): ν̃ = 2922 (w), 1558 (m), 1525 (m), 1504 (s), 1436 (m), 1354 (m), 1303 (m), 
1248 (m), 1166 (w), 1121 (m), 1084 (m), 1028 (m), 987 (w), 926 (m), 800 (m), 767 (m), 759 
(s), 697 (m), 687 (m), 667 (s), 640 (m), 604 (m).  
 
3-Methyl-5-nitro-1-phenyl-4-(pyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridine (6.2.1m).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 5-bromopyrimidine (0.636 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, 
the product 6.2.1m was isolated as a brown solid (0.226 g, 68%Pd). 
Mp: 149-151oC.  
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1H NMR (300 MHz, DMSO-d6): δ = 1.98 (s, 3H, Me), 7.41-7.47 (m, 1H, CHAr), 7.47-7.66 
(m, 2H, CHAr), 8.15-8.18 (m, 2H, CHAr), 9.09 (s, 2H, Py, CHAr), 9.43 (s, 1H, CHAr), 9.48 (s, 
1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.7 (Me), 115.1 (C), 121.3, 127.1 (CH), 127.7 (C), 
129.4, 135.6, 137.7, 139.1, 145.2 (CH), 146.6 (C), 149.9 (CH), 155.5, 158.7 (C).  
MS (GC, 70eV): m/z (%) = 332 (M+, 100), 285 (10), 77 (22).  
HRMS (EI): calcd for C17H12N6O2 (M
+) 332.10163, found 332.10176.  
IR (ATR, cm-1): ν̃ = 2923 (w), 1594 (w), 1561 (w), 1547 (m), 1505 (s), 1483 (m), 1422 (m), 
1387 (m), 1330 (s), 1303 (s), 1236 (w), 1159 (w), 1118 (m), 1082 (w), 1044 (w), 970 (w), 918 
(w), 843 (w), 789(m), 764 (s), 725 (m), 694 (s), 682 (m), 623 (s), 571 (w), 550 (m).  
 
3-Methyl-5-nitro-1-phenyl-4-(pyrimidin-2-yl)-1H-pyrazolo[3,4-b]pyridine (6.2.1n).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 2-chloropyrimidine (0.458 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH 
(0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, 
the product 6.2.1n was isolated as a yellow solid (0.156 g, 47%Pd). 
Mp: 183-185oC.  
1H NMR (250 MHz, DMSO-d6): δ = 2.01 (s, 3H, Me), 7.39-7.45 (m, 1H, CHAr), 7.57-7.63 
(m, 2H, CHAr), 7.77 (t, 1H, 
3J = 5.5 Hz, CHAr), 8.14-8.18 (m, 2H, CHAr), 9.08 (d, 2H, 
3J = 5.0 
Hz, CHAr), 9.40 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.9 (Me), 113.4 (C), 121.4, 121.7, 127.0, 129.3 (CH), 
137.7, 138.2, 144.5 (C), 146.3 (CH), 150.7 (C), 157.9 (CH), 160.2 (C).  
MS (GC, 70eV): m/z (%) = 332 (M+, 100), 285 (10), 77 (22).  
HRMS (ESI): calcd for C17H13N6O2 (M+H) 333.10945, found 333.10947.  
IR (ATR, cm-1): ν̃ = 3306 (w), 2920 (w), 1596 (w), 1558 (s), 1505 (s), 1487 (s), 1436 (s), 
1412 (s), 1342 (s), 1311 (m), 1261 (m), 1244 (m), 1172 (m), 1093 (m), 1020 (m), 940 (w), 
913 (w), 816 (m), 784 (s), 765 (s), 728 (m), 694 (s), 635 (s), 620 (s).  
 
3-Methyl-5-nitro-1-phenyl-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridine (6.2.1o).  
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Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-b]pyridine 
6.1.3a (0.254 g, 1 mmol), 5-bromothiophene-2-carboxylic acid 
(0.828 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 
1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.1o was isolated as a yellow 
solid (0.094 g, 28%Pd). Mp: 197-199oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.09 (s, 3H, Me), 7.27-7.30 (m, 1H, CHAr), 7.39-7.45 
(m, 2H, CHAr), 7.57-7.64 (m, 2H, CHAr), 7.94 (dd, 1H, 
3J = 5.5 Hz, 4J = 1.3 Hz, CHAr), 8.12-
8.16 (m, 2H, CHAr), 9.27 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 13.6 (Me), 115.4 (C), 121.3, 126.7, 127.4, 129.3, 129.4 
(CH), 129.9 (C), 130.2 (CH), 134.4, 137.9, 141.0, 145.0 (C), 145.6 (CH), 149.6 (C).  
MS (GC, 70eV): m/z (%) = 336 (M+, 100), 318 (45), 275 (22), 247 (19), 207 (26), 77 (75).  
HRMS (ESI): calcd for C17H12N4O2S (M
+) 336.06755, found 336.06777.  
IR (ATR, cm-1): ν̃ = 1594 (m), 1563 (m), 1505 (s), 1435 (m), 1382 (w), 1335 (s), 1301 (s), 
1260 (m), 1145 (m), 1114 (m), 1028 (w), 952 (w), 899 (w), 854 (w), 811 (w), 787 (m), 759 
(s), 710 (s), 688 (s).  
 
5-(3-(Trifluoromethyl)phenyl)-1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-
dione (6.2.2a).  
Starting from 1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione 6.1.3b (0.236 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.900 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), 
CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.2a 
was isolated as a yellow solid (0.243 g, 64%Pd), (0.103 g, 
27%Ni). Mp: 204-206oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.15 (s, 3H, Me), 3.67 (s, 3H, Me), 7.52-7.55 (m, 1H, 
CHAr), 7.64-7.69 (m, 2H, CHAr), 7.78-7.81 (m, 1H, CHAr), 9.37 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -61.0 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 28.3, 30.3 (Me), 108.3, 121.1 (C), 124.0 (CH), 124.1 
(q, 1J = 274 Hz, CF3), 124.8 (CH), 128.5 (q, 
2J = 32 Hz, CCF3), 128.8, 131.1 (CH), 132.0, 
134.8, 141.8, 145.0 (C), 148.7 (CH), 150.3, 153.1, 159.0 (C).  
MS (GC, 70eV): m/z (%) = 380 (M+, 100), 311 (21), 265 (14).  
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HRMS (ESI): calcd for C16H12N4O4F3 (M+H) 381.0805, found 381.0808.  
IR (ATR, cm-1): ν̃ = 1720 (m), 1681 (s), 1558 (m), 1534 (s), 1469 (m), 1365 (m), 1325 (s), 
12844 (m), 1204 (w), 1164 (m), 1129 (s), 1070 (s), 1016 (w), 925 (w), 831 (w), 806 (m), 752 
(m), 705 (m), 661 (w), 597 (w).  
 
5-(4-Ethylphenyl)-1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(6.2.2b). 
Starting from 1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione 6.1.3b (0.236 g, 1 mmol), 1-bromo-4-
ethylbenzene (0.740 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.2b was isolated as an orange solid (0.156 g, 46%Pd). Mp: 
146-147oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.24 (t, 3H, 3J = 7.7 Hz, 
Me), 2.68 (q, 2H, 3J = 7.7 Hz, CH2), 3.15 (s, 3H, Me), 3.64 (s, 3H, Me), 7.11 (d, 2H, 
3J = 8.03 
Hz, CHAr), 7.25 (d, 2H, 
3J = 8.03 Hz, CHAr), 9.25 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 15.2 (Me), 27.9 (CH2), 28.2, 30.2 (Me), 108.3 (C), 
127.1 (CH), 130.3, 143.1, 143.7, 146.5 (C), 147.6 (CH), 150.4, 152.9, 158.9 (C).  
MS (GC, 70eV): m/z (%) = 340 (M+, 100), 323 (35), 295 (32), 269 (19), 140 (23).  
HRMS (ESI): calcd for C17H17N4O4 (M+H) 341.12443, found 341.12451.  
IR (ATR, cm-1): ν̃ = 2973 (w), 1716 (s), 1673 (s), 1585 (m), 1553 (s), 1531 (s), 1471 (s), 1360 
(s), 1331 (s), 1201 (w), 1060 (w), 1005 (w), 957 (m), 834 (m), 731 (m), 751 (s), 718 (m), 664 
(w), 636 (w), 610 (m).  
 
5-(4-(Trifluoromethyl)phenyl)-1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-
dione (6.2.2c). 
Starting from 1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione 6.1.3b (0.236 g, 1 mmol), 1-bromo-4-
(trifluoromethyl)benzene (0.900 g, 4 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), (NiCl2(PPh3)2 (0.033 g, 0.05 mmol)), 
CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.2c 
was isolated as a yellow solid (0.213 g, 56%Pd), (0.095 g, 
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25%Ni). Mp: 197-199oC.  
1H NMR (300 MHz, CDCl3): δ = 3.33 (s, 3H, Me), 3.81 (s, 3H, Me), 7.30 (d, 2H, 3J = 8.0 Hz, 
CHAr), 7.71 (d, 2H, 
3J = 8.0 Hz, CHAr), 9.16 (s, 1H, Py). 
19F NMR (282 MHz, CDCl3): δ = -62.6 (CF3).  
13C NMR (62.9 MHz, CDCl3): δ = 28.9, 30.8 (Me), 115.6 (C), 107.9 (CH), 123.9 (q, 1J = 270 
Hz, CF3), 125.1, 125.2, 125.3 (CH), 127.3 (C), 131.0 (q, 
2J = 35 Hz, CCF3), 136.7, 142.3, 
147.0 (C), 148.7 (CH), 150.4, 153.4, 159.1 (C).  
MS (GC, 70eV): m/z (%) = 380 (M+, 100), 363 (33), 306 (19), 236 (16).  
HRMS (EI): calcd for C16H11N4O4F3 (M
+) 380.07269, found 380.07227.  
IR (ATR, cm-1): ν̃ = 2925 (w), 1722 (m), 1672 (s), 1593 (m), 1562 (s), 1520 (m), 1470 (m), 
1411 (w), 1348 (m), 1323 (s), 1164 (m), 1106 (s), 1062 (s), 1005 (m), 943 (w), 843 (m), 814 
(m), 751 (m), 725 (m), 661 (w), 618 (m).  
 
1,3-Dimethyl-6-nitro-5-(pyrimidin-5-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
(6.2.2d).  
Starting from 1,3-dimethyl-6-nitropyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione 6.1.3b (0.236 g, 1 mmol), 5-
bromopyrimidine (0.636 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 6.2.2d was isolated as a yellow solid (0.173 g, 55%Pd). 
Mp: 113-115oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.16 (s, 3H, Me), 3.68 (s, 3H, Me), 8.73 (s, 2H, CHAr), 
9.25 (s, 1H, Py), 9.49 (s, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 28.4, 30.4 (Me), 108.6 (C), 128.7 (CH), 129.4 (C), 
131.4 (CH), 140.9 (C), 149.6 (CH), 150.3, 153.4 (C), 154.3, 157.5 (CH), 159.5 (C).  
MS (GC, 70eV): m/z (%) = 314 (M+, 66), 297 (13), 284 (100), 267 (17), 147 (21).  
HRMS (EI): calcd for C13H10N6O4 (M
+) 314.07580, found 314.07520.  
IR (ATR, cm-1): ν̃ = 2952 (w), 1716 (m), 1660 (s), 1592 (m), 1557 (s), 1471 (m), 1428 (m), 
1352 (m), 1328 (s), 1187 (m), 1118 (m), 1072 (m), 1002 (m), 963 (m), 912 (w), 813 (m), 753 
(m), 720 (s), 694 (m), 629 (m), 615 (m), 538 (s).  
 
3-Cyclohexyl-1-methyl-6-nitro-7-(3-nitrophenyl)-1H-imidazo[4,5-b]pyridine-2(3H)-
thione (6.2.2e).  
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Starting from 3-cyclohexyl-1-methyl-6-nitro-1H-imidazo[4,5-
b]pyridine-2(3H)-thione 6.1.3d (0.292 g, 1 mmol), 1-bromo-3-
nitrobenzene (0.808 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.2e was isolated as a yellow viscous oil (0.268 g, 65%Pd).  
1H NMR (250 MHz, CDCl3): δ = 1.24-1.78 (m, 10H, CH2Cy), 
2.82 (s, 3H, Me), 2.90-2.94 (m, 1H, CHCy), 7.66-7.69 (m, 2H, CHAr), 8.22-8.23 (m, 1H, 
CHAr), 8.34-8.39 (m, 1H, CHAr), 8.58 (s, 1H, Py).  
13C NMR (75.5 MHz, CDCl3): δ = 24.6, 25.6 (CH2Cy), 29.8 (Me), 33.3, 34.5 (CH2Cy), 64.6 
(CHCy), 122.1, 123.3, 124.5, 124.6, 129.5, 130.3, 133.0, 135.5 (CH), 136.2, 145.0, 147.8 (C).  
MS (GC, 70eV): m/z (%) = 413 (M+, 47), 370 (100).  
HRMS (EI): calcd for C19H19N5O4S (M
+) 413.11523, found 413.11493.  
IR (ATR, cm-1): ν̃ = 2925 (w), 2851 (w), 1633 (m), 1582 (w), 1519 (s), 1462 (m), 1435 (m), 
1342 (s), 1280 (m), 1206 (m), 1129 (m), 1021 (w), 969 (w), 891 (w), 829 (m), 817 (m), 77 
(w), 32 (m), 704 (m), 688 (m), 630 (m), 599 (m).  
 
1-Methyl-6-nitro-7-(3-nitrophenyl)-3-phenyl-1H-imidazo[4,5-b]pyridine-2(3H)-thione 
(6.2.2f).  
Starting from 1-methyl-6-nitro-3-phenyl-1H-imidazo[4,5-
b]pyridine-2(3H)-thione 6.1.3e (0.286 g, 1 mmol), 1-bromo-3-
nitrobenzene (0.808 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.2f was isolated as a yellow viscous oil (0.301 g, 74%Pd).  
1H NMR (250 MHz, CDCl3): δ = 2.89 (s, 3H, Me), 7.47-7.51 
(m, 1H, CHAr), 7.54-7.66 (m, 4H, CHAr), 7.73-7.75 (m, 2H, CHAr), 8.30-8.42 (m, 2H, CHAr), 
8.86 (s, 1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 29.8 (Me), 122.3 (C), 124.2, 124.4, 126.8, 129.5, 129.6 
(CH), 132.0, 132.7 (C), 135.1, 138.8 (CH), 141.0, 146.0, 147.9, 153.3 (C).  
MS (GC, 70eV): m/z (%) = 407 (M+, 100).  
HRMS (EI): calcd for C19H13N5O5 (M+H) 392.09895, found 392.09894. Resubmission of 
compound 6.2.2f showed that after first synthesis of the substance (approximately 1 year ago) 
the C=S bond was hydrolysed to C=O.  
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IR (ATR, cm-1): ν̃ = 1723 (m) 1622 (w), 1528 (m), 1497 (m), 1469 (m), 1453 (s), 1389 (w), 
1348 (m), 1326 (s), 1289 (m), 1255 (m), 1149 (m), 1128 (m), 1073 (m), 1029 (w), 906 (w), 
882 (w), 783 (w), 808 (m), 760 (m), 738 (m), 710 (m), 686 (s), 632 (m), 536 (m).  
 
7-(4-Fluorophenyl)-N,N-dimethyl-6-nitrothiazolo[4,5-b]pyridin-2-amine (6.2.2g).  
Starting from N,N-dimethyl-6-nitrothiazolo[4,5-b]pyridin-
2-amine 6.1.3f (0.224 g, 1 mmol), 1-bromo-4-
fluorobenzene (0.700 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 
0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 6.2.2g was isolated as a yellow viscous oil (0.204 
g, 64%Pd).  
1H NMR (300 MHz, DMSO-d6): δ = 3.21 (br. s, 6H, 2xMe), 7.36-7.42 (m, 2H, CHAr), 7.53-
7.58 (m, 2H, CHAr), 9.06 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -111.9 (CF).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 318 (M+, 100), 289 (62), 202 (32), 158 (35).  
HRMS (ESI): calcd for C14H12FN4O2S (M+H) 319.06595, found 319.06607.  
IR (ATR, cm-1): ν̃ = 2927 (w), 1719 (w), 1593 (m), 1532 (m), 1489 (m), 1410 (m), 1378 (m), 
1323 (s), 1219 (m), 1067 (m), 906 (m), 829 (m), 734 (m), 587 (m).  
 
1-Tert-butyl-4-(3-(trifluoromethyl)phenyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (6.2.3a).  
Starting from 1-(tert-butyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile 6.1.3h (0.244 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.450 g, 2 mmol), PdCl2(PPh3)2 (0.035 
g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.3a was isolated as a yellow solid (0.144 g, 37%Pd). Mp: 133-
134oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.81 (s, 9H, tBu), 7.72-7.90 (m, 4H, CHAr), 8.78 (s, 1H, 
pyrrole), 9.22 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -61.2 (CF3).  
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13C NMR (75.5 MHz, DMSO-d6): δ = 28.5 (tBu), 59.7, 84.2, 113.3, 119.4 (C), 120.4 (q, 1J = 
273 Hz, CF3), 125.3, 125.4, 125.8 (CH), 128.9 (q, 
2J = 32 Hz, CCF3), 129.3, 132.5 (CH), 
133.2, 136.5, 139.5 (C), 140.4, 140.8 (CH), 147.1 (C).  
MS (GC, 70eV): m/z (%) = 388 (M+, 24), 332 (100), 57 (29).  
HRMS (EI): calcd for C19H15N4F3O2 (M
+) 388.11416, found 388.11386.  
IR (ATR, cm-1): ν̃ = 3156 (w), 2985 (w), 2225 (m), 1615 (w), 1574 (m), 1520 (s), 1435 (w), 
1399 (m), 1326 (s), 1292 (s), 1229 (w), 1170 (s), 1120 (s), 1075 (s), 1013 (m), 929 (m), 862 
)w), 812 (m), 797 (m), 782 (m), 707 (m), 661 (m), 620 (m).  
 
1-Tert-butyl-2-(4-(trifluoromethyl)phenyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (6.2.3b).  
Starting from 1-(tert-butyl)-5-nitro-1H-
pyrrolo[2,3-b]pyridine-3-carbonitrile 6.1.3h 
(0.244 g, 1 mmol), 1-bromo-4-
(trifluoromethyl)benzene (0.450 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMF, the product 6.2.3b was isolated as a brown solid (0.144 g, 37%Pd). Mp: 175-177oC.  
1H NMR (300 MHz, CDCl3): δ = 1.72 (s, 9H, tBu), 7.61 (d, 2H, 3J = 8.1 Hz, CHAr), 7.80 (d, 
2H, 3J = 8.1 Hz, CHAr), 8.85 (d, 1H, 
4J = 2.6 Hz, Py), 9.33 (d, 1H, 4J = 2.6 Hz, Py).  
19F NMR (282 MHz, CDCl3): δ = -62.9 (CF3).  
13C NMR (62.9 MHz, CDCl3): δ = 30.4 (tBu), 63.1 (CtBu), 89.4, 112.3, 118.3 (C), 122.4 
(CH), 122.8 (q, 1J = 280 Hz, CF3), 124.6 (q, 
3J = 4 Hz, CH), 126.2, 126.4 (CH), 127.2 (C), 
129.2, 130.2 (CH), 131.5 (q, 2J = 33 Hz, CCF3), 134.5 (C), 138.9 (CH), 138.9, 139.2, 145.9, 
149.3, 150.1 (C).  
MS (GC, 70eV): m/z (%) = 388 (M+, 2), 332 (100).  
HRMS (EI): calcd for C19H15N4O2F3 (M
+) 388.11416, found 388.11409.  
IR (ATR, cm-1): ν̃ = 3167 (w), 2975 (w), 2223 (m), 1861 (w), 1744 (w), 1605 (m), 1576 (m), 
1516 (s), 1471 (w), 1415 (m), 1402 (m), 1337 (s), 1292 (s), 1250 (m), 1198 (s), 1119 (s), 1067 
(m), 1020 (m), 934 (m), 913 (m), 875 (m), 815 (m), 786 (m), 762 (m), 745 (m), 702 (w), 661 
(m), 618 (s), 569 (m).  
 
1-Tert-butyl-4-(4-(trifluoromethyl)phenyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile (6.2.3c).  
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Starting from 1-(tert-butyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile 6.1.3h (0.244 g, 1 mmol), 1-bromo-4-
(trifluoromethyl)benzene (0.450 g, 2 mmol), PdCl2(PPh3)2 (0.035 
g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.3c was isolated as a yellow viscous oil (0.167 g, 43%Pd).  
1H NMR (250 MHz, CDCl3): δ = 1.86 (s, 9H, tBu), 7.48-7.53 (m, 
2H, CHAr), 7.78-7.81 (m, 2H, CHAr), 8.02 (s, 1H, pyrrole), 9.11 
(s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -62.7 (CF3).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 388 (M+, 24), 332 (100).  
HRMS (EI): calcd for C19H15N4O2F3 (M
+) 388.11416, found 388.11383.  
IR (ATR, cm-1): ν̃ = 2928 (w), 2226 (m), 1426 (w), 1583 (m), 1521 (m), 1468 (w), 1405 (m), 
1345 (m), 1322 (s), 1286 (s), 1204 (m), 1168 (s), 1121 (s), 1108 (s), 1066 (s), 1020 (m), 863 
(m), 833 (m), 769 (m), 669 (m), 631 (m), 609 (m), 544 (w).  
 
1-Tert-butyl-5-nitro-4-(3-nitrophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6.2.3d).  
Starting from 1-(tert-butyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile 6.1.3h (0.244 g, 1 mmol), 1-bromo-3-nitrobenzene 
(0.404 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.3d was 
isolated as a yellow solid (0.157 g, 43%Pd). Mp: 166-168oC.  
1H NMR (250 MHz, CDCl3): δ = 1.87 (s, 9H, tBu), 7.71-7.74 (m, 
2H, CHAr), 8.03 (s, 1H, pyrrole), 8.24-8.26 (m, 1H, CHAr), 8.39-8.43 (m, 1H, CHAr), 9.19 (s, 
1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 29.1 (tBu), 60.2 (CtBu), 85.7 (CN), 113.0, 119.7 (C), 
123.7, 124.5, 129.7 (CH), 133.4 (C), 134.4 (CH), 136.2 (C), 137.8 (CH), 139.6 (C), 140.9 
(CH), 147.7, 148.0 (C).  
MS (GC, 70eV): m/z (%) = 365 (M+, 20), 309 (100).  
HRMS (EI): calcd for C18H15N5O4 (M
+) 365.11186, found 365.11148.  
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IR (ATR, cm-1): ν̃ = 3082 (w), 2977 (w), 2225 (m), 1575 (m), 1522 (s), 1398 (m), 1338 (s), 
1232 (m), 1192 (s), 1150 (m), 1105 (m), 926 (m), 864 (w), 842 (m), 809 (s), 773 (m), 739 
(m), 727 (s), 699 (m), 670 (m), 651 (m), 623 (m), 595 (w).  
 
1-Tert-butyl-5-nitro-2-(3-nitrophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6.2.3e).  
Starting from 1-(tert-butyl)-5-nitro-1H-
pyrrolo[2,3-b]pyridine-3-carbonitrile 6.1.3h 
(0.244 g, 1 mmol), 1-bromo-3-nitrobenzene 
(0.404 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 
0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.3e was isolated as a 
brown solid (0.142 g, 39%Pd). Mp: 213-215oC.  
1H NMR (250 MHz, CDCl3): δ = 1.72 (s, 9H, tBu), 7.72-7.84 (m, 2H, CHAr), 8.34-8.35 (m, 
1H, CHAr), 8.42-8.46 (m, 1H, CHAr), 8.87 (d, 1H, 
4J = 2.5 Hz, Py), 9.36 (d, 1H, 4J = 2.5 Hz, 
Py).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 365 (M+, 4), 309 (100), 263 (15), 217 (12), 78 (29).  
HRMS (ESI): calcd for C18H15N5NaO4 (M+Na) 388.10163, found 388.10171.  
IR (ATR, cm-1): ν̃ = 2920 (m), 1713 (w), 1579 (w), 1515 (s), 1456 (w), 1407 (m), 1345 (s), 
1293 (m), 1242 (m), 1200 (m), 1165 (m), 1095 (m), 915 (m), 26 (m), 813 (m), 781 (m), 717 
(s), 579 (m).  
 
1-Tert-butyl-5-nitro-4-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6.2.3f).  
Starting from 1-(tert-butyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-
carbonitrile 6.1.3h (0.244 g, 1 mmol), 3-bromopyridine (0.316 g, 
2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.3f was isolated as a yellow 
solid (0.144 g, 44%Pd). Mp: 160-162oC.  
1H NMR (250 MHz, CDCl3): δ = 1.81 (s, 9H, tBu), 7.54-7.66 (m, 
2H, CHAr), 7.93-7.97 (m, 1H, CHAr), 8.66-8.73 (m, 1H, CHAr), 8.80 (s, 1H, pyrrole), 9.23 (s, 
1H, Py).  
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13C NMR (62.9 MHz, CDCl3): δ = 28.5 (tBu), 59.8 (CtBu), 84.2 (CN), 113.6, 119.6 (C), 
123.0 (CH), 128.7 (C), 131.4 (CH), 135.0 (C), 136.3 (CH), 139.8 (C), 140.4, 140.9 (CH), 
147.0 (C), 148.1, 150.0 (CH).  
MS (GC, 70eV): m/z (%) = 321 (M+, 33), 265 (100), 235 (17), 192 (18).  
HRMS (EI): calcd for C17H15N5O2 (M
+) 321.12203, found 321.12202.  
IR (ATR, cm-1): ν̃ = 3060 (w), 2924 (w), 2226 (w), 1731 (w), 1575 (m), 1516 (s), 1483 (m), 
1398 (m), 1370 (m), 1329 (s), 1287 (s), 1189 (s), 1144 (m), 1105 (m), 1025 (m), 997 (w), 937 
(w), 853 (w), 806 (m), 771 (m), 749 (m), 718 (s), 672 (m), 642 (m), 621 (s), 566 (w), 540 (s).  
 
1-Tert-butyl-5-nitro-2-(pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile (6.2.3g).  
Starting from 1-(tert-butyl)-5-nitro-1H-pyrrolo[2,3-
b]pyridine-3-carbonitrile 6.1.3h (0.244 g, 1 mmol), 3-
bromopyridine (0.316 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.3g was isolated as a brown solid (0.123 g, 38%Pd). Mp: 
137-139oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.67 (s, 9H, tBu), 7.61-7.66 (m, 1H, CHAr), 8.14-8.18 
(m, 1H, CHAr), 8.80-8.86 (m, 2H, CHAr), 8.94 (d, 1H, 
4J = 2.5 Hz, Py), 9.36 (d, 1H, 4J = 2.5 
Hz, Py).  
13C NMR (75.5 MHz, DMSO-d6): δ = 30.6 (tBu), 63.7 (CtBu), 89.7 (CN), 113.6, 118.6 (C), 
123.2, 123.5, (CH), 128.3 (C), 137.5, 139.7 (CH), 140.0, 149.5 (C), 149.6 (CH), 150.2 (C), 
151.1 (CH).  
MS (GC, 70eV): m/z (%) = 321 (M+, 1), 265 (100), 219 (25).  
HRMS (EI): calcd for C17H15N5O2 (M
+) 321.12203, found 321.12190.  
IR (ATR, cm-1): ν̃ = 3044 (w), 2928 (w), 2227 (w), 1731 (w), 1598 (m), 1577 (m), 1514 (s), 
1471 (m), 1404 (s), 1350 (s), 1293 (s), 1229 (m), 1194 (s), 1170 (s), 1113 (m), 1024 (m), 986 
(w), 942 (w), 833 (m), 779 (m), 748 (m), 722 (s), 708 (m), 613 (w), 582 (s).  
 
1-Tert-butyl-2-(3-acetylphenyl)-5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 
(6.2.3h).  
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Starting from 1-(tert-butyl)-5-nitro-1H-
pyrrolo[2,3-b]pyridine-3-carbonitrile 6.1.3h 
(0.244 g, 1 mmol), 1-(3-bromophenyl)ethanone 
(0.398 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 
g, 0.3 mmol) and K2CO3 (0.179 g, 1.3 mmol) 
in 8 mL DMF, the product 6.2.3h was isolated as a brown solid (0.141 g, 39%Pd). Mp: 137-
139oC.  
1H NMR (250 MHz, CDCl3): δ = 1.70 (s, 9H, tBu), 2.67 (s, 3H, Me), 7.64-7.66 (m, 2H, 
CHAr), 8.05 (br. s, 1H, CHAr), 8.11-8.13 (m, 1H, CHAr), 8.84 (d, 1H, 
4J = 2.4 Hz, Py), 9.33 (d, 
1H, 4J = 2.4 Hz, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 26.7 (Me), 31.4 (tBu), 64.0 (CtBu), 90.3 (CN), 113.5, 
119.3 (C), 123.3, 129.0, 129.3, 130.2 (CH), 132.4 (C), 133.8 (CH), 137.1 (C), 139.8 (CH), 
140.1, 150.3, 151.8 (C), 196.8 (C=O).  
MS (GC, 70eV): m/z (%) = 362 (M+, 100).  
HRMS (ESI): calcd for C20H19N4O3 (M+H) 363.14517, found 363.14609.  
IR (ATR, cm-1): ν̃ = 3040 (w), 2930 (w), 2226 (w), 1745 (w), 1580 (m), 1530 (s), 1470 (m), 
1404 (s), 1370 (s), 1293 (s), 1230 (m), 1180 (s), 1153 (s), 1110 (m), 1025 (m), 987 (w), 945 
(w), 831 (m), 780 (m), 752 (s), 702 (s), 626 (w), 580 (s).  
 
1,3-Dimethylbenzofuro[2',3':5,6]pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (6.2.4a).  
Starting from 7-(2-hydroxyphenyl)-1,3-dimethyl-6-
nitropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
6.1.5b (0.328 g, 1 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.4a was isolated 
as a white solid (0.228 g, 81%). Mp: 265-267oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.37 (s, 3H, 
Me), 3.74 (s, 3H, Me), 7.57 (t, 1H, 3J = 7.2 Hz, CHAr), 7.76-7.81 (m, 1H, CHAr), 7.86-7.89 
(m, 1H, CHAr), 8.24-8.27 (m, 1H, CHAr), 8.68 (s, 1H, Py).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 281 (M+, 100), 253 (33), 169 (62).  
HRMS (EI): calcd for C15H11N3O3 (M
+) 281.07949, found 281.07931.  
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IR (ATR, cm-1): ν̃ = 3082 (w), 1705 (m), 1667 (s), 1627 (s), 1583 (m), 1516 (m), 1447 (s), 
1407 (s), 1379 (s), 1314 (s), 1384 (s), 1193 (m), 1099 (m), 968 (m), 922 (m), 842 (m), 772 (s), 
751 (s), 703 (m), 671 (m), 611 (m).  
 
3-Methyl-1-phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine (6.2.4b).  
Starting from 2-(3-methyl-5-nitro-1-phenyl-1H-
pyrazolo[3,4-b]pyridin-6-yl)phenol 6.1.5a (0.346 g, 1 mmol) 
and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 
6.2.4b was isolated as a yellow viscous oil (0.278 g, 93%).  
1H NMR (300 MHz, CDCl3): δ = 2.69 (s, 3H, Me), 7.26-7.32 
(m, 1H, CHAr), 7.40-7.45 (m, 1H, CHAr), 7.52-7.60 (m, 4H, CHAr), 7.99 (s, 1H, Py), 8.28-8.31 
(m, 1H, CHAr), 8.41-8.45 (m, 2H, CHAr).  
13C NMR (62.9 MHz, CDCl3): δ = 12.6 (Me), 109.6, 112.1 (CH), 116.0 (C), 120.5, 122.1, 
123.1 (CH), 123.3 (C), 125.2, 129.0, 130.2 (CH), 139.9, 142.5, 145.3, 146.3, 148.9, 159.4 (C).  
MS (GC, 70eV): m/z (%) = 299 (M+, 100), 284 (16).  
HRMS (ESI): calcd for C19H14N3O (M+H) 300.11314, found 300.11335.  
IR (ATR, cm-1): ν̃ = 1628 (w), 1588 (m), 1506 (m), 1416 (m), 1374 (m), 1328 (m), 1250 (m), 
1168 (m), 1122 (m), 1074 (m), 987 (m), 893 (m), 854 (m), 803 (m), 747 (s), 686 (m), 650 (m).  
 
1-Cyclohexyl-1H-benzofuro[3,2-b]pyrrolo[3,2-e]pyridine-3-carbonitrile (6.2.4c).  
Starting from 1-cyclohexyl-6-(2-hydroxyphenyl)-5-nitro-
1H-pyrrolo[2,3-b]pyridine-3-carbonitrile 6.1.5c (0.362 g, 1 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the 
product 6.2.4c was isolated as a yellow solid (0.280 g, 89%). 
Mp: 258-260oC.  
1H NMR (300 MHz, DMSO-d6): δ = 1.21-1.36 (m, 1H, Cy), 1.49-1.62 (m, 2H, Cy), 1.74-1.94 
(m, 5H, Cy), 2.06-2.08 (m, 2H, Cy), 4.87-4.96 (m, 1H, CHCy), 7.47-7.52 (m, 1H, CHAr), 7.64-
7.69 (m, 1H, CHAr), 7.78-7.81 (m, 1H, CHAr), 8.22-8.24 (m, 1H, CHAr), 8.48 (s, 1H, Py), 8.78 
(s, 1H, pyrrole).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 315 (M+, 26), 233 (100).  
HRMS (EI): calcd for C20H17N3O (M
+) 315.13661, found 315.13650.  
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IR (ATR, cm-1): ν̃ = 3121 (w), 3931 (m), 2221 (s), 1719 (w), 1568 (w), 1531 (m), 1446 (m), 
1421 (m), 1379 (m), 1328 (m), 1262 (m), 1185 (s), 1142 (m), 1097 (m), 997 (m), 932 (m), 
861 (s), 742 (s), 614 (s).  
 
2-Methylbenzofuro[3,2-b]pyridine-3-carbonitrile (6.2.4d).  
Starting from 6-(2-hydroxyphenyl)-2-methyl-5-
nitronicotinonitrile 6.1.5f (0.255 g, 1 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.4d was 
isolated as a white solid (0.177 g, 85%). Mp: 206-208oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.91 (s, 3H, Me), 7.44-7.49 (m, 1H, CHAr), 7.59-7.64 
(m, 2H, CHAr), 7.98 (s, 1H, Py), 8.20-8.23 (m, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 23.5 (Me), 105.5 (C), 112.5 (CH), 117.4 (C), 121.9, 
122.0 (CH), 122.1 (C), 124.3, 131.1 (CH), 146.4, 147.1, 157.2, 159.0.  
MS (GC, 70eV): m/z (%) = 208 (M+, 100).  
HRMS (EI): calcd for C13H8N2O (M
+) 208.06311, found 208.06311.  
IR (ATR, cm-1): ν̃ = 2219 (w), 1633 (w), 1590 (w), 1553 (w), 1446 (m), 1402 (m), 1345 (m), 
1250 (w), 1104 (m), 1019 (w), 948 (w), 906 (s), 855 (m), 755 (s), 734 (s), 648 (m), 607 (m). 
 
N,N-dimethylbenzofuro[3,2-b]quinolin-3-amine (6.2.4e).  
Starting from 2-(7-(dimethylamino)-3-
nitroquinolin-2-yl)phenol 6.1.5e (0.309 g, 1 
mmol) and K2CO3 (0.179 g, 1.3 mmol) in 8 mL 
DMF, the product 6.2.4e was isolated as a red 
solid (0.189 g, 72%). Mp: 184-186oC.  
1H NMR (250 MHz, DMSO-d6): δ = 3.08 (s, 6H, 2xMe), 7.20 (d, 1H, 4J = 2.5 Hz, CHAr), 7.38 
(dd, 1H, 3J = 9.2 Hz, 4J = 2.6 Hz, CHAr), 7.46-7.52 (m, 1H, CHAr), 7.66-7.78 (m, 2H, CHAr), 
7.92 (d, 1H, 3J = 9.2 Hz, CHAr), 8.21-8.25 (m, 1H, CHAr), 8.38 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 40.0 (Me), 105.8, 112.3, 114.9, 116.9 (CH), 119.6 (C), 
121.5 (CH), 122.6 (C), 123.6, 128.4, 130.6 (CH), 145.3, 145.8, 147.7, 150.2, 158.4 (C).  
MS (EI, 70eV): m/z (%) = 262 (M+, 100), 219 (20).  
HRMS (EI): calcd for C17H14N2O (M
+) 262.11006, found 262.10936.  
IR (ATR, cm-1): ν̃ = 2798 (w), 1618 (m), 1515 (m), 1545 (s), 1376 (m), 1305 (m), 1180 (m), 
1124 (m), 1099 (m), 973 (w), 891 (m), 844 (m), 798 (s), 735 (s), 703 (s), 636 (m).  
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2-Morpholinobenzofuro[3,2-b]thiazolo[5,4-e]pyridine (6.2.4f).  
Starting from 2-(2-morpholino-6-
nitrothiazolo[4,5-b]pyridin-5-yl)phenol 6.1.5d 
(0.358 g, 1 mmol) and K2CO3 (0.179 g, 1.3 
mmol) in 8 mL DMF, the product 6.2.4f was 
isolated as a green solid (0.202 g, 65%). Mp: 251-252oC.  
1H NMR (250 MHz, DMSO-d6): δ = 3.62-3.67 (m, 4H, Morpholine), 3.74-3.79 (m, 4H, 
Morpholine), 7.44-7.7.50 (m, 1H, CHAr), 7.57-7.64 (m, 1H, CHAr), 7.75 (d, 1H, 
3J = 8.2 Hz, 
CHAr), 8.10-8.13 (m, 1H, CHAr), 8.64 (s, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 47.7, 65.4 (Morpholine), 112.3, 113.4, 120.5 (CH), 
123.0 (C), 123.6 (CH), 123.7 (C), 128.8 (CH), 140.3, 144.9, 156.8, 160.8, 169.4 (C).  
MS (EI, 70eV): m/z (%) = 311 (M+, 100), 254 (80), 226 (25).  
HRMS (EI): calcd for C16H13N3O2S (M
+) 311.07230, found 311.07209.  
IR (ATR, cm-1): ν̃ = 2860 (w), 1589 (w), 1540 (m), 1446 (m), 1379 (m), 1286 (m), 1264 (m), 
1174 (m), 1113 (s), 1033 (m), 972 (m), 898 (w), 867 (s), 752 (s), 632 (m).  
 
2-Methyl-4-(naphthalen-1-yl)benzofuro[3,2-b]pyridine-3-carbonitrile (6.2.5a).  
Starting from 6-(2-hydroxyphenyl)-2-methyl-5-
nitronicotinonitrile 6.1.5f (0.255 g, 1 mmol)one-pot, (2-
methylbenzofuro[3,2-b]pyridine-3-carbonitrile 6.2.4d (0.208 
g, 1 mmol))consecutive, 1-bromonaphthalene (0.828 g, 4 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.320 g, 2.3 
mmol)one-pot, (K2CO3 (0.179 g, 1.3 mmol))
consecutive, in 8 mL 
DMF, the product 6.2.5a was isolated as a yellow solid (0.210 g, 63%consecutive), (0.157 g, 
47%one-pot). Mp: 237-238oC.  
1H NMR (250 MHz, DMSO-d6): δ = 2.94 (s, 3H, Me), 7.44-7.49 (m, 2H, CHAr), 7.53-7.67 
(m, 2H, CHAr), 7.69-7.71 (m, 2H, CHAr), 7.75-7.80 (m, 2H, CHAr), 8.13 (d, 1H, 
3J = 8.2 Hz, 
CHAr), 8.22 (dd, 1H, 
3J = 7.6 Hz, 4J = 2.4 Hz, CHAr), 8.27-8.31 (m, 1H, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 23.7 (Me), 106.7 (C), 112.8 (CH), 116.6 (C), 121.8 
(CH), 121.9 (C), 124.6, 124.8, 125.5, 126.7, 127.3, 128.2 (CH), 128.3 (C), 128.6 (CH), 130.2 
(C), 130.4, 131.4 (CH), 130.1, 134.9, 145.5, 157.7, 158.3 (C).  
MS (GC, 70eV): m/z (%) = 334 (M+, 100).  
HRMS (EI): calcd for C23H14N2O (M
+) 334.11006, found 334.10935.  
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IR (ATR, cm-1): ν̃ = 2222 (w), 1713 (w), 1627 (m), 1586 (m), 1547 (m), 1444 (w), 1375 (s), 
1243 (m), 1196 (s), 1100 (m), 982 (w), 887 (w), 805 (s), 777 (s), 746 (s), 670 (m), 611 (m).  
 
3-Methyl-1-phenyl-4-(p-tolyl)-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine (6.2.5b).  
Starting from 2-(3-methyl-5-nitro-1-phenyl-1H-
pyrazolo[3,4-b]pyridin-6-yl)phenol 6.1.5a (0.346 g, 1 
mmol)one-pot, (3-methyl-1-phenyl-1H-benzofuro[3,2-
b]pyrazolo[4,3-e]pyridine 6.2.4b (0.299 g, 1 
mmol))consecutive, 1-bromo-4-methylbenzene (0.684 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 
1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.320 g, 
2.3 mmol)one-pot, (K2CO3 (0.179 g, 1.3 mmol))
consecutive, in 8 
mL DMF, the product 6.2.5b was isolated as a yellow solid 
(0.303 g, 78%consecutive), (0.163 g, 42%one‑pot). Mp: 169-170oC.  
1H NMR (250 MHz, DMSO-d6): δ = 2.47 (s, 3H, Me), 3.32 (s, 3H, Me), 7.31-7.37 (m, 4H, 
CHAr), 7.43-7.51 (m, 3H, CHAr), 7.57-7.73 (m, 2H, CHAr), 8.24 (d, 1H, 
3J = 7.5 Hz, CHAr), 
8.38-8.42 (m, 2H, CHAr).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 389 (M+, 100).  
HRMS (EI): calcd for C26H19N3O (M
+) 389.15226, found 389.15200.  
IR (ATR, cm-1): ν̃ = 1628 (w), 1596 (w), 1504 (m), 1438 (w), 1354 (m), 1211 (m), 1350 (m), 
1017 (m), 930 (m), 874 (w), 743 (s), 690 (s), 606 (m).  
 
3-Methyl-1-phenyl-4-(3-(trifluoromethyl)phenyl)-1H-benzofuro[3,2-b]pyrazolo[4,3-
e]pyridine (6.2.5c).  
Starting from 2-(3-methyl-5-nitro-1-phenyl-1H-
pyrazolo[3,4-b]pyridin-6-yl)phenol 6.1.5a (0.346 g, 1 
mmol)one-pot, (3-methyl-1-phenyl-1H-benzofuro[3,2-
b]pyrazolo[4,3-e]pyridine 6.2.4b (0.299 g, 1 
mmol))consecutive, 1-bromo-3-(trifluoromethyl)benzene 
(0.900 g, 4 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI 
(0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.320 g, 2.3 mmol)
one-pot, (K2CO3 (0.179 g, 1.3 
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mmol))consecutive, in 8 mL DMF, the product 6.2.5c was isolated as a yellow viscous oil (0.363 
g, 82%consecutive), (0.248 g, 56%one‑pot).  
1H NMR (300 MHz, CDCl3): δ = 2.61 (s, 3H, Me), 7.21-7.39 (m, 4H, CHAr), 7.41-7.56 (m, 
4H, CHAr), 7.66-7.92 (m, 2H, CHAr), 8.19-8.23 (m, 1H, CHAr), 8.36-8.41 (m, 2H, CHAr).  
19F NMR (282 MHz, DMSO-d6): δ = -62.5 (CF3).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 443 (M+, 100).  
HRMS (EI): calcd for C26H16N3F3O (M
+) 443.12400, found 443.12378.  
IR (ATR, cm-1): ν̃ = 2921 (w), 1327 (w), 1598 (m), 1573 (w), 1505 (m), 1460 (m), 1416 (m), 
1373 (m), 1327 (m), 1265 (m), 1250 (m), 1212 (m), 1167 (m), 1121 (s), 1072 (m), 1012 (m), 
987 (m), 892 (m), 854 (m), 803 (m), 745 (s), 686 (s), 650 (s), 616 (m), 559 (m).  
 
1,3-Dimethyl-5-(4-(trifluoromethyl)phenyl)benzofuro[2',3':5,6]pyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione (6.2.5d).  
Starting from 1,3-dimethylbenzofuro[2',3':5,6]pyrido 
[2,3-d]pyrimidine-2,4(1H,3H)-dione 6.2.4a (0.281 g, 1 
mmol), 1-bromo-4-(trifluoromethyl)benzene (0.900 g, 4 
mmol), PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 
g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 
(0.179 g, 1.3 mmol) in 8 mL DMF, the product 6.2.5d 
was isolated as an orange viscous oil (0.247 g, 
58%consecutive).  
1H NMR (250 MHz, DMSO-d6): δ = 3.19 (s, 3H, Me), 
3.76 (s, 3H, Me), 7.49-7.56 (m, 1H, CHAr), 7.69-7.91 (m, 6H, CHAr), 8.18-8.24 (m, 1H, 
CHAr).  
19F NMR (282 MHz, DMSO-d6): δ = -60.9 (CF3).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 425 (M+, 100), 313 (33).  
HRMS (EI): calcd for C22H14N3O3F3 (M
+) 425.09818, found 425.09691.  
IR (ATR, cm-1): ν̃ = 1703 (m), 1658 (s), 1582 (m), 1514 (m), 1448 (m), 1408 (m), 1367 (m), 
1314 (m), 1282 (m), 1193 (m), 1064 (m), 968 (w), 842 (m), 772 (m), 749 (s), 672 (w), 611 
(w).  
 
3-Methyl-4-(5-methylpyridin-2-yl)-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-amine (6.3.1a).  
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Starting from 3-methyl-4-(5-methylpyridin-2-yl)-5-nitro-1-phenyl-
1H-pyrazolo[3,4-b]pyridine 6.2.1l (0.345 g, 1 mmol), Pd/C (0.030 
g, 0.10 mmol) and H2 balloon in 25 mL MeOH, the product 6.3.1a 
was isolated as a brown solid (0.265 g, 84%). Mp: 163-165oC.  
1H NMR (250 MHz, CDCl3): δ = 2.16 (s, 3H, Me), 2.45 (s, 3H, 
Me), 4.31 (br s, 2H, NH2), 7.21-7.27 (m, 1H, CHAr), 7.38-7.51 (m, 
3H, CHAr), 7.69-7.72 (m, 1H, CHAr), 8.17-8.24 (m, 3H, CHAr), 
8.63 (s, 1H, Py).  
13C NMR (62.9 MHz, CDCl3): δ = 15.3, 18.4 (Me), 114.5 (C), 120.7 (CH), 121.1, 124.0 (C), 
125.2, 125.6, 129.0 (CH), 133.1, 135.5 (C), 137.5 (CH), 139.6, 140.7 (C), 141.2 (CH), 147.0 
(C), 149.9 (CH), 150.6 (C).  
MS (GC, 70eV): m/z (%) = 315 (M+, 100), 77 (23).  
HRMS (EI): calcd for C19H18N5 (M+H) 316.15567, found 316.15578.  
IR (ATR, cm-1): ν̃ = 3442 (w), 3341 (w), 1713 (w), 1592 (m), 1504 (s), 1434 (m), 1404 (s), 
1355 (m), 1324 (m) 1309 (m), 1290 (m), 1129 (m), 1109 (m), 1084 (m), 1030 (m), 986 (m), 
946 (m), 904 (m), 836 (m), 799 (m), 755 (s), 692 (s), 625 (m), 610 (m), 555 (m).  
 
3-Methyl-5-amino-1-phenyl-4-p-tolyl-1H-pyrazolo[3,4-b]pyridine (6.3.1b).  
Starting from 3-methyl-5-nitro-1-phenyl-4-(p-tolyl)-1H-
pyrazolo[3,4-b]pyridine 6.2.1b (0.344 g, 1 mmol), Pd/C (0.030 g, 
0.10 mmol) and H2 balloon in 25 mL MeOH, the product 6.3.1b 
was isolated as a brown viscous oil (0.245 g, 78%).  
1H NMR (300 MHz, CDCl3): δ = 2.04 (s, 3H, Me), 2.45 (s, 3H, 
Me), 4.20 (br s, 2H, NH2), 7.20-7.36 (m, 5H, CHAr), 7.45-7.50 (m, 
2H, CHAr), 8.19-8.22 (m, 2H, CHAr), 8.23 (s, 1H, Py).  
13C NMR (75.5 MHz, CDCl3): δ = 14.5, 21.4 (Me), 115.7 (C), 
120.6, 120.9, 125.2 (CH), 128.6 (C), 129.0, 129.3, 129.7 (CH), 130.2, 138.8, 139.7 (C), 140.5 
(CH), 141.8, 147.1 (C).  
MS (GC, 70eV): m/z (%) = 314 (M+, 100), 77 (14).  
HRMS (EI): calcd for C20H18N4 (M
+) 314.15260, found 314.15199.  
IR (ATR, cm-1): ν̃ = 3336 (w), 1594 (m), 1504 (s), 1435 (m), 1409 (m), 1385 (m), 1356 (m), 
1288 (m), 1182 (w), 1134 (m), 1100 (m), 1079 (m), 1021 (m), 981 (m), 933 (m), 902 (m), 816 
(m), 787 (m), 753 (s), 677 (s), 626 (m), 552 (s).  
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6-Amino-5-(4-(trifluoromethyl)phenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine-
2,4(1H,3H)-dione (6.3.1c).  
Starting from 1,3-dimethyl-6-nitro-5-(4-(trifluoromethyl) 
phenyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 6.2.2c 
(0.380 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol) and H2 balloon 
in 25 mL MeOH, the product 6.3.1c was isolated as a yellow 
solid (0.263 g, 75%). Mp: 229-230oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.11 (s, 3H, Me), 3.55 (s, 
3H, Me), 4.58 (br s, 2H, NH2), 7.35 (d, 2H, 
3J = 7.9 Hz, 
CHAr), 7.71 (d, 2H, 
3J = 7.8 Hz, CHAr), 8.33 (s, 1H, Py).  
19F NMR (235 MHz, DMSO-d6): δ = -62.8 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 27.9, 29.3 (Me), 107.3 (C), 125.3 (q, 3J = 3.6 Hz, 
CHCCF3), 127.8 (q, 
3J = 3.1 Hz, CHCCF3), 128.8 (q, 
1J = 271.3 Hz, CF3), 129.1 (CH), 131.6 
(q, 2J = 33 Hz, CCF3), 139.2, 140.6 (C), 136.7, 142.3, 147.0 (C), 141.1 (CH), 150.2, 160.4 
(C).  
MS (GC, 70eV): m/z (%) = 350 (M+, 100), 364 (39), 196 (17).  
HRMS (EI): calcd for C16H13N4O2F3 (M
+) 350.09851, found 350.09780.  
IR (ATR, cm-1): ν̃ = 3428 (w), 3339 (w), 1702 (m), 1653 (s), 1469 (m), 1409 (m), 1349 (m), 
1316 (s), 1286 (s), 1161 (m), 1103 (s), 1061 (m), 984 (m), 942 (m), 791 (m), 750 (s), 654 (m).  
 
4-(3-(Trifluoromethyl)phenyl)-N,N,3-trimethyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-
amine (6.3.2a).  
Starting from 3-methyl-5-nitro-1-phenyl-4-(3-(trifluoromethyl) 
phenyl)-1H-pyrazolo[3,4-b]pyridine 6.2.1e (0.398 g, 1 mmol), 
CH2O (0.180 g, 6 mmol (37 wt % in H2O)), Pd/C (0.030 g, 0.10 
mmol) and H2 balloon in 25 mL MeOH, the product 6.3.2a was 
isolated as a yellow solid (0.230 g, 58%). Mp: 87-88oC.  
1H NMR (300 MHz, CDCl3): δ = 1.63 (s, 3H, Me), 2.22 (s, 6H, 
NMe2), 6.85 (m, 1H, CHAr), 7.08-7.14 (m, 2H, CHAr), 7.23-7.25 
(m, 2H, CHAr), 7.33-7.34 (m, 2H, CHAr), 7.83-7.87 (m, 2H, CHAr), 8.17 (s, 1H, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -62.6 (CF3).  
13C NMR (62.9 MHz, DMSO-d6): δ = 14.9 (Me), 44.8 (NMe2), 115.6 (C), 120.7 (CH), 124.0 
(q, 1J = 272.0 Hz, CF3), 124.7 (q, 
4J = 4.1 Hz, CHCCF3), 125.4 (CH), 126.6 (q, 
4J = 4.1 Hz, 
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CHCCF3), 128.5, 129.0 (CH), 130.5 (q, 
2J = 33.2 Hz, CCF3), 133.0 (CH), 136.3, 136.5, 139.4, 
141.6, 141.8 (C), 144.0 (CH), 148.1 (C).  
MS (GC, 70eV): m/z (%) = 396 (M+, 100), 379 (11).  
HRMS (ESI): calcd for C22H20N4F3 (M+H) 397.15618, found 397.1620.  
IR (ATR, cm-1): ν̃ = 2927 (w), 2784 (w), 1598 (m), 1504 (s), 1435 (m), 1411 (m), 1354 (m), 
1325 (s), 1262 (s), 1164 (s), 1121 (s), 1071 (s), 1018 (m), 971 (m), 904 (m), 845 (w), 781 (m), 
754 (s), 724 (m), 676 (s), 614 (w), 562 (s).  
 
1-Methyl-3-phenyl-3H-benzo[c]pyrazolo[4,3-f][1,7]naphthyridine (6.3.3a).  
Starting from 2-(3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-
b]pyridin-4-yl)benzaldehyde 6.2.1i (0.358 g, 1 mmol), (3-methyl-5-
nitro-1,4-diphenyl-1H-pyrazolo[3,4-b]pyridine 6.2.1a (0.330 g, 1 
mmol)), (CH2O (0.180 g, 6 mmol (37 wt % in H2O))), Pd/C (0.030 g, 
0.10 mmol) and H2 balloon in 25 mL MeOH, the product 6.3.3a was 
isolated as a yellow solid (0.202 g, 65%from 6.2.1i), (0.143 g, 46%from 
6.2.1a). Mp: 143-145oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3H, Me), 7.28-7.33 (m, 1H, CHAr), 7.51-7.57 
(m, 2H, CHAr), 7.85 (d, 2H, 
3J = 8.3 Hz, CHAr), 8.02 (d, 2H, 
3J = 8.3 Hz, CHAr), 8.26-8.29 (m, 
2H, CHAr), 8.67 (d, 1H, 
4J = 2.2 Hz, CHAr), 8.98 (d, 1H, 
4J = 2.2 Hz, CHAr).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.1 (Me), 116.8 (C), 119.7 (CH), 122.1 (C), 125.4, 
125.7, 125.8, 127.7 (CH), 128.2 (C), 128.8, 129.1 (CH), 139.0, 141.4, 143.5 (C), 148.4 (CH), 
149.8 (C).  
MS (GC, 70eV): m/z (%) = 310 (M+, 1), 252 (100).  
HRMS (ESI): calcd for C20H15N4 (M+H) 311.1291, found 311.1294.  
IR (ATR, cm-1): ν̃ = 2920 (s), 2851 (s), 1595 (m), 1505 (s), 1444 (s), 1411 (s), 1381 (s), 1285 
(m), 1217 (m), 1168 (w), 1125 (m), 1068 (s), 973 (w), 906 (w), 835 (w), 756 (s), 689 (s), 669 
(s), 601 (m), 584 (m).  
 
3-Methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridin-5-amine (6.3.1d).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-
b]pyridine 6.1.3a (0.254 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol) 
and H2 balloon in 25 mL MeOH, the product 6.3.1d was isolated 
as a grey solid (0.191 g, 85%). Mp: 102-104oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.49 (s, 3H, Me), 5.27 (br s, 
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2H, NH2), 7.18-7.23 (m, 1H, CHAr), 7.26 (d, 1H, 
4J = 2.5 Hz, CHAr), 7.46-7.51 (m, 2H, CHAr), 
8.16 (d, 1H, 4J = 2.5 Hz, CHAr), 8.24-8.28 (m, 2H, CHAr).  
13C NMR (75.5 MHz, DMSO-d6): δ = 12.1 (Me), 109.8 (CH), 117.2 (C), 118.7, 124.2, 129.0, 
139.6 (CH), 139.7, 140.4, 140.8, 144.8 (C).  
MS (GC, 70 eV): m/z (%) = 224 (M+, 100).  
HRMS (ESI): calcd for C13H12N4 (M+H) 225.11232, found 225.11233.  
IR (ATR, cm-1): ν̃ = 3346 (w), 1632 (w), 1591 (m), 1503 (s), 1441 (w), 1410 (m), 1385 (m), 
1268 (m), 1201 (w), 1128 (m), 1066 (m), 966 (m), 906 (m), 862 (m), 754 (s), 717 (m), 691 
(s), 671 (s).  
 
5-Bromo-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.4).  
Starting from 3-methyl-5-nitro-1-phenyl-1H-pyrazolo[3,4-
b]pyridine 6.1.3a (0.254 g, 1 mmol), Pd/C (0.030 g, 0.10 mmol), H2 
balloon in 25 mL MeOH, tert-butyl nitrite (0.131 g, 1.5 mmol) and 
CuBr2 (0.268 g, 1.2 mmol) in 40 mL MeCN, the product 6.3.4 was 
isolated as a white solid (0.245 g, 85%). Mp: 110-112oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.56 (s, 3H, Me), 7.28-7.34 (m, 1H, CHAr), 7.50-7.56 
(m, 2H, CHAr), 8.15-8.19 (m, 2H, CHAr), 8.66 (dd, 2H, 
3J = 9.1 Hz, 4J = 2.2 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.0 (Me), 112.2, 118.3 (C), 119.9, 125.6, 129.1, 132.6 
(CH), 138.7, 142.4, 148.4 (C), 149.5 (CH).  
MS (GC, 70 eV): m/z (%) = 287 (M+, 100), 272 (13), 207 (18), 167 (12), 140 (130), 77 (40).  
HRMS (ESI): calcd for C13H10N3Br (M
+) 287.00526, found 287.004794.  
IR (ATR, cm-1): ν̃ = 1592 (m), 1564 (w), 1504 (s), 1438 (m), 1414 (s), 1380 (m), 1321 (m), 
1266 (s), 1209 (w), 117 (w), 1114 (m), 1070 (m), 1010 (w), 949 (m), 904 (w), 883 (m), 820 
(m), 766 (s), 744 (s), 688 (s), 668 (s), 651 (m).  
 
3-Methyl-1-phenyl-5-(p-tolyl)-1H-pyrazolo[3,4-b]pyridine (6.3.5a).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), p-
tolylboronic acid (0.204 g, 1.5 mmol), PdCl2(PPh3)2 
(0.014 g, 0.02 mmol) and K2CO3 (0.276 g, 2 mmol) in 
4 mL dioxane, the product 6.3.5a was isolated as a 
yellow solid (0.260 g, 87%). Mp: 130-132oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.36 (s, 3H, Me), 2.63 (s, 3H, Me), 7.27-7.32 (m, 3H, 
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CHAr), 7.54 (t, 2H, 
3J = 8.2 Hz, CHAr), 7.68 (d, 2H, 
3J = 7.8 Hz, CHAr), 8.30 (d, 2H, 
3J = 8.2 
Hz, CHAr), 8.53 (s, 1H, Py), 8.90 (s,1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.1, 20.6 (Me), 116.9 (C), 125.2, 126.8, 127.6, 129.1, 
129.6, 129.7 (CH), 134.4, 137.0, 139.2, 143.2 (C), 148.1 (CH), 149.5 (C).  
MS (GC, 70 eV): m/z (%) = 299 (M+, 100).  
HRMS (EI): calcd for C20H17N3 (M
+) 299.14170, found 299.141349.  
IR (ATR, cm-1): ν̃ = 3023 (w),1612 (w), 1594 (s), 1504 (s), 1416 (s), 1381 (m), 1344 (m), 
1279 (m), 1256 (m), 1212 (w), 1118 (m), 1078 (m), 1011 (w), 957 (w), 903 (m), 852 (w), 816 
(s), 760 (s), 695 (s), 665 (s), 589 (m), 569 (m).  
 
5-(3,5-Dimethylphenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.5b).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), (3,5-
dimethylphenyl)boronic acid (0.225 g, 1.5 mmol), 
PdCl2(PPh3)2 (0.014 g, 0.02 mmol) and K2CO3 (0.276 g, 
2 mmol) in 4 mL dioxane, the product 6.3.5b was 
isolated as an orange solid (0.298 g, 95%). Mp: 96-
98oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.36 (s, 6H, 2xMe), 2.65 (s, 3H, Me), 7.05 (s, 1H, CHAr), 
7.30 (t, 1H, 3J = 7.2 Hz, CHAr), 7.41 (s, 2H, CHAr), 7.52-7.58 (m, 2H, CHAr), 8.30 (d, 2H, 
3J = 
7.9 Hz, CHAr), 8.57 (d, 1H, 
4J = 2.0 Hz, Py), 8.91 (d, 1H, 4J = 2.0 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.2, 21.0 (Me), 116.9 (C), 119.7, 124.8, 125.2, 128.0, 
129.0, 129.1 (CH), 130.0, 137.2, 138.1, 139.2, 143.3 (C), 148.3 (CH), 149.6 (C).  
MS (GC, 70 eV): m/z (%) = 313 (M+, 100).  
HRMS (EI): calcd for C21H19N3 (M
+) 313.15735, found 313.156954.  
IR (ATR, cm-1): ν̃ = 2914 (w), 1589 (m), 1504 (m), 1430 (m), 1411 (m), 1365 (w), 1272 (m), 
1219 (m), 1181 (w), 1118 (m), 1030 (w), 960 (w), 898 (m), 880 (w), 836 (s), 757 (s), 683 (s), 
669 (s), 603 (m), 589 (m).  
 
5-(4-Chlorophenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.5c).  
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Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), (4-
chlorophenyl)boronic acid (0.234 g, 1.5 mmol), 
PdCl2(PPh3)2 (0.014 g, 0.02 mmol) and K2CO3 (0.276 
g, 2 mmol) in 4 mL dioxane, the product 6.3.5c was 
isolated as a yellow solid (0.288 g, 90%). Mp: 157-
159oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3H, Me), 7.30 (t, 1H, 3J = 7.6 Hz, CHAr), 7.52-
7.59 (m, 4H, CHAr), 7.84 (d, 2H, 
3J = 8.4 Hz, CHAr), 8.29 (d, 2H, 
3J = 8.4 Hz, CHAr), 8.63 (d, 
1H, 4J = 1.8 Hz, Py), 8.95 (d, 1H, 4J = 1.8 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.2 (Me), 116.8 (C), 119.7, 125.3, 128.2, 128.5, 128.7, 
129.0, 129.1 (CH), 132.6, 136.2, 139.1, 143.4 (C), 148.2 (CH), 149.7 (C).  
MS (GC, 70 eV): m/z (%) = 319 (M+, 100).  
HRMS (EI): calcd for C19H14N3Cl (M
+) 319.08708, found 319.086462.  
IR (ATR, cm-1): ν̃ = 3037 (w), 1611 (w), 1593 (m), 1558 (w), 1500 (s), 1440 (m), 1414 (s), 
1343 (m), 1277 (m), 1255 (m), 1210 (w), 1118 (m), 1093 (m), 1076 (m), 1010 (m), 956 (w), 
902 (m), 849 (m), 827 (s), 762 (s), 695 (s), 647 (m), 586 (m).  
 
5-(4-Fluorophenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.5d).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), (4-
fluorophenyl)boronic acid (0.210 g, 1.5 mmol), 
PdCl2(PPh3)2 (0.014 g, 0.02 mmol) and K2CO3 (0.276 g, 
2 mmol) in 4 mL dioxane, the product 6.3.5d was 
isolated as a yellow solid (0.267 g, 88%). Mp: 168-
169oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, Me), 7.27-7.38 (m, 3H, CHAr), 7.50-7.56 
(m, 2H, CHAr), 7.81-7.86 (m, 2H, CHAr), 8.27-8.30 (m, 2H, CHAr), 8.57 (d, 1H, 
4J = 2.2 Hz, 
Py), 8.91 (d, 1H, 4J = 2.2 Hz, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -115.1 (CF).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.1 (Me), 115.7, 116.0 (CH), 116.8 (C), 119.7, 125.2, 
128.1, 128.8, 129.0, 129.1, 129.2 (CH), 133.8 (d, J = 3.0 Hz, C), 139.1, 143.3 (C), 148.2 
(CH), 149.5, 162.0 (d, J = 245 Hz, C).  
MS (GC, 70 eV): m/z (%) = 303 (M+, 100).  
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HRMS (EI): calcd for C19H14N3F (M
+) 303.11663, found 303.116054.  
IR (ATR, cm-1): ν̃ = 1610 (w), 1594 (s), 1563 (w), 1504 (s), 1490 (s), 1416 (s), 1346 (w), 
1259 (m), 1224 (s), 1163 (m), 1117 (m), 1076 (m), 1012 (w), 957 (w), 901 (m), 855 (m), 834 
(s), 804 (m), 762 (s), 969 (s), 665 (s), 588 (m).  
 
3-Methyl-1-phenyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-b]pyridine (6.3.5e).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), (4-
(trifluoromethyl)phenyl)boronic acid (0.285 g, 1.5 
mmol), PdCl2(PPh3)2 (0.014 g, 0.02 mmol) and 
K2CO3 (0.276 g, 2 mmol) in 4 mL dioxane, the 
product 6.3.5e was isolated as a yellow solid (0.322 g, 
91%). Mp: 144-145oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.65 (s, 3H, Me), 7.29-7.33 (m, 1H, CHAr), 7.55 (t, 2H, 
3J = 8.0 Hz, CHAr), 7.86 (d, 2H, 
3J = 8.0 Hz, CHAr), 8.04 (d, 2H, 
3J = 8.0 Hz, CHAr), 8.29 (d, 
2H, 3J = 7.8 Hz, CHAr), 8.71 (d, 1H, 
4J = 2.1 Hz, Py), 9.00 (d, 1H, 4J = 2.1 Hz, Py).  
19F NMR (282 MHz, DMSO-d6): δ = -60.9 (CF3).  
13C NMR: due to bed solubility it was not possible to measure.  
MS (GC, 70 eV): m/z (%) = 353 (M+, 100), 338 (14).  
HRMS (EI): calcd for C20H14N3F3 (M
+) 353.11343, found 353.113271.  
IR (ATR, cm-1): ν̃ = 1612 (m), 1598 (m), 1505 (m), 1408 (w), 1441 (w), 1418 (m), 1384 (w), 
1324 (s), 1283 (m), 1258 (m), 1163 (s), 1104 (s), 1067 (s), 1012 (m), 955 (m), 904 (m), 849 
(m), 837 (s), 773 (m), 752 (s), 702 (m), 689 (s), 668 (m), 635 (w), 594 (s), 552 (w).  
 
5-(3-Chlorophenyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.5f).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), (3-
chlorophenyl)boronic acid (0.234 g, 1.5 mmol), 
PdCl2(PPh3)2 (0.014 g, 0.02 mmol) and K2CO3 (0.276 
g, 2 mmol) in 4 mL dioxane, the product 6.3.5f was 
isolated as an orange solid (0.278 g, 87%). Mp: 140-
142oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.64 (s, 3H, Me), 7.30 (t, 1H, 3J = 7.2 Hz, CHAr), 7.46-
7.57 (m, 4H, CHAr), 7.79 (d, 1H, 
3J = 7.5 Hz, CHAr), 7.91 (s, 1H, CHAr), 8.29 (d, 2H, 
3J = 7.5 
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Hz, CHAr), 8.68 (d, 1H, 
4J = 2.0 Hz, Py), 8.97 (d, 1H, 4J = 2.0 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.7 (Me), 116.9 (C), 119.8, 125.4, 125.7, 126.8, 127.4 
(CH), 128.3 (C), 128.6, 129.1, 130.8 (CH), 133.9, 139.1, 139.5, 143.5 (C), 148.3 (CH), 149.8 
(C).  
MS (GC, 70 eV): m/z (%) = 319 (M+, 100).  
HRMS (EI): calcd for C19H14N3Cl (M
+) 319.08708, found 319.087283.  
IR (ATR, cm-1): ν̃ = 3031 (w), 1594 (m), 1569 (m), 1497 (m), 1460 (m), 1436 (m), 1412 (m), 
1383 (m), 1273 (m), 1251 (m), 1176 (w), 1097 (m), 1075 (m), 1045 (m), 957 (w), 896 (m), 
878 (m), 787 (s), 775 (m), 742 (s), 697 (s), 683 (s), 607 (m), 589 (s).  
 
5-((4-Methoxyphenyl)ethynyl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.6a).  
Starting from 5-bromo-3-methyl-1-phenyl-
1H-pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 
1 mmol), 1-ethynyl-4-methoxybenzene 
(0.264 g, 2 mmol), PdCl2(PPh3)2 (0.014 g, 
0.02 mmol), CuI (0.010 g, 0.05 mmol) and 
TEA (0.131 g, 1.3 mmol) in 4 mL DMF, 
the product 6.3.6a was isolated as a yellow 
solid (0.288 g, 85%). Mp: 92-94oC.  
1H NMR (250 MHz, DMSO-d6): δ = 2.62 (s, 3H, Me), 3.81 (s, 3H, OMe), 7.01 (d, 2H, 3J = 
8.9 Hz, CHAr), 7.29-7.35 (m, 1H, CHAr), 7.53-7.59 (m, 4H, CHAr), 8.52 (d, 2H, 
3J = 8.3 Hz, 
CHAr), 8.56-8.57 (m, 1H, Py), 8.76-8.77 (m, 1H, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.0 (Me), 55.2 (OMe), 85.3, 90.9, 113.0, 113.9 (C), 
114.4 (CH), 116.3 (C), 120.0, 125.6, 129.1, 132.9 (CH), 138.8, 143.3, 148.5 (C), 151.3 (CH), 
159.6 (C).  
MS (GC, 70 eV): m/z (%) = 339 (M+, 100), 324 (31).  
HRMS (EI): calcd for C22H17N3O (M
+) 339.13661, found 339.136346.  
IR (ATR, cm-1): ν̃ = 2916 (w), 1595 (s), 1556 (m), 1504 (s), 1455 (m), 1438 (s), 1413 (s), 
1382 (s), 1351 (m), 1299 (s), 1265 (m), 1242 (s), 1206 (m), 1173 (s), 1117 (s), 1066 (m), 
1031 (s), 970 (m), 911 (m), 896 (m), 824 (s), 772 (s), 746 (s), 671 (s), 649 (m), 593 (s), 563 
(m), 531 (s).  
 
(E)-5-(4-fluorostyryl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.7a).  
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Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 
mmol), 1-fluoro-4-vinylbenzene (0.366 g, 3 
mmol), PdCl2(PPh3)2 (0.028 g, 0.04 mmol) and 
TEA (0.408 g, 4 mmol) in 4 mL DMF, the 
product 6.3.7a was isolated as a yellow solid 
(0.214 g, 65%). Mp: 115-117oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.60 (s, 3H, Me), 7.19-7.30 (m, 3H, CHAr, C=CH), 7.37-
7.39 (m, 2H, CHAr), 7.50-7.55 (m, 2H, CHAr), 7.62-7.67 (m, 2H, CHAr), 8.26 (d, 2H, 
3J = 7.6 
Hz, CHAr), 8.50 (d, 1H, 
4J = 1.9 Hz, Py), 8.81 (d, 1H, 4J = 1.9 Hz, Py).  
19F NMR (62.9 MHz, DMSO-d6): δ = -114.1 (CF).  
13C NMR: due to bed solubility it was not possible to measure.  
MS (GC, 70 eV): m/z (%) = 329 (M+, 100).  
HRMS (EI): calcd for C21H16N3F (M
+) 329.13228, found 329.131861.  
IR (ATR, cm-1): ν̃ = 3035 (w), 1593 (s), 1505 (s), 1440 (m), 1413 (s), 1384 (m), 1280 (m), 
1228 (s), 1158 (m), 1118 (m), 1069 (w), 1030 (w), 1012 (w), 950 (m), 900 (m), 853 (m), 771 
(m), 750 (s), 687 (m), 668 (m), 588 (m).  
 
(E)-5-(4-methoxystyryl)-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyridine (6.3.7b).  
Starting from 5-bromo-3-methyl-1-phenyl-
1H-pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 
1 mmol), 1-methoxy-4-vinylbenzene 
(0.402 g, 3 mmol), PdCl2(PPh3)2 (0.028 g, 
0.04 mmol) and TEA (0.408 g, 4 mmol) in 
4 mL DMF, the product 6.3.7b was 
isolated as a yellow solid (0.240 g, 70%). Mp: 131-133oC.  
1H NMR (300 MHz, DMSO-d6): δ = 2.61 (s, 3H, Me), 3.78 (s, 3H, OMe), 6.97 (d, 2H, 3J = 
8.5 Hz, CHAr), 7.22-7.40 (m, 3H, CHAr, C=CH), 7.51-7.57 (m, 4H, CHAr), 8.27 (dd, 2H, 
3J = 
8.6 Hz, 4J = 1.1 Hz, CHAr), 8.49 (d, 1H, 
4J = 2.0 Hz, Py), 8.81 (d, 1H, 4J = 2.0 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.2 (Me), 55.1 (OMe), 114.2 (CH), 117.0 (C), 119.6, 
122.7, 125.2, 125.9 (CH), 127.4 (C), 127.7, 128.6, 129.1 (CH), 129.5, 139.2, 143.1 (C), 148.8 
(CH), 149.4, 159.0 (C).  
MS (GC, 70 eV): m/z (%) = 341 (M+, 100).  
HRMS (EI): calcd for C22H19N3O (M
+) 341.15226, found 341.152368.  
 
 
  
208 
IR (ATR, cm-1): ν̃ = 1593 (m), 1559 (w), 1504 (s), 1436 (m), 1414 (m), 1385 (m), 1281 (m), 
1250 (m), 1213 (m), 1176 (m), 1119 (m), 1068 (w), 1019 (m), 964 (m), 951 (s), 902 (m), 581 
(s), 810 (m), 773 (s), 747 (s), 688 (s), 671 (m), 588 (s).  
 
(E)-3-methyl-1-phenyl-5-(2-(pyridin-2-yl)vinyl)-1H-pyrazolo[3,4-b]pyridine (6.3.7c).  
Starting from 5-bromo-3-methyl-1-phenyl-1H-
pyrazolo[3,4-b]pyridine 6.3.4 (0.288 g, 1 mmol), 
2-vinylpyridine (0.315 g, 3 mmol), PdCl2(PPh3)2 
(0.028 g, 0.04 mmol) and TEA (0.408 g, 4 mmol) 
in 4 mL DMF, the product 6.3.7c was isolated as a 
yellow viscous oil (0.222 g, 71%).  
1H NMR (300 MHz, DMSO-d6): δ = 2.63 (s, 3H, Me), 7.25-7.32 (m, 2H, C=CH), 7.47-7.56 
(m, 4H, CHAr), 7.78-7.89 (m, 2H, CHAr), 8.27 (d, 2H, 
3J = 7.6 Hz, CHAr), 8.59-8.65 (m, 2H, 
CHAr, Py), 8.92 (d, 1H, 
4J = 1.7 Hz, Py).  
13C NMR (62.9 MHz, DMSO-d6): δ = 12.2 (Me), 117.0 (C), 119.7, 122.3, 122.4, 125.3 (CH), 
126.4 (C), 127.3, 128.4, 128.8, 129.1, 136.9 (CH), 139.1, 149.5, 149.7, 154.7 (C).  
MS (GC, 70 eV): m/z (%) = 312 (M+, 29), 311 (100).  
HRMS (ESI): calcd for C20H17N4 (M+H) 313.14477, found 313.14502.  
IR (ATR, cm-1): ν̃ = 2919 (w), 1595 (w), 1582 (s), 1561 (m), 1504 (s), 1467 (s), 1430 (s), 
1413 (s), 1384 (m), 1259 (m), 1218 (m), 1148 (m), 1115 (m), 1069 (m), 1011 (w), 964 (s), 
604 (m), 849 (w), 752 (s), 739 (s), 689 (s), 670 (s), 588 (s), 568 (m).  
 
General Procedure for Pd-catalyzed C-H Arylation of 3-Nitropyrrole Derivative and 2-
Nitrothiophene. Synthesis of Compounds 7.2a-c: The corresponding 3-nitropyrrole 
derivative or 2-nitrothiophene 7.1h,i (1 equiv.), CuI (1.2 equiv.), K2CO3 (1.3 equiv.), 
(CH3)3CCO2H (0.3 equiv.) and PdCl2(PPh3)2 (0.05 equiv.) were weighed in air and placed 
successively into a Schlenk flask equipped with a magnetic stir bar, which was capped with a 
rubber septum. The reaction vessel was evacuated and back-filled with argon (three times). 
Dry DMF (8 mL for 1 mmol of starting nitroarene) and aryl bromide (2 equiv.) were added 
with a syringe (in case of solid aryl bromide, first it was dissolved in dry DMF under inert 
atmosphere), and the reaction was heated to 130oC for 16h. Upon completion, the reaction 
was cooled to room temperature and concentrated under vacuum. The residue was purified by 
column chromatography typically using heptane/ethyl acetate mixtures to provide the desired 
arylated product.  
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5-(4-Methoxyphenyl)-1-methyl-4-nitro-1H-pyrrole-2-carbonitrile (7.2a).  
Starting from 1-methyl-4-nitro-1H-pyrrole-2-
carbonitrile 7.1h (0.151 g, 1 mmol), 1-bromo-4-
methoxybenzene (0.374 g, 2 mmol), PdCl2(PPh3)2 
(0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 mmol), 
PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 g, 
1.3 mmol) in 8 mL DMF, the product 7.2a was isolated as a brown solid (0.123 g, 48%Pd). 
Mp: 150-152oC.  
1H NMR (300 MHz, DMSO-d6): δ = 3.52 (s, 3H, NMe), 3.84 (s, 3H, OMe), 7.10 (d, 2H, 3J = 
8.5 Hz, CHAr), 7.45 (d, 2H, 
3J = 9.0 Hz, CHAr), 7.85 (s, 1H, pyrrole). 
13C NMR (62.9 MHz, DMSO-d6): δ = 34.2 (Me), 55.3 (OMe), 104.0 (CN), 112.1 (C), 114.0, 
116.1 (CH), 119.1 (C), 131.8 (CH), 132.7, 138.1, 160.4 (C).  
MS (GC, 70eV): m/z (%) = 257 (M+, 100), 195 (16).  
HRMS (EI): calcd for C13H11N3O3 (M
+) 257.07949, found 257.07949.  
IR (ATR, cm-1): ν̃ = 3149 (w), 2224 (m), 1611 (w), 1502 (m), 1454 (m), 1404 (m), 1322 (s), 
1239 (m), 1174 (m), 1108 (m), 1026 (s), 851 (s), 796 (m), 760 (s), 655 (m), 570 (m).  
 
1-Methyl-4-nitro-5-(3-(trifluoromethyl)phenyl)-1H-pyrrole-2-carbonitrile (7.2b).  
Starting from 1-methyl-4-nitro-1H-pyrrole-2-
carbonitrile 7.1h (0.151 g, 1 mmol), 1-bromo-3-
(trifluoromethyl)benzene (0.450 g, 2 mmol), 
PdCl2(PPh3)2 (0.035 g, 0.05 mmol), CuI (0.228 g, 1.2 
mmol), PivOH (0.030 g, 0.3 mmol) and K2CO3 (0.179 
g, 1.3 mmol) in 8 mL DMF, the product 7.2b was isolated as a brown solid (0.174 g, 59%Pd). 
Mp: 118-119oC.  
1H NMR (300 MHz, CDCl3): δ = 3.59 (s, 3H, NMe), 7.47 (s, 1H, pyrrole), 7.55-7.58 (m, 1H, 
CHAr), 7.63-7.71 (m, 2H, CHAr), 7.80-7.83 (m, 1H, CHAr).  
19F NMR (282 MHz, CDCl3): δ = -62.7 (CF3).  
13C NMR (62.9 MHz, CDCl3): δ = 34.3 (Me), 105.4 (CN), 111.2 (C), 115.7 (CH), 123.4 (q, 1J 
= 273.4 Hz, CF3), 127.0 (q, 
3J = 3.7 Hz, CF3CCHAr), 127.3 (q, 
3J = 3.7 Hz, CF3CCHAr), 
128.2, 129.6 (C), 131.6 (q, 2J = 31.2 Hz, CCF3), 133.5 (CH), 134.0, 135.9 (C).  
MS (GC, 70eV): m/z (%) = 295 (M+, 100), 179 (27).  
HRMS (EI): calcd for C13H8N3O2F3 (M
+) 295.05631, found 295.05619.  
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IR (ATR, cm-1): ν̃ = 3159 (w), 2922 (w), 2229 (w), 1558 (w), 1498 (m), 1458 (m), 1425 (m), 
1320 (s), 1227 (m), 1114 (s), 1074 (s), 1021 (m), 905 (m), 835 (m), 815 (m), 759 (m), 700 
(m), 651 (m).  
 
5-(2-Nitrothiophen-3-yl)pyrimidine (7.2c).  
Starting from 2-nitrothiophene 7.1i (0.129 g, 1 mmol), 5-
bromopyrimidine (0.318 g, 2 mmol), PdCl2(PPh3)2 (0.035 g, 0.05 
mmol), CuI (0.228 g, 1.2 mmol), PivOH (0.030 g, 0.3 mmol) and 
K2CO3 (0.179 g, 1.3 mmol) in 8 mL DMF, the product 7.2c was 
isolated as a brown viscous oil (0.108 g, 52%Pd).  
1H NMR (250 MHz, DMSO-d6): δ = 7.35 (d, 1H, 3J = 4.1 Hz, 
thiophene), 7.97 (d, 1H, 3J = 4.1 Hz, thiophene), 9.04-9.29 (br m, 3H, pyrimidine).  
13C NMR: Due to bed solubility it was not possible to measure.  
MS (GC, 70eV): m/z (%) = 207 (M+, 100), 177 (19), 117 (39), 63 (41).  
HRMS (EI): calcd for C8H5N3O2S (M
+) 207.00970, found 207.01000.  
IR (ATR, cm-1): ν̃ = 3112 (w), 1579 (w), 1551 (m), 1492 (s), 1438 (m), 1406 (m), 1336 (s), 
1265 (m), 1181 (m), 1114 (m), 1050 (m), 911 (m), 826 (m), 814 (m), 732 (s), 631 (s).  
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A.1.3. Crystallographic data 
 
Crystal data and structure refinement for 4.1.3g 
 
Identification code ag95 
Empirical formula C12H13N3O2 
Formula weight 231.25 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 13.2661 (8) Å α = 90o  
b = 8.4355 (4) Å β = 110.075 (3)o 
c = 11.2895 (6) Å γ = 90o 
Volume 1186.61 (11) Å3 
Z 4 
Calculated density 1.294 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 488 
Crystal size 0.31 x 0.18 x 0.09 mm 
Θ range for data collection 3.1 to 23.3o 
Limiting indices: -18≤h≤18, -6≤k≤11, -15≤l≤15 
Reflections collected / unique 15718 / 3151 [R(Int) = 0.0445] 
Completeness to Θ 26.07o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3151 / 0 / 157 
Goodness-of-fit on F2 1.033 
Final R indices [I>2σ(I)] R1 = 0.0901, wR2 = 0.1274 
R indices (all data) R1 = 0.0507, wR2 = 0.1062 
Largest diff. peak and hole 0.228 and -0.269 e. Å-3 
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Crystal data and structure refinement for 4.1.6a 
 
Identification code sm6002 
Empirical formula C12H12BrN3O2 
Formula weight 310.16 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic P212121 
Unit cell dimensions a = 7.0209 (2) Å α = 90o  
b = 7.6049 (2) Å β = 90o 
c = 23.4143 (5) Å γ = 90o 
Volume 1250.17 (6) Å3 
Z 4 
Calculated density 1.2648 mg/m3 
Absorption coefficient 3.29 mm-1 
F(000) 624 
Crystal size 0.19 x 0.15 x 0.08 mm 
Θ range for data collection 5.6 to 55.1o 
Limiting indices: -6≤h≤10, -11≤k≤10, -33≤l≤34 
Reflections collected / unique 16351 / 4127 [R(Int) = 0.0326] 
Completeness to Θ 28.68o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4127 / 0 / 164 
Goodness-of-fit on F2 1.028 
Final R indices [I>2σ(I)] R1 = 0.0450, wR2 = 0.0645 
R indices (all data) R1 = 0.0322, wR2 = 0.0613 
Largest diff. peak and hole 0.517 and -0.984 e. Å-3 
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Crystal data and structure refinement for 4.2.1d 
 
Identification code ib13 
Empirical formula C22H23N3O5 
Formula weight 409.43 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 8.5834 (3) Å α = 90o  
b = 14.8435 (5) Å β = 99.823 (1)o 
c = 16.2877 (6) Å γ = 90o 
Volume 2044.76 (12) Å3 
Z 4 
Calculated density 1.330 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 864 
Crystal size 0.52 x 0.12 x 0.12 mm 
Θ range for data collection 5.5 to 66.1o 
Limiting indices: -12≤h≤8, -21≤k≤21, -23≤l≤23 
Reflections collected / unique 28259 / 5047 [R(Int) = 0.0274] 
Completeness to Θ 28.46o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6497 / 0 / 274 
Goodness-of-fit on F2 1.031 
Final R indices [I>2σ(I)] R1 = 0.0616, wR2 = 0.1242 
R indices (all data) R1 = 0.0445, wR2 = 0.1121 
Largest diff. peak and hole 0.319 and -0.285 e. Å-3 
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Crystal data and structure refinement for 4.2.1t 
 
Identification code sm680 
Empirical formula C17H21N3O5 
Formula weight 347.37 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic Pbca 
Unit cell dimensions a = 14.4847 (4) Å α = 90o  
b = 14.2985 (4) Å β = 90o 
c = 16.2284 (5) Å γ = 90o 
Volume 3361.06 (17) Å3 
Z 8 
Calculated density 1.373 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 1472 
Crystal size 0.85 x 0.14 x 0.06 mm 
Θ range for data collection 4.7 to 60.4o 
Limiting indices: -21≤h≤21, -21≤k≤21, -24≤l≤24 
Reflections collected / unique 46084 / 6085 [R(Int) = 0.0676] 
Completeness to Θ 29.69o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6085 / 0 / 230 
Goodness-of-fit on F2 1.018 
Final R indices [I>2σ(I)] R1 = 0.0974, wR2 = 0.1337 
R indices (all data) R1 = 0.0485, wR2 = 0.1073 
Largest diff. peak and hole 0.344 and -0.300 e. Å-3 
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Crystal data and structure refinement for 4.2.2b 
 
Identification code t29 
Empirical formula C12H11N3O2 
Formula weight 229.24 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic, Pna21 
Unit cell dimensions a = 15.7337 (7) Å α = 90o  
b = 7.0498 (4) Å β = 90o 
c = 9.9110 (10) Å γ = 90o 
Volume 1099.32 (10) Å3 
Z 4 
Calculated density 1.385 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 480 
Crystal size 0.27 x 0.19 x 0.05 mm 
Θ range for data collection 2.6 to 24.1o 
Limiting indices: -20≤h≤21, -6≤k≤9, -12≤l≤13 
Reflections collected / unique 11098 / 4956 [R(Int) = 0.0277] 
Completeness to Θ 31.07o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4956 / 2 / 226 
Goodness-of-fit on F2 1.017 
Final R indices [I>2σ(I)] R1 = 0.0822, wR2 = 0.0974 
R indices (all data) R1 = 0.0439, wR2 = 0.0819 
Largest diff. peak and hole 0.118 and -0.175 e. Å-3 
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Crystal data and structure refinement for 4.2.4a 
 
Identification code sm652_1 
Empirical formula C18H14N4O2 
Formula weight 318.33 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, Cc 
Unit cell dimensions a = 10.4755 (4) Å α = 90o  
b = 14.1633 (6) Å β = 100.198 (2)o 
c = 10.9706 (6) Å γ = 90o 
Volume 1601.97 (11) Å3 
Z 4 
Calculated density 1.320 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 664 
Crystal size 0.25 x 0.18 x 0.18 mm 
Θ range for data collection 4.9 to 60.3o 
Limiting indices: -15≤h≤15, -21≤k≤21, -16≤l≤7 
Reflections collected / unique 10868 / 3671 [R(Int) = 0.0255] 
Completeness to Θ 29.12o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3671 / 0 / 217 
Goodness-of-fit on F2 1.031 
Final R indices [I>2σ(I)] R1 = 0.0475, wR2 = 0.0886 
R indices (all data) R1 = 0.0363, wR2 = 0.0826 
Largest diff. peak and hole 0.299 and -0.235 e. Å-3 
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Crystal data and structure refinement for 4.2.4c 
 
Identification code sm786 
Empirical formula C17H14N4O4 
Formula weight 338.32 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, Pn 
Unit cell dimensions a = 7.5869 (4) Å α = 90o  
b = 14.3161 (8) Å β = 117.226 (2)o 
c = 7.9651 (4) Å γ = 90o 
Volume 762.28 (7) Å3 
Z 2 
Calculated density 1.461 mg/m3 
Absorption coefficient 0.11 mm-1 
F(000) 352 
Crystal size 0.38 x 0.18 x 0.13 mm 
Θ range for data collection 3.1 to 31.3o 
Limiting indices: -11≤h≤10, -21≤k≤18, -12≤l≤11 
Reflections collected / unique 11098 / 4956 [R(Int) = 0.0277] 
Completeness to Θ 31.07o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4956 / 2 / 226 
Goodness-of-fit on F2 1.037 
Final R indices [I>2σ(I)] R1 = 0.0669, wR2 = 0.1051 
R indices (all data) R1 = 0.0454, wR2 = 0.0919 
Largest diff. peak and hole 0.263 and -0.276 e. Å-3 
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Crystal data and structure refinement for 4.3.1a 
(4.2.1g) 
 
Identification code sm644 
Empirical formula C19H17N3O3 
Formula weight 335.36 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 13.9795 (4) Å α = 90o  
b = 8.4328 (2) Å β = 91.868 (2)o 
c = 14.2374 (4) Å γ = 90o 
Volume 1677.50 (8) Å3 
Z 4 
Calculated density 1.328 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 704 
Crystal size 0.26 x 0.19 x 0.13 mm 
Θ range for data collection 5.7 to 54.4o 
Limiting indices: -19≤h≤19, -10≤k≤11, -20≤l≤20 
Reflections collected / unique 18626 / 4868 [R(Int) = 0.0384] 
Completeness to Θ 27.14o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4868 / 0 / 227 
Goodness-of-fit on F2 1.021 
Final R indices [I>2σ(I)] R1 = 0.0838, wR2 = 0.1234 
R indices (all data) R1 = 0.0484, wR2 = 0.1062 
Largest diff. peak and hole 0.258 and -0.196 e. Å-3 
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Crystal data and structure refinement for 5.2.1n 
 
Identification code ag407 
Empirical formula C12H11N3O3 
Formula weight 245.24 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 7.2879 (12) Å α = 90o  
b = 18.828 (3) Å β = 93.045 (6)o 
c = 8.5038 (14) Å γ = 90o 
Volume 1165.3 (3) Å3 
Z 4 
Calculated density 1.398 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 512 
Crystal size 0.27 x 0.15 x 0.05 mm 
Θ range for data collection 5.3 to 49.3o 
Limiting indices: -7≤h≤10, -26≤k≤25, -11≤l≤11 
Reflections collected / unique 16039 / 3387 [R(Int) = 0.0486] 
Completeness to Θ 27.0o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3387 / 0 / 165 
Goodness-of-fit on F2 1.018 
Final R indices [I>2σ(I)] R1 = 0.1153, wR2 = 0.1387 
R indices (all data) R1 = 0.0564, wR2 = 0.1127 
Largest diff. peak and hole 0.310 and -0.297 e. Å-3 
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Crystal data and structure refinement for 5.2.1v 
 
Identification code ag421 
Empirical formula C16H14N4O2 
Formula weight 294.31 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 11.8416 (4) Å α = 90o  
b = 6.0888 (2) Å β = 105.700 (2)o 
c = 21.1714 (7) Å γ = 90o 
Volume 1469.53 (8) Å3 
Z 4 
Calculated density 1.330 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 616 
Crystal size 0.70 x 0.46 x 0.32 mm 
Θ range for data collection 4.5 to 65.2o 
Limiting indices: -17≤h≤17, -8≤k≤7, -30≤l≤26 
Reflections collected / unique 19154 / 4681 [R(Int) = 0.0369] 
Completeness to Θ 29.2o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4681 / 0 / 200 
Goodness-of-fit on F2 1.038 
Final R indices [I>2σ(I)] R1 = 0.0575, wR2 = 0.1310 
R indices (all data) R1 = 0.0460, wR2 = 0.1218 
Largest diff. peak and hole 0.350 and -0.223 e. Å-3 
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Crystal data and structure refinement for 5.2.2c 
 
Identification code ag506ff 
Empirical formula C17H11F3N4O4 
Formula weight 392.30 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic, P  
Unit cell dimensions a = 7.7337 (2) Å α = 99.709 (1)o  
b = 9.7692 (2) Å β = 95.981 (1)o 
c = 11.6204 (3) Å γ = 106.250 (1)o 
Volume 820.10 (3) Å3 
Z 2 
Calculated density 1.589 mg/m3 
Absorption coefficient 0.14 mm-1 
F(000) 400 
Crystal size 0.54 x 0.15 x 0.10 mm 
Θ range for data collection 4.4 to 63.9o 
Limiting indices: -11≤h≤11, -14≤k≤14, -17≤l≤17 
Reflections collected / unique 27547 / 5917 [R(Int) = 0.0207] 
Completeness to Θ 29.72o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5917 /0 / 254 
Goodness-of-fit on F2 1.026 
Final R indices [I>2σ(I)] R1 = 0.0698, wR2 = 0.1305 
R indices (all data) R1 = 0.0459, wR2 = 0.1128 
Largest diff. peak and hole 0.394 and -0.291 e. Å-3 
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Crystal data and structure refinement for 5.2.1'' 
 
Identification code Ag636lf 
Empirical formula C17H15N3O2 
Formula weight 293.32 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, Cc 
Unit cell dimensions a = 12.4481 (14) Å α = 90o  
b = 14.0884 (16) Å β = 121.412 (3)o 
c = 9.7990 (11) Å γ = 90o 
Volume 1466.6 (3) Å3 
Z 4 
Calculated density 1.328 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 616 
Crystal size 0.40 x 0.12 x 0.08 mm 
Θ range for data collection 4.8 to 49.6o 
Limiting indices: -16≤h≤16, -19≤k≤19, -13≤l≤12 
Reflections collected / unique 8140 / 3675 [R(Int) = 0.0327] 
Completeness to Θ 26.39o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3675 / 2 / 205 
Goodness-of-fit on F2 1.041 
Final R indices [I>2σ(I)] R1 = 0.0801, wR2 = 0.1312 
R indices (all data) R1 = 0.0523, wR2 = 0.1155 
Largest diff. peak and hole 0.223 and -0.293 e. Å-3 
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Crystal data and structure refinement for 5.3.1c 
 
Identification code Od010 
Empirical formula C19H21N3O 
Formula weight 307.39 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 5.7024 (11) Å α = 90o  
b = 18.533 (3) Å β = 92.984 (5)o 
c = 15.727 (3) Å γ = 90o 
Volume 1659.8 (5) Å3 
Z 4 
Calculated density 1.230 mg/m3 
Absorption coefficient 0.08 mm-1 
F(000) 656 
Crystal size 0.22 x 0.20 x 0.12 mm 
Θ range for data collection 5.6 to 51.2o 
Limiting indices: -7≤h≤7, -24≤k≤23, -20≤l≤20 
Reflections collected / unique 19009 / 3975 [R(Int) = 0.0604] 
Completeness to Θ 26.22o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3975 / 0 / 212 
Goodness-of-fit on F2 1.018 
Final R indices [I>2σ(I)] R1 = 0.0808, wR2 = 0.1165 
R indices (all data) R1 = 0.0464, wR2 = 0.1000 
Largest diff. peak and hole 0.169 and -0.205 e. Å-3 
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Crystal data and structure refinement for 5.3.2c 
 
Identification code Ag459 
Empirical formula C20H19N3O2 
Formula weight 333.38 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 9.6100 (3) Å α = 90o  
b = 26.7655 (8) Å β = 105.485 (1)o 
c = 6.8056 (2) Å γ = 90o 
Volume 1686.97 (9) Å3 
Z 4 
Calculated density 1.313 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 704 
Crystal size 0.55 x 0.44 x 0.21 mm 
Θ range for data collection 5.4 to 65.2o 
Limiting indices: -12≤h≤14, -40≤k≤30, -10≤l≤10 
Reflections collected / unique 30515 / 6109 [R(Int) = 0.0244] 
Completeness to Θ 29.80o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6109 / 0 / 229 
Goodness-of-fit on F2 1.071 
Final R indices [I>2σ(I)] R1 = 0.0591, wR2 = 0.1390 
R indices (all data) R1 = 0.0498, wR2 = 0.1314 
Largest diff. peak and hole 0.406 and -0.291 e. Å-3 
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Crystal data and structure refinement for 6.2.1a 
 
Identification code ag229  
Empirical formula C19H14N4O2 
Formula weight 330.34 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Orthorhombic, Pbca 
Unit cell dimensions a = 6.8138 (3) Å α = 90o  
b = 18.164 (9) Å β = 90o 
c = 25.7766 (2) Å γ = 90o 
Volume 3191.0 (3) Å3 
Z 8 
Calculated density 1.375 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 1376 
Crystal size 0.36 x 0.16 x 0.06 mm 
Θ range for data collection 4.8 to 49.4o 
Limiting indices: -8≤h≤9, -23≤k≤24, -30≤l≤35 
Reflections collected / unique 20505/ 4235 [R(Int) = 0.0515] 
Completeness to Θ 25.8o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4235 / 0 / 227 
Goodness-of-fit on F2 1.016 
Final R indices [I>2σ(I)] R1 = 0.0844, wR2 = 0.1205 
R indices (all data) R1 = 0.0466, wR2 = 0.1007 
Largest diff. peak and hole 0.229 and -0.201 e. Å-3 
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Crystal data and structure refinement for 6.2.1h 
 
Identification code ag336 
Empirical formula C20H16N4O3 
Formula weight 360.37 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic, P1 
Unit cell dimensions a = 5.8619 (2) Å α = 73.883 (2)o  
b = 11.6586 (3) Å β = 83.073 (1)o 
c = 12.9563 (4) Å γ = 89.011 (1)o 
Volume 844.32 (4) Å3 
Z 2 
Calculated density 1.417 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 376 
Crystal size 0.33 x 0.21 x 0.11 mm 
Θ range for data collection 5.6 to 64.9o 
Limiting indices: -8≤h≤8, -17≤k≤17, -19≤l≤19 
Reflections collected / unique 28963/ 6092 [R(Int) = 0.0233] 
Completeness to Θ 29.7o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6092 / 0 / 246 
Goodness-of-fit on F2 1.037 
Final R indices [I>2σ(I)] R1 = 0.0573, wR2 = 0.1213 
R indices (all data) R1 = 0.0424, wR2 = 0.1088 
Largest diff. peak and hole 0.452 and -0.277 e. Å-3 
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Crystal data and structure refinement for 6.2.1l 
 
Identification code ag242  
Empirical formula C19H15N5O2 
Formula weight 345.36 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic, P1 
Unit cell dimensions a = 7.2260 (3) Å α = 114.869 (2)o  
b = 10.7957 (5) Å β = 104.592 (2)o 
c = 11.9938 (5) Å γ = 90.707 (2)o 
Volume 814.00 (6) Å3 
Z 2 
Calculated density 1.409 mg/m3 
Absorption coefficient 0.10 mm-1 
F(000) 480 
Crystal size 0.38 x 0.15 x 0.10 mm 
Θ range for data collection 5.9 to 60.1o 
Limiting indices: -10≤h≤10, -14≤k≤15, -16≤l≤16 
Reflections collected / unique 4697 / 3808 [R(Int) = 0.0234] 
Completeness to Θ 27.10o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4697 / 0 / 237 
Goodness-of-fit on F2 1.032 
Final R indices [I>2σ(I)] R1 = 0.0556, wR2 = 0.1183 
R indices (all data) R1 = 0.0428, wR2 = 0.1079 
Largest diff. peak and hole 0.367 and -0.238 e. Å-3 
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Crystal data and structure refinement for 6.2.2d 
 
Identification code ag345lf 
Empirical formula C13H10N6O4 
Formula weight 314.27 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 8.9906 (5) Å α = 90o  
b = 9.5173 (5) Å β = 99.095 (3)o 
c = 15.7437 (7) Å γ = 90o 
Volume 1330.19 (12) Å3 
Z 4 
Calculated density 1.569 mg/m3 
Absorption coefficient 0.12 mm-1 
F(000) 648 
Crystal size 0.99 x 0.09 x 0.06 mm 
Θ range for data collection 4.6 to 49.4o 
Limiting indices: -11≤h≤12, -12≤k≤12, -21≤l≤21 
Reflections collected / unique 17814 / 3527 [R(Int) = 0.0555] 
Completeness to Θ 26.71o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3527 / 0 / 210 
Goodness-of-fit on F2 1.061 
Final R indices [I>2σ(I)] R1 = 0.0783, wR2 = 0.1273 
R indices (all data) R1 = 0.0479, wR2 = 0.1106 
Largest diff. peak and hole 0.305 and -0.278 e. Å-3 
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Crystal data and structure refinement for 6.2.3h 
 
Identification code Tg47 
Empirical formula C20H18N4O3 
Formula weight 362.38 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/n 
Unit cell dimensions a = 8.3921 (5) Å α = 90o  
b = 10.6133 (7) Å β = 91.414 (3)o 
c = 19.9941 (13) Å γ = 90o 
Volume 1780.3 (2) Å3 
Z 4 
Calculated density 1.352 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 760 
Crystal size 0.34 x 0.24 x 0.10 mm 
Θ range for data collection 4.9 to 59.9o 
Limiting indices: -11≤h≤11, -14≤k≤14, -28≤l≤28 
Reflections collected / unique 25064 / 5171 [R(Int) = 0.0533] 
Completeness to Θ 27.96o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5171 / 0 / 248 
Goodness-of-fit on F2 1.040 
Final R indices [I>2σ(I)] R1 = 0.0861, wR2 = 0.1251 
R indices (all data) R1 = 0.0487, wR2 = 0.1083 
Largest diff. peak and hole 0.291 and -0.213 e. Å-3 
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Crystal data and structure refinement for 6.2.4b 
 
Identification code ag596 
Empirical formula C19H13N3O 
Formula weight 299.32 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 5.1753 (3) Å α = 90o  
b = 22.4997 (15) Å β = 99.267 (4)o 
c = 12.3015 (8) Å γ = 90o 
Volume 1413.72 (16) Å3 
Z 4 
Calculated density 1.406 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 624 
Crystal size 0.28 x 0.21 x 0.03 mm 
Θ range for data collection 2.5 to 23.7o 
Limiting indices: -6≤h≤6, -30≤k≤29, -16≤l≤16 
Reflections collected / unique 17157 / 3558 [R(Int) = 0.0486] 
Completeness to Θ 26.59o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3558 / 0 / 209 
Goodness-of-fit on F2 1.061 
Final R indices [I>2σ(I)] R1 = 0.0896, wR2 = 0.1296 
R indices (all data) R1 = 0.0494, wR2 = 0.1115 
Largest diff. peak and hole 0.222 and -0.329 e. Å-3 
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Crystal data and structure refinement for 6.2.4d 
 
Identification code Ag614ff 
Empirical formula C13H8N2O 
Formula weight 208.21 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Monoclinic, P21/c 
Unit cell dimensions a = 12.4241 (4) Å α = 90o  
b = 6.5008 (2) Å β = 115.559 (2)o 
c = 13.3572 (4) Å γ = 90o 
Volume 973.24 (5) Å3 
Z 4 
Calculated density 1.421 mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 432 
Crystal size 0.71 x 0.35 x 0.09 mm 
Θ range for data collection 6.3 to 62.0o 
Limiting indices: -18≤h≤15, -9≤k≤9, -19≤l≤16 
Reflections collected / unique 14843 / 3084 [R(Int) = 0.0393] 
Completeness to Θ 29.17o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3084 / 0 / 146 
Goodness-of-fit on F2 1.025 
Final R indices [I>2σ(I)] R1 = 0.0520, wR2 = 0.1206 
R indices (all data) R1 = 0.0424, wR2 = 0.1125 
Largest diff. peak and hole 0.442 and -0.242 e. Å-3 
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Crystal data and structure refinement for 6.3.1c 
 
Identification code Ag581lf 
Empirical formula C16H13F3N4O2.C2H6OS 
Formula weight 428.43 
Temperature 173 K 
Wavelength 0.71073 Å 
Crystal system, space group Triclinic, P1  
Unit cell dimensions a = 8.7505 (3) Å α = 68.601 (2)o  
b = 10.1118 (4) Å β = 81.680 (2)o 
c = 12.5661 (5) Å γ = 67.008 (2)o 
Volume 953.00 (6) Å3 
Z 2 
Calculated density 1.493 mg/m3 
Absorption coefficient 0.23 mm-1 
F(000) 444 
Crystal size 0.29 x 0.23 x 0.12 mm 
Θ range for data collection 4.7 to 63.0o 
Limiting indices: -10≤h≤11, -13≤k≤13, -16≤l≤17 
Reflections collected / unique 27069 / 5046 [R(Int) = 0.0509] 
Completeness to Θ 27.26o 
Absorption correction multi scan 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5046 / 22 / 357 
Goodness-of-fit on F2 1.034 
Final R indices [I>2σ(I)] R1 = 0.0734, wR2 = 0.1445 
R indices (all data) R1 = 0.0513, wR2 = 0.1277 
Largest diff. peak and hole 0.515 and -0.496 e. Å-3 
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List of Abbreviations 
 
Ar, Ar1, Ar2 etc - Aryl group  
ArH - Arene  
AIBN - Azobisisobutyronitrile  
Ac - Acetyl group  
aq. - Aqueous  
acac - Acetylacetonate  
Alk - Alkyl group  
ATR - Attenuated total reflection (IR)  
BINOL - 1,1'-Bi-2-naphthol  
BINAP - 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl  
BINEPINE - 4,5-Dihydro-3H-dinaphtho[2,1-c;1',2'-e]phosphepine  
BINAM - 1,1′-Binaphthyl-2,2′-diamine  
BQ - 1,4-Benzoquinone  
Bz - Benzoyl group  
Bpin - Pinacol boronic ester  
br - Broad (NMR)  
Cy - Cyclohexyl group  
cod - 1,5-Cyclooctadiene  
CMD - Concerted metalation-deprotonation  
CDCl3 - Deuterated chloroform  
calcd - Calculated (HRMS)  
CI - Chemical ionization (MS)  
DavePhos - 2-Dicyclohexylphosphino-2′-(N,N-dimethylamino)biphenyl  
DCM - Dichloromethane  
DMF - N,N-Dimethylformamide  
DME - 1,2-Dimethoxyethane  
DMA - N,N-Dimethylacetamide  
DMSO - Dimethyl sulfoxide  
DMSO-d6 - Deuterated dimethyl sulfoxide  
dppp - 1,3-Bis(diphenylphosphino)propane  
dppf - 1,1′-Bis(diphenylphosphino)ferrocene  
dppe - 1,2-Bis(diphenylphosphino)ethane  
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dppm - 1,1-Bis(diphenylphosphino)methane  
DIOP - 2,3-O-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane  
DPEPhos - Bis[(2-diphenylphosphino)phenyl]ether  
DG - Directing group  
DFT - Density functional theory  
d - Doublet (NMR)  
dd - Doublet of doublets (NMR)  
dt - Double of triplet (NMR)  
EWG - Electron withdrawing group  
EDG - Electron donating group  
Et - Ethyl group  
Et2O - Diethyl ether  
equiv. - Equivalent  
EI - Electron ionization (HRMS)  
ESI - Electrospray ionization (HRMS)  
eV - Electron-volt  
FG - Functional group  
GBH reaction - Gomberg-Bachmann-Hey reaction  
GC - Gas chromatography  
GC-MS - Gas chromatography-mass spectrometry  
g - gram  
Hal - Halogen  
h - Hours  
hν - Light irradiation (photon energy)  
HFIP - Hexafluoroisopropanol  
HRMS - High resolution mass spectrometry  
Hz - Hertz  
(Het)Ar - (Hetero)arene  
iPr - Isopropyl group  
IR - Infrared spectroscopy  
J - Coupling constant  
LG - Leaving group  
Ln - Ligand  
MOP - 2-(Diphenylphosphino)-2′-methoxy-1,1′-binaphthyl  
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MePhos - 2-Methyl-2′-dicyclohexylphosphinobiphenyl  
M - Metal or metalorganic functionality  
M - Molar solution  
MTES - N-Methyl-N,N,N-triethylammonium methylsulfate  
min - Minutes  
Me - Methyl group  
MXn - Salt of metal  
Ms (OMs) - Methanesulfonyl group (mesylate) 
MS - Mass spectrometry  
m - Meta position  
m - Multiplet (NMR)  
m - Medium intensity (IR)  
MeOH - Methanol  
MeCN - Acetonitrile  
Mp - Melting point  
MHz - Megaherz  
m/z - Mass to charge ratio  
mL - Milliliter  
NOBIN - 2-Amino-2'-hydroxy-1,1'-binaphthyl  
nBu or Bu - Butyl group  
NMP - N-Methyl-2-pyrrolidone  
NMR - Nuclear magnetic resonance  
Nu - Nucleophile  
o - Ortho position  
Pr - Propyl group  
Py - Pyridine  
Ph - Phenyl group  
PivOH - Pivalic acid (dimethylpropanoic acid)  
Piv - Pivaloyl group  
p - Para position  
ppm - Parts per million (NMR)  
q - Quartet (NMR)  
R, R1, R2 etc - Functional group  
SPhos - 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl  
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s - Strong intensity (IR)  
s - Singlet (NMR)  
TM - Transition metal  
TFA - Trifluoroacetic acid  
T - Temperature  
THF - Tetrahydrofuran  
TMS - Trimethylsilyl group  
TMSCl - Trimethylsilyl chloride  
TCP - 1,2,3-Trichloropropane  
Tf (OTf) - Trifluoromethanesulfonyl group (triflate)  
Ts (OTs) - p-Toluenesulfonyl group (tosylate)  
TEA - Triethylamine  
tBu - Tert-butyl group  
TBAF - Tetra-n-butylammonium fluoride  
Tol - p-Tolyl group  
TLC - Thin layer chromatography  
t - Triplet (NMR)  
td - Triple doublet (NMR)  
tt - Triple triplet (NMR)  
ttt - Triple triple triplet (NMR)  
XPhos - 2-Dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl  
w - Week intensity (IR)  
XantPhos - 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene  
δ - Chemical shift (NMR)  
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